var title_f29_50_30496="Prevention falls algorithm";
var content_f29_50_30496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Prevention falls algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 626px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Prevention of Falls in Older Persons: Clinical Practice Guideline (file://www.medcats.com/FALLS/frameset.htm) from the American Geriatrics Society. For more information visit the AGS online at www.americangeriatrics.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30496=[""].join("\n");
var outline_f29_50_30496=null;
var title_f29_50_30497="Mastocytoma infant hand";
var content_f29_50_30497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mastocytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutaneous mastocytomas on the hand of a child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Soter, AN. J Invest Derm 1991; 96(3):S32.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30497=[""].join("\n");
var outline_f29_50_30497=null;
var title_f29_50_30498="Suramin: Drug information";
var content_f29_50_30498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Suramin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F553978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiprotozoal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Trypanosomiasis, hemolymphatic stage  (unlabeled use);",
"     </b>",
"     I.V.: Initial: 100-200 mg test dose, followed by 1 g on days 1, 3, 7, 14, and 21",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9776967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Trypanosomiasis, hemolymphatic stage  (unlabeled use):",
"     </b>",
"     I.V.: 20 mg/kg (maximum dose: 1 g) on days 1, 3, 7, 14, and 21",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F224433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F224434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: 1 g [Limited by law to investigational use only]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suramin is not commercially available and is only available in the U.S. under an Investigational New Drug (IND) protocol to licensed physicians through the Centers for Disease Control and Prevention (CDC). Information is available at",
"     <a href=\"file://www.cdc.gov/ncidod/srp/drugs/formulary.html\" target=\"_blank\">",
"      file://www.cdc.gov/ncidod/srp/drugs/formulary.html",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F224418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Usually administered as a carefully titrated continuous infusion",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F224440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of early human African trypanosomiasis (sleeping sickness), without CNS involvement, due to",
"     <i>",
"      T. brucei rhodesiense",
"     </i>",
"     (East African sleeping sickness) or as an alternative agent in infections due to",
"     <i>",
"      T. brucei gambiense",
"     </i>",
"     (West African sleeping sickness)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F224442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, fever, headache, loss of consciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Polydipsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic Pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Polyuria, proteinuria, renal impairment, renal toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Immediate hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to suramin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reaction: Use has been associated with immediate hypersensitivity reactions, including severe reactions leading to shock and loss of consciousness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: Use has been associated with proteinuria and renal toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid use in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid use in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events have been observed in animal reproduction studies (Medical Letter, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Not absorbed orally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Does not penetrate the CNS",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, Suramin IND Protocol #84459, 1997:  1-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1017):1-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/50/30498/abstract-text/9442765/pubmed\" id=\"9442765\" target=\"_blank\">",
"        9442765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Treatment Guidelines From the Medical Letter",
"      </i>",
"      , 2007, 5(Suppl):e1-154.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Voogd TE, Vansterkenburg EL, Wilting J, et al, &ldquo;Recent Research on the Biological Activity of Suramin,&rdquo;",
"      <i>",
"       Pharmacol Rev",
"      </i>",
"      , 1993, 45(2):177-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/50/30498/abstract-text/8396782/pubmed\" id=\"8396782\" target=\"_blank\">",
"        8396782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;WHO Model Prescribing Information: Drugs Used in Parasitic Diseases,&rdquo; Geneva: World Health Organization, 1990.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10291 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30498=[""].join("\n");
var outline_f29_50_30498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F553978\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224432\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9776967\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062223\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224433\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224434\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224417\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224409\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234335\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224418\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224440\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224442\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224421\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224412\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079781\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224420\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10291|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_50_30499="NK cell electron microscopy";
var content_f29_50_30499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    NK cell electron microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    NK cells (top) are distinguished from other lymphocytes by the presence of large cytoplasmic granules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30499=[""].join("\n");
var outline_f29_50_30499=null;
var title_f29_50_30500="Arformoterol: Drug information";
var content_f29_50_30500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Arformoterol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/33/22037?source=see_link\">",
"    see \"Arformoterol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4010583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brovana&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4010587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"     <li>",
"      Beta",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist, Long-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4010621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      COPD:",
"     </b>",
"     Nebulization: 15 mcg twice daily; maximum: 30 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4010622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4010623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4010624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required, but use caution; systemic drug exposure prolonged (1.3- to 2.4-fold).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4010985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brovana&reg;: 15 mcg/2 mL (30s, 60s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4010585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088566.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088566.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4010981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nebulization: Remove each vial from individually sealed foil pouch immediately before use. Use with standard jet nebulizer connected to an air compressor, administer with mouthpiece or face mask. Administer vial undiluted and do not mix with other medications in nebulizer.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4010588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4010598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (7%), peripheral edema (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Pain (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (6%), leg cramps (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (4%), sinusitis (5%), congestive conditions (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Abscess, agitation, allergic reaction, arteriosclerosis, arthralgia, arthritis, atrial flutter, AV block, bone disorder, calcium crystalluria, cystitis, cerebral infarct, CHF, circumoral paresthesia, constipation, dehydration, digitalis intoxication, dry skin, ECG changes, edema, fever, gastritis, glaucoma, glucose tolerance decreased, glycosuria, gout, heart block, hematuria, hernia,  hyper-/hypoglycemia, hyperlipemia, hypokalemia, hypokinesia, inverted T-wave, kidney calculus, lung carcinoma, melena, MI, neck rigidity, neoplasm, nocturia, oral moniliasis, paradoxical bronchospasm, paralysis, pelvic pain, periodontal abscess, PSA increased, pyuria, QT interval increased, rectal hemorrhage, retroperitoneal hemorrhage, rheumatoid arthritis, skin discoloration, skin hypertrophy, somnolence, supraventricular tachycardia, tendinous contracture, tremor, urinary tract disorder, urine abnormality, viral infection, vision abnormalities, voice alteration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4010593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to arformoterol, racemic formoterol, or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional contraindication for all long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists: Use in patients with asthma (without concomitant use of a long-term asthma control medication)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4010594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Asthma-related deaths:",
"     <b>",
"      [U.S. Boxed Warning]: Long-acting beta",
"      <sub>",
"       2",
"      </sub>",
"      -agonists (LABAs) increase the risk of asthma-related deaths.",
"     </b>",
"     Monotherapy with an LABA is contraindicated in the treatment of asthma. In a large, randomized, placebo-controlled U.S. clinical trial (SMART, 2006), salmeterol was associated with an increase in asthma-related deaths (when added to usual asthma therapy); risk is considered a class effect among all LABAs. LABAs should not be used for acute bronchospasm.",
"     <b>",
"      Safety and efficacy of arformoterol in patients with asthma have not been established.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, arrhythmia, hypertension, HF); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias and prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	COPD: Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute episodes of COPD. Do not initiate in patients with significantly worsening or acutely deteriorating COPD. Data are not available to determine if LABA use increases the risk of death in patients with COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Hepatic impairment: Use with caution in patients with hepatic impairment; systemic clearance prolonged in hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Hyperthyroidism: Use with caution in patients with hyperthyroidism; may stimulate thyroid activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Seizure disorders: Use with caution in patients with seizure disorders; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Pediatrics: Arfomoterol is approved for COPD, which is a disease that does not occur in the pediatric population. Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Patient information: Patients using inhaled, short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists (eg, albuterol) should be instructed to discontinue routine use of these medications prior to beginning treatment; short-acting agents should be reserved for symptomatic relief of acute symptoms. Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use of short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may indicate deterioration of COPD, and medical evaluation must not be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Tolerance/Tachyphylaxis: Tolerance to the bronchodilator effect, measured by FEV",
"     <sub>",
"      1",
"     </sub>",
"     , has been observed in studies.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F4010605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4010604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4010589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4010590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects, decreased fetal weight and increased fetal loss were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Beta-agonists may interfere with uterine contractility if administered during labor.  Use in pregnancy and/or during labor should be limited to situations where benefit outweighs risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4010592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Brovana Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mcg/2 mL (2 mL): $8.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4010983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation; serum glucose, serum potassium. Monitor for increased use of short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist inhalers; may be marker of a deteriorating COPD condition.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4010610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arformoterol, the (R,R)-enantiomer of the racemic formoterol, is a long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist that relaxes bronchial smooth muscle by selective action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with little effect on cardiovascular system.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4010612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 7-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: A portion of inhaled dose is absorbed into systemic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 52% to 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via direct glucuronidation and secondarily via O-demethylation; CYP2D6 and CYP2C19 (to a lesser extent) involved in O-demethylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 26 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 0.5-3 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9433 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30500=[""].join("\n");
var outline_f29_50_30500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708628\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010583\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010587\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010621\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010622\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010623\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010624\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010985\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010585\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874550\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010981\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010588\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010598\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010593\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010594\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010605\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010604\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010589\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010590\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010592\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324025\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010983\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010610\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010612\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9433\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9433|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/33/22037?source=related_link\">",
"      Arformoterol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_50_30501="Metolazone: Pediatric drug information";
var content_f29_50_30501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metolazone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=see_link\">",
"    see \"Metolazone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/46/5861?source=see_link\">",
"    see \"Metolazone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zaroxolyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zaroxolyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=see_link\">",
"      see \"Metolazone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 0.2-0.4 mg/kg/day divided every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edema: 5-10 mg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edema associated with renal disease or cardiac failure (ACC/AHA 2005 Heart Failure Guidelines): 2.5-20 mg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypertension: 2.5-5 mg/dose every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaroxolyn&reg;: 2.5 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to decrease GI distress; administer early in day to avoid nocturia",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild to moderate hypertension (Zaroxolyn&reg; only); treatment of edema in CHF, nephrotic syndrome, and impaired renal function",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metolazone may be confused with metaxalone, methadone, methazolamide, methimazole, methotrexate, metoclopramide, metoprolol, minoxidil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zaroxolyn&reg; may be confused with Zarontin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F195744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain/discomfort, necrotizing angiitis, orthostatic hypotension, palpitation, syncope, venous thrombosis, vertigo, volume depletion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, depression, dizziness, drowsiness, fatigue, headache, lightheadedness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Petechiae, photosensitivity, pruritus, purpura, rash, skin necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gout attacks, hypercalcemia, hyperglycemia, hyperuricemia, hypochloremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal pain, anorexia, constipation, diarrhea, epigastric distress, nausea, pancreatitis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic/hypoplastic anemia, hemoconcentration, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Joint pain, muscle cramps/spasm, neuropathy, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, glucosuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metolazone, any component, other thiazide diuretics, or sulfonamide-derived drugs; anuria; patients with hepatic coma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe renal disease, impaired hepatic function, gout, lupus erythematosus, diabetes mellitus, moderate-high cholesterol concentrations, and/or high triglycerides",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with thiazide or sulfonamide allergy is specifically contraindicated in product labeling, however, there is potential for cross-reaction with any of these compounds; avoid use in patients allergic to these compounds particularly if the reaction was severe. Large or prolonged fluid and electrolyte losses may occur with concomitant furosemide administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1060371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss); avoid garlic (may have increased antihypertensive effect); avoid ephedra, yohimbe, ginseng (may worsen hypertension)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B  (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3343861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Metolazone crosses the placenta and appears in cord blood. Hypoglycemia, hypokalemia, hyponatremia, jaundice, and thrombocytopenia are reported as complications to the fetus or newborn following maternal use of thiazide diuretics.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, renal function, blood pressure, body weight, fluid balance",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium reabsorption in the cortical diluting site and proximal convoluted tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rate and extent vary with the preparation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 6-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Enterohepatic recycling; 70% to 95% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/46/5861?source=see_link\">",
"      see \"Metolazone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F4298008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metolazone 5 mg is approximately equivalent to hydrochlorothiazide 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F195688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made by with tablets and one of three different vehicles (cherry syrup diluted 1:4 with simple syrup; a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush twelve 10 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". Stable for 60 days.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 0.25 mg/mL oral suspension may be made with tablets and a 1:1 mixture of methylcellulose 1% and simple syrup. Crush one 2.5 mg tablet in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     10 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 10 mL. Label \"shake well\" and \"refrigerate\".  Stable for 91 days refrigerated (preferred), 28 days at room temperature in plastic, and 14 days at room temperature in glass.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata, MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arnold WC, &ldquo;Efficacy of Metolazone and Furosemide in Children With Furosemide-Resistant Edema,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1984, 74(5):872-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/50/30501/abstract-text/6493882 /pubmed\" id=\"6493882 \" target=\"_blank\">",
"        6493882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/50/30501/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells TG, &ldquo;The Pharmacology and Therapeutics of Diuretics in the Pediatric Patient,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1990, 37(2):463-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/50/30501/abstract-text/2184406 /pubmed\" id=\"2184406 \" target=\"_blank\">",
"        2184406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12604 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30501=[""].join("\n");
var outline_f29_50_30501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195707\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195708\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060360\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060354\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195668\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060364\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060363\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195746\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195744\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060369\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060353\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060352\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299705\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195677\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060371\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195678\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343861\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060359\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060351\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060367\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060368\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060358\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4298008\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195688\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12604\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12604|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=related_link\">",
"      Metolazone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/46/5861?source=related_link\">",
"      Metolazone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_50_30502="Precut over pancreatic stent";
var content_f29_50_30502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Precut papillotomy over a pancreatic stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 461px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHNAfIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigArE1vxb4c0G7S11zX9J025dBIsV5eRwuUJIDAMQcZBGfY1t18iftSWVvqPx28P2t5H5sD6Ku5NxXOJLkjkc9QKAPo/8A4WT4H/6HLw5/4M4f/iqP+Fk+B/8AocvDn/gzh/8Aiq+LLvwnosYOyz6f9NX/AMaxrrQNNjPy22PrI3+NAH3Z/wALJ8D/APQ5eHP/AAZw/wDxVH/CyfA//Q5eHP8AwZw//FV+fl1plpHu2xFeuPmPH61lz20Sk7Vxz/eoA/Rf/hZPgf8A6HLw5/4M4f8A4qj/AIWT4H/6HLw5/wCDOH/4qvhr4a+G9M1qx1CTUrUzNG6rGQ7KBkE9iK6efwR4fUnbp+PT99J/8VQB9ff8LJ8D/wDQ5eHP/BnD/wDFUf8ACyfA/wD0OXhz/wAGcP8A8VXxbP4R0Zc7LIj6ySf41lXHh3TFHyW2P+2jH+tAH3R/wsnwP/0OXhz/AMGcP/xVH/CyPA//AEOXhz/wZw//ABVfn/d6RaJ9yHH/AAI8frXQ/BjwvpniT4o6Lo+r2Ru9PuDJ50JkePIEbNncpBGCPUUAfb//AAsnwP8A9Dl4c/8ABnD/APFUf8LJ8D/9Dl4c/wDBnD/8VXj3xI+Fnwq8MXfhyGfSEsY769KzStfXBxCqEnrIQMsYxn39a4P4g+Cfh8IdQuPCNlGLRFFlbzi7mkR7jO6WQEuciNAfYtnOeKAPpz/hZPgf/ocvDn/gzh/+Kpf+FkeB/wDocvDn/gzh/wDiq+XfBfww8P6tq/hawuNMLPfXBluszyAiBEZ2XhuD9xcj1OK94/4Z8+GP/Qs/+T91/wDHKAOq/wCFkeB/+hy8Of8Agzh/+Ko/4WR4H/6HLw5/4M4f/iq5X/hnz4Y/9Cz/AOT91/8AHKP+GfPhj/0LP/k/df8AxygDqv8AhZHgf/ocvDn/AIM4f/iqP+FkeB/+hy8Of+DOH/4quNuf2fvhsnzJ4a+Xv/p9z/8AHKqP8BfhuGB/4R3CjJbN9c//ABygDvP+Fk+B/wDocvDn/gzh/wDiqP8AhZPgf/ocvDn/AIM4f/iq8t1H4N/D1GdLTwi21BlpDe3Rz7/6zpVC0+E3w9WdftPhhJIicEC+ugfz8ygD2H/hZPgf/ocvDn/gzh/+Kpf+FkeB/wDocvDn/gzh/wDiq8uuvgp8OjrjQweHwLb7HHMFF7cn5i7gn/WZ6KKk/wCFH/Dz/oXf/J255/8AIlAHpv8AwsnwP/0OXhz/AMGcP/xVH/CyPA//AEOXhz/wZw//ABVeZf8ACj/h3jP/AAjwx6i9uP8A45R/wo/4eYz/AMI6Pr9uuPz/ANZ0oA9N/wCFkeB/+hy8Of8Agzh/+Ko/4WR4H/6HLw5/4M4f/iq8z/4Ud8PP+hex9b24/wDjlJ/wo/4d/wDQu/gb64/L/WdaAPTP+Fk+B/8AocvDn/gzh/8AiqP+Fk+B/wDocvDn/gzh/wDiq8sf4J/D5dY0qA+Hv3U0kqyL9tuPmAidh/y09QOlaj/A/wCGSby3hpQq/wDT/dc/+RaAPQP+Fk+B/wDocvDn/gzh/wDiqP8AhZPgf/ocvDn/AIM4f/iq8gb4Q+AplZYfCapJ2P266OPzkqNPg74Jt5VS68KrIAfmIvLoZHtiSgD2P/hZHgf/AKHLw5/4M4f/AIqj/hZHgf8A6HLw5/4M4f8A4qvKP+FM/Dq81Z/snhwxWdtGEkQ3twS8rYJ5MmcKPTHJOe1Wv+FH/Dzj/inf/J25/wDjlAHpn/CyfA//AEOXhz/wZw//ABVH/CyfA/8A0OPhz/wZw/8AxVeTav8ABr4fWdkWh8NCS6kYQwRm9ucNK3TP7zoOWPsppNB+BHg2ZVS80Et5YAeR7q4XzD3IAfFAHrX/AAsnwP8A9Dl4c/8ABnD/APFV0OlalY6vYRX2k3ltfWUufLuLaVZI3wSDhlJBwQR9Qa+bviT8KfAejeGNdm0zw6sN5a2E88cv224ba6xsVIBkI4IBwQRxXo/7Lf8AyQrwz/29f+lUtAHqtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyd+0l/wAnB+G+M/8AElH/AKHc19Y18n/tIDP7Qvhv/sCj/wBCuqAORvwfm4OO3rXOX4wp4PftXUX4Oc+3+f8AP1rnL4YBPb/61AHOXoG49MHmsO5HJ46iugvR7DP8utYd0CH596APRvg4h/sfVDgf8fCjJ9k5rsbpDz/QZrlPg0v/ABIdT6n/AElQc/7ldncpknI6ZHSgDnruP5jxnv0zxWJegD7zKATgZ/Suu0uw/trxRpmiRyeW97MI2l4IhXBJb3J2kAV9Q+FfBOgeGYkGl6fCLkDDXUih5n+rnkfQYHtQB8b6f8PfFevFRpfh6/lUkYkki8lMHvufAI9xmvf/AIEfBmTwRfya7r80E2sPGYoYYeUtlPU7v4mI4z0Az617bjPekdgilnIVVGSScAD1oA4FodN1q88T6pqyRSwWxawjSQfcjiU7/wA3ZznuAvpXzbfwRWfhrw9pMC7YmgMu3GMi4lAOfcIjV0vjjw/4tm0LWvEsGopZ6Jq2pFhafN5nkSTBAc9PmyD9DXN6rP8Aa/GQgjx5VttUDGNuxNoGPTLvxQB678FbY3vjq9uWXMemWCxqf+mk7bj/AOOxpXuleX/AOxEWg6vfkEPe6g/Pqkaqi/yNeoUAFFFFACMccnpXGxaodQ1S5QMvlLwiDj8fxrqdUkMWnXMg6rGT+lcL4SELXM0jNiTB2qeBigDoy3lJwuee38/5VyS2lzd38oihOA53fLgD+lb+raqbW5SBEVxgFs/yrQtZxcQLIi7d3UAigDmdPtpYdfv1mYMY7eKIBT0yWf8A9mqpqvieG3uHtdOh+3XaHbIQ22KJvRnPf/ZGffFUfFOozR63qmm2chjnumiMsq9YYViVSR6MzZA9MMe1eF/FH4hvpjt4e8LN5Lwfu7i6T+A9409/VuuffmgD1LX/AByult/xPPEllpzEZ8mBBvA9s7mx/wABrn4/iz4e839340ug/QGSFiv/AKLH618wS7pZWeR3eRzuZmOST6+596hMeSMjtn1/z0oA+0fD/jt78brG90vXIx8zrA4hmUfTJH5gfhXa6NrFnqyMbZ2WVMCWCVdsqZ6bh+HUZHHBr8+rV5rS4SezlkgnjOVkiYhlPqCK97+EnxBudeuU03Uplh8Q26k2V6Fx5w/iRx0PuO/1AoA+i7sM+s6Js4PmzdO/7iStTUU8iwkYnBK8jpzisDRdUj1W90C4dPKkE88c8ROTHIIHBGfTuPUEGtLxfC4gjkVz5QP3Rjr/AI0AO8MGK4jmYqpYEAeuKsXk6RXwgRNzgb29NvU/yrO8NsYztUH5zkfTFaHiUGPQtVvUUefDZylHHUEKcYoAzfD6n+yIZmOXuibpm7nzCWX8QpUfhWiRk9P0/X0pEiWBEhjACRgIoPoOB/hSkHA6gfmaAMee+ij8VWwkRnjs7d5sKeBI52jP/AQcenNaFr4ihEpR4mVSeGHbpzisOO2nvNc1qeFMqskdvn3VM/8As9aFrpNtPbGe4nIIBbYozj2NAEPxTsLWb4feK70De40a8KkNx/qX5qn+y5/yQnwz/wBvX/pVLR44uhd/DPxciIwjj0a82k+ggej9lv8A5IV4Z/7ev/SqWgD1WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5R/aNBP7Q/hoD/oC9v966r6ur5T/aJGf2ivDI9dF/9muqAOX1Bec8D6H/AD71zl6v3sV0+oD5SRjr1zmudv1OT6f/AFqAOZvQdh7e3+f88Vh3ikHgf5/zmuhvV46nOep96wbxcAdAcd+KAPS/gsv/ABI9UxyftS/+g11N/OzyNb2QV5hw7n7kP19+4A/SuS+D9vLc6NqaeeYoPtK7wmQ7fJ03fwj6c+4rvGt44I1ihjVEXoB6/wBeaAMSKJrF45bWSVbiOQTLOG+cSDB3Z6ZyB7Y46V1z/GLxnF8om0p8DALWbAntziTFc5dJk+5rHvE5P50Ae3/CH4q6n4n8RvouvQ2YkkhaS3nt0ZNzLglSpJ/hyc57V6L8Q7sWXgXX7kuU8uylOQMnO04GPfpXy98MLhrD4m+HZU4L3Qg49HBB/Cvor4w6pZ6R4Qhu9TIFmuo2YlB6FfPTIPtjOaAPEvEnxB1HVvDegeHtS0C901TLCzvMm1CsK78Dnn7o/KuB8MSNPrV5dS53MdxPsct/Wu8+OfjXSdc1+yh0G5huItL06eeWSI5AkcDAyOpCrn/gVeeaFmz0/UpQOYIMZz3WIUAfWvwYhaH4ZaGXHzzRvOTjGd7sw/Qiu2rA8A232PwN4dt8YMWnW6H6iNc1v0AFFFFADXUOpVuQRg1gy6PFZyNLbRBR1+UY4/pXQU2Q4Vj6DNAHG6vp019tMXEieo61Y0GwvIJWimHyEY4bg/So7ye+tgZDcKRuwBtHv7VraJqCywqsrxmUfexgH6n2oA8Q8c6gNGXxprSNvnFxIseeRlQqIB7bj296+WWjclmZmdySzMeSxPJP4nP519U/GjS9Pt/g7LqDQuuoX96vziVwrEys+SudvKp6V8zNAM96AMt4OowcDj9P8/lUTQ9ccH0rUaE9eOlRtF2x+XIFAGY0R9AcfpUunXc2l6hbX1sSs9tIsqEccqc4/p+NWjFnByPWmGHORz0oA+s/D88l34j0p7EEx38D3YIHCssRGR7lZFH/AAAV6jYu15E0NxDuT7rBgMHp+nFeN/DvUJdL07wRNPa3AkNnjMiFQw+zE8N05Ar3W0u1kt/O8rO5N2xhzQAsFnaQpmKMI3fvWf4mj2+HrpiwKyvFG2fRpUBH5E1nwXdw7vdq5JztZADgCm6zq0dxpZjOQwubZyhOc4mQ/wBDQBdbO4nnqc96TGP8/wCc0pB59j7cUg7Yx7elAGTpguZLnUYbVmCf2i3mFV+6PKirrYdPtfLAJwqjlV71y+kXU1sNYW1iWST7cz8nsYo/8K2tMF6Ymlu5Bl+i4HFAGB8VbgQfDzxVawQbIm0W85XgD9y/GKz/ANlv/khPhn/t6/8ASqWn/GBFuPh54naMgvHpd0c57eU5Iz9KZ+y5/wAkJ8M/9vX/AKVS0Aeq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfKf7RIz+0X4YGM/wDEmH/oV1X1ZXyp+0MM/tGeGR/1Bf8A2a6oAwNQXO7v/n/Cubvl79x+ddTqC8t6kdf8/Wubv16knOCelAHM3y/eH1rCvBkZAJ/z/wDWror1eT9OABWDeLyeMnigD0b4IY/svWVyMi4Q8dhs6131wnHTH+f/ANVef/A1swazGMf6yNv0Ir0aZQP55xQBj3KH5gQMfzrIukwD+fWt24THAHHtWXdJjPYAZP8AWgB3w9tHuPiL4bSIEst8khHcKuWJr6F+Jmh2/i+70Xw3fLus5Gkv5xn7yxBVVf8AvqVT/wABNch8B/BcsMzeJ9ShaMshjsUYYJU8NLg8jI4Ge2T3Fa3xavNcg8U6J/wiNvHNqcFtM9z5jEKIGZQq8Z5ZkOOP4D0oA+efiR4SsfCnjjxFo+lII7WSG3RQOxkAz/M1Tt/3nh7XZlHEomIx2HQfyo8XX+r3/jHU7rxDHHHqZuY0kSPJVQkJKjP/AAEVNo8WfBl16yWxOT3Lc/zNAH21p8X2ewtoQCPLiVMHrwAKsUUUAFFFFABVe/EjWkohOHK8GrFVr+4W2h3uwVSQuT05oA861C7nN48Um4tGdv40lvfw2dpezT8N5TEP17H/AOtXQ6lo66nK7wnyZ2PVvut9fSsjVPDc0NiEunVkmlht22/7cip+WDQBwH7SrvZ+AvCWky4WQyCRx23RxBT/AOjDXzm0R549jivfP2pLozeKdFscgrBZtN16F3wf0QV4k0X/AOvFAGY0QJ47+tRtFznPfj/P51pmIcZHFRmHkdQeh5xQBmGEE8jP/wCoVBPGEidjnhScVqmI/njg9v8AOas6PpzajrFhYqhY3VzFDt9mcA/pmgD7BtNPhtND8D2lxjbYWZlYEZGBbmP+bipLzXHHFqAka4xkelbOpW8cmuR24H7m301439g7pt/9FN+VYraCWcHzSFB6bR/ntQBqaHfPd2MjTxAEPt+VQAwNc34k0xvJvLyFwsMA+0+XzkbCHwPyFdDHqNno0cdvIGdxxsX6d6i1i7gvdEvrWzVGe7tpI+eoypoAluGWJZJJXSONeruQAB06ngdqoRa5pU05ij1K1aTONvmgZ9h2NeA/F34jXN1PCumMuJo/Ph3AMsMZ4DbTwztyQTkBcY5NZXxR1HUNAuPCs2l3syR3ui291LDM3mxvIVG4lG45OemPagD6R097mPxPqcEMKOHSCXLDpwwb+QrrWjWeMoqhfl2lAf5V4d8CPFr63qUKzuv7yzeBYDIWaF42DEDPJjIIK55XleeK9avdXFjO3lqHmAwSegP+NAHL/EjTJLf4feL2Zw0Y0i8IB658l6b+y5/yQnwz/wBvX/pVLVzx5qa6j8K/GJl2CddIvMhOP+WD461T/Zb/AOSE+Gf+3r/0qloA9VooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+Vv2gxn9o7wwD/0Bf/Zrqvqmvlf9oAZ/aQ8MD/qCn+d1QBj34/I/hXN3y9evXvx6iuqv164znP1zXM34+/gc80Ac1eqPwxWBer97HXGOv5V0l8vYZzyBjvyK5+9X5uhwf8KAO4+BjZvtci/h8uNx7jcRzXp84568/wCf615R8EJNviPUoj1ktVPpyG/+vXrV5JHBE0kzqkQ6sx2gexoAzLhckgD9a7D4WeBY/EbRa5q6B9HVs20BHF0Rn52/6Z56D+Lr0xngr2FtXVYZi9vpssiRMTlZJAzhc/7KgHPPJxzgdfq6wggtbKC3tFRLaGNY41QfKFAwAPbigCdRgAAYA6CuPa/tLH4gaql+8aSS2Nq0Rc4ygaYY/Bt3/fQrsa8g+OfhW78U+IfBltp101m5muFnuEHzCEIHI98lR+JzQB4j8S2XUPiPrcsDB0l1BkRh0OIcA1n2KFvAl3t6rbEHPGNuAf5GtzxZ4Pbwjrt1YiaaeOG9t7jzZDlmEsRX/wBDbFVpLcrofia2AOQkrqB0w0e4UAfZIIIyOlLVHQ7gXWi6fcDpNbxyD8VBq9QAUUUUAFR3EKzptcAjryM81JRQBWjtVVssS1UNa/e6lotv1BuWldf9lI3IP4OY/wBK2Kw5ZEbxWzucLY2BYn/rq/P5CEfnQB8yfGy7GpfEzWGViUt9lsB1wVQZ/UmuEaEZzjHtmtzV7ltT1a/1B8Mbq4kmye4Zzg/liqLRY7HGKAM1oie5Of1qJos54GPatR4gcjrmo3iyT3/zzQBmFP8AGu6+BejHU/ijpBKEx2e+7dh2KrgZ+pI/GuUaL+p57817f+zZp0VjZ+I/EdyCIolFurjrtVfMk+v8FAHrCRNeavq9yGG0SR2iHPBWNdx/J5XB/wB2rcVsIkZyQT2UGue0+7uNNito7oc3A+0Pt7SSHe2PbLGt+zZxP5sufLAyc9DQBx01q97dMEUvIWJ2+vrU+hRPJqsdqY2xkhsjoMcmt4Xds9y0lmkSEkglR1+tbOmSxykkoqzHqR1NAHxT8VtFOleJUiLiRGsoghVduAm6PAGT/d/Wtj41xKbbwCwOWbw/DuGemCPyrU+P9uB4l00BTj7LMufXFw/P64qn8Z4gJvCEQGGj0C2VuRg5UHr+dAGp+zTNHFqGpRbEDx3FtcGTaNwRvMjKg+hJXNe9a9pzyztJasGD/eGeh9a+evgHE39u62VRnIt4DgDkkTjH8ia908+7a73RM7kvkKen+cUAcl8QknsfBXieP5l3aXdDIPDKYmBro/2W/wDkhPhn/t6/9Kpaj+J6b/A/idTGWZNGvGPt+4epP2XP+SE+Gf8At6/9KpaAPVaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvln4+/8AJyfhb/sC/wDs11X1NXyz8ff+Tk/C3/YF/rdUAZ9+o+cYxg/5zXN6gAWPSuqv16jt/wDW7VzV+Dj/AANAHL3y/IePp7/41gXowTj0610t6CCeOc/1rnr1eAPyz9RQBvfByTy/HDJ0D2sgwB1IKn/GvYW06ATedMZLiYco0zb9vXoOg+uM+9eJfDKXyfiDph6eYZIz+MbH/wBlr32UYz1OD260AZdwgYFWUENnIODn6/nUOn6jqOiuH0a/urLHISNyY+3BQ5XH0xVyZcdfzP8An2rPuF68Z4/z/SgD2f4Y+O38SmbTtUSOPVrePzN0Yws8ecFgOxBIyPcY9qfxz1y58J6No/iWytzcyWN+sckQPLRyqyED3yVI+lee/C9mj+I2jYLYbzlYdMjym6/pXrvxTsYb/wANQLdLm1jv7WSf0EYmXcT7Ac/hQB4PqXiW4+IWt60ZdNlsZf7IVrbzGBLvFIz54JHBdah06CO71C5RVHk6jYJIMfxZBX+W2vZ/Hvhqz07wpNqmnwqt5paNdJsGDIqqRJH9GUsv4g9q8d8JzxXjeGrq1YtbyW86IxHJAaPbn3wP50AfQfwxuPtPw98OOcblsIYm5/iRQjfqprp683+AGofbfh6sLY32N/d2pHptmYj9GFekUAFFFFABRRRQAV594t1N9P8ACfjPVYmKyyM1rb56hwqxD8N5J/Gu7vJ1tbWadwSsSFyB1IAzXjPxVuHtPBHh7SWZjNeSNeTbuCyqN2D775E5/wBmgDxkQKiKkYIVRtA9v8imNFg4xn+tabx9Tx3P+f8APeo2iwcf5/KgDMaIdxxnn8s/nUZi7Y59vWtMxnqRk9PfrUbRD3Hp6ZFAGW6iNS5+6ozn6f8A1q+mvC+itonw+8O+HioS8v3V7kA4IyTLLz3wPl57V4n4D0H/AISDxlpWnlc2/mief2jTDEH6kKOexIr6WsP9O8Q317j/AEeyX7FBjoW4aU+/OxfYqwoAvaqttFCJrgINn3crnn2rEk1O8a7jht7ZXt2IJbHJ/Gl1SV9WQxxgoUcHBb+lXrSERRhVzgDHvQBzOpRtpeteaqHyJfmBz2PUfUHtW9od6l5e7YtxCrknHFbMlhBcwKlzEr8DrTJkttL0+4liRII442diB6DqaAPlj44N5/iHSyNxYWkuQfU3MnT8AKr/AB0QJ4+Fou0rZ6fbQAj1CnNaXim2bU/ipplhIvKGxtZl7q52tL+RdjWJ8Ubj+0PiFr84OUFz5aEeiKo/Qg0AdX+zzYbpr+fZl5riOFPdI0Zn/Vl/OvfrfTYodzRx7P7zH9RXnfwT0kab4ftpZFVStv5zdxvnO/8AAiMRZH+1Xez3cep2dza29yykgBnA6f5xigDA+KGB8N/F3kkbTo14C/dv3D96zf2W/wDkhXhn/t6/9Kpa0PiTD5Hws8VxrnC6Ndrn2EDVn/suf8kJ8M/9vX/pVLQB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8t/Hr/k5Twt/2BT/ADuq+pK+XfjsM/tL+FQP+gKf53VAFbUFyx/L/P5VzWoLkEn/AA/z2rqdQBxk9f8A9Vc5qC43cd/T/PagDlr8ckHvmufvVJBwPf65/wA4rpb5T1/LNc9fL94Y60AQ+Epvs/jPRJc/L9rjT/vpgv8A7NX0hKCevOa+XhN9lvre5B5hmWQH3DAj+VfUsoDHg5B6H+VAGfMpzn+XH/6qz51yD9MdOua1Zlz2zWddFY43kkJ2Iu5iBzgc/jQB0vwd0xrzxubsDEOnwNIzDs8gKKMe43n8K9p1zTo9X0a90+fHl3MTRk9cZHB/DrXP/C/QG0LwrD9pQC/vD9qufZmA2r/wFQo/AnvXX0AfKPiD4k+J/EPhq90G0064luI99neTglfuEq+CP4jg8e9TWXh5vB+iaZ5U5uNOVBq1lIASfL+7PGfdVfOPUj0Ne2eB9GsYbzxB+5jWb+1bh2AX+8wYfmCPzrg/EOo6fFdWnhh8R3dpq08MUJHItZonK/gWZD+FAHR/CKH+yfE/ijThxb3rxarAO3zDy5AP+BJn8a9VrxXwfemzh8M6o7HED/2fcsTncjnycn38xIj7AmvaqACiiigAoooJoAw/FpM1nb6cv39QnS3IBwdnLSEe4RWNeJ/FLUP7W8c3xjYGGyVbNOuMrkvx67mI+gFep67rsdlHqviFgXgsI2srJR/y2nZgGIHf5giD/dbsa8OSFwuZG3ysSztn7zHJJ/MnrQBQaM+n169KjZOn+FaRj6HA4x+fX/P1qMxE8c8/r70AZzRY7dvypjRYJ4xjj/D/AD7VoNFkjA6ntTrLTrjUb+0sLLAurqURRHH3SeSx9gMn8PegD0L4QWDaP4d1XxIYQ93dN9jsEI+/hsduxk6+yE167o1iNO0y3tdxd0XLyHrI55Zj7liSfrWFpOnQjU7LT7IY0rQYViQZzunK4APqVQ5PfLj3rqhQBlXFxD9pwsKlj/ER1q1bOWcfuwR/eAxipTaxGTeR81TAADgYoAWsTxc6tpP2R8bbyRbdweMxn5pfxEayH8K268p+MeuG2s7yKF9riL7DCRkHzZhmRh/uxLww7yYPWgDzfwBOutfFO4164YCNWudTLk/KEwVT/wAdZT+Fcdp1odf8QRrdFkjvJ3ublsf6uPJllPthd2PfFddpKf2R8P8AXL7BSfVZV0q3VR0jGTKfUcblz7rWp8I9DF1qf2q4XCznCEjjyY2BY5/2pNi+4jOetAHf2MV5BpSm5iaBrlzPLH0Cs38P/AQFT6LWro6+XbTvtI3Fe2M+tdBcQoIWD8r7Vztzq76bcvapbxtb4BO4nJz79qAIfidt/wCFW+LcEYGj3gz/ANsXrL/Zb/5IV4Z/7ev/AEqlqH4pTR33wz8RPbSeWP7MumKMcHiFsj36VN+y5/yQnwz/ANvX/pVLQB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8vfHP/AJOa8Kf9gU/zuq+oa+X/AI5c/tNeFP8AsCn+d1QAl+vBycjvXNaguQ3Hb1rq9QX73XHXiuavx36k9/zoA5W/Gcn+tc/fLy3oc5Paulv1+Ujrk44xXPXy5b19/agDnL1chwcjPUelfTmhXH23w/plyTkzWsUhPXkopP65r5ovF5PH0Br3P4c6x9o8EaTDbRvc3kcRjdFIAjAdsF26DjHHU0AdVKvPPXOeRUNhbJea3pNpKMxT3kUbjPbO7+gFRSW1/LkzXaW4/uW8YJH/AAJgQR77RVK60qKRSs013IOvNw4HHfAOB+AoA+nqWvl6BZrBibG8v7dhjBju5FI+nzV678IfEmoazbajZapKbmWxKFLkqAzI+7CtjgsNvXuCPqQDhvi/4s1L4eeOWnghlkstbRZY/LQtmWNQjrge2w/jXEeFrLU/iNrmteJrm2eDVdFSGa1idQGkClnGT2BKkfSvoD4i6TZ6hd+GbnUIkeK31ERsW6ASxuij8ZDFWH4x1LR/h14h0nUphHb2WphtNucAAbsF4mPsD5in/fHpQBhaDFBqVnr1hG+baeXzYnXj91PGHQj35z9a9V8Iam+r+HLG8mGLkp5c6gYxKhKuPpuU49q8h8GzIs2kXUZP2bUrSWJM8DdDK+0H38s4HshrvfCE/wDZnie+01ziDUV+3W4P/PRcLKo/8cbHuaAO5ooooAKyPEt3LBZJb2ZIvbxxbwkdVJ6v/wABUFvwrXNcR4n1g2TarqyAO1ggsLJT/HcyYLEdjjMa+21xQBwvj69jutVg0ex40vRh5Kc8PNjDscd1B2/Uv7VzBizz0Jq7FB5USoxMjY+ZzzuJ5JPuSf1oMf50AZ5iPBHP/wCqo2j9Rx+daLRZyB1A/wA/zphj/I9/x/8A10AZ5j5P5YNdp8NbA2cV14keESzsxsNLjbpJKxwzfTIwT2CtXPWGlzaxqdrplmSs9yxBcDPlRjBd/wAB0z3IHrXsnhixgmuIri1iEelWCG006MdCBw8vvkjAPcAnnNAG5otiunadDbbzJIAXllPWSRjuZz7liT+NXqKKACiignFAFPVr5NN0+e7lDMsa5CqMl2PAUAdSSQPxr5x8TTXPiHxJFY2pFxKkrW6MvSW4c/vX9MZ+XPTbGDXofxU8UEEWVlLtZGZEcdpQMPJ9IwcDrmRh/cNcLYbfDHh8akuI9Vvomi09W/5d4MYe4OfyXPX8WoAreKETUtbsPD+lSr9g0tGtI5T93cBuuJz7Lg/98464r0vQdDmsbKN1Roo/KEixOfmSNF/do3TnHzN/tM1cR4O0X7KI2nQpLKqPKGGTFDkNHEc/xOQJH74CA5ya9W0gXd484fc0LIQ2ex9Prz0oAp6fNcyReddys24/KWbAx7CotZMN3LAFKhh95/Qf5FTato11OYUtiPKUEcN0496W1t7G1ja31Bx5xOMqDhfx/wD10AYnxI023b4Y+JyhwItIunXbjnELkE0fst/8kK8M/wDb1/6VS1Q+I8aw/D/xUkUm+MaXd7T7eS1X/wBlz/khPhn/ALev/SqWgD1WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5g+N4z+054T/7Ap/8Abuvp+vmL42DP7T3hMf8AUFP/ALd0AT6gvzHjqK5m/Hykf/W9DXV36+mT171zV8uAQOx9KAOV1BeXrnb5cDoTjI+ldRfryT2IrnL5QQc4GPT9aAOcvV+f65r2L4FzrN4Qu7fAzBeMWOOu9Rgn8jXkN8P6V6H8ArrF7rtlnAaNJwPoSv8AI0AesyrnnHr+FU5l46jn/PrWjKvJHqT/AJ/z61UkXOeTk8/p6UAZN7lI2KLliQqqeMkkKP1x+te/eDPD0PhrQobGIh5j+8uJe8sp+839B6AAV4PcxllOxtjjDBsA7SOR/LvXsfw/8Zf8JJHJZ30Ig1S3jDybP9XKucb07jnqD0yOT1oA0PiJpzat4H1uzjZkme1cxOpwyOBuVgexBAIPtXj9v8L7aWXwlLqOoXWpaXflo/stxIXjBeBpQ656cIQf978a+gZI1liaOQZVwVI9Qa8G1nU/FD3EfgnS9NmGp6RcRNBqaLmKKMHKSZPH+rJUqeTyO9AGm3h/+x1n8L2REU2nOL/R2YnBj3H5T3Iyzxt7P9DWtJdNqmhWWtaUj/bLZheQRHAYuuVkhPuRvQ9s4PauF1C31m38Qalq3jDXYhqHh2wF3p5XbCJ1YnzUdeAQyoF4HBIPUV3ehMtpreraduASR11G2ycZSUAPj2Dr+bUAekadeQahYW17aOJLe4jWWNh/ErDIP5GrNcd4Cn+yXOqaGxwlvJ9qth/0xlJYqPXa+8ewIFdjQBW1O7Sw0+4u5BlYYy+3ON2BwB7npXk/ipn83TdKdtxs4jeXLdN1zMSecdwC5I/21NeieKis406wbG26uV8wN0MaDe2T2+7XlvnvqU91qUgIe9mabB5IU8Ip+iBB+FAFJojjp19P8/5zTGj4Of8AP+eKvlMZ4HB7UwoO38qAKDR+lQzlYoWllIVEG5ic8Af5FaTRA8Dv/hV3w1Y/ariDU5YPtEAl2adbMcC8nH8Z9IkxnPqM84AIBq+D9BmhVrWQNFquoRh709GtLTJxED2d+c9xknggGvULeKOCGOKFFjijUIiqMBVAwAB6VS0TTRptswkk867mcy3E5GDK56nHYDoB2AFaNABRRRQAVyvjvxJFolg8SSlbqRc7lGWjUnGQO7E8KO59gSLPi/xLbeH7J2Zo2uiu5EYnCjONzY5xkjgcseACTXj1yravLLq+uTTppvmkJgfvruQjBSMf3sDBI4RflHO40AVrO3jnWTXNfRv7ORhFHbIctdOM7LeM9wOS79yW9SRPoWnX3ivXzf3qRzSyyYjiwfKdkIwo/wCmEXG7+82F6kimQwXfiXVYleNo4IibWG3tMbYhjP2eEngvjl5Dwo5P8IPsOjaSnh3S8hYvtbqqHylISNB92NO+xcnrySSTyaAK+q2WnaTp0MNwXnkDGTcf9ZNIT8zsR6n6eg6CsZNVnupo4VlWBc4Gw7QuavanNFeA22wtc5zuIzg9awVspI5ORz0+lAHcQmSFkSaQyITt3MOaj1TRjNdLKJFUEfN6/UVBFP8AZrKGW9OWJ24JyWP/ANapF1RBAkk773bPKjpigDnfiPp9vbfDbxe43SMNGvNpY9P3D81S/Zb/AOSE+Gf+3r/0qlp/xN1JZfh34sCxMEbSbtQ2e/kOKZ+y5/yQnwz/ANvX/pVLQB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8x/Gnn9qHwl/2BW/8AbuvpyvmT4z/8nReEf+wK3/t3QBe1EdckYBxn2rm9RXl/cHjNdXqK/e44HfvXM368kYOD3oA5XUFGeMe1c7fDrk8DoD2rp9QGQT3ye/8An6fjXO3w+Y8e/NAHNXy7fw454rofg3dfZPiBFGcbbqCSH8cbh/I1hXgwCRwB/hTPC12dO8YaNddNl1GDnsGO0/oxoA+n5Bz/AJ4qpIPTNX5ANxx35qpIv69fz/8ArdaAM+YAD8q7X4O6NNJql1rjNtto43sox3kbcpdvoCgH1z6CuPlBxnGD616V8Hb22/4R+50/zEW7t7uZ3iJwdsjl1YDuCD1HcEdqAPQK4nxPd2/hnxZZazdER2V/F9iuHPQSp88R/FfMGf8AZUV21cv8S9A/4SbwPq2lLGsks0W6JW7upDqPbJXFAHjnxEtfDnxH+J2gWUVzHJN9knidUYHKqVYfjy/5V1F1a6jphhtZwZ9a0GPzIHX/AJf7NvlYf7+Fxj+8oPRjiSz8OadovhzQ/EXhXSxMbWYTyxQRATNGY3R1CjkspbJXr8rYycA874p+LmhXGuaDdWshZoJ2hnKgkrC4w+R22kKx9AD60Ad1DqEEXiDw7rMEgazvs2bSDoyyrviz7bl/MivRiQASeAOteQSWAng8QeHYX2ll/tDTm67CzbwR7JMob/geKhu/Hvh/xfdeHNP1LUvs2m3Vl9qvYg7IrTlVK28kgwOjM20HnAzx1AOx8d3RRbyRAJEt9OkHB+48zLGpH4b/AMq5FIBEix9dgC/l/wDqrN8PQ2K6Rqn9kTSSabc66ILQPIXTyIEDOFJP3d5lwOnpW8yY78+/FAFFk4P0+mKa0W44x1P+f8/4VdKf7NQx2i6lcTW8s32fT7ZPM1C5HHlpjIRT/fbP4DnqVyAVrOwj1NHubsvFoiOEdk+/eueBBCO+TwSPoO5Hpnh/SXt5Df3yRrevGIo4kxstYR0iTHHYZI6kegFQeHNMLtFqF1bC2WJPLsLMrgWsWMZI7Ow6+g49c9JQAUUVn6vrFnpMIe8l2s2dkSjc8mOu1R+p6DqSBzQBfYgAk9BXEeK/HNvYQtHpzrJIwYCcDcuRwfLH8ZHOTkIuDubjaeX8QeK9Q11vLtF8iwLbVUZYSnPAwOZCfQfL/vjmsWRY9NucOgvdacrGIZF81IDxtDhf9ZIOCIlG1ep9SARSxmaVdR8QedM0xMtvYLJ+9uP+mjMfuoM43kDrhAARlbOyvvEl/DIy7gymKFbYeWvlg4MduOiRjjdKe5AG5uBraL4YvdZu5mu83E7t/pAmfeisP+e7rw7DtCh2rn5j6+q6Lo9vpUDCHdJPJjzZ3+/JgYA9lHZRgDsKAKfhbw7DolshIia62eXujXCRJnOyMdlzySeWPJJ7W9ZUsEAxxzgnArUqtfRF4Sy53LyABkmgDjrC2vEv5ZpoivUA/X0rX+yRlxNMi+bn9agtL9p70xLA+0fekYYx7Vfa1juLuCaaSVViO4KCQCe2cUAZfiL/AJYRntlgCO9Z/wBmkWzbKnfn5RnkCpfGUjnU48ZKbAVx3zVbS7i6lukikDFDn74+6PUUAZPjpWPwu8VDYTjSbzcR7Qtz/KpP2W/+SE+Gf+3r/wBKpav/ABNAj+GfixRwf7IvM/XyHzVD9lz/AJIT4Z/7ev8A0qloA9VooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+ZvjL/ydJ4R/wCwK3/t3X0zXzP8YQT+1N4QxnP9it0/7e6ANfUFHzcDp0/z9K5q/Tjn8f8AP+etdVqA/u9D0/WuZ1BcKRg8cYxQBy2oDIJOCK5u+U5HHP8AL1rqdRXO7OBkHt7VzeoL146ZwOvegDmr1eTnnkdvesG73JhlJ3ocqR1BHeujvk5fA4I61gXozu4zn/OP8+lAH1XpN0NQ0ixvIzxPCkox7qDT5AOvbg8c8f5Pb3rmPhFefbvh/phJ3NBut2PUZVuP/HStdVJkdc5HJ59v8/nQBRkAyR07cfzrPuYI3dWaNd6H5Xxhl69D1HStSYHGev61UmXg8cHj+dAHqXwcuJZvCciTyyytFdyqGlkLkDOQMkk4GcV3VfPeieI9W8Om4XSp4RDO+94p4t43AAZBBBHAGetXZPib4oSQMG09h/cNswz+O7P6UAanxL1/Uvhu11PbWbz6Jqc+6F4usNy4w0ZHoxG4HpnP45HgHwnc2OtfbvGllaPLr0zOs68+VKVyIXz1BVeCO4I9K9LsvsvxG+HSrqtqIodShKvGrZ8t1YgMp9mUMD2wK4DxD48nksn8F3Ol3s3i8ABYrdMYdCClyrHgJlQwOfY55oAi8btN4DivJbZ41fTLaWfTRMcJcWzD57bPXdG+1l/2T7VF8HX8Oab8KVtfEklkb2MSf2hFcKu6NxwUYHuoUDnuO9cn8WfEfibUE03SPEOhtY3cbpdyEr5sOYsMXVhwUB25zg4JrsfGHgnwnJ8PbjUFEUmsSxq0eoFt073DEBHLdS28igC54WtVt/C/hG1jJaJbCXUFJJJTzXGwc9gjkD2Wtxo8KcA4x/hUrRBdXvljGFtYreyA7Yjj3fzlI/CmX00dnbtLIGbB2qiDLyMeFVe+ScAUAU7hbiaeKz05Fe/uSRGP4UAxmRv9lc/jkDqRXReGdJtpxClszPo9lKXWQ9b65z80zHuqnp2J56KtU9K0i4Z5bB3UahdKr6pcRn/j2h6pbIfUjOT6Et3UV3kESQQxxRKEjRQqqOgA4AoAfijNIzBFLOQqqMkk4AFed+JPFlzqk7ab4e3LEQDLd5K5U9weoU9iOT2wPmoA2PFfjGHTWNnYYnvSxQkDcEOMkAD7zcjjgDOWKjrwUkF1qN2Wvw91eTjd9m3ZDAHO6Vum0enCDsCeakSC20y3uHM8cXkqBdX04+SAddoA7kn5Y15JOTk8mC003UfE072UdtPb6WxDSW0jbJ7roQ1245iTBysK/NjrjNAFf7bJNK8OhTK8pPkzasQ3lxk/8srcAFiT6qCxHIwPmrsvCngkwxq8yy2cTDDMSBcyg8lcrxEpzyqkse7Gum8OeGrPRkjZVWW5RNiyeWEWNe6xqOEBPJxye5Nb2KAIbW2htLaO3tYkhgjXakaLhVHoBUwoooAKQkAEnoKWq15MFRlyASO9AGXqNykqnyQBGOp9f/rVTe+Nvp4nVVkG7BOfzpbqz82IqzkLnOB7c4qtd2iQ2EsO4+VktnGfx/SgCA6sbx1AhBZc7SD/AEqzpxe5mdz8iqACQOp9KxPDRabWbdEU4Vstx2ru7iFFJKMB3Iz0oA4f4o7YPhx4uDSEtJpN5gE/9MH4H5VR/Zc/5IT4Z/7ev/SqWn/FfRZrjwL4tvHmBSPSrtwPTEL8Uz9lv/khPhn/ALev/SqWgD1WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5j+NE/2f8Aal8GtxhtJEZz2DNdKT+tfTlfLXx8iab9pDw0qNtZdBeQH/d+1t/SgDr9RB5+9n9fyrmL9QN3AwDnp1/z/SuqvGE8IlAIEqiQA8cEZrm79Mk8cEc/l/8AWoA5XUEOMcAkd/WuB08XV5Z3N1dvLKtu5jcB9vI4JwMenevQ79TjP1NclpIWHxFq+mttWO6QSp2yWHP60AWtETTLqUQppkd5OT9wJvP4kngfWuzb4dadqum3El1Y2sFz5L/Z4rPKhZNp2l2/iwccAAfWsjwSI7eARRxrEY2KsqgDkdz/ADr1HSXO1c9ffjmgDyf9nu+36Vq+ns2DBMsyD2YYP6qK9WcHPb2A5rx3wCDoPxr1zSPuR3BmRF9BuEkY/IivZGGQelAFOReP65x2/wA/rVSVRz7HGcf5xV+Qc55yOf6/4/nVSUf4GgDNnHGf/r4rOuIpZGWO2jaSeZljiQdXdjtA/Mj9a15l75x/+o/5/Ctf4cQ2snj3TxfEKUSR4FI4eYLwM+oQyMPp7UAez+GtKTQ9BsNMiIK20KxlgMbm/ibHucn8ayPFnhqXUdS0/WtIkgg1qwDRxvMpMcsTfejcjkDIBBHQ9ua6S6uIbS2luLqVIYIlLvI7BVVRyST2FSd+e9AHk/jnRdVuLT+0vEU1rbm4aPS2+yMxFtayuPNbewB3OQqHAGAfeszUPh7oWi+MvB66SirC0rNNA8zFFSNTIJAucAhgOfQ133xRje58L/2es5toNQuIrO4nUcpE7YbB7Z4XP+1XmmneFYPD3i7X7a0u7m+KWNtYW73crSNE07OHRGJOP3ceT74oA7TSG83Tvtk2I/tLSXjbzjYHYvyfYHGf9mm2JmuJ7a/iiD3lxuXSYJAcIuMPdyDsMHgehx1fhmoyQ3MwtNjy2Fu4haGPreTAZW3X2GMuew49cdroemPaq9zesk2pTgedIowqgZ2xoOyLk4HfJJ5JoAsaPp0Wm2SwRs8jkl5ZX+9K5+8ze5P+FXCcZ6YFLzXn/jDxKLwvp+nOht+RLIWIEgBwRkc+WDwxHLH5F5yVAIPFOtza9c/2bphH2Pq0hGVkXOC79jHwcL/GRz8gO7LeW3s7IBHeK0JY+aCPNunz8xUnjGTlpTwOAM8Cs7U9Qj0qRNOSD7XqdxiQWj8FweBJc7fuIeixD5mAxjGa7fwl4Xl3pqniL9/qDYZY2UAJjoSBkZHZRwg6ZJLEAzND8MXOsTW95fqbOxi+a2hXIKA90B+6x7ytlzk42ZzXoNjZ29jbJb2kKxQp0VRx6k+5J5z3qxRQAUUUUAFBOBmio5ZFQfMev50AYHiHxDJp2xYI0ZmBJ3n7o+lYup+IjJYpKke2eQkBeoBBGTVu5s7OFprq8jldeoV256//AFv1qW3utK1CCJVhSJouFjJGRQBzVtdX1sxlkmZjJ82HP64q7HqlzcRmOQgJxgAe9bd0LaSBnuIcoq8bT82KZplhpkkbXKO7RLz5bdvrQBQsJ00q1a6KfPIQkeOuO5H0zUGuNO8sRLS7SDxnofr681TS6l1XWUd03DOVUDhQO38q3tWkihMEcsbbZG6qBxQBzXj6/kHwt8UJuznSLtH3d8wOOKX9lz/khXhn/t6/9Kpak+LlpHB8MPEpg+UjTbkHJ6jymqP9lv8A5IT4Z/7ev/SqWgD1WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5q+Liq37VXg9XGVOiuGHqMXdfStfNXxc/5Oq8Hf8AYFb+V3QBsWIYaRHHIcyw7oXJ/vISp/lWVqC/N/npW4q+VqGo2/IBlWdB7OvJ/Fw9ZGoL8vHTNAHK368N69Mk15/4nd7HXtOvouCQYzj2II/nXo2oLjdj+VcF45h36aJRjMUqt07Z2kf+PUAdHp91HFfQXqMBa3mAxHRH9/rXp+jN8q5wOn+FeJeHrr/Q2SYGS1kGZBwdp/vCvRvCGrCCZNOvpP3hAFvOTxMvYZ/vfzoA4z4mZ0H406HrAO2O48l2btnJjf8AIFa9nfAPB+XnHpXlf7SWn+boui6kgO+GZ4Cw6qGGR09xXofhq/8A7W8N6ZfgZNxbI5HoSOR+eaALMg9eg71VlXj9KvOO+ce9VZV6jnPv+P8An8aAKEynHA59Kn8Lxs3jDQkjyGN4pXB6AAsf/HVYUyYcHNbnw1tPtPjq1cjK2sEtwSOzHCL+jv8AlQB2vxFuhci10QDck3+kXQ7eUrDap/3nx+Ckd6tfD/UnksZNKunLXNhhUZuskB+434YKn3X3qp8RrK1E2k3ohjF6bryjMB8xj8qQ7c+mcH64qf4daVappg1n7Mi39+XZpiPmaLcdgz/d2gEfWgDD+I/9n6n4hXRfFGtHTtEfT2u1hS5EHnOjgsWI+Y7QAQBx36iuH8JznQdAjbUb2WCWON9Uvby8be1qsuFjL56usIUBD/HIOMZpmtCDxD4g12fV9Etp9Ns9aR4pJWzcXdyo8qOyXK4VdyeYxBICPz3qG0uY9Vmjxqlm6DUQ1xclxlrghvMuJIXQq0KrlIgTgDDc8UAevfD62tLvSrbV4FYRujRWsT9beMMQwJ7yMwJZucnoSBk9czBFLMQqgZJPAHvXm1j8QdC0j+ztC0XT7+9tooNtvJbNE6CFDs8xiXG1cqcM2MgEjjmqmr6/d+IYQ29INLc7UbaZI3IPRFxuun9gBEO+8jkA0vF/iw3sqaRoayXUtyDtWJtrXCjqQ38EIwd0nGcbUyTleQa5ktSINJkju9VbaHvI0zDA2CFWBB95sAqp6AZ2jrVbV9WstKtZYlLA3TfvFLedNckDrMw+/gf8sk/doPvHHFbHwylhlvtC1CDU7S/uNQEu+yh2yLZxbGPmbsBt+QqsxwDu2gAAAAHXeBPBUOhqt9er5mpyEuxdt5Vj1Zm/icjgnnA4HHJ7aiigAooooAKr3MxRgiEbjU5OBwK4OfV722v5ZXXzEZj8p6DnsaAOua5kB4bj6dayo1mm1Ka6lf8Ad8rGp9M+n51Y02U38auE2hgDg9gayNQ1c2eoNAU4Xqen+etAFfxPetkWqqVTG5jj73/1q5xEkaVFjDFycADrXZFoLvYZYyG5ILHPXnpRBFDHcqsapv5+6MGgBLWynisUWdxISPmAOQPb3q3Y2sdtC0WBiQncOx7YqQvhxCWAfHCk9RWff3s9vdQxQ2zSM/f0/wA/0oAzrZYtD1S4WeNmjbmNx12mugs7iG+jEkQyoPII5BqeWG3ktCtzCJe4XjgfyqnNDFbafKlmDEDk5zlvzoAxfijHHL8M/F+ShKaPeMATzkQPjisj9lv/AJIT4Z/7ev8A0qlrnfiPclfBXiPyJG50q6VyTnOYWBHv1rov2XP+SE+Gf+3r/wBKpaAPVaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvmr4uf8nVeD/+wK38ruvpWvmv4t8/tV+DuM/8SVv/AG7oA6LUl8rWbd8DFxA0ZPXLKdyj64aQ/hWVqK/e+v8AX/61bPiIeXb21xx+4uEYn0VvlYn/AICxrL1FeXB46/yoA5W/XJx2PeuR8QW/2jT7iHjLqyj2JFdnqI/XP+f1rmr9ckgdv/1UAcr4MuMxxn24B6V3p0aSS2b7HE1xbY3NbD76f7Sev0/KvPPDYFtqs8DcbJWAyex5/Hg17r4VFvH5TtcRLnuXFAHnni2+vtY8C3mjyob8ApJBNnEsbKfuyDv3GetdD8EbiSfwQllOpW4sppIWR/vbSd4P0+YjPtXovijw1omrwC6a4htL/H/H1FIqEntuzww+teQ+HNP1nWZZXt9OkW7gUt5ltKI3ODjIyRn6UAeti2+Qk56Vn3KgH6+lcc/iLxFpY8m8uJ1A6Lf2uG/76wKibxdfOOV0og99zj+tAHUyAdh09/er3w48S2ujeLNTj1DCW8yRwCbBwpXLE5zyMsc8ZAweRu28ZZeJZrh5RNBDMwI2LbRzyfgSkb49s4/Gr3hyXULi3MljoN5emeRpPNMIVGOf+mjxkYwPpjNAHrXjkNrur6RZWcoWx8uSW5vg4EcSNtHytnBkI3YHbOegq5qviO2jsIrXRpFtrLaIku0TqBwEt0P+sbA+991cck4Irz+y8MeM7t1+zWmmaXFn7s8yzD8ECEj1z5mferL+BY/tk9zrviK81O+Zdsy2WE2rx8skzliie2RnsCRQBj+P3mRLMraS3UKK0EdtaTsTCJFfzCJFDZlcKUMmMAuwB6samitrV1Cbia6aCC2nikubqZ0VJgkYG2cvuRcN0JLvgLhB1rX1PV9EsNMFhpenRX1hbKyKNjSW6FmBK72+e4ZmYHau1ORllrOu9K1nxHHZvHFL51vfiA6etoG8iFTy8e7ECcYI474yTmgCK1bRrGGO20+2trlHYbPMXybR3HdYj89ww9Wz1yqEcVLcXWuX/hu98RwWlzNaLGf9OuQgXZnBKQhgxVRk4YAHHCCuq0HwHqEuseILuS1077LdpHbW7apYq8yxqvOAGwFBJxnqeemK6/R/h7oem6Tb6aYri5s4QMQzzs0eRznbnHJ5x0oA8U1fxhp/gHxGl14du38Q6jeacqbbi13SMAS+6PbtCoFZyQBg4AHOSJtG8RHQtQ0tJ9UFv4e1GBRp2sWESRBpyxYpc8EEnOFzx8uDzk118XgeHxHFr2tgKfEH26WS1lbkxNE+2OP6BVCY9K860sWFprL+HNVgD+FPFIaS0jccW13n95Bn+EluR6N06mgD3/wrrt0982ja4yNqCxmWC5RNi3UYIDHb2dSRuA45BHXA6yvnjwhq95Cl74eupTP4k8JzLcWkjnDXdsB8pP8AvRs0bH3B64r3/T7yG/sba8tX329xGssbYxlWAIP5GgCxRRSMcAk9KAA4xkmsYpZ+azBlcnnB6VU1rW7aGUwyOd3dFGT+NVYryzmAMUgJYcUAaEWsRCUxRhUUcBugNRX9ja386zTwhpB3z1qtPZRSZMZ2OecdvpS6M8yzPDIDgDPPY5oAytXMtreIiArH0XjrW5p0MCIHVT5uPmJOalv7cTtGpXep6NjO047ntzUOlwXSXMqzquzOIyp9/SgCtcQyX2rK0DMoixubsMVV1DVpINWCKxaKJsFegPFdY8MdtaylFGW+ZiO5rkE0yG6vnYyFvmLsooA6KX99EoRypI61npZzoArvuBGOetVptctoNR+wp8u35d38PTgVJZX4S+lSZ28tjwW6A0Aee/FLT/sPg7xMoB2nTLkpn08pq3P2W/8AkhPhn/t6/wDSqWpfjPx8NvEbGPcDp1yAf7v7pqi/Zc/5IT4Z/wC3r/0qloA9VooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+avi5z+1X4Oz0/sVv/buvpWvmv4t/8nV+Dv8AsCt/7d0Adlq9v9r0u7g2nMkTcDrnBxj8a555ftVnbzkgmVAzY6biOf1zXWZI5/GuRhi8iK4tfu/Zp3jUHrtzlSfqDmgDBv1yrcAY4x6VgXsZ3ElTjvxxXUXYAYluQPfNUv8ARjxIFHbkUAYFnolpfSFmhjMzckkZLf59a9L8C+GmikVHhUoDwcYFYOmpYLMp3gHPJJFex+DGtpIF2YyMfWgC83hq2uLEQugK/hUFl4attKlje3RUGCGwMcH0rrV6cEcelZWv3KQWjM52gc5FAGBqEVvbFgzc9x/LiuS1P7JIzYtrZn7FolJ/lXTatALlPNjfcGAYYPqK5K7hMTc9OmDQBnOqhgEQKueirjr1/pXW+C5oItBsY443uLlUJaKIDKfMfvnoo+pyecA1zMVvDLHcXN9MbfS7QgXEqDLuxxiKMd3Jx9M+vTovBksGu3s1hf2y2VnEBNaaZE2EdO5lI/1j5xnnHzfxUAa63V9q8jw2YWdM7T5DlLaPsQ83WQ/7KAdOStZeu2Ahnt9Jib7dqDkHykUJDBnnaifdDHk723FQN33tufQLyeHStKnuWXbBaws+1FwAqjOAB9Olc74C06Qi61a/w15cSOuf7uDh8fVgR/uqtAGhoXhaxsLF4rqCC6mnULNvTcmM52KGzhQeecknkknmtu2tobWBYbaKOGFc7Y41CqMnPAHvU3SjNAAKDSBs0tAHkPik+JfC3jMWvhuK1ubLXZJLmNZpCgt5QFMu44OQSd4xzkkdBXIeNvBV7HF/ZniCcyrrsrXEN/BGVjsNQGCgB6qr54yeWBH8Ve1eNtIutRsLe60ryzqunzC6tVkOFkOCrRk9gyllz2JB7V4x8TPiheav4T1fTdK8OarLeW4Md2rQkfZWUjOT6jGcrnp1oAwS+q3y6f44s4G/4Szw27adrtgnW7iX7+PUlTuHr+Ar2T4ceIrCMw6Mk4a0u0N7o85Py3EDfMyA/wB9CSCvXGPQ44aHWLLTvEmh+JPMRdK8VWkdvPLkCNLpV3REnp8wLxk+qisbX4f+ED1Oa01m1nufAN9cfaLe7gyJtFuSckgjlV3EkEdM49QQD6Pu7qO1hMku7A7KMk1m2fiCxvpGhRyjkYG4dfYV55N4pvtG0xf7fuItR0iVV+za7DtAwfu+eo4HXiRflPfFXdJxBLFO3PIYY5445z70AT+K9Na3vTOhJWbLfj/nFV/De5r7aVLIAW6Zx/nNdreWUWoW6iUBlQg4zUcFvFawFLeJU9sUAZ1xdQQMTM21h/D39v51Qm8SmJWjgtwWbOCx6ZputHJRdhMhOVOOlW7qysFt4xEiefgAh857dfQ0AU/Dn9oTarFPteSFmw5YkLj2ro7q8dbsw2qgIg+Zm6t9KZpjukQSXbkfdwMYFW2Yhxk4BFAHKxa7qNleuJ8TxZKtGeB+FXdKjtry+nu7QSwt91opPU96t6vbr5kc8Ue5wfmHqPU1QZHN558Y2EoAGXqfrQBU1fw5Ibky238R3bG7d+KoO09hKsM8an+IENkfp+NdPod1eyyz294jOi/dlIxz6e9UNetbi91COKGPdwRz0HPUmgDJ+Ieow3/wx8WoqhXXSLslSM9IX71F+y3/AMkJ8M/9vX/pVLVHxpbfZfAXjFJyvnDRrwADn/lg+f0q9+y5/wAkJ8M/9vX/AKVS0Aeq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfNXxb/AOTq/B3/AGBW/ld19K181fFw4/ar8HE/9AVv/bugDvv5/Tqea5vUo/K1u5UD5biGOYf7TKdh49gI/wA66TnpyOexrD8Rx7Z9OuABxI0DEdArjj/x9YxQBzeoKTnPQ+/Fc3fFsZB7etdTqC8g4/SuX1OaK2AaeZIwTxvbGfYZ6/hQA3SLOWa6Ul9q5FeoaF4it9GjihEgLEAnkD8K8ck8RrFEfsaSScZ3Y2rj6nGKp6Tqk11qAllmhVQeQHLn/wAdBFAH1FH4ythGokIBYZrnfGHiu0vbZ4BKoYj5cn+fpXi99rMj30YE8+0fwpFn+ZrJ8Tzea6S/bbiFh1LRZ9+oNAHtvhjUpbjw5asXLGIGE++0kD9MGn3css2I7cFppHEca+rMcCuB+Dl9dGy1axupFlSN450lXod4IOff5Afxr0rRfl1mGYKD9ljmuApHBKocfkSD+tAGZqxja+FlbHNlpbGCLHHmT/8ALWX6knaPbPqaqJJLbzxzW0jRTRNujdOqnnn+fH1o05T/AGdbkZJdBIT7t8x/U0SLnpz/AF/z/SgDoZ/H1zc6TdWOp6f5qzwtE09rIFYAgjOxu/PrUnhn4mWVnpKwanpWpwTxu/yxRrIpBOcg56ckc+lcfKMk1SlX16elAHoWo/FyBEb+z9Fu5WIO03DrEM+4GTivNPFHjDxBr0jG61CW3h/htrORoY19iykM31Jx7VDcIcehA5/z/Wsy5UYYcEAk44oAPEelTaRpeh6rYaldSW2pQsfMVmjMUy53R5U89/8Avg+tM0D4m+KvDU6tHqEmoWuRvtr9zKD6gOcsD+JHtW86m8+Eeoo+fM07VI5o2/uq4AZR+O4/8CrzS7jxuA7etAH1j8OviDpHji0c2LNb6hEMz2UpG9P9of3l/wBoe2cUzWvs3hDXbnXpoiNI1AAXzomfs8wGFlOP4GA2t2BCnuTXyBbX17o+pW+o6ZcNbX1u++OVOqnrj3B6Ed84719i/DXxXb+PvBUN+0aJM4a3vIFPEcoGGH0III9iKAPItL8Kaj4x/wCEil0SO0bwHqLl7bSrrK+ZJ/FLCw/1ILZYcEZ5wOtU9F1rWfB9nJZ+J4pNb8IRsbSW6mTfdaaRwY7hOd8eD94Zypz7V216PEvw1s7LR9Egs9R068ufslldTuUa2ypYLIoHzYCkAgjOOcGq76TrvhzxI+s+JtQsbvSNZRbS7AgMKwS4Plu2SRsI+QknutAGZpSw+BbmOz81LvwBq5/0SVn8xLCSTpGx6GB88HseDjNaemz/APCCa/a6PqOZfC1/J5em3UpybCbtbOT1Rv4Cen3ayntovAl1JpGqolz4C1VjHD53zLp0r/8ALJ88eS56Hop9Ks3sK6Gv/CMeKh/aHg7U/wDRrO8mOXt2P3IJj+WyTrkAHnBoA9m0wFMlzhQMZNSOINxwW/DpXm/gzXr3SdQTwd4muDJfKh/snUpel/Cv8LH/AJ7IPvD+IcjPNdDYTXMd7Iryh2z84Y54zigDqY1tySyoBIM8nrXOXFsTq3mkbk68+tasbr5j7XBYcHB6VKnlltoYCQ9s4oA5TxDqc1rcRxQjbxktjAA5/wAOaqXep39xCn7wpgZIUYJ+tbmo2r3ig3EPktEx2jGdw7H9KpwWX7xfOYKg6kHOBQBb06Se5sT5p2yDgn3x1qvFcyi6a3EDSIgAD/41o3clvYWAkQgRgZBBzn3zVfTbyK7UvFnOeeMEe+e9AGpE3IXn2HesHxReXGl61HIgP2dlBIxgH15/Cuhc+RbPOcKVXIHv2/DNZ6SSapCY70RuDkodvKmgDlPiAkd18OPF99wWOj3mFxjH7hxTf2W/+SE+Gf8At6/9KpatfEPSVh+G3jCQ3Gdmj3pCJx/ywfg1V/Zc/wCSE+Gf+3r/ANKpaAPVaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvmv4t/8nWeDv8AsDN/7d19KV81/Fv/AJOr8Hf9gVv5XdAHe9uo59ef/wBdZ3iGCS50e4WBS06gSxKTyXUhl/UCtEEZ659cHrQvGD365wO1AHhvijxdJcTPHphMNqHKLKFBlkOcfKDwo4PXP4VyflTzSGWdtjN1OfMkP1Zs/wBfwr2/WPh/oWo3JuPKmtLgsWLW0m0bj1+Ugr39KyH+GFuW+TVZ9v8AtxKT+JBH8qAPKxaw7gZF8xh/FIdx/DPSrlvMYfu5XjtivTYfhjYg5n1O9fHP7tUQfqrfzrTtPAHh+3IMlrJcnv58rMG7crnb+lAHj3ntNc7Iw0k2cbI1LsD9BzXW6P4J1fVNj6kDp1p334MxHoq9B9T+teq2VlaafGI7C2gtlAwBEgXH5VKwOTjOT6j/AD7UAZmjaRY6JYLZaZAIYF6jksx/vMTyTx1Na+iKX1mOH+K6hmtgTxyyE/Tqo/OoCPTP59aq3XnoiTWZxdQOs0OO7KQQPcHBGKAKOnEHTbYY+7GEII/u/L+XFPkH48/n/nmrV6I/tf2u0Df2dqeby2PZWP8ArIj6Mpzx6H64gkU9uc0AUZVPb5uB0qpMvPt/TvV+Qc+5/wA/nVOVePpzQBmzLkdsGs24Xv8An/n862J05OBzVB4ZJpo4bdPMnlYRxIOrM3Qfn37UAX+bX4VaoWxvvdThgRem4IAxI/M/lXnV2nXnjpzXofjt47b+z/Dls6yQaNG3nuvR7pxmQ/hk/wDfWO1cNeR5zx7UAc1dxnn+deg/s3+J/wCwvHh0q4k22WsL5WCeFnUZjP4jK+5K+lcReJkZ/l6j/P8AnvjvPNp97Be2jMtxbSLNGw6qykMP1FAH3lr+k2+taXNY3RZVfDLIhw8bqQVdT2IIBH0rybxxoOva94k0HQPFN1bTaMySOr2+VW7kQjmSM9GCnIGSOpHt6z4c1WLXNA07VLcqYruBJhtOQNwyR+B4/Cm+IdGt9bsPs9w8kTo4lhuITiSCQdHQ4OCPyIJByCRQB5pd+GLTwfaTaZfO1z4O1FTGY7o70sXPVCe0Tds/dbvgisLTY18MK3hXxSRfeEr9fL0y/uCGRVb/AJdZn7HH3HPXp1ArS+J9z4yttI/sy9toDptzItvPrNuRsjiY4LPGTlDjjuoJBz2q1aeDG8HeHFttOgk1jw5LCRPYzSiR4+M7ow/DKe6ZznBHcUAcp4kkuPCln/ZnjO2udc8GMytb6tHk3WnkH5PNI+b5eqyLz65q5pt9PYWKXy6kNa0CXmPWICGZAf4bhV6EcfOBj1ArB0HU47z5/htrzNASyHQNbR/IlAPzJC7fMnpgEjjpxVPTLWzj8Qzv4RuZPBfi0/8AHzod+M2d51zgfdZT2ZPyBoA9f0C1vrkLdQTKkTAEOeQ4I7diMHr0rpEt3kJDMcnq1eYeFfEN5Z6g2nW9kuk6wMvNoF1JiC57s9pL0GeTgceoGdw9H8PeKNN1qSS1gaS21OIfvrC6Xy54/fb/ABL/ALS5HvQBNL4m0xiYJVlkCfKZAuRkU+3itLoebBMJYu6gcj6+9Z9/oEMsjSQMI9xJYEZBqSFIdEsG2HfM/Jz3P9BQAmt2s19EsVvHld+SAcADH/16m0SKOyje3GxmBy8g7nFUNa1SWbSoXtFMRdispB7j0PpSaPqkCIi3TkSDgsR1P9P0oA2tSkLxNEg3M/BPbFR6XaSQwsJHzzkL6VVl1GBwphcFCOAOfpmtDzXht1O0A4zz270Aef8Axgt5rXwZ4lmSQiOTSrpDg8f6luKt/suf8kJ8M/8Ab1/6VS1c+Js8N38MfFhLKSNIuyBn/pi5Bqn+y5/yQnwz/wBvX/pVLQB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV81fFz/k6vwd0/5Ardf+3uvpWvmv4t/wDJ1fg7/sCt/wC3dAHe9eOp9P8AP9aOw6c0dR/n1/z1o7f4j/PSgBCOMZxjijOepJ+lL7d8HFN47EdMdKAFIyB2XtTfpTieck5amkc9qAE5zgE/X0phUen0BFPP1Ix1puBjgcY44oAjP/16jbjnnrnn8f8A69TEfl9cVGRx+P8An/P+SAVEkWzW4guY5ZtKuX8yZYuZLeQD/XRgf+PDv1HOQyXtvJaW8dw8kd1YS/6m+g+aKT64+43sfwqdwMen+c1WhNxYTyTaXdPZySE+aqgNHLn+/Gcqfr1680AVnAK7hgqe/Y8//W/Wqsq8nGfQ+taz3tvI5a+0CyMrHLTWNy1uze2wgj/x6o3vNJXlPD1xMR1S71A7T7cBqAMJIZbu6W2soZLm5Y4WKIbm/HsPqcVflmj8KmWO1eG58UMpRpF+aLTVYc89GlPp2+nV95reoy2rW1v9n0uzYYaDTo9hcejSH5j+GK58wpEgjjUKoJ4Hr6+vNAGPLEFUgsTnJLMcknqST3JyT+NZlymc+p65rcuF6/1NZd0gw3oef8/57UAc7dp8vr6f5/z0rDvIs5xjI710t4mCx/H61i3kfB4JHQcUAfTX7M2qnUPhnFaO2ZNOuJLbH91c7lH5MK9Zr57/AGTrkqPE9iD8oeC4/Fgy/wDslfQlADZUWWNkkVXRgVZWGQQeoIrzXxv4G8Qy+G7/AE3wVrkdjBNGwjtLpGYRE9VilByi9eCGx2wK9MoNAHmHw+0bQLnwaNGvbGFJLPEVzaSgCSCUfTkHuGHXqDXm3jVdPvfEjeFNTsrzxBp8cJuY76BC9zYYPVmXkj0Yc8chute7+JfCWl+IGWW7SaC9Vdi3dpKYZlHpuXqPY5FeU+C9NuPg74g1v/hK7h77RtSdZrfXZByrAEeVP/cOOh6HnucAA4G6utS8O6fFB4j3eLPBZIa31GP5rux9GJHJx6g5Ht0rrDqVpfaTb3d6T4k0JPmt9TtCTe2eP7xXDNj+8uGHdT1p+nabfeJfEGu+LvCbn+wZgn/EqCAi9KjDyqP4GI6D+Ig564rmzY6XoeuyXXhXUotN1CVszafI2yOc+jwtgqfcYINAHp3h/WtSisI7mwv4vFGjsMxymRVulHpv4SQjnhtrDuSa0LC/XxLfSG1fy1t+JbeVSk0XGfmQ8884PT3ry62ntH1J7rRLv/hHvELDdcWsmPKuD6shwsg/21w3uDT9f8QWk5gbxbb32ganbcQazpjsyRnP94DcoPPyuu33NAHuVrCDI0QRfKA+7j34rO8URWkdso2xidjnIUZx61x/hrxzqkFors9j4r08dLzTnSO5A/2os7H+oKn2NaV94j8N65KkiaxHYXQwpt9QRraTI/2XAoAs6XBKwyiE4IOB2rpL28RlS2mRleXA4PviszQGmFyLdDHNA4LbonDD2OQa2bnSo5bqOaQOChBA6A4oA4D4i6bc2vgHxWMhoBpN2Q27/pi9Xv2XP+SE+Gf+3r/0qlq/8VYnk+HXi08bV0e8bj/ri5qh+y3/AMkJ8M/9vX/pVLQB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV5b+08M/A7xIDyM2v/pVDX5+0AfqpRX5a6dY3Go3sVraRmSaQ4UD+f0r2jw14H0/T7FYrqC2u7huZJZYlcA+i5HA/nWc6ihubUaLquyPuKivjY+F9HjGTpenlc4JNsn+FC6F4dUAy6Vp5B9LdB/So9urXsdKwEn1PsmivjVtJ8MAARaRYOT2+zL/AIUyPwtp87kxaDaBe2bdMfyrKWMhHdG0cqqS2Z9m0V8iweFLFQu7w9pTf71qn+FbUHhLTGQbvC+iEAdRZx5/lUf2hDsX/Y9T+ZH1BRXzbB4O0XylMnhbSCe/+hxf/E1YXwn4bUbn8K6Tgc/8eMX/AMTR/aEOw/7Gn/Mj6Krx34t/Bm78eeNbHxHp/iufQbq0sls08i1Lvw8jFg4kQjIkIx+vNc2vhvwonLeFtHx76fEf/Zanj8LeEJCAPD2iKfewiH/stWsbBkvKKi+0iof2e/FJH/JW9bx/1wl/+SKP+GevFPH/ABdvW/8AvxL/APJFXm8IeFceWvhrQ2BHUWEWf/Qaov4P8M2pT/intGKDhhLZREn8dtX9aiOOTzf2kH/DPfinn/i7et/9+Jf/AJIo/wCGe/FP/RW9b/78S/8AyRWDd+F/DV/eiPT7DRIljYb41soy3/oNX5PBWgSxssWh6UHKna32OIYP/fNH1ldjR5HUW80Xx+z14pHT4t63/wB+Jf8A5Io/4Z68U/8ARW9b/wC/Ev8A8kV5P8QPhzp81s02heVBfwKS0AUKs+OwwMZ/nXiU6MkrK6FHU4ZSMEGuiMuZXPLxOGnh58svvPsX/hnrxT/0VvW/+/Ev/wAkUh/Z58UE8/FrWv8AvxL/APJFfG+K+1P21v8Aklmlf9hqL/0RPTOcp/8ADPPij/orWtY/64S//JFJ/wAM8eJ/+is6z/4Dy/8AyRXxwK3/AAh4buvEWoeTAuyBPmlmYcIP6n2pNpK7KhCU3yxV2fVH/DPHif8A6KzrP/gPL/8AJFIf2dvEx6/FjWT/ANu8v/yRXD6f4Z0iC2it4vD9jIqDHmXEKu7epJI5NXf+EV0vGf7E0n6fZI/8K5Prkex6iymb3kjqj+zr4kPX4r6wf+3aX/5IpD+zn4jPX4q6v/4DSf8AyRXNp4S0ng/2LpRH/XnH/hTv+EU0YHJ0TSv/AAEj/wAKX12PY0WSzf2kdB/wzh4hyP8Ai6eq5H/TrJ/8kUh/Zt18jB+KWqH/ALdJP/kisu28KaJtGNC0hj/tWUZ/pV+DwvoPyibwzoxx1KWMX/xNT9fj2K/sSp/Mh5/Zq1w9fifqR/7c5P8A5Ipp/Zm1k9fibqB/7cn/APj9XYfDfhTb83hrRgfewi/+Jq/beE/CVzj/AIp3QUPodPiH/stWsbBkTyWrFXcjAP7MOqt974k3x782L/8Ax+o2/Zb1BvvfEW7P109v/j9dUPBHhSRf+Ra0QfSxi/8Aiaq3ngDw4uGTw9ow/wC3OL/Ch4tdiY5TJuzmkZek/s3+INHeV9I+Keq2DygCRrW1kiLgZwDtuBnGTj6mtL/hRvjf/otHiT/vmf8A+SapS+BPDjAn/hH9KUe1pGP6VWPgPw6rbk0PSyR2a0Qj+VT9dX8pusik/wDl4jW/4Ub43/6LR4k/75n/APkmj/hRvjf/AKLR4k/75n/+Sa5C/wDAukea7R6Ppygn7q2qY/Dis0+GbOCQp/wjmlygetpGDj8qPr0eqN1w3UauqiPQf+FG+N/+i0eJP++Z/wD5JqK6+AvjG7t5Le6+MXiCaCRSjxyRzMrg9QQbjBFeb3WhaaZEP/CP2UJQ9PskeG+vy815t4+8IpYu2o6ZCy2rcywgf6o+o/2f5VrTxUKjscmMySvhaftLqS62PojSf2dvEuj2q22kfFfWLC2U5EVrbyxID9FuAKq6t+zLrGszedq/xM1C/l2hN91ZPK2B0GWnPFfIrjnpXvv7FP8AyVPVf+wLL/6PgrpPFO4vP2XdSvYo47z4jXlxHGQUWWwZwuOmAZ+Ks/8ADNmveSIh8UdU8oDAT7JJtA9MfaK8X/aiYr8cvEuAvW26qD/y6w15T5jei/8AfIoA+sbX9la8tLo3Nr8QbiC4P/LWPTmV/wAxPmtKT9nXxLKhWX4r6w6nqGt5SD/5MV4F8NPAkviADUdRURaahwgMYzMw9OPu+9etQeDPDkJxLp+nydzm3j/wrmqYlQdkrnfQy+daPPexqxfsvalC++L4jXiPnO5bBgf/AEfWtbfALxfajFt8YNfhHpHFMv8AK4rEi8M+FVAzoukHnvaxn+lSJ4c8Il8HRNIJP/TnHx+lQsWrbG/9kz/mRsXfwD8YXltNbXfxh1+e3nRopYpY5mSRCMFWBuMEEEgg1638LfCP/CCeBNM8N/bft/2Lzf8ASPK8rfvleT7u5sY346npXix8F+FmAZNH0rBHa0j/AMKdD4C8O72I0fSiMdDZxH/2Wk8bFdC1k039pH0jRXzyvgHQkBb+wNGce9hF/wDE08eEPDiEl/DGi7cdfsEX/wATU/X49hLJ5vaaPoOivAo/CXhORML4c0Pdjp9gi/8AiasR+CvCzqB/wjWiE45IsIuP/Ha0WLi9kJ5RNbyR7rRXgsngfwosbMnh/Rif+vGLj/x2qEvg3wx827QNGUZ6iyi/+JpvFJdC4ZNOe019zPomivmWfwh4XJIXRtJz1wLOMH+VM/4QnRAuU0XSuOm6xi/+Jqfrkexv/q9U/nX3M+naK+Q9c8F6bPBcQNothbxunE9vbojKfUYGRXg3ijQ7zw/qJtrlEKEkxShBtdfWtaWIjVdlucWOyqrg0pvVd0fprRX5XeY3ov8A3yK+qP2GiWPjYnH/AC49Bj/n4rc8s+qaKKKAPLf2nefgf4j/AN61/wDSqGvgaxtJr27it7dC8shwqj/PAr7/AP2kbeW7+DeuW1um+aaWzjRfVjdwgD8zXz14P8DWnh22zqAWTUG/1r5+Uf7I9v51nUqKCudOGw7rS8iDwbZ2vhnSZLTS7b7TqVzF5d5cmMOWzzsQ/wAKj1710trb3ZtZI2sUE0u3ErucxAHnAHXNaEVzawnEQUKvHyLVhLuaUZiQDtlutcEqzb5lue5Rw8KS91FCDQJpJf311IFBztFa1voVnGxkkRXkY5y3NRbroA75Mf7ozSRI7tgvIB78Vlru2dkdtjVS2sLcABYix9gKuwz2WAHKLtrPgtYyuCqhvfmp47XIGIgW9QtZu1zRF5LyzGQGXjkccVet9SsycsyZx1rPjtQI/miAb6UqW0T5DIoYDPSo59R8tzbiu7WZ8IyHHvVoLAw421zccEZJGzcw4+XjipEtdoBjklHqAelLn7i9l2Zvm3hYY2rTZNHWRATECO1Youbm3PykMM/xDk1aj8QXCgb4iAewNNTp9US6VX7DJLrSQg/dNIjfXis25juY0PmqJUxgk1sRalHOcs4BPGCelTkxOCAV571qlF/CxqU4/EcBKYrCVbiKzUyjOTgciq194jtB+8d5IJFHAC5H0NdRqVuFLncGB6DsK4TxBbQMpE6I5PUgYIpqTgdcfesRanrcFxHG3mbQGzlQMg+3rXmXjrw3Dqbzanp06Pd43SIBjzP8G/nXRX9pbbV+yu0Lofut8wb3z2+lZhluIMqyxsvoB1qliJJ6CxGDp14ckzx+UEMQQQR1B7V9oftq/wDJLNK/7DUX/oievmLxZpMU6S3tsnlyqpaRezDufrX1h+1jpT634I0DT43WMza3Hl2/hAt7gk/kDXpU6sZx5kfGYrB1MNV9lLrt5nx/4E8KXfirUpIImW3tIE8y4un+7Ev9WPQD1r6C8O6BZaZpkNtp/wAsCHOR1du7E9zVjwTBZeEYbP8As2zgmihbLpP/AMtSRyze/NbN5qAvrme5aKC38xt3lQjCr6Yrhr1nJ76HpYLDSoz236kUMHzEYHHTNWktOfmKjIqnDIPMPzdTWpBg4Ldulcc5JnuRjYI7REyd2SR0xUf2dlIYYwa17eUJGCAof3FQXEnmO2FQFj95e34VjzjTdzOjjbcxU4Ge1W4sY+fjPf0pFXyx8rgHvUckyKfnYVLqKO5001csLAW5yPL9fWplsHJ3RggClsWWQ4BzjtWnEVGMNyO2eKlTizGpVlB2RSQXUTD5ty+wqU3ZUgTKcH9KvryRlVxUwgR1AIG49q0jJrqc0qy+0ikjo4GMFae0Kryi5z6VZm0qFVLCURMBwmPvVW+zSxt8r7l+vat1Jp6kKpGXwslNlHMgD8HHpVJ9JUknYDjv0qyJJUHLMB71Is7CPAIYnmt4uEl5lKdSGzMmfREf7ykt2BrB1Tw/AyMZ4xs5GwjOR7+tdq7rtTc3PWs3U7mJoyAyMcYx3rXlja5tTrVJaM+Vvib4G/saaTUNKUtpznLxjkwn/wCJ/lXcfsWDHxU1X/sDS/8Ao+Cur8QR5875Ay4+bC5GD1z7VF+zNokOkfGHUHtW/cT6NOVQ/wABE9vkfTmtsPiOb3JbnhZplypXrUvh6rseYftSf8ly8S/W2/8ASWGub8AeEJdfuFuLlSmnRt8xPHmn+6P6mvUfjH4Tm8S/H/xK0m5NPhe282QdWP2WH5B7n9K6vTtNitYooLRBFFGAqxqMBRWlatyaLc48HhPaPnnt+YthaXMix28GUjRcLDCmAqj09qvQaYo+ZiST6mprZjbNu3OGb5flOM5qbzucDBA75rz2z2oqzsVPsEaMWOGWpFskYfJGAfWpzKDH8w/AVasWLAg8kcZrCUuh2RjZXKIs3ToHx/smpU+025ykrdO9bKQljjIqKaMHKgYbFZSk1saxdxtrrF0gAdVceg61s2utWs4CSp5bjj5xjNYcdozYIPbNPMf/AD0XPoDUurIboxnudMsVrdrjau71FOk0qaNf3LkZ7Gudt3nibNuzDFbFnrUqkJdqcetawrQk7SOerQqw1g7+RQuxLaq6SIUiwcjHH1qpoKwywSsrO7ZzmTI49AK67fFdxc4OfxrFvtOMUrC3LITz14ra6TvuiqeIUlyS0ZSaKyhuD54CyOc7sk/QUkEMaLIluX3gnaJWzk/X0qheT3lurrLEJE7EVjSasBLvSV969Uf+lE69KKPQp4aVTZmnrLPGMSAE4+Yg964jxJoVn4k06W1u14+9HKB80beorWub1p5fOMjKT/CxpYpg0gDAhTzkGvHxWMakp0nZo9KOFXsnTqq6Z8yeJNEu9B1OSzvUwwGUYD5XXsRX0l+wx/zO3/bj/wC3Fa2qfDi3+ImnfY1lEE8YLQ3BXPln3x2NSfsk+GtT8JeIfiBo2t25gvLdrEEfwuP9Iwynup7Gvo8tx31ylztWa0Z+b5lhY4Wu4Qd0fSFFFFegeecB8dQW+Gt4F+8b3TwP/A2CvE1tS0qeazSEnpjNe3/HD/knVz/1/wCnf+l0FeU2qGKZJY22SA7lYdjXHinqj2Ms+GRq+HvDmn6tHaJZa5apqczPmzkXoq5/HPQ1ZuLBNPiuLG70U3GowriW6EuI41J+V1HU5FVHvQt8L+GCMXojIaU9d543rjoa349Lu20T+17+Gys4oLZWjkt5GeSVwRjfnjn+ZrKLjGWmpdWM6c05S0Zz0irgbcBe2aa8YKMQOAKn+3yLfTTiCGZpQfllG7bnv9arPMzRBFG0Hg8VzTlHuetRjJou2bxYXADAcZNagbJ2hOB096xLJckBwAK2YpFIwGGBXPOZq00SkN/EOOvSmyRIV3HjirolBjzlQAO9VlKTZbA2jj61lzEp6kNvDGuTlhnpVlQoBwTn3prMvQdqjkmQccZqXM1SbFeNZSA6MCOQQKckcZ4OMVEt27MDwO1Xd42DfjJ6UvaIUuaJXlsoG6AE+uKoSwSW5JhdsenUVqSlVHG5fpWJql4IlJdsAZzjrWsXfZlU5Pq9DI1TWZbdWSVFx6rXJ6jf29y52llHvzW7qEzadOtxqVp5iTRF7UFlkR892+melcVcqHbhlBHXHFRObWlzqpNT1jt3EuoXK749joOCVPI/CqcluGbHO7vVqKMh8nBx3rQhszIpIBbuc1HtO250cpymv2jroWosxyFt5MZH+wa+mf2gwW0fwuFQuTrQwq9T/od1XmknguW6+HvinVrpCkFvpV1JHnuywsRXqfx0YpZeFGHUayf/AEiuq9uhCUMPJy6p/kfJZhXjWxtNR6NL8TzSx0y5mB3RgAjo5wVNaVr4dv5lAjTzd3GVxx7VG1xJ5RxgnrjpVOW9uYwC0xiX/ZJArzbreWx7NrL3dzdbQLi2JSZdsmOcnpRFp0vKrMMjsprFt5552RXuW2Ej5zkgCtaK/d5kMiwqH6MikZArJuL2LTl13JjDNDnezEeuOlQxv5e7e3J5FXpbtZYztOBWYYGmkBAOKnlRvCN9xXl8w4WmKFD7mAOBngZrSisgi5xhu9N+xyhw0QG4nqegFNw8jRTih9tMLeykkfa8gXKKowST0zVjRtRW8gHmyosvCkHg5pWsFmTa6kk+nXNUZvDSxv5sUsgc84Y5q1Hl0sYfuZ35nZs7G1ijMJGCxJBDdhU6W0TsRLKYcAkMEJzXNWdxdW8Yjkbco/u8EVs22qkJgyn6EVcXHojy6+HqK/Kyx9nzKqoMgjq3rSvakyEKfkAxx0NOW9HKuqHPpxUizJvJyV9gavlTMPfW5SkhAG0AFvQd6rXNmPL3ISpP4VqSyxEE5rM1C7AHycqPWqSUdTek5tqxiXc89opG5mHsM1zmo6mHQ4fD/kau61qYUkA/lXB6rePJn7p5rCdaR7dGKSu9x17eSh3ZHOSCHAOCR6V03wBlim+K7tErp/xJbrKs2cfv7XnNeevctglgSe+D2rvv2epVl+KZZQQf7Fus5H/Te1rowcr1o3/rQ4c4S+pza8vzRoeL0Q/EbxizDJF9D/6Q2tV8oi8KQfTFaHiaMyfETxkAP+X+H/0htahjtEUAzvwT2NViJNVZHLgYp4eHoT6PrDabM00FrHPcoMKsi5A9fpxU10l9rV19pj0wQTOC0qxZKk+oHbimJqENrGfIhXd64yaq3GualkeRK8WBjIOD+lZOcnHlNXQipc8V7xebRLyN9ssLI3cN1qRbaWHpHjv9awzeaof3jXkzN6udxNXNC1q4kvVgvjkn7rYrCSN481tbM0orllY7oirfnRvW4YjlcdTVu+ZHICMFk7EVSLmJto5z1PrWDbTsaQhfZE6SIAEdSqjpg/rTTIjsFZ+ewAqGR1wWfgUsE8CkHAyx/Gk22aqFlc0LSI49qu+XGy8qD6giqtlKjOYkBLLyeMVobWIBx2oTscdWT5ip9laEh7c7fxpH1DIKTArJjv0p9xceSOv4VzOs6nEwOD8/Tir9pya3Lo0XV3Ra1i6DD5mwR6Vyl2kc5YgjPrUct7KXPJYds0I449fTFefiqrm9D3MNTUFZFGSKSBcKu5M8jNaWkWL6hdxWltkTynaiMTjP+FLFGZWwOc8AYr2D4d+FxpsSahfKou3X5AeqKf61nhKE8VUVMyzXM44Og5P4uh0Hg/w7F4e0mK2X55usj+p/wqppX/JU/EZ9dG03/wBH39dQZFxwy4+tctpDK3xQ8QlGDD+xtN5Bz/y3v6+4o0oUYqnTWiPzKrVlWm6k3ds62iiitzM4P438/Du5GM/6fp3H/b9BXlaEhRuAAFerfGwZ+Hs49dQ07/0ugrzFIVDfN0rz8bKzR9BkyThK/ch88jIjXdnsBmpILDUboYiguGXIYruIQHsSOn41dtbo27n7NFHuPG4jJH0ptzd6jOSHll2dMK2AfwFcSb3bPVmltZGg2g6jDAkd+6RxoSeGXIJ+lNTTrWMAS3aDnoTWImmXl1OsVvDPJIwJVEzk46/lWk3grVY9Gl1S5SGOBFLGKUnzdvr9faiVNyXuIylXhR0nJL+vmX2gsDjF1HnsAanhtrV48xyDP1rjmtDEcbByKs2FwbedVVmIx93qK5G9bNHQlzq6Z080BCYkJ29sGofPjgTaTn2zVU6itxEWDAHuBVaBRLJu7U+RJbmlOCeki011vPy8expjS4zu4JqdbdAjEDmoJIcBWVGds5AWocbnRFxQsM5abaoVguN3PINNk1V4tSSCcKsT8Kff61dW3UqX8sLu+8McmqWoeH5rmxlmt5JVi6kIVJXHfB5qoU3bQhzpX/eaGpcXChHO4MwHQHpXG6vrE9sJltigkkBTzGXLKO+D2qneyvYFhHcyEYwdwHze/Fc3d3Jmc5cHPIzxSlO2iRSw0GrPVFrWdUudXvBcXcVrGyoI0W1iEYAHrjqapxw5J4bk1EisWG5SK19PszM4I+maibcndm0KcKUeWCshllZKSAVY59K7/wAE+D31W5jlkTFqjDcT39qzFFrpNmk90ArcAe/1r3Lwtbx2+j27REbZFD8fSvRwGEU/3k9keJm+YOguSG7Mj4mW8dt8JvGMUKhUXRrwAD/rg9YvxyGbPwn/ANhr/wBsrqtn4q3MR+F/jFCwDto17gH/AK4PWR8bxm18J5H/ADGT/wCkV3Xr19Kcr9mfM4VuVeDfdfmcVerbyLHFBAFJILueo47dqntIJrWaC4tYoZWjJwJk3KRjnIqqF9sfjU9sS4ClmUAdjXgX6n2DpXXL0K88JZ5JGWNXdyzLEu1Fz2A7VScBSBhuFI3A9KvyRMEYg5DVnzuiFRJnG7ANZSaN6MOWyL9oiiJI0LuoGMt1+lbtpbKAD3rKgXZjHK+tdBYBSEXqzfpVQXNoPES5VoTNYoyAtIc9cDtTtOjYzNG4XAPbmt+w0yKOCWW7fdGF3BVPX6VoRWFrc2u+OJonUZHmcHAruhRTWuh4NTHxV46+pnR2LPGTFGSQOtU5rQpGGkXaG6Z71qGaa2gxkE85UelcLc+KVh1IreW0wjz8qjJz+NVNwglzl4anWrt8mqRq/Z0ld1VfqaSbThDHlEc56ccmr0OtaPd20ZtYHgmH3vmx/wDrqaxFmJ1kJLjJyhNRyRkvdNHWqwu3FryM46TqMVkbgwNJEPmI2/OB9KrJKmcRnLYzg8V3yTRXkXlrPLApGFIOD+dUZvD0F5IftEqOxGBLH8sgH171vPDJx9xnHTzKXM/bK3ocXNdbEyQwB9axdTvlZThq7/XvCwSxaSymYtGNzLJzuFeU60hUlJMJnv2rir0alJJPY9rLsRRxPwPVHP6xeNubAyufXpXM3E25t3Xmta+ikUvsIYGsWZGJwy9PbFcid9T02QqTvzj8a9K+AK4+KQb10W6/9H2tcFZQFiAF716V8E7U2/xQhJBG/RrzH/f+0rtwX8aP9dDy83f+xzXp+aLuuED4h+MsjP8AxMIf/SG1qreEMuAFQDqeuam8Rbv+FheMsYx/aEP/AKQ2tNiMbR7jy4PI9qeJa9rIyy//AHeHoQQxYAPU+tXLSwjubqKO4u1tTLkBjEX+bsMD1qRQrJsAyM5IHWpZ7ltwMcbIUYbTu+YY+lZRklqzetGc48sXYn8T6BLobW+WNxbzAbZSAMOOqkfSuOuXMd9HImQ4bAAroZ2mdMSzyugYlUeQsAT1IFYCJv1OJW9TjnvSqVIS0SIwkZwXLUd2dRCpHH8R5PNTJGCNzDvSW4aRmcRhQuCyhs7a0EjSRgCcA9sVkqd9UdNSpymTNB5jNhc8cCpI9Od0UvEN4HBUYxWl5HkSblOVBxyM1p2yi4QhSOO+aSotsxninFaHIXemXUc3n2lwY5P9oZB9qsW2sXlsgW5hX5eGYHINaF9eQwyNHIRuXqK5vWtQgEDBcAk9Kmdo7nTTTrpe0VybVPEUEi7dq7vrXMTyNO5ZRwe9UdryOX2/LmtOyt2mjx5gVMZwK4Kl6mx1wgqWiK4RUP72Xaf7qDJqXdCpB3Sn6gVoW1kkfPIx3Nd34H8HrNex6lqEbCJSGiiccseoJqI0ZTait2Ri8dDCU3OW/wCY/wCHnhI+YmpajEy/xRRMP1Ir0e5QMu0orn0PpVkDHTimvGG619LTy90IctPV9T4PF42eMqe1qGLLaWp+/Yhh/vGsnwvDDD8SPEK28IhQ6Ppp2+/n3/NdW0K92JrndGUL8T/EIH/QG03/ANH39bYZNVLSOebjbQ66iiivRMjhfjWM/D6cf9RDTf8A0ugrzdEAHOAa9J+Nf/JPpv8AsIab/wCl0FecQqGYg9q8zH/Ej6HJvgl6gkeSArZyevpWrDACuU34UfMT2qGBFBVlXPPTPWre5AJMryvJXnNcSbuerJmr4X1S20me5e7LyllzAEjLOW7gY9Rima7qtg9vBY6ZdXc9sWMlwhmJ687CSM9e1YxfzN7rcJbNEu9d5IJ+hFaeoaUdPitGZ3kluY/NEoICjplffr1rphWcI2R5FXDUVW5qktWc5cIGVigITPese7JikVlX5RnJziuiulUHAxtP6VzGrTrESp55rilLm1Pbp2srFixiZwEhRtmcn8a6a0tQoVRwaw7J/LKspGMcg+ldBDjajK3HUClFXZq27E01r5a7kclxxtzwamsYzLGo2YPtyKbyFD8tx0q7bsYtg8vHGeOlWop7HNObUbdR0lskKbsc+hrF1t1it97BPmXOV6/jWt4g1ezjhV5CY8DGPevPtT1KG7nWOS4NvBIwDSDDbB64zVVJqmVhKM6i9pNaI5vWpzLOcHgVjiJpCc44NaF3CWmk2yiSIOVWQjG4A8HFPsLMzSKsTZfPIIrz225M91KNg0+1y/3m4/hrsHNtoGmG81BDASu5FlTaW+nrUazQ+GLA6heQ2cjKCFSf5tx9gO9ecarquo+JZklv7uWWKInyYpGztBOcV6OFwrq7nz+ZY90JWjsJq+qXXiLUBKxMdupGxAele/eAPENzc+HLaEPho8Rsc9MV4rpmmIeSQHB+7XZeErybRbkNtDW7EF484zX1GChCjHlep8Xiqrrz5mz1L4h2Lp8L/GVxdSea50W828fd/cPVf42nbb+Ej/1Gj/6RXVaPxCv7fUfg/wCLbi0kV430S8Iwen7h+Kz/AI2KWt/CQHX+2T/6RXdceKk5QnfszfBJe3p+q/M4tRlxnIY54qWNAjdc/jUW4gc+nWkVhGpZ927HFfNSdkfdNJIW4lCoSR26etZ0VsbxmZvubgcetWZHMrAbcKeM+1aNhAIwv90c1kryYR93UJEMYXaAorT0Vi7CT723jHrVO9ZWB2HjvV3wtsuINgdAd5XLHHOOK6qcfeMMRK1FtnY+IZbWXSEgt71beZQpXZzj2+lZXhaeQagF+0PKSSp39GHU4rjdetpWDYbbJznn9KPCl2mmaxYPqbybRl424KhsYxXTJupVWh5VbCwwuElPmuj1PVYAkXmqzMrDIArkb0o8uwgH2wMiut8Ssz6Ql3bH7pBb3U1xtyyBvMHBPP1rqxNKyObK5KpG/UpNYQFiygBwexxmn2tyQ5UxsqqcA5zUJuz821SxB7dqR5i0isD1HK1yRsj3OWUtJGyNSdVwRwBxzTofEHlkFsjB7dawzMCRvyAKUNA5IBIz6im5W1Rk8LTekkddF4qVsfvkI7q3eub1eytdQZiyrhiTxxVGS0ilxtOfrUP9nyRDMTSKaJVnJWYUsHSpS5qbsznNZ8LYLPbP17Vzs2kXkBCyR7wc9v61380F42Nswb6iqrefE+ZI1OK5ZU4vY9CMnbVnL6fp24DGQfSu7+GasnxPsUZcY0a+GfX9/Z1mpeWyk74GB9VPStL4c6hb3vxZtY7cH91ot7uz15ntP8K6sHDlqxf9bHmZvNfVZJ+X5opa+ufiD4zJ6f2hCP8AyRtaiECnHarOuH/iv/GIxnOpQ/8ApDa00uoIQceuKxxd/aysVl/+7Q9BEyExk7Ceg/xqbyrgbCNp3ngFhk1CZRjAO4Afd6c1XheXY6BflfgsRyK5723Ombsri6o9pCkYhu3nnIPnoY8CJh2B7iuctVkk1NXJCqDkZ53e1dC+mExsHR1Y9dwI4qjOsFu64GwKMHnrVSs9bWM6MYx1vc3dJnMM6kMU3jacjIwa6K1USXPkquTnAx3rgbbUVD/IwI712mhXZs5YrgKGYKTyeuRx9Kum9dR4iF4ucNy3r7x6HEqoDLO7YcueFz2A71Viu/7S8vazWoDfM0WAce9Go3jarbBp7cloWyGHIyaoafGfNzknuCDiuXH4yVCSa2OejR/dtz+JGb4r06y+2sba8ubmRl2YA6sMdfbmuUtrVkumSWTzXQ4znIHtXqSxaedwdvsszLtbc2VYex7Vzs+g20ZKwX8Eq9sdfzrgeNp1naWh14XHRgvZ1Ht3MKW1DRbU+UmrHh6zmM/kGPkcBh0NaUGj7uA8jHqRjt9K7vwrpMcAVjC2OzuOv0q5TikuTUeJzWnTg+XVieHfC0YZLjUAsrqcomMKK7eKMKOP5VFbrtqyOmK9vLMNG3tJbnxuJxM68uabFHFKxwM0gyD0qCVyDzXrufLHTc5UrgzjrXN6OQ3xQ8Qkf9AbTf8A0ff10EaSPy/yqfWue0Yp/wALR8RiNgcaPpoOD0Pn31Z0KXLLmZcrW0OvooorrMzhvjV/yT+b/sIab/6XQV55FHlSUOfwr0L41/8AJPpv+whpv/pdBXn6ExphWAyeleVmL96J7+T/AAS9SxbOtvNE1xCLmNW3NDnG4fWnC4cCT5UVZGzt6lB6Cqkswg+YDcT2qMTAKzyE5rgU7Hs8kb83UvjUrWCRDPZPeRr99M4B+p7U/V9afUrjz2R7e2VAsdsWyI8DBxis4atqMUEllZ3Dx28xy6bBhvx61FFpsk2BPI2T146USrNK0TH2CnU55L01ILm6kkcrAu49yKii08upaQlmzya1YoYbIlETOO5PWq13qQRGWJAo796xp73kdF0ijdyqhO6TBHetvSHe4td3JUAHNeea1espdgTjnmu48OXZk02FYyFJiAxj7wreNm7IuMk46G/FOiqFdhx6c/nV+ArJCPLzgHqorInQxopjwjY5yM5NdZoGm6vcxNY6pbxwWyJkXEZy0hPQV2UsNKb3PNx+Lp4a19Wzi9aFvcbomQStyCa5h/CkTgmHfHu9ea7jULKCC5uIo2LmGQpuYbd3vWVcXSxnBYlu2DXNXw3vWkevhcVzUk6T0Zy//CNTwSAlg0Q6/LzUr3lhoNk90+WkBwqEck1a8QeMLXRovLXbNdOMKnpXnIn1PXL3zdrPOWwkSDPPtW2Hwik1ocOOzZUovuSatPfa1qCXWolVhY5hjU5AHuKt2VkgAGzLZyKlbSJ7K7eG9G25UB23dq29LtpHlj3hViY8yNwBXu0qCpqyPjsRiXWfNJ6jLOAPlyoChhWlcNBGgSQgg9CB0qDVru1tne3tPnAOGcdD9Kz7a1n1B+MhCfvelaynGCvJ2M6VOVV2gria9r15png3xBaQyEwXGn3MLKeQQ0bD+tezfG3P2fwkFOGOtED/AMArqvOfEOi6Vb/DrxI80omu10u5KEHowibFej/GoEw+EQuc/wBtHGP+vK6rhr4iNanNx6J/kejSw08PiKUZ73X5nFSq4yo+bBxwKkt7NpWBZj05UjvV6Gyx88hOKlnuoLRMAnf/ADr5xq59fKp0RYt9ORUBluIrdB3cE59gKqX8nlfJF83HJA6/Ss+5vrudXEC8gHDE5GaZDDHLh5YTG4AyWZjuPc8/yo93lstzGMZKV5O5T+0yXExQs/ljqFxmrGj3JsbhkkP7uc4yeMGpLyBSCChQjuvBAqq1sDCBvMh65PX61nTurNlzndWZ1MsZni+f5kI4OK5XVreaaSeSKMlYgFVQOhPpXTeEor3ULr7JDLGIwu7MoyB9PU12H/CEWDK5nmnd5PvFXKAfQCvTpUpVveh0PJxWOpQUqU9bkHge+Ou+DDARiaNWt3z6gcGuGiuZ208mVWEsbGMj3Bx0rofCtpN4T8cS6bO7SWt+u6GQ8biOfz7GuY+JcFzoPjXMJC2Wp/v1J6CUcMo/n+Nd9dOUPM8nK68aNW3Rj4EaLfJtYMwySadHuYlpCee46VXtYppFBactkdMVZFqUALOx5xXmSfLofUQqX3ZJGPmO7JT1qQtEvUZBqEoAPkKj3JqOXf7E1zymurN1Z9Sy+wruQFfpUInZR8jn86hEmV2kEetVZiWPyOFHQikpdi7JLU1E1ALxKM++Kd5trccF1UnmsJ/tCJjKHnqTWXqc/wBmiaWXaAoySGxWkXfQynywXNexu62YNPtnmjZGOOuMmsj4Dztc/GS6lYABtGucYPH+vtq821K/udTuvkaVIR0AJ5r034AosfxKiCjn+xrvJ/7b2levhKHLHmZ8xmWMdZ8i2NvWlLfEPxiAeBqMP/pDa0yVwh2ooZzxS665Xx/4zC9f7Rh/9IbWnxtBajzLhx0zt715mK/iyPbwEksND0Fgsj5ReXjuajfUba1JFmheRe+MgVRutQn1A7FzHCORg4zVbYAhVOAeOK5zpeq1Jb3VNT1Bybu6cgjjnJFVZ9PRl824yjEAcsTkfSrqlbODznXcxHyis5bya5vUkaESnBYiQfLtHX8qesmc00or3SpNpjsJJbaGRFiTezA42rnGcd663R9RE9rHE4PmIAr9jx3rlL2Vjp0kiQxuYnEUTCcZDdeU6le2amsZZYnSaOT/AElG+aIr8jAj1pv3HqZUa0rvm2PV/BFtb3E2oWtwryF1D8t0U8cVX1zRDa3flWk8TybS32dT85Qd8d6zvh3r6jxUmntA0Zu4m+ZxyCozgH061s/EK2ca/pN7mUWkUMz3PlcMVTBAB7ZJxXoPD0sXh3GSPHrYmph8RKVzmDLvcxSKsoBxtbqKngt4FA227DvgE0Qa3PfOX1TTrS4DtuVUBR0B6Dd3xVpv7NIyo1GzY+jBx9Oa+Zll/sZNKWh6XtpSSco7l7TIgrZihEbHueSa6Wy3oBJI3yjjJP6VytnLZpJn+0rjI/vqoP61vQ6npUVoIbu8t3jVt2ZpRkH8K6KMKMXaUjjxEpS0UTpLaQOMgj6VZRwe4rjZfG3h20QhNRjdh/BboXNYd/8AFCNVK6XpsjEHAe5YID+AzXq0cRCl8L0OOODrVXaET05m3Nt6Y71n3Wq2NsWRp43mUZ8tWBb8q84Txdc6tF5d7P8AZy3GyL5Qf61kX2llQZ4SdxO7ep/rWtTGtv3Y/f8A5HdQyeV/30rHW6z4pvpZcW48i3GcjHLfU0fDy5+1eO/EMhUq39k6aGyOp86+/wAa8/fUr6xOyVvOiPBDjJ/Ouu+D10t54w8SyohT/iW6cCCc/wDLW9p4Ocp1rye5tmWGp0cMuRW1PWaKKK9g+dOF+Npx8Pbg/wDUQ07/ANLoK8y85cg5+YdjXpnxuOPh5cEdf7Q07/0ugrzay0e7uXBEbJEF3tNINqqPqa8zH/Ej3colGMJcztqQh3c8As45q3bWkl45DDjHIUcUk1xaWEQcyh5QcFVXOR65qlLqd/cwhEbybcHKg4yPpXnOK3Z7XO38JstNZ2CKGd3lH8BUbcfXrVX+07rULgW+nQPJI3ChAM+9ZJEZGWJdhyWc806KIOP3KsrHupINQ4pvbQl3t7r1FdZptxkc71YgqehI9xUMyNGvmlWIB6ZyR9KtExwja+MD+FTzUJfzXRUATe20bvWmqeuhM59GYWqQrc2xeOMhWz1HNP8ABmomGY2FwSJYTlQT1X/61XLvdLG2HBXOM+4rkNVnljuY5oZUWaI5UqQSPr6108l9DKNdwfkesarPt0+SUNnC7tueTXo01t4j1SHTLvRdattOtGt0aSB7QSliR/eJ4r56TxpBLpUkV8hguhGVJz8jcdj2r6m0AD+w9OC4x9njP/jorvwnMm7nkZq4z5Wjxn7VLJdXvnX8UkolcS74iAGBxxjpW1N4RjbwTeat5pnvxbPNGIj8oIBxisXVdRMFxq2nRabaJKtzLGJ9p38uTuPqcH8Ko2ct7aKRa3t1DCwIeISEoQevB6VNSpyVW5K500FXnQiqUrHjUW6WISygSSSjc8j8nP8ASvTvD/h/VvB72l9Jc2n2e+QCOaP5jCxHU/41jXvhVLFjIkd1eQEkrHHgYB7ZqNNG8QanG6JD9hs0ACRu5ORmu6liKUVzXR4+Iw2JqVORxZ0WojSNJuvMuLr+0bmVSzlWyN2ehNY8t7qGrt5Flb/Ko3BAMLj696t6R4SstOybuWS4kPVf4Qa6W3ZEVYo9sagYUIO2a56+aR2po7sHkUpa1ZWMvSPDkKqkmpyHz1P3AcgiuhEKRR4ijEaj+7VC5ZVk5OT696Yty8LDnKjrzxXk1sROs7yZ9Lh8JTw6tBGd46t1PgrxA4xxp9wef+ubV6r8W9nm+DjJ93+2Wz/4A3deWeNLqKbwN4g5Ab+zrnp3/dNXpHxxz9k8J4JBOskZH/XldV1YXShU/roeTmnvYuivT8zndV1A7/JtQSW6YrNWMJuklO+UnrToIzEox98nAzzxUoUFCpIDZ6V5Tdz3FBRjZC26eYQgBC9SPep7mSG1jwp3SjgEn7tCk29u0g5btXP310z+a4IITOSe9O3Uyk7I0Y5FlCNcMmyQHayyhyMf3gOlV7HUIJ9VNoJg87DAVYSPlA6fU+tUFaGTTnKhklMZYyt8mw/XvSWGsTXL2cF0IlWFcK/Blm/3mzkiqUFZyZySUpPTc6rSTJp+rxXoWWHywGRI3DBx0IYdvcda9jsrmK8tIp4sFJF3D/CvG7CLyYsqAMnJ967XwbqIhnazkciOU7kJ6Bu4/GujLsQ1UcX8LPFzDCuP7y92bni3Rv7W0vbAfLvbc+dbSDgq46fgelcl41uG8RfDSTUraMfabUiSaNkBZChxKvsRg/lXpRHFYK6alrqt6uwGw1JD5qDoJcYJx/tL+or3pRueSnZ3R5doE9tPZo2xmlz8rBwE2n29a3FhRgCAB7V434k1HVfBuu6jo8MEB+yS4jaXJ3xnlG/Kqlv8SfFU8hW1j0WMBMs1xkBRkDPXmvPlhJVNbHt08dSitWz2yW3QD5dmcVVNqHIwoz3rxzVvil4h0vUZLJ7bSLt48BpI1kVST/dyeRTbb4razcSAPYWULdOGY1zTwE+qOynmFLoz1y5twFPAH0qnNY4BPl5B6Y715hf/ABL1qOVUNtZLGerbST/OpP8AhYevxxrsgspAcYGGGf1rP6o0joeYQS3O8v7OC0tGnupNijsTXl+sahJq1y0NruNspwWB612Tw6lrtvHdeISlvZAbjGvAPt9ayLbS4IZH+xq4hLHYG64r0sLl7j70zxcdmqq+5Ao2VoEUJjp3xXovwXthB8ToCBjdo172x/y3tKzdN0KaaEv5IyDxzgmum+GUbR/E6x3IU/4k18OR1xPZ16kocsTxOdOWhj+LJjF8RPGQXgm/h/8ASG1rPVzKTvGc9M1c8Xkf8LH8Ygj/AJfof/SG1qkvysuTx9K+ZxX8WR9pgf8Ad4ehaiAAA7AVLboHZpCOKo7xjGc80+WcRWxcsVAHT1rnOhsra/dl5AuTtHYVj+ascTyuXZgOPRRUH2z7Xcud2VRufapZP9JeMMDgLtI9fepnUSdkYNXZlPNNqF8r2qiLH3pnGMj0xXYWRWKMKeWxgHrXN3WmiCEzxSbO/J6VzOqa9qrWzRWc6xA8eYBkke3pTpwlWdmZznGnoj1rRNXttO8UaM89yiuLtI1Tdyd/y/1r174mx3LeBNVksbV7q7SHesSEBmAILAE+wNfEMd5f6e63jb5Z4WEys5JOVIb+lfecUyeIfCscsDYj1Gy3Kw7CROP517eEp+zTifPYyalPRHyzZ/EmNolnjsbpEYZ+8D+lbenfFDSAUXUWubYMerRcfmK8ctopbJJLOf5ZrZ2gkB4wykqf5Ux1aaB0zlsbgetYToxbZ30sRNRPpKx17R9YTdYXkM5IwQGGfxFWXsIpOfLQ5GDwK+Ukn8uYNCzRyrj5lbac/hW7D4/8T6LOY7bU0uI42A2TgSDHpurmeBT+E6Y49R+JH0FdadFH9xQuemBWXc2MgG4ZI96850v423iui61o0E0f962kIYfgeK73RviH4U1do1e4NjM+MJcLt59M9KynhqlM7aeMp1FuQy7gNrqQRwOxFT2et3VhgJI0kQ4McgyD+NdDPa297F5lvJFKh5DIwJrDvNMaPOzd9DWXqbuSa0NCPVNM1ceU/wDo9xjJDHg/Sul+C9t9l8Y+KkBypsNPYH2828ryy7hYFhJj8BzXof7Pkjv4k8VCR2fbZaeoJ7DzLvj9a9DBJe10PLzSd6FvM9uooor1z5w4H45sU+G1246rfaef/J2CvFpL28usB53OOgyeB7V7R8dv+SaXvGf9N0//ANLYK8TtpBnOcYrz8buj2crlaMi5b28cQDtlpO4NWWch1x2FVI5oo545LmGWeANl445PLZhjs3apNs8drFcy2ssFpOxMDyuCWUf5615zVj1lWS0LMabsu3OOvvUNzdmIbY22ewPNQ3N3sX5HHPYGsie4DOSGBbu3YUW0uKVX7zRN0gk54JpwuCD5nmfd5U9zWOXjhiaaVmkkzjJ7D0ArPdry8ugLImNAP9Y68D/69EXqYyfNqz1X4caLovim4vIdaWV7uIK6RiQoGQ9Tx1Of512fiL4V+GtQ0Wa2sNOhs7zGYrlAdwYdMnuPWvL/AAncNoN7bahD800B+fB5kQ/eFfRen3UN7ZQXNu4eGZA6N6g16WDlGScWtTwsVGVOb1Pi7xJokuny3dpexNHdQkxyRnsf8PSvtDSo/K0uzj/uQov5KK8h/aC8K+ZYr4ktEO6HbHdqo+8m4bX+ozj6fSvZLfH2eLHTaP5V0U4OM2znlUclZnj3iuzitvFmprCyv5riZl6FGKjI/rWTJbpkY+WtfxyYI/G1+HuIo3aOKTBOD93H9Kq2oSTpNE4Pqwrz8Ym5s9/Ln+6TbKDq3IA6VE74ILMyjoAOea6QQoiAuisT6VXbFvcJcWL7J0bcGdMr7jaa89xd99D0fapLQ58SMfut9aj8593zLkDvWxJpt7dyfaUijnM7tykiL83U8Z4qK60PWUidotGkuHGFHkTKxGe5APShQlL4UH1mnH4mjHnmUKSfxzVASurj95uBHIrpbjwZrDX72kDWtzcR2/nSqGI8tuP3ZPTcQcj6Vx8zOpw8csbk7drqVwfT61Sp1IfFGwQx1CppGRU8YzY8Ja0FYjNlMD/37ava/jbj7P4Sz0/tk/8ApFd14D4saT/hGdYGQR9jmz/3wa99+N5xa+E/+wyf/SK7r0MNrQn8/wAjzMbK+Lpeq/M5K3bD5ZeMcc1JEVklyDhewqrvIQYGcDpSwS4BbofQ15ltLHuN9Cxq8vkW2N2AOlclvWXKvzH/ABe9afiG7YQgE8nt61iWEvzSSsgJUDpk4B78UbIylLoWL7zrhAkIBSQchjlQKuaVp0UEqyMTLMeN7Dgew9qht2LHgKcDqByfrVxJBEGbOCPU1hKrze6Oyirl691GOxty8sgRFH5n2rnrrxFeXjZjle3VSGTbwcjoa5XVtUbUtSDFz9nifai54+tWhIOeDXp4XDqKuzxMbXdRNI+n/AXiCPxL4ctr5SPOx5c65+7IOD/j+NdEyhhzXzh8HfFI0TXfs10xGn37CNyTxHJ/Cx+vQ19Hqc17FN6We54bVjwX9o7RSuqaVq8ScXEbWkrAfxD5kJ/DcK8EvoNheMyHg4Oxeo96+vfjLYLfeAr7dGXe3ZJ0+qtz+hNfJWtExloolADNyTzgema1p6NiMea2tgbhJJJDKSuydpDtVR1zwSc9KrmaNpsWu4RB/lVzk/nT7hkUbSSY/wCJBxkfWpFl02a6DSrJaWABCoQZGYj+EsoHX1pzeljSMuXWxPfMSqK/Ddwe1TaFem3ukRssqsJFz6Z5FU70WsVvALe+humZA7eXuzF/0zYsBlvpUHnGOSN8gAEVwOLjLQ7ub2kT3q5u3137NLjFtFEFSIdM+p9TWppOkxzEBlwc9hXl3gDxjHp850/UGURk/JIx4+hNevabfWyKssE6spPBBr2KVVNeZ5NSDhpbQ37SRNMk8srGw2kFjziqHgl42+Llp5Ryo0a+5/7b2dYusa5HHHINykcnNV/g1rEWrfFvELBhDo12CQcjJntf8KVWtFxcRUqT+Iz/ABy5X4l+LgDgfboT/wCSVtWaZstjkmrXxAk2/E7xfknH2yA4/wC3K2rCkutuRyB2r5jEx/eyPr8FL9xH0NJJmD4qn4kv3S2SKPqwwPrUFvdGS5UZwqrk1j3139q1UsCQkYIGPWs7aXNKstbFqyC29uEDbifvEjqa1LZ0SIyN0HesazZJp2TcDtIwAO3eqnirVlizZWj4cD96wPr2rjVB1J3RjKsoRutzS1y11690xbqz0bUpdKfk3McBZWUdxjnHviuWBRgy7grjjy2Uqw/A16l4M+NmraHaWtnrVjHqdkiCNZIMRTIoGOnRsD6V6VaXfw5+KERjeCzmvSPmilTyblT+hP4Zr3KVKlypLc8eeJq815HzZ9nWW3KOobjkHvX0t+znqn9pfDKxgZy0umySWLg9gpyv/jrLXH+KPgheWkcknhK/89MH/RL1vmH+7J/j+dQ/s8XV34b8Xa14V1i3ns7m6jW7hhmXGXT5Xweh42n8K2hFwmuzOatNT1POvjjof9h/FjVBGNsGoBb+IY4y3D/+PKT+NeeQu6T8jjJr6O/aw0MyaboevwrzbStaTH/Yk5X/AMeH6183XMbvcBVDZ2F8AZ6U5w94uhLSxV+0i2gu1MUUol4O5fmXBz8p7Vu+KE8PafpVpYWbazJNc2ou5YLi2WFoLjgL8xGTHjd068GuVmmimDMDnAIyGpNSuLq6kS4u9Re7kMYQGaUu4C8Beeg9qq+lmKpHmdnsVkO084P0NXWkL29uTjK9OfSqIJwvNWLSYQyRsY4pQjZ2SDKt7EelS1c2p6HWWOs3emvb3mn3MsQKgsgYlW/CvQ9M8fO0UTaku+3b7sqjkfWvHUl/0KNeAQTj2rR0a7+SaykY+W6FkzztNcc6abszsjVlF6M90jms9ZjLWsit7A8iuv8AgHAbfxX4tjJJ/wBD088/9dLuvmzR9UksLgK0rIucKwJyp/wr6H/Zu1CTUtf8WSTD94lpp8bEd8PdnP61eEhy1NCcdUc6Wvc92ooor0zxjz/48Hb8Mr4+l5p5/wDJ2CvBFudrE4r3b9oORIfhRqkkjBUS5sWZj0AF5Dk184faVIHzAgjIOe1cGMTuj1cufuyN9rosRzxioi4itmXy4yGxhmyWGOw9BWVBchydjBtvUjpVLU9QPmpGrZfnArjtoelc0LrVkhkEayEXD9EXnH1qaCfDbrgDDD7w6g/QVztnHFbl5AC8zH5mY8n2+lXY7hnKoWO0HI9qwqO2pN76GvG5mctklTxyP1rSgwpBc5IHSseO4jhjPI4GfpXP6trsl9M1pbybEX77Kev41FKjKbFOooRsdlc+IrG1YqZDNKv/ACzj5/M9q9R+AvjIahNd6DdL5ZRftFpuOcpn51/AkH8TXzFZOoUKpO7PXtXW+Etcfw/r2n6tCSTaSh2UH76Hh1/EZr0qcPZWkuh5OJn7TVn2ffWkGoWM9pcoJLedDG6noVIwRT7aLyII4gciNQoJ74GKjsLuC9s4Lm1cSQzIJEYcgqRkGrNekn2OE+Wv2nrQRePLCcglbjTtpwe6uf8AGvFiDtx5k0Z7YkYf1r3f9qVQPFmiEdDYv/6MrwO4kIZTjGDxzWE0nI6KNSUU0mMGq6jbEfZtV1COVeBidsfzqzF458VW3EOv3je0mG/nWNdyA3EhB6HjiqZZTKuTxnnnHFL2cXujR15r4WdbF8S/EtvKfMls7zuTJbgZ/EYrY0/4wajBMrzaZGjDrJaTNE2Pz5rzRwA7bemTjnP600HnFDo0+iGsVV6yv6n0J4b+MlokiMmoX+mvv3slz88Uh/2j3z616LF4t0vWNBms7mJru3uJ1mDW5EiooIO1OcryD9Mmvj2F8RSKRkHsa09GvZbJBLBNJEV4PlsV/GueVDl1izWNSFR+/H7j6J8a6B4Z1HwP4lvdPvp9L1COzuZ0sJpQwdVjJ24Pc4PQ16V8dTtsfCh6/wDE6/8AbK6r5XvvF9y/h3UbXVvKuFmtZY4Z8c5KEDPvzX1L8enEeneFWYgf8TrHJxybO6AFaRT9lNW7/kDssTTad1db+pwnnnnrmnRzb3yRwaznmIAz970HaiOYszdjivHitT6hytqY/jG7yRHEWMjsFGO1Ms3MaxqrsMDGPWqGrS79WIJPyDJH1p8U44A69M1OIjpocfNzM6O3bqSenU1keJNTW3snw+Gb5VIPU1LJOIbWSXcAAuTn0rz7Wrz7U8Nw/QvkL7UsHQb1YsTX5Y8qLUQKLGc8mtaOXcuc8dM1zZuJX2HHy+1aNnMTEcNxXsarY8iWpo6ZP80sTH5WJxX078JvETa74UhFzJvvbNvs05PViPut+I/rXydbTHDnqdxxXq3wO182Pi+K1mbEWox+S2f+eg5U/Xgj8a2jJppnBWSUj6OmiSaJ4pVDxuCrKRkEHtXx18R/Dr+G/E19pzriFH8yFh3ibJX8ulfY6nIzXiP7SekbrfS9YjT7rG0mbH8LcqfzB/Oul23MD5jvgA2HjYkjGWNVZLmQQC2d/kXlF7DNbF+FWF0KNnfu34ySMVd1i58MP4T0mPTL7Wn1u3ZlmSe1VYdp5bB6nHGOaJyja5Ub7I5ZfNWBnCkRq3zNimeaWAP3gemK19OlutKdrufSDdQBNkiXEDNAA44YkHhscjNY3l7GfDLsJyoXsKzlDTmubwk9hQWuLjauMnitfTL++sjJ9nvZUgiBBG44J9s1mW58mP5QXnkO1QK1LOBpoVgLBYYWy2eMuetYyehvBJvUstdXtxa77q7mk3DO0nivWP2YrYweP0kK4aXSLxvw8+0xXk80JdxG7sqsduUGeK9t+AoEfxLtoAf9VoV0P/I9r/hU03761LrxtSf9dTD+KMxj+KXi1e32uA9f+nK2rmPtQ3ZJzWr8YZwvxd8WRB8MLi3YgdQDZ24zj8K5q2jaR8g4XqAeuK5cQr1Hc7sJO1KJeluvs1rLMemOAB0rIt5ysBd+JHORVHW78yT/AGeI/uo+TjoT6U20mZ5AOSx44rOUfd0NJzu73N8XaabYTXXLOq454+b0rkyf3McsxzJMzOxzyaseKL8z3EVnGQyR/NIR/ExrP1JwssEQzhEx17mro03FHJN8xpTzYtrZxxg4NOS4LOr/AHZFO5ZE+Vl9wRyKz0YzWUnPKUxZT5YyfyrWzIaTWp7V4I+M+taDAkOtBta09cDcTi4jHsej/jzXvHhjxF4c8c2cd/pFxHPLCeeNk8Bz90jqP5GviYSk2jr3xxzWx4T8QXvh/WLbWtMfZeQH5lzgTJ3RvUH9K3pzlFHFWpRWqPsX4n6D/wAJL4D1nTFUNNLAWh9pF+Zf1Ar4euoLpbcXEkM8AXH+siOx/Y56ivvnQdUh1rRbPUrU5guoVmTnoGGcfh0r43+MelXOj+ONas5XuJYopRJbKxLqsTjcqj0xkgCt52aujCnPlkcdrXiCbUJr0y29lDJcRxxD7DbLCgRe2319+tULHRJde1aKw8P28lxdTuVjikKpwBkknOPWopJY5ImdJVW6X5XieLGR7GqpQnG3dn+EqSP5VntudKtLVBrGm3Oj6lcWF8YDcQNtcwyiRc/7w4qoDzkU941VD7nn61GBkYWk7MadtGWFbMaAnoc4q1ZNi9iZc7d2PrVPBLKAMk8CrQOJFQ5KxcnHc1lJGibLkkm6OYn14z2r6R/ZPbff+KW7m008n67rqvmh1IjKjOG5wetfSf7JbodS8XxIys0Nvp8b47Nm5OP1FVh/iDE/w/mfRdFFFdp5x5d+04cfBDxF/vWn/pVDXxN4Z8RNbsLS9kY25G1HJ/1f/wBb+VfbH7T3/JDvEf8AvWv/AKVQ1+f64zzUygpqzNKVSVKSlE9oF4LOzBTaw65z1rMiuDLO07kZbt6Vw2k6y6iO1uWJhB+Vj/D7fSutgcbMKRnGeuK8+rS5D14YiNVXRqi5V5dhJwe49auvcW9jZmSdj04HcmsUSxIBJ2VQznGMH0rBvr2TUbos5Plj7qdhWEaKm9QqVVFaGjf6pJcr5scjLkfdHb2NMsyY7cucAgHJHeqU5VJI4s5wAxq0sqm0cL1rqjDlVkjldSUtWOsyVQ7iQSOAa17KXbsXj6Vz6TnYCWLY5GKv2k2SCeD6nvT5WyJPRn1L+zf4mN7o114euXzNpx8y3yeTCx6f8BOR+Ir2cdOK+PPglqzad8UNHwQqXe60f3DDI/UCvsFc45rooPTl7HEz5n/arLx+KPD8nAU2cqj67xXz5qBYyHHIxnmvpf8AawtP3Xhq6Gd26eEn2IB/pXzFek7jycjj8KbV5MqDsU523Dvk1EgCyBiqtGR/F2qQkZANRyLGVyN3TvQaJaEDHgketIOenWn4HTtTdwB6UEjlJFTQzLCsrMQARnmqzSBQWPQVnXM5lPoo6Cmo31BysrEt1eyTp5ZY+WpOFr7L/bQkaL4YaRJGxV11uEqwOCD5E9fFFfav7a3/ACSzSv8AsNRf+iJ6tJIzbb1PGPAfjr+2II7DUpQuooMK/TzwB/6F/OuzsbniYvnPQc9PevmKGVonV42ZXUgqwPINev8AgPxeuqQta37qt+q8N084Dv8A73rXn18Ik+eB7mCzDmj7Kq9ejNu4naXVLlwvHC1YtiXkchgEQAnLViR3O66uHPK7jzU9tIpZmP3gRgHvXDVimzocrbFrxlqBh0uO3XO6dgCV6he9cvcYNir5Y7WzU/im4aW8I6iFVA+pqhFIXt2Qtw3auujDlictSd3qx4mOAwz6fSrlhLkEZIrGglK/Kx5zgg1bgm2vuXBA5xW1mYc5pRzeXKVY+4rc0S/ktruC5iP723dZlx3KnNcpM5LLID1GDV2wuxG2QcYxkk1sldHJXV7s+6tIvY9S021vYGBiuI1lXHoRmsj4h6OmueDtVs2HzmEyRnGSHX5h/KvOfgj8QdMXw6uj6vfRW1xaMfJMzBQ8RORgnuOldX4w+J/hjRdNnP8AaUV3ctGVjt7ZvMZiRxnHAHua2iny2Zyc8b2ufJ+txx5DkbSw6Vz0gUAiU++0f41saxfpcHKLtULxzkiuauJg5CAgDqaTNoeZoWWu6tZ2N5ZWeqXtvpl1xLaxv+7k4xyKoNtDBifLQDjNSbF2K0mQOy+tQTB538tQCew7Vm3rqbwhyvQ1tQ0u3imsRZalHem5gFwXSJ4mgycbSD1+orTKpb2qQxnIHUnqTUTybmR/Khify1QrECFAH1rO1W+SxgMkzDP8K92NZTfO7I6YRt70nsSTanb6cwurnc3ltlUBx5h9P/r16J+yNqtzrHxi1i6vH3OdGlCqPuoPPgwB7V89aheSXlw0sp5PQDoB6V7r+xV/yVTVf+wNL/6Pgrop0+Va7nHiK7qy02MH9pO9msPj14int32yK1t9CPssPBrIg8Qrc6WrW7Hz5flZO6mrn7Un/JcvEv1tv/SWGvMbK7e0mEkZ9ivYilVpKovMeHxDpO3Q7eIFGwSrZ7+9aEN3HaQtMedg4Hqa5+0uhdIjofr6g+lOu5hI6QA5QdcdzXC4a2Z3qrdXQ+3y9wZpWyzHJ+tSak269fn+AVXgwrjJ6Gn3J3XLNnOVHNaWJT7k9jJghT0fKt7VAkjxuVYcqMUxTtOQcEnNSXDb2SQEDeMfiKAb0LUNzk84545qaCYxSqSvHYis2N0SSNpo/MjByyBsZH1qYTowwgK4+6SeRRexlJXVj6a+BfxP0LTfCb6L4j1OGwmsXYwNO2BJCxyMHuQSRj0xXE/F7xRpfifx1Zan4YmmnjWBIROj+UskqsxBBbpjPU15E14ysTLtJYALkdMDHFTi5064nKXslzDaeWSv2dQ58wLwCCQNpPWtk7LlOdULas6C38K3useHr3WbuyFuIJGjW68wGO4kLdHIPBHY45rjZZ4beJ4N6zPlcPC/AHcfWmvK0txEs0z2lvI6mTY5Ma4/i29M1Be3Ml00av5IEKmNXjjCFxngn1ND97c01sVp28xyseRHnIDEZqWBEQ7nK7RyQT972FNijB+UE9PvEVIiqh3Kdx7k/wBKWy0BLuKvyfNxvPQDooqeFFkTy0BUAhmYnPPpVNN8soVBl6l1O8Wwh8mJladuSR2qbNuxaairsh1nUDCoSBv3ncj+Gvof9htizeNyxJJ+xZJ/7eK+VncuxY9TX1P+wx/zO3/bj/7cV1Qhyo46k3N3PqqiiiqMzK8UeH9M8U6Fc6Nrtt9q0252ebD5jR7trB1+ZSGGGUHg9q8//wCGfPhh/wBCz/5P3X/xyvVaKAPKv+Gffhj/ANCz/wCT91/8cqwnwJ+HUYUJoUyhemNTuxj/AMi16bRQ1cabR5m3wL+HjKVbQ5yvodTuyP8A0bTB8BvhwOmgSj6ald//AB2vT6KVkF2eYH4DfDgnJ8Pyk+p1K7/+O0o+A/w5AwNBmA/7CV3/APHa9OoosguzzAfAb4cDpoEo+mpXf/x2nj4FfDsdNDn/APBnd/8Ax2vTKKLILs84t/gn4CtriO4ttJvIZ4mDpJHq14rIw6EES5Brd/4QPSP+fzxJ/wCFHqP/AMfrqqKLCOF1b4U+FNZSJNXg1e/SIlo1utcvpQhPUjdMcGso/Ab4cHroEp+upXf/AMdr0+imB5efgJ8Nj/zL0n/gxuv/AI7Tf+FA/DT/AKFx/wDwY3X/AMdr1KigLnl3/Cgvhr/0Lr/+DG6/+O0n/Cgfhp/0Ljf+DG6/+O16lRQB5Yf2f/hmw+bw2xHvqF1/8dpv/DPnww/6Fn/yfuv/AI5XqtFAHlX/AAz58MP+hZ/8n7r/AOOV2vjXwdoXjfSotN8T2P26yimFwkfnSRYkCsoOUYHozcZxzXQUUAeVf8M+fDD/AKFn/wAn7r/45To/gB8M43Vo/DbKynIK6hdAg/8Af2vU6KAPNh8EPAA6aPdD/uK3n/x2nf8ACk/AYGP7JvMen9rXn/x2vR6Knlj2K55dzzST4G/D6UsZNEuHLfeLapdnP/kWmr8Cvh2v3dCnH01O7/8Ajtem0U7IXM+55kfgT8O2OToU5PqdTu//AI7Sj4FfDsdNCn/8Gd3/APHa9MoosguzzT/hRnw9x/yBLj/waXf/AMdpP+FGfDwdNDuP/Bpd/wDx2vTKKdguzzU/A/4f4wdGusen9q3f/wAdoHwP+H4GBo1yB6f2pef/AB2vSqKCbI8yb4FfDth82hzn66nd/wDx2m/8KF+HH/Qvy/8Agyu//jten0UDPMT8CPh0Rg6DMfrqd3/8dpU+BPw7Q5TQp1Ptqd2P/atem0UrDuzzU/A/4fnrotyf+4pd/wDx2oZvgJ8N52Bn8PSSEcAvqN0f5y16hRRZBzN9Tyr/AIZ8+GH/AELP/k/df/HK6DwV8LfB3gjVZdS8MaP9hvZYTbvJ9qmlzGWViMO5HVV5xniu1opiOA8U/B3wL4q1251nXtD+1alc7fNm+2Tpu2qEHyq4A+VQOB2rJ/4Z8+GH/Qs/+T91/wDHK9VooA8uj+AXw1iz5Xh10z126jdD/wBq0v8AwoT4b/8AQvSf+DK7/wDjteoUUrId2jzAfAb4cZz/AMI/Ln/sJXf/AMdoPwG+HBOToEp/7iV3/wDHa9Poosg5n3PMP+FC/Dj/AKF+X/wZXf8A8doPwG+HBGP+Eflx1x/aV3/8dr0+iiyDmfc8wHwF+HA6eH5f/Bld/wDx2j/hQ3w4/wCgBL/4Mrv/AOO16fRRZBzPueYn4EfDojnQZj9dTu//AI7Sf8KG+HH/AEL8v/gyu/8A47Xp9FFkHMzy/wD4UJ8N/wDoXpP/AAY3X/x2j/hQfw2/6F6T/wAGN1/8dr1CiiyC7PMP+FC/Df8A6F+T/wAGV3/8dpP+FCfDfGP+Eekx/wBhG7/+O16hRRZBdnmK/Af4coTt0CVc+mpXY/8AatRP+z/8M3Ys/hssx6k6hdEn/wAi16nRTsF2eVf8M+fDD/oWf/J+6/8AjldX4F+H3hjwJ9t/4RTTPsH23Z5/+kSy79m7b99mxje3THWuqooEFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin L Freeman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30502=[""].join("\n");
var outline_f29_50_30502=null;
var title_f29_50_30503="General principles of the treatment of edema in adults";
var content_f29_50_30503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of the treatment of edema in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30503/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30503/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30503/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30503/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30503/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30503/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/50/30503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema is defined as a palpable swelling produced by expansion of the interstitial fluid volume; when massive and generalized, the excess fluid accumulation is called anasarca. A variety of clinical conditions are associated with the development of edema, including heart failure, cirrhosis, and the nephrotic syndrome, as well as local conditions such as venous and lymphatic disease or malignant ascites (",
"    <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general principles for the treatment of edema in adults, including the use of diuretics to remove the excess fluid, will be reviewed here. The specific effects of diuretics in the three major generalized edema states (heart failure, cirrhosis, and the nephrotic syndrome), the clinical features and diagnosis of the generalized edematous states, and the treatment of refractory edema are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Diuretic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=see_link\">",
"     \"Clinical manifestations and diagnosis of edema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"     \"Treatment of refractory edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of edema consists of reversal of the underlying disorder (if possible), dietary sodium restriction (to minimize fluid retention), and, in most patients, diuretic therapy. Before initiating diuretic therapy, it is important to consider the following questions, which apply to all edematous states:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When must edema be treated?",
"     </li>",
"     <li>",
"      What are the consequences of the removal of edema fluid?",
"     </li>",
"     <li>",
"      How rapidly should edema fluid be removed?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     When must edema be treated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema is the only form of edema that is life-threatening and requires immediate therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most other edematous states, removal of the excess fluid can proceed more slowly, since it usually is of no immediate danger to the patient. This is particularly true in patients with cirrhosis in whom hypokalemia, metabolic alkalosis, and rapid fluid shifts induced by diuretics can precipitate hepatic coma or the hepatorenal syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Diuretic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     What are the consequences of the removal of edema fluid?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retention of sodium and water by the kidney in heart failure and cirrhosis is",
"    <strong>",
"     compensatory",
"    </strong>",
"    in that it raises the effective arterial blood volume (also called the effective circulating volume) toward normal. In comparison, fluid accumulation is",
"    <strong>",
"     inappropriate",
"    </strong>",
"    with primary renal sodium retention (eg, renal failure) where both the effective circulating volume and the total extracellular volume are expanded. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the retention of edema fluid is compensatory (eg, heart failure or cirrhosis), then removal of this fluid with diuretics should diminish the effective arterial blood volume (ie, tissue perfusion). To the degree that the fluid lost by diuresis initially comes from the plasma volume, there will be a decrease in venous return to the heart and therefore in the cardiac filling pressures. From the Frank-Starling relationship, the reduction in the left ventricular end-diastolic filling pressure (LVEDP) should lower the stroke volume in both normal and failing hearts, possibly resulting in a fall in cardiac output and consequently in tissue perfusion (",
"    <a class=\"graphic graphic_figure graphicRef58693 \" href=\"mobipreview.htm?32/56/33677\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is a large body of evidence that this sequence is common in edematous patients with heart failure or cirrhosis, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of diuretics to patients with either acute or chronic heart failure frequently leads to a reduction in cardiac output [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. A similar sequence can occur in cirrhosis, particularly in patients who are rapidly diuresed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diuretic-induced fluid removal leads to increased secretion of the three \"hypovolemic\" hormones (renin, norepinephrine, and antidiuretic hormone) in many patients with heart failure or cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/6-8\">",
"       6-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of diuretics in patients with heart failure\", section on 'Hemodynamic effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Overly rapid fluid removal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the reduction in the effective arterial blood volume, most patients benefit from the appropriate use of diuretics. As an example, the diminished exercise tolerance and symptoms of pulmonary congestion in patients with heart failure are often improved by diuretic therapy, even though the cardiac output may fall by an average of 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/2\">",
"     2",
"    </a>",
"    ]. This observation suggests that small reductions in the cardiac output can be well tolerated. Similarly, relief of symptoms of fatigue and bloating are common in patients with noncardiac causes of edema.",
"   </p>",
"   <p>",
"    However, in some patients, the decrease in effective arterial blood volume with diuretic therapy is sufficient to significantly impair tissue perfusion. This most often occurs in two settings: when there is very low baseline effective arterial blood volume, as in severe heart failure, and after overly rapid fluid removal in cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adequacy of tissue perfusion following diuretic therapy can be estimated simply by monitoring the blood urea nitrogen (BUN) and serum creatinine concentration. As long as these parameters remain constant, it can be assumed that diuretic therapy has not led to a significant impairment in perfusion to the kidney or therefore to other organs. In comparison, significant and otherwise unexplained elevations in the BUN and serum creatinine concentration indicate that further fluid removal should be avoided if possible (eg, no pulmonary edema) and that other therapeutic measures should be attempted (such as vasodilator or inotropic therapy in heart failure). The decline in tissue perfusion in this setting can also lead to weakness, fatigue, postural dizziness, and lethargy or confusion due to decreased cerebral blood flow. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of diuretics in patients with heart failure\", section on 'Hemodynamic effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients have an otherwise unexplained rise in BUN (eg, not due to variceal bleeding in cirrhosis) with no change in serum creatinine (often called prerenal azotemia). It is likely that there is a reduction in renal perfusion that is too small to lead to a reduction in glomerular filtration rate and therefore an elevation in serum creatinine. This finding alone is an indication for more frequent monitoring of the serum creatinine. In some cases, however, an attempt to achieve additional diuresis may be justified if the patient still has symptomatic edema and does not have symptomatic hypovolemia. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In contrast to the adverse hemodynamic changes that may be seen in heart failure, cirrhosis, or some cases of the nephrotic syndrome, impaired renal perfusion should",
"    <strong>",
"     not",
"    </strong>",
"    occur after the appropriate use of diuretics in patients with primary renal sodium retention (",
"    <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"     table 1",
"    </a>",
"    ). In these conditions, the effective arterial blood volume is increased by fluid retention. Although diuretic therapy will still reduce the effective arterial blood volume, it will be from an initially high level back toward normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     How rapidly should edema fluid be removed?",
"    </span>",
"    &nbsp;&mdash;&nbsp;When diuretics are administered, the fluid that is lost initially comes from the intravascular space. This results in a reduction in the venous pressure and consequently in capillary hydraulic pressure, thereby promoting partial restoration of the plasma volume by the mobilization of edema fluid into the vascular space.",
"   </p>",
"   <p>",
"    The rapidity with which this occurs is variable. In patients with generalized edema due to heart failure, the nephrotic syndrome, or primary sodium retention, the edema fluid can be mobilized rapidly, since most capillary beds are involved. Thus, in patients with anasarca, removal of 2 to 3 liters of edema fluid or more in 24 hours can usually be accomplished without a clinically significant reduction in plasma volume.",
"   </p>",
"   <p>",
"    An important exception occurs in patients with cirrhosis and ascites but",
"    <strong>",
"     no",
"    </strong>",
"    peripheral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In this setting, the excess ascitic fluid can only be mobilized via the peritoneal capillaries. Direct measurements have indicated that 300 to 500",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    is the maximum amount that can be mobilized by most patients with isolated ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/4,5,8\">",
"     4,5,8",
"    </a>",
"    ]. If the diuresis proceeds more rapidly, the ascitic fluid will be unable to completely replenish the plasma volume (",
"    <a class=\"graphic graphic_figure graphicRef70893 \" href=\"mobipreview.htm?10/29/10717\">",
"     figure 2",
"    </a>",
"    ), resulting in azotemia and possible precipitation of the hepatorenal syndrome. This limitation does not apply to patients with cirrhosis who also have peripheral edema, due to the rapid mobilization of the edema fluid into the vascular space (",
"    <a class=\"graphic graphic_figure graphicRef70893 \" href=\"mobipreview.htm?10/29/10717\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Overly rapid fluid removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Venous insufficiency, lymphedema, and malignant ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with localized edema due to venous or lymphatic obstruction or malignant ascites represent another setting in which diuretic therapy can lead to volume depletion. As discussed in the preceding section, a reduction in venous and therefore intracapillary pressure with fluid removal in a patient with edema allows the edema fluid to be mobilized and the plasma volume to be maintained. However, this sequence will not occur in patients with venous insufficiency, moderate to severe lymphedema, or ascites due to peritoneal malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/9\">",
"     9",
"    </a>",
"    ]. As a result, diuretics should be used with caution in such patients with monitoring of the serum creatinine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention and treatment of lymphedema\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mainstays of therapy of lower extremity edema due to venous insufficiency are leg elevation and well-fitted, knee-high compression stockings. Some medical therapies also may be effective. These modalities are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     USE OF DIURETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretic therapy in generalized edematous states is generally begun with a loop diuretic, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    . In addition to monitoring the degree of diuresis, patients should also be monitored for electrolyte complications, such as hypokalemia, metabolic alkalosis, and hyponatremia, and for signs of tissue hypoperfusion, such as an otherwise unexplained rise in serum creatinine.",
"   </p>",
"   <p>",
"    The approach to diuretic therapy has some unique features in each of the generalized edematous states:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with cirrhosis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      and a loop diuretic is the preferred initial regimen. Spironolactone contributes to the diuresis but, importantly, tends to raise the plasma potassium. Hypokalemia induced by the loop diuretic can precipitate hepatic coma, and spironolactone provides protection against hypokalemia. The diuresis should proceed slowly in the absence of edema, since there is a limited rate at which the ascitic fluid can be mobilized to replenish the plasma volume, and patients with tense ascites are often treated with therapeutic paracentesis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'How rapidly should edema fluid be removed?'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link&amp;anchor=H8#H8\">",
"       \"Initial therapy of ascites in patients with cirrhosis\", section on 'Diuretic therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35465?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of diuretic-resistant ascites in patients with cirrhosis\", section on 'Therapeutic paracentesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with heart failure, the rate of diuresis is usually not a limiting issue, but careful monitoring for signs of hypoperfusion (eg, rise in serum creatinine) is important. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"       \"Use of diuretics in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with nephrotic syndrome, higher-than-usual doses of a loop diuretic may be required because of binding of the loop diuretic by albumin in the tubular lumen, thereby rendering it inactive. A higher dose is also required in patients with renal failure because transport of the diuretic into the tubular lumen is impaired, and the maximal response to the diuretic is limited by a reduced number of functioning nephrons. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link&amp;anchor=H23421802#H23421802\">",
"       \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\", section on 'Diuretics and sodium restriction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with idiopathic edema who are already on diuretics, the initial approach is to discontinue the diuretic for at least two to three weeks, since some and perhaps many cases are diuretic-induced. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20981?source=see_link\">",
"       \"Idiopathic edema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with resistant edema from any cause, high-dose intravenous loop diuretics and the use of diuretic combinations acting at different sites in the nephron (usually a loop and thiazide-type diuretic) may be required. Although",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=see_link\">",
"       metolazone",
"      </a>",
"      has been championed as the preferred thiazide in this setting, there is no evidence that it is more effective at equivalent doses than more commonly used thiazides (eg, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      or, if available, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/2/35878?source=see_link\">",
"       chlorothiazide",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of refractory edema in adults\", section on 'Enhanced tubular sodium reabsorption'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Choice of loop diuretic",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     Furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    , which are sulfonamides, are the most widely used loop diuretics.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/10/7334?source=see_link\">",
"     Ethacrynic acid",
"    </a>",
"    , which is not a sulfonamide, is rarely used because it may be more ototoxic than the sulfonamide loop diuretics in high doses, and its relative insolubility makes it difficult to administer intravenously. The main indication for ethacrynic acid is a hypersensitivity reaction to one of the sulfonamide loop diuretics, which is usually manifested as a rash or rarely acute interstitial nephritis (as can be produced by other sulfonamide drugs).",
"   </p>",
"   <p>",
"    A separate issue arises for patients with a history of allergy to sulfonamide antimicrobial drugs. Although patients who have a documented allergic reaction to a sulfonamide antimicrobial have a higher risk of allergic reaction when treated with a sulfonamide non-antimicrobial, most will not react (90 percent). Thus, patients with a history of allergy to sulfonamide antimicrobial drugs would be expected to tolerate non-antimicrobial sulfonamides, such as loop diuretics. Allergic reactions that do occur appear to be related to a predisposition to allergic reactions rather than to sulfonamide cross-reactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=see_link&amp;anchor=H22#H22\">",
"     \"Sulfonamide allergy in non HIV-infected patients\", section on 'Between sulfonamide antimicrobials and non-antimicrobials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diuretic dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that there are significant differences in efficacy among the different loop diuretics if given at equipotent doses. All diuretics have a dose-response curve characterized by a minimum rate of drug excretion that is required to induce a diuresis, an ascending portion of the curve in which increased diuretic excretion is associated with increases in sodium excretion, and a plateau at which further elevations in diuretic excretion do not add to the diuresis (",
"    <a class=\"graphic graphic_figure graphicRef67654 \" href=\"mobipreview.htm?16/36/16973\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Studies in subjects with normal renal function indicate that a diuresis begins with as little as 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , with the maximal effect being seen with 40 mg given intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/11\">",
"     11",
"    </a>",
"    ]. Going above this maximum will produce little or no further diuresis but may increase the risk of side effects.",
"   </p>",
"   <p>",
"    The effective diuretic dose is higher in patients with heart failure, advanced cirrhosis, or renal failure. In these settings, decreased renal perfusion (and therefore decreased drug delivery to the kidney), diminished drug secretion into the lumen (due to the retention of competing anions in renal failure), and enhanced activity of sodium-retaining forces (such as the renin-angiotensin-aldosterone system) combine to diminish the diuretic effect (",
"    <a class=\"graphic graphic_figure graphicRef67654 \" href=\"mobipreview.htm?16/36/16973\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The initial aim is to find the",
"    <strong>",
"     effective single dose",
"    </strong>",
"    . Most patients with generalized edema are begun on a loop diuretic. Depending upon the circumstance, the drug can be given orally or intravenously. The onset of diuresis is earlier and the peak diuresis is greater with intravenous therapy because of more rapid excretion in the urine. This difference is not likely to be important in stable patients who are typically treated with oral therapy.",
"   </p>",
"   <p>",
"    The intravenous equivalent for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , but not the other loop diuretics, is one-half the oral dose because of decreased oral availability. A typical oral dose of furosemide is 20 to 40 mg. Selected hospitalized patients may benefit from a continuous intravenous infusion of a loop diuretic, which can produce a greater diuresis than intravenous boluses (",
"    <a class=\"graphic graphic_figure graphicRef75714 \" href=\"mobipreview.htm?31/33/32285\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=see_link&amp;anchor=H3#H3\">",
"     \"Loop diuretics: Maximum effective dose and major side effects\", section on 'Intravenous infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described below, the maximum diuretic response at a given dose in stable patients is generally seen with the",
"    <strong>",
"     first dose",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef75714 \" href=\"mobipreview.htm?31/33/32285\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/12\">",
"     12",
"    </a>",
"    ]. Lack of significant net fluid removal may be due in part to an insufficient rate of diuretic excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/13\">",
"     13",
"    </a>",
"    ]. In this setting, it is important to ask the patient if there is a diuresis in the few hours following diuretic ingestion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the answer is yes, then the dose is effective but short-lived. The appropriate response is to give the same dose twice daily.",
"     </li>",
"     <li>",
"      If the answer is no, then giving the same dose twice a day will also be ineffective, since adequate urinary levels are never achieved. The appropriate regimen is to double the individual dose until a diuresis is obtained or the maximum dose is reached (eg, for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , 320 to 400 mg orally or 160 to 320 mg intravenously) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/11,13\">",
"       11,13",
"      </a>",
"      ]. Additional measures are required in patients who do not respond to this regimen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=see_link\">",
"       \"Loop diuretics: Maximum effective dose and major side effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"       \"Treatment of refractory edema in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Time course of diuretic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;When treating patients with edema, it is important to appreciate the time course of the diuretic response. Assuming that the patient is stable, the diuretic dose is not changed, and dietary solute and water intake are relatively constant, the diuresis of water and electrolytes is maximum with the first dose (",
"    <a class=\"graphic graphic_figure graphicRef75714 \" href=\"mobipreview.htm?31/33/32285\">",
"     figure 4",
"    </a>",
"    ), gradually declines over one to two weeks, and reaches a new steady state in which solute and water excretion are again equal to intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reason for this time limitation is that the initial solute or water loss leads to compensatory changes that limit further losses. Fluid loss eventually leads to increases in a variety of sodium-retaining factors, such as angiotensin II, aldosterone, norepinephrine, and a possible reduction in systemic blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30503/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These sodium-retaining forces eventually equal the sodium-losing activity of the diuretic; the net effect is a new steady state in which the extracellular fluid volume is reduced by the amount of sodium lost during the first few days of therapy, but sodium intake and excretion are equal. If the patient remains edematous when the steady state has been achieved, then a higher diuretic dose or combination therapy is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Refractory edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with generalized edema do not respond adequately to therapy with loop diuretics. The therapeutic approach to such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"     \"Treatment of refractory edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"       \"Patient information: Edema (swelling) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Edema is defined as a palpable swelling produced by expansion of the interstitial fluid volume; when massive and generalized, the excess fluid accumulation is called anasarca. A variety of clinical conditions are associated with the development of edema, including heart failure, cirrhosis, and the nephrotic syndrome, as well as local conditions such as venous and lymphatic disease or malignant ascites (",
"      <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pulmonary edema is the only form of generalized edema that is life-threatening and requires immediate therapy. In all other edematous states, removal of the excess fluid can proceed more slowly, since it is of no danger to the patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'When must edema be treated?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the retention of edema fluid is compensatory (eg, heart failure or cirrhosis), then removal of this fluid with diuretics should diminish the effective arterial blood volume (ie, tissue perfusion). To the degree that the fluid lost by diuresis initially comes from the plasma volume, there will be a decrease in venous return to the heart and therefore in the cardiac filling pressures. From the Frank-Starling relationship, the reduction in the left ventricular end-diastolic filling pressure (LVEDP) should lower the stroke volume in both normal and failing hearts, possibly resulting in a fall in cardiac output and consequently in tissue perfusion (",
"      <a class=\"graphic graphic_figure graphicRef58693 \" href=\"mobipreview.htm?32/56/33677\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'What are the consequences of the removal of edema fluid?'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      In patients with generalized edema due to heart failure, the nephrotic syndrome, or primary sodium retention, the edema fluid can be mobilized rapidly, since most capillary beds are involved. Thus, in patients with anasarca, removal of 2 to 3 liters of edema fluid or more in 24 hours can usually be accomplished without a clinically significant reduction in plasma volume. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'How rapidly should edema fluid be removed?'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      There are important exceptions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with cirrhosis and ascites but no peripheral edema, the excess ascitic fluid can only be mobilized via the peritoneal capillaries. Direct measurements have indicated that 300 to 500",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      is the maximum amount that can be mobilized by most patients. If the diuresis proceeds more rapidly, the ascitic fluid will be unable to completely replenish the plasma volume (",
"      <a class=\"graphic graphic_figure graphicRef70893 \" href=\"mobipreview.htm?10/29/10717\">",
"       figure 2",
"      </a>",
"      ), resulting in azotemia and possible precipitation of the hepatorenal syndrome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'How rapidly should edema fluid be removed?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with localized edema due to venous or lymphatic obstruction or malignant ascites represent another setting in which diuretic therapy can lead to volume depletion. A reduction in venous and therefore intracapillary pressure with fluid removal in a patient with edema allows the edema fluid to be mobilized and the plasma volume to be maintained. However, this sequence will not occur in patients with venous insufficiency, moderate to severe lymphedema, or ascites due to peritoneal malignancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Venous insufficiency, lymphedema, and malignant ascites'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diuretic therapy in generalized edematous states is usually begun with a loop diuretic, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      . In patients with cirrhosis, the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      and a loop diuretic is the preferred initial diuretic regimen. For other causes of generalized edema, loop diuretics are usually preferred, and higher doses may be required in patients with nephrotic syndrome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Use of diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some cases of idiopathic edema are diuretic-induced, and the initial approach in patients with idiopathic edema who are already on diuretics is to stop the diuretics for at least two to three weeks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20981?source=see_link\">",
"       \"Idiopathic edema\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with resistant generalized edema from any cause may require high-dose loop diuretics in combination with a diuretic acting at a different site in the nephron, typically a thiazide diuretic. There is no evidence that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=see_link\">",
"       metolazone",
"      </a>",
"      is more effective at equivalent doses than more commonly used thiazides (eg, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      or, if available, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/2/35878?source=see_link\">",
"       chlorothiazide",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of refractory edema in adults\", section on 'Enhanced tubular sodium reabsorption'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/1\">",
"      Cohn JN. Blood pressure and cardiac performance. Am J Med 1973; 55:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/2\">",
"      Stampfer M, Epstein SE, Beiser GD, Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation 1968; 37:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/3\">",
"      Lal S, Murtagh JG, Pollock AM, et al. Acute haemodynamic effects of frusemide in patients with normal and raised left atrial pressures. Br Heart J 1969; 31:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/4\">",
"      Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986; 90:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/5\">",
"      Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970; 282:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/6\">",
"      BARTTER FC, DUNCAN LE Jr, LIDDLE GW. The effect of changes in body sodium on extracellular fluid volume and aldosterone and sodium excretion by normal and edematous men. J Clin Invest 1956; 35:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/7\">",
"      Arroyo V, Bosch J, Gaya-Beltr&aacute;n J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/8\">",
"      Boyer TD. Removal of ascites: what's the rush? Gastroenterology 1986; 90:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/9\">",
"      Pockros PJ, Esrason KT, Nguyen C, et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992; 103:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/10\">",
"      Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.",
"     </a>",
"    </li>",
"    <li>",
"     Brater, DC, Voelker, JR. Use of diuretics in patients with renal disease. In: Contemporary Issues in Nephrology. Pharmacotherapy of Renal Disease and Hypertension, vol 17, Bennett, WM, McCarron, DA (Eds), Churchill Livingstone, New York, 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/12\">",
"      Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115:360.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, chap. 16.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/14\">",
"      Bock HA, Stein JH. Diuretics and the control of extracellular fluid volume: role of counterregulation. Semin Nephrol 1988; 8:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30503/abstract/15\">",
"      Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) 1980; 59:443.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6884 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30503=[""].join("\n");
var outline_f29_50_30503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      When must edema be treated?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      What are the consequences of the removal of edema fluid?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      How rapidly should edema fluid be removed?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Venous insufficiency, lymphedema, and malignant ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      USE OF DIURETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Choice of loop diuretic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diuretic dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Time course of diuretic response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Refractory edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/6884\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/6884|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/56/33677\" title=\"figure 1\">",
"      Frank Starling curves in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/29/10717\" title=\"figure 2\">",
"      Rapid diuretic therapy  in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/36/16973\" title=\"figure 3\">",
"      Loop diuretic dose response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/33/32285\" title=\"figure 4\">",
"      First dose diuretic response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/6884|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/3/5181\" title=\"table 1\">",
"      Major causes of edema by primary mechanism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20981?source=related_link\">",
"      Idiopathic edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=related_link\">",
"      Loop diuretics: Maximum effective dose and major side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_50_30504="Metagonimiasis life cycle";
var content_f29_50_30504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Metagonimiasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 475px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHbAlcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorj7T4i6DeWsN1Zw+IJ7aZFkili8PagySIRkMrCDBBBBBFAHYUVyq+PdE863jlj1u38+aO3SS50O+hj8yRwiAu8IVcsyjJIGSK6qgAooooAKKhvLu2sYPPvbiG3h3KnmSuEXczBVGT3LEADuSBU1ABRRRQAUUUUAFFFI7KiM7sFRRkknAAoAWiqek6pp+s2KXmkX1rf2bkhZ7WZZY2IODhlJBwauUAFFFQLd2zXr2a3EJu0jWZoA48xUYkKxXqFJVgD0JU+lAE9FQ2t3b3YlNrcRTiKRopDG4bY6nDKcdCD1HUVNQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeMXGka3rnwU+G1l4a1mLS77yNOlcPqEtkbqFbXLwq8QL5PBwB0Ge1ez15hpnh3xJH4L0Xw5rfhPwdrNtptrBbj7Xqkjo7RRhA+xrNgCcH1xnrQBiaFr1tr3w7nNtaX1pJZeLNPsp0utTm1EGVNQtQTHPKSWTpjGBnPHOT0/ivTteuPiroN3oLwWqxaTeRyXd1YyXMClpYCEO2SPDHaSMt0U8HqC50XxLdaXp2jweHvC+j6Xb39nckWWpysI0huo52CRC1RST5ZGMgZNdD4h8W6d4f1HydVnhgtksJb+SQ+Y0ipHJGhIRUIIzKM/MGzjCkZKgHj+k3PjfQfCVjZW0etWc0NhLLZw2mkecl3em6mzHcbkYwx7fKIO5OHY7jjFWfGUvi7WYPGOkyNrt3A8Mz24tdP8uGIJMhWMCW1VpHKggGOWUNhjhflr0z/AIWJ4aMJcXd2ZRcfZfso0+5+1GTZ5mBB5fmkbPmyFxjnNIPiN4XMVpKuoTNFcxJOrrZTsscbMUVpSExCCwIBk29D6UAYvxFiur/4SYsZdZvp/tNjKJpNPYXhVLyFmc26xKcqqk48scL0rktV174hx2EP2B9XfTmvrpI9Rm04x3jQhIjCZIUs5SoLmcf6hchFyVz83deIPiZpGm6RqF9YQahqP2KYQuY7C5ELN56wuFm8ooxVieFJyVIq1J8QtFt5Zvtsk8SfaIbWCNbK6e5eSSEyhGg8kMrbVYgDd05wTigDlrTWfF73VwNSuNWj1FLKF9PtbPSWNheym1VmM0rwF4szb12s0RUBcjmqFlqvji8SO3sr7xCYJpbBJ7280aOCa2kd2FwsaNCFaNV2neVYA/xNXbXvxN8J2enxXsuoztbvbtdkw2NxK0USsUZ5VSMmIBlZfnC8qR2NdJqWr2OmXOnW97P5U2oT/ZrZdjN5kmxn25A4+VGOTgcUAeVQXfxFso5JorrUtUuDNq1rFbXdhDHGRCJPskpZI0ILlE5LBG38AcGsyy134gSeH7yW4v8AUIpVuLbZnSrlrgApL5qAjTQoUkRkMIpduCC3zKa9Fu/iZ4UtUV5dRmKGN5maOxuJFjjSVondyqEIodGBZsDjOcEE1/EnxCsbHXNN0zTplmlfUo7S9la2lMECGNnYeeAIw4AU7SxIBPFAEevT6te/C/TJ0sLyXU5ZtOeW3vbWOadR9qhMheMJsDKu5iQo243AKRxxWu/8J3eeEb6O6udZujqmkawstqNOjXyJIzi3VNsQYGRSRhiSwOVwea9Ei+JHhZ4GmbUZYYwYMGeynh3rM+yN0DoN6M3G9cr6mpovHvh+W4mhE96pt4zJcvJptykdqAnmETOYwsR2c7XKnBHHIoA88lvPHukeJ9N0q2uLxtKhFmsMs9mzpcI2PNEvkWTqhGSg/eQhQqk7uSamtnxFrfhmB9UvvFaaxa6raXV5ZQaMvk2qR3aktbt9mPnbVw4w8hO3JBGVr0mP4jeGZLV5heXQKyRRiBtPuVuHaQMY9kJj8xwwViCqkEKx7GqP/CxdNOu2uy6hOhz6c9ys3kyec0wnWHywmN27JI2bd24Y9qAOMttf+Ip8S3MduLqW3TzvssN7Yyol1EICYXYrZqscrNtLBp1AO5dinArY+Fw1S68cajqWpya7c+bollE9xqum/Y9swlnaSKMCKMFV3A/xH5vvEYrr/wDhPvDYv5rSTUGieLzg8sttKkIaJS0qiZlEZZFViyhsja2Rwaq+D/Ga+JvFeu2VnHINNsbWzngkms5reR2mM+44lCkriNNpC45PJ7AHDaIPE9v4svtP0m41u2W81u/a4SbSwtpBbMkhS4Sd4sPJ5nl4UOykdV6muv8AhZrOveIoL3UNbYRQQbdOSBFXZJcQ5W4nVgMlWkyqjOMR5xzWZ4f+JYu9U1KTVZbaz0mG7vLeNZrG6gkjjthIXkMjKUlOI2JUbCg4JZuKszeO9L0iTw3Bo9hc2+h3c00LxjRbqKRQsJkXyYfLDMCSMlUYdfQ0AejUVU0jUrPWNLtdR0ydbiyuoxLDKuQGUjIODyPoeat0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHNeIfEN/a67Z6LoWlxahqU8D3Tm5ujbQQxKQuWcI7ElmAChT3JwKrr450+ya3tfEaPpuqsE+0W8aSXUVsXcpH5k8abEDEDBcrnPSrviHwvFq+p2ep2+o6hpWqWsbwpd2LR7mjfBZGWRHRlyoPKnBGRiuTHwv8ADWr6pFq66lNqF5AwguLmeOzvmlkikbIdpYXKMpypCFMbQOCBgA3m+IvhkR70vLqUGdrVRDp9xKZJlZ1aNAsZLuDG5KrkhRu+6QTbl8Z6NDfWFpcnUbaW+aNIGuNMuoo2dxlUMjRhFc9NrEHPGM8VSbwFYJpWn2lnqGpWc+n3txf2t7C0ZmjkneRpB8yFCp851wVPGO4zWXd/CfSr3xTa+IL/AFPU7rUYJ7e53ypaktJCFCnd5O9FO3LIjKpJJwM0Aa1n4+0bUbrT10uZrm3uvMxKba4XfsjZyIv3REjDYQVDAjpycKXJ8QvDjQ3Dm5vY5YJo7d7aXTbmO5MkilkVYGjEjZVWI2qeFJ7Gsz/hEfDN1BY+F4tam+2aPazoIIbyMXSRzxtGXcAbhxJlSAOcda53SfhH4GvIdV06y1Rb+4iuYHuFjSxY2s0SyKu6FIRHkrI4IkQ5xnqM0Aejf8JVo3/CKS+JDeEaNDE80k5icFFQkPlNu8FSpBXGQQRis/8A4WD4c8l3+1XfmJOtv9m/s+5+0s7KXULB5fmMCoLAhSMAnOBVPW/BAPwp1TwjockCPcWc1vDJLDFbpufJyywRqgGW/hT8zknM1f4YeHtZupYNa1a61DXZpEvftF2tpJPsjUxL+5MPlGMByOYzy2c5waANlviX4UEsaf2lK2+OKUutlOyRLI5RDI4TbHllZfnIwRg4puu/EfQdLi1NI5Z7m8so7grElrN5c0sKFniWYIULjacgElcMSODWZJ4H8K6LpuoWF5qos47+zgjkDNbWoEVvKz70RI0RfnnwxC4+ZehOTInwl8OJruo6nGrK1+1w00X2W1J3TqyyFZjD56/fYgCTAzjGOKANPSPiFomoi1iA1FNQmtY7w2f9m3RkSNywDY8oHbuRhuxg8f3lzQ1b4paLaNaLa2+p3Mr38VlcQNpt1HPbiRGdX8oxb2yE4AHPODwauWXgC0t4L9LjV9Xu5bzSk0dp5JIo5EgQyFSpjjTDDzWG7HYe5PP6Z8KfDmhzG0stavbPU7qWG9gaJbOGUNbBl3pEsIRsCfDEo33lzzyQDsNK8aaFquqjTrK6me5ZpEQvaTRxyNH99UkZAjMvOVUkjByODXM+MPiX/Y8viyytLGb7bottDOk0ttM8Em8ZIZgoVcDp8/zHOOQRV3wz8MND8OeJX1rT2c3DPLLtktLQkPJneRKIRNyWPHmY5xjHFTat4P0rxHqWuyx61eKt7HHY6la2ksLJvjG5N2UZkcK4OAwBBBINAFlfiF4caBnW6vGlW4+ym1GnXJufM2eZgQeX5pGwhs7cY5zXQ6RqVprGmW2oabOs9ncoJIpFBG5T7HkfQ8iuO8UfC3QfEmoXd9ftcfari5S63GOCZY2WEQ4EcsboQVUE7lY5GQRWlqMn/CDeCrSHSLSK8aGa1sYIpClojNPcJCC3lRbUAMm47Y+3SgDqqK4fWPE3iXRLQXWs6d4O0+2LiMTXfiWWJCx6Dc1oBng8Ve0vXtc/4Sq10bXtI020+1WVxeRTWWpPc/6l4UZWVoI8Z88EEE/dPFAHVUUUUAFFFFABRSMSqkhSxAzgdT7V5nefGbw/YXs9nqNhrNpdQNskilgTIP4OazqVYU/jdjswmX4nGtrDwcmt7Hptcx4q8Fad4mu3uL+a7jdrCXTyIXUDy5JIpCeVPzZhXB6YJ46YyfDPxS0TxJq8WnaTaapLcSckmBQqL3Zju4A/zzS+OtQ1e28S6dAt5rmnaG9tI73Wj6YL2VpwygI48mXYu0kg7Bk5+bjFOnUjUV4O5GKwdfBz9niIuL7Mh8X+BbibU5tc8MzzRa/NdrP5rXq26xKLfyWC5t5gQVVcqyHnkMMAHJ0z4LaR9g0V9WlWTVbOzjtriRbS1uI5trFulxDIVwWYZXaSMZ6DGdf6948QaybT+2X1JIdULWh0lfs1sESQ2jW8vl/vnYiL5d0mdzZVcYqt4mtfFj3ltHqOpeI7ix0+/wBPvVvLbTIpJk8yKcTbESAhwjbONjEb/mzxizmOzu/hbpV3f6xeXGo6ibjU0KSPFHbQlD5iSK37uFfMZWRcGXeQMjuc6MXgOyGqwandajqV3fR3sN+0spiHmSx27wDcEjUYKyEkADkDGBxXm+peIfGt34k1KztbHXZtHkt9QgaG/wBODqSsDmFwBaIuHdQAplkzuwVBOK2rO68bR6msyzalHY2+paZaJp66dEsLW0lvB9ofPl78K7ScqwClSDwMAAh8X/Ce8uLGXTvCt7Ja219ayWd/PPeqpeN55JsGL7O2/aZpMYeM4OCT1r0bxX4cg8RRWHmXl3Y3NhdC7tbq0KeZFIFZOjqykFXYEFT19hXk8Vz49t9JvpNP/tKwFhpv2q3srfSYVS5uTe3IZCvlZ5jWIlUKn5g2fmydabxJ4jt/iJptje3uq263Wuy2i2J05RZvYrbyOjrOYstISik4k4+YbQBmgDobT4XaNb6Je6YL3VJIrzTZtMlkklQyGOWWSVmzsxv3StzjGMcHqZLv4a6Zdag8suo6qbB7z7e+mh4vs7TGPy2bPl+ZypOQHxk5AFZfxOuPGMV/q0nhi81K3gstF+128NrYxzrdXYkYeWS0bE5UD5VIPIPHfH8T6h8QNHN/Z2Nzqeo2sWowL/aJs1E4ga33NsEVtIGUS8ZELkZwf7wAN7Q/hDoGjRxx2k04SO4trhNtrZxODBKsqKZI4FdwSoB3sxI7g81s3vgSzurvWT/aOpRadrIf+0NMQxG3nZ4hEzZaMyKSoX7jryoPrnzKC48U2OuS69qTeIrnULjw7HFGml6Ydk8qS3PyMZbXMbKrJIAyJuZiArLhKm0bxH47lhePWH8QW2mLqWxtRttIM92IDbhlCxtaRll8zIL/AGfI6f7VAHdD4a2rSi7n17XZ9XjeB4NSkkh86AQrIqKoEQjK7ZpQdyHO8k5ODUL/AAo0NmspvteqDULJJfIvhMvnpNJN5zz7tuPMLFs8bSGIKkHFc7a6344b4g21qJL4aJ59usTXNhKFubYxKXkk2WRCTFixIaWIKRgoB1LLUPGceg+ErnxBqniK3TULRpdTlsNGjmuLWcKnlx+SsDsitmQsSjfMoA2A4oA3F+D/AIbGqajeMJH/ALQFwLhGtbQsxnRllYTeT5y53scLIAM4A28V0PhTwjH4e1G/v21bVNUvL2C3t5Jb5oiQkPmbAPLjQf8ALRsk5zx3znzm58TeN/8AhOhb6db+IG0ndcwuLuwyuFt3aKVStogUM6pgGZzltpQdBZu7jxZpy2Gp3EWr6ley+HJZZXg06BZ7a4aS0HlRt5DFcDzHMZDk7WO07VAAO0/4QHTl2GK7vo5Eur68R8xPiS73+ZwyFSB5h2gg9Bndzmv4Z+G+leHru0urW6vZJba5lukDLDFHuki8ogRRRoijHPyqCWJJJrzaLxN8S30Ub4tUWJdTmia8+xSCfyPJjaL5fsDMyl2kBb7MPugZHU+0+EZtQuPC+lTa00bak9tG1w0cTxBnwMnY6qy567WUEdMCgDC1q0PgX4QavDoNxMsmj6PcvaTTBXdWSJ2ViMbSQQO2PavFtG8W+PdW1CO0t/GF8sjgkH+z7aToM/djtmbt2Fe5/Fj/AJJZ4y/7At7/AOiHr5/8Aa3beHfFFtqN6k0kEaSKVhALfMhA6kDqfWg8LOMTOjUoqM+VNu/4HQfDrxx4tvfiH4d0/U/EVze2N5NNHNBLbWyBgttNIOUiVhhkU8GvoqvlX4Yf8lV8If8AX1cf+kdxX1VQdGTVqlfDKdR3d2FFVtTv7TS7GW81G5itrWIZeWVtqr+P6VxOu+Kr59Pa+81fDmiFgiXt7CXu7gnoIbfqCe28Fv8AYoPVO8mljhiaSZ0jjUZZnOAB7msWTxh4ZjbbJ4i0dW9Dexj/ANmrx+7um1OYy2ul78Z23/iIm9uCfVIMiOL2/wDQRTPsd2xzLrOp5/uwyiBB7BIwqgfhUOaRwVcyoU3a9/Q9y0/WNM1IkadqNndkdRBOsmPyNXq+eptOuHCbruG7CnO3UbKG4z/wPasg+ocVr+HvEWr6ZqFtZRzLayzkJb29zcvcWNy//PIO+ZbdyPu8uh6YzgU1JPYujj6NZ8sXr5nt1FZPhvXINdsXlijkt7mFzDdWs2BJbygZKMB9QQRwQQRkGtaqOwKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzn4n6p4h03VtK/sOTVXtmU+da6dZF5JG3KAfNa2mjUYz8rNF1zv4rjYT4qs9M8cafJpd/FZzf25PpsUenC5S+meWdlEwZGwCChRcbZMn5myEr2S/wDEGladfmy1C/htZxbm7PnnYgiDqhYufl+86jGc/MPWszVPHegaZBdT3c16ba1llhuJ4dOuZo4WjAL73SMqoG4fMSBweeDgA5LSrnxnHq9nczXGomyOt/YGsDp8awpZ/Zy3m5EYcYkAAbdt7YNWvidqniax1Rk0WTV4LYae0tp/Zumi8Fze78CGYlG8uPG3nKfeb5xitDTviXo891r8V5HeWsel3ws0lFpPKtzlYiuwrHhnZpcCNSzEAOMqc1o2/j/w5cTWsEF5cSXN15nl262M5mzHIscgaPZuUqzrkMAQMseASADJ+F2kapZXfiy61ae+SS81WSRYJoo1jH7uP50IQMw/hBLEYQd8k8x4B0nxXpsXhvTF1PWbaxuRqlxfGWygBidbhDENxh+Tfukb5gSwZsdBt6Px547ufD/iiLTbcQxW8GmT6rdzXFjczIyRnhPMiBEQwHJkIfHyjYSQDa8RfEGytfD3iKfR/NudT0uwuLnmxuHtVljgMoR5ggT+7ldwbnsaAPP9F1/4kz2Gqtqtxc2N2LTcYzpdxMYJ/PjBEOyx2ldhcffuMfK3IVsybfGGoOdbtZPEVlqdpoF95cs1lE73MyTgxxFWt0+V9oIXyo5CuOAa9W8J+KdO8Swyixll+1W6RtcQy20tuyb1ypCyKCVODhhkHBwTVS++IHh3T7i+h1G5vLOSzgluZPtOn3MQaKIgSPGWjAlA3D7m7qCOKAOB8QxX3ivwj4z1xLWeW6+yppNnDDCzv+6YNOVQAkkzF0I5/wBSKt6PfeM9R16Gyh1HXV0GW8kjTU7zSY4LnyxbBjuR4VCAS8KzRjPI+auyX4geHGtJp/tdyPKnS1MDWFwtw0jrvRVhKeY+5QWG1SCAT2NM8F+Ll1bwK/iPWGis7eOa88xzG8QjihuJYwWV/mU7IwSDznPA6UAebS+KfiI2u6sNM0/WmtTa3rRw3tlu8iRHXy9hFtEpJUuVUSzbsDJz1n8QT+Iv7U8Pap4cPiPWXt7bUIrm71HSfs9xbI7WZPlxGGJXbarlFI+Yhhltu2vQG+JHhlVj3XN+s0kwgS2Ol3QuGcoZABD5fmYKqxB24ODg1Zi8eeH5zp4tLq5u3voVuIUtLGedhGWKh3VEJjG4EZfbypHY0AecapqXimxg1W40ptXhjfV3dBBorR3N9D9jttrlhZyqG37wTJGuSNu5QmBc0C28U6f4g1DUrd9Wht73xJCtxYTWcbJJA9nAHnZgm7hhjcjBAUIwa7e4+IPhiCwt7yTUm8ieJ5o9ttKzlVlWE5QLuDeY6oFIDFjgAnNQW/j6yuPF1hokdhqoF5ZtdJPLp11GVIl8va6NECg6ncxAHH94EgHZVyvxL/5Fyz/7DWk/+nG3q9r/AIq0rQLmGHVnvIFl2ATixnkgUu2xQ8yoY0JbAwzDqPUVl3t7o/ju2utGsb3VImt7hJvttvZSIiS21wjDZNLEYXIkjAKjd0bjg4APKP2mPCPi3xBZ315Bp0WqafbmCPTbezmme4hJZTLI0CxEOxPy7t/yoDxkmvWJ2nb4k+GGu444rg6HqJlSJy6K3nWGQrEKWAPQkDPoOlS/8Ivq/wD0PfiT/vxp3/yLUuk+FpbPX4dXv/EGr6tcwWstpEt4tsqRpK8TOQIYYySTCnUnv60AdLRRRQAVV1K/tNMspbvULiK2tYhl5JWCqP8APpWP478VWvg/QJNSvIZpvmEccca/ec5wCeijjqf1PFeLabonir4vagmo61O1joKMfLABCY9Il/iPYuf1xiuatiOR8kFeT6f5nuZbk31mm8ViZqnRW8nu32iur/rU1/E3xc1PXL/+yPh9YzSSudoujHukb3VOij/abt2FchrPwx8WXGr6UupTC61XVTI8paQyeQqbMtI/T+PtnoAM5xX0R4V8L6T4WsBa6ParEDjfIeZJD6s3f+XpitvvWDwUqyvXld+WyPTp8S0sulyZZRUY66y1lLTRt9FfWy/A5jwD4M07wZpP2WxHm3MmDcXLLhpW/oB2Hb65NdPRRXdCCguWK0PlsRiKmJqSrVpXk92FFFFUYhRRRQAVwvi7VfBvgnWINY1HTLKLWr5tn2qCzQ3DLwGZpAN20DGecnoAa7quY+IXhK18Y+HpbCfbHcpl7acjmN/8D0I/qBWdXn5H7Pc7MAsM8RBYu/s7623/AK7+R0cE0dxBHNA6yQyKHR1OQykZBB9Kkrw74JeK7rSdTm8FeI90U8LstqZD91h1iz6Hqv8A9cV7jU0KyrQ5l8zbNctnluIdGTut0+jT2YUUUVseaFFFFABXC/FyPxe+h2z+ByFuoZvNm2MBIygHCqrDawyckH0HBzXdUVvhq/1erGryqVuj1T9SKkOeLjex4P4T+Oclrdf2Z4902WzuYzse5ijKlT/00iPI+o/Kva9I1Sx1iyS80q7gu7Z+kkLhh9OOh9qzfFfhDQ/Fdt5Ot6fFcEDCTAbZY/8Adccj6dK8U1j4XeLfAl9Jq3w+1K4uoRy0C4E230ZPuyj8M+1e77LLcz/hP2FTs9YP0fT8jk5q9D4vfj+P/BPoW7toLy0mtbyGKe2mRo5YpUDJIhGCrA8EEEgg1zX/AArjwP8A9Cb4b/8ABXB/8TXn/gf442l1MNP8ZW39l3ytsM6qfKJ9GU8ofzH0r1m71vTrSPT5JruIRahMtvbSBgUkdlZlAI45CnH4eteVi8sxWDqezrQd3t1T9H1OinXp1FzRZQ0vwV4V0i/ivtK8NaJY3sWfLuLawiikTIIOGVQRkEj6E10FFVtUu10/Tbu8kUslvC8xUdSFUnH6VwGxx7XFnqOqal4j12aOPRNDleGzWXiMSR8S3B9WDZjX02tjlq8/mvrvxLqKa9q6skhQiytD920ibtjvIwxub/gIwBzs+KbOax+F/hNZjm2+1289/tOcvJucHPp57ofyrOrKpLoeLm2IlG1JbMKKKKyPCCoLy1hvbWS3uo1khkGGU9/8+tT0UBsXvB+tXEGpW11eStJfWlxFpOpSd7u3l/49Z29XVz5ZPu/tXsdfPN2dt7qrRMQ40d3fHZluYDEfrnfj8a+hq6Yu6ufXYSq6tGM5bhRRRTOkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOd8TeENK8SappN9qiSu+nNIUjVgElDgZWQY+ZcqjAZHzIp7VyGp/BPw5qGi2WmTXmqfZ7aCeDdIYJ3k85y7yEyxPtkyTiRNrDpmr/xFk8VNrPk+HL7UbK1i0W9vN1rZxTCW6RohDES8b8nc/wAowSAcdMjmNU1P4iabY30dvLqN/wDJps5uXsVSSESib7SsQjt33bCkXHlSMofnPBoA6nUPhVo1/a6haXF7qDWN5NFdNauIJI0uI0jRZgHiOSViUFW3Icn5fTS8K+AdL8NX1pd2Mspmtrae1UCC3gRllkjdiUhijXcDEoBAHGc56jzSyn8Uxa1p+v6xL4inuBo93DGumaWSZ3WfdHFJ5topjZlx8xSNSUBXAJBk0PxH4/nsNTF6Ndjs0vLLF5/ZpkuobdxJ55jRrSHzGVlQH9y2A5PzcUAepeI/CFhr81/LeTXSNe6VPpEnlMoAhlPzMMqfn9DyPY1han8LNJ1PUb67u7/UC11ZTWDLHHbRFY5IjEfnSEO+FJwJGcA844Fcrc6544Hi2yg0651STRi9r5E9/pkqG6Qt++89Y7E+W33lGXgAAViCMk3WvvGUWj6NeanqWvQQ3d3PHfGx0mOae0jRpfK2RCF2w+E3MVYYC4C5JIB6LpPh600vWL/UreSdp7yC3t5FdgVCwhwpGADk7znk9ulcK/wS8Ovc6hM97qZe9t7q2kYC3V9k5BfMghDyEY+UyM+BxWdL4j8Xf8J/pFtpsXiKXRjc28Nw19YbUmgaEbp8LZqIzuIJ3TBgwYeUo6R2t14xg0LwxrOqw6vqeqyaRdzXUMemwJNazeUm1I8xZjdjnIbIYj7uBtoA7nWvAljqeqz6ml/qNlqT3MN3Hc2zR7oJIo3iGwOjKQUkcEMGBz2qay8E6Xb+B7nwrPJdXmnXIuBM9w6+a/nSPI5JVQM7nOMD0ryiLxN8SjpV2Fh1VoE1GFRdvZOLhYGhYttH2AFh5gAJFqSM46fOO71CbX7z4MSy3kC32vPb8xixZ/NIkwMwyxKSdoBIMY5yQAMUAT+Gfhdovh6+sLu0mlM1lcG5jK2lnbhmMMkOH8iCPcNsrEZ5z3xkF8HgbTvDixajY69qWkR2dqY7qfzLfZLAkjy/vvMjZQFMknzLtIBOTWbp1z4xXxVa3FzdajLps+u3dlJZPYxrDFZrFK0Uu8Rh/vKgDltp3AYzycL4paVqcninxdJbnXJItR8JSWttDaWPnQXEyrdZhd1iYoRvVl+ZSzPjLDCgA6fTPh9C7+LZ7meOH+3bgNEbZY51htgd+0LNGyZd2kkYbSMvxnANXfD/AMO7Hw/d6ZcaZqmqRSWUcsJH7jZPHJIJDGyeVtRQwGBEEwOBXG6reePtE07ULPTpdSv4oTp7JdyWaLLFFIsnniPy7dw20pGMeVIyhznPFegfDe61i88JW03iKTzb8ySDe0EkLsgc7N6yQwkNjAJ8tQcZAwaAMnxr8LtG8X62up6ndXyTBIk2IsDqvlsWUoZI2eMknny2XdgZzWloXgiy0jxXf+IUvLqe+vEdJA0VvEmGYN83lRIZCNoAaQuQM4PJz1dZF7rUdjeNDdwSpHjKyjkMKTdgNeiqsGoWk8XmRXMTJ3O4DH19Kz9S8SafYxkh5buQHAitIzKxP4cfmapJvYlyS3NW6mW3t5Jn+6ik1lWXiK0uGVJt1u5/v/d/OuV1i88QeINqWtoumWg5BuGDux7HaOB+JNVE8ErdMDq+oXl3xzGG2Rn/AICMVfsnfVpGTrN/BG/4f19x2muahoElnLaazd6e9vKuHhnkUhh1+737GqX/AAm/hi1jSNdRiSNAFVUhfaoHAAwuAKraZ4b0rT0VbWxjXHfaM/nVnUNLhuLNoZIUKNgBPXvgflQowuU51nHlv8tSW08b+GbuTy4dast/9132Ef8AfWPUV0MciSxq8bq6MMhlOQfoa88i0K22Xtra2vlNPyxjUBxnjAPYV0HhLw8NEad4h5EUwBNurZUN/e9AfpROMFsEJTfxHS0UUVmahRRRQAUUUUAFFFFAHj3x78HvcWsfirSFaPULHBuDHwzRryJOO6evp/u12Pwt8XJ4w8Lw3TkC/gxFdoOzgfeA9G6/mO1ddIiyIySKrowKsrDII7givndfM+EnxVx848P6h+I8pj/NG/HH1rgq/wCz1far4ZaP/M+rwL/tjAPAS/i0k5U/NdY/5f5I+iqKRWDqGQhlIyCDkEUtd58oFFFFABRRRQAUUUUAcZ8QPAPhzxXZyz6xCltcRoW+3xEI6ADqx6ED/a/SvkfW7mSwmm0nTdal1DSLe4823kUNGhcD76ofunk9P8K+66zNU0DR9Vz/AGnpVheEjGZ7dHP5kV9LkvEEsvTp1k5x6K609Lr9UjhxWDVbWOjOO+C3jtfGXhtY7yQf2zZAR3IPBkH8Mg+uOffPqK6fxrqK6d4duiI/PubkfZbaDvNNJ8qJ+ZyT2AJ6Cquj+A/Dei6yuqaPpq2N4FKFoJXVWUjlSmdpHQ9OoBrz7402uvTa/ZzvFM+gxhYEWGQRhmlyjBnGWVmJVOgBViNwywPi5lVw860quFi1F620un2Wtrdjqw8J8qjUav3K0+ualqOmDR9MubB9BsoF0/dPaidNR2KEkdgSMRkgqMHJwTnBFc3YJfabMINW1AWGl7uLzyDdpCPRyXV1Uf3mD47tjmtDVdSbw4kcOr6TPpgCgRxyS2yjaOPlAl6dqzrLxppt/cC2tYLmWVuBGDFls+g3/N+Ga+M+t5kqrk6bce1v1PoKuAyytTUJyV11udnqng3XtJEV3plzJ4ksZYgzooiilQ9Q0YGFdSD0JzkDGc8Ysl99nu4bbULS90+WcHyvtkDQiUjGVUtwzDI4FXfAesnR9e0u2028mXRru6ayn0+UELbSlGZdqsA0TbgAU4HzZx0Nex6vpdjrOny2OqWsN1aSjDRyruB9/Y+45Fe7h60MVDnimujT6M+Yx2S04T5dn0tseNUkjpFG0kjKkaAszMcAAdSTWlefCnVZNYsEXWVm0a1nV90ss0Vy8XIeJmjIDHGCH4ORyDyTta34X8HeHzahNDbUdSlb/QtPaaSczOvfa7FVVcjLsMKD7gHVU2eVDKKj+KVjl/h/YpdaRpulRwM0+p3zX9zeS5aW4sIJN0TuTzhm2Io4BXcwHWvb6wfCuizaclze6nKk+s37CS6lQfIuBhIo88iNASB6kljyxrerY96EeWKiugUUUUFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByeueNbfR/Gdl4fns7pzdWEt4txHBNIiFZEQK2yNgqneSXJAXAz94U3SPH+i6hFZgTTPcTWkN3KbW0uZreFZIxIpabygqgqcjfsOMZA6Ve1zwtBq2uWWrC/vrK7toJbVvsxjKzQyMjPG4dG4JjXldre9YNt8L9Lt7zRLiPUNQzo9rFaWv7q1DBY4vLXdKIfMbPUqX2E/w44oA2dK8caFqk+nQ2s94r6i5SzNxp9xAtwRG0pKNJGoZdik7gcdOeRmvc/EXwvbwQTyajIYZYjPvjtJ5BHFvKeZIVQ+Um5WG59o+U88VjWPwl0uwkW4stW1W21BLoXcV3bpawtE3lvGwWNIBF8yyPuJTcTg54FQXXwY8N3CafukuGms7f7KJri2tLppY/MaQBhPA6ghnblQpIPJOBQB2/iHxDpvh+O2bU5Zg9zIY4Ire3kuJZWCljtjjVmOACSQMDvXL6L46/4SH4gjStEmjfRobCG8ec6fO5uDKJNoWXiOILsU/OCWJZQAVbHQ+JPDcOtyafPHfXumXtg7Pb3VkY96BlKsuJEdCCD3U9BjFV/CXg3TfC1xPNpsl27zWtvav58gfIiMrBs4B3MZnLHODxgCgDlda+Ka2r6tFBYXET6Xrttpk0ktncSRyQu8AkdWCAeZiZtqAsTtDAMrCuhf4i+GUtI7j7ZdMHaZTCmn3LTRmIgSGSIR74wuRksoAyPUU258A2Nxql5dnUdTSC61G31WSzVovK+0wtEVcExl+RAgI3YxnAB5GXr/AMI/D2tXbXdy84ujcz3PmPBbXABm2ll2TwumMoCDt3Dnnk0AaXxC8XtoHhrT7/Sds8mo3dvbW8wtZbtFWUj94Y4vmf5ckKCNxwAeabpfj/TJIooL2aSfUWlnh8vTrC7nJ8mUxO7IIi0Q3cENkKTgO2Nx2b3w3ZXemaRYu0kcGmT288AhCR5aHG0FQu0LxyFA9sVzWq/CzSdSjWKa/wBQSEXtxflVjti3mTTGV9sjQmSPliAUZTjuTzQBP4M8f2us6ld6VqLGDVF1O+s7dFtZkilSCZ1AErAoz7FDMobPU4Arua5ex8E6bZX1jdRT3hks9RvNSjDOuDLc+Z5gPy/dHmtgdeBknv1FABRRRQAVj+JLi3isik8Ykkf/AFa9wfX2rYrn/FOo6FoqpqHiC7hgVVwiyNkt/uoOWP0BqZtJXZdOlOrJQpptvotWY/h/RjcySS3NjFJEcGJ5lBwR3HH61t3VhfQhfsC2jIByjArz7dqzvAXjSLxm+ozafZyw6dausUc0pG6VyCT8o6ADb3P3u1daxABJOAOc+lKnNSinF6FYjCVMJUdKsrSW6+VzIs4L2SHNxbwQvn7vmFv5Co9RF/AYUtLWGZ5G25LEKg9TxW4OlFXdmNjPjs5yi+dMgbv5acfhnNZth4YtotRe/vGa5ui7MjMxwmfQeuK6EMCSAQSOo9KWgNBscaRrtjUKPQDFOoooGFFFFABRRRQAUUUUAFFFFABXDfGHwp/wlPhCdYI92o2ebi2wOWIHzJ/wIcfUCu5oqKkFUi4S2Z04TFVMHXhiKT96Lv8A16nl3wC8VHW/C50u7k3X2mYjGerQ/wAB/DBX8B616jXz14iVvhp8ZINUiBTR9RJdwo4COcSLj/ZbDAf7tfQisGUMpBUjII5zXPhJtxdOW8dP8j2OIsLTjWjjKC/d1lzLyf2l8n+YtFFFdZ88FFFFABRRRQAUUUUAFee/HnTYdR+GeqPLYT30lltuokhmMbRuvHmZHUIGZtvfGK9CrD8b6dc6t4XvrOzRJZZApMLvsWZQ6s0RbsHUFc/7VAHi3w3+E02rXM974utr+zt41VI42k8ue6b+JpGBLhBwAARn6ACu81z4M+E9RsJILS3udPmIO2WK4dxu9WRyVfnrkfjXQJ40srdV/tfT9V0dMhTJeWpESn0MibkA9yQK09I8SaLrNw8Gk6rZXsyLvZIJlc7c4zwemSOfes40oRVrGMKEIx5bX9T5Z0qfVNB8YXdnqsvnSabLBISSSQ9tcR8AnkqY3yueQpA6AAfXlfOnxx063sfHWp6rHKojbQ2ku0HVJd6orn/eRMf9s6+iUYOispDKwBBHcVhhly1KkfNfl/lY65RlGlDm8/uu7Dq5fRF+2+OPEV+wUraJBpsR7rhfOk/PzUB/3B6V1Fcx4NGzUvFcbffGrFj9Gt4SP0IrrMjp6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimu6xqWdgqjkljgCgNh1M8xPMKb13gZ255x9KxLvWnuGa20OM3U/Qy4/dx+5PesG80+80C7tdUkmNwxf9+w9T2+hH61108K5aSdm9l3/yOCtjlDWEeaK3fRf5neUVHBKk8KSxMGjcBlI7ipK5GraM7k7q6CimyOsaM8jBUUZLE4ArkdX1+9uBKdFRvssAzJcbMg/TPatqNCVZ2j/wDDEYmGHV5fctzsKKoaJfjUtNhuBjcRhwOzDrV+s5RcJOL3RtCanFTjswooqOaVYlBc9TgDuT6Cp3G3bVjb2My2kyLcPbFkIE0e3dH/tDcCOPcGvjjxl/pviTVJbG/vdYtoDzezjcxXIXJPZdxAB46jgZxXtnx48Yy20MfhXRWd9RvsLceXyyo3AjGO7fy+tdH4A+HljoPg6bTNShjuLrUI/9Pb1yPuA+i54Prk15mJh9an7KH2d359j7nI8Qsgwv17Eauq7RjpflT1lff06ffpa+D2i/2H8PtLiZNs9wn2qX1LPyM+4XaPwrs2AIIIyDxihVCKFQBVAwABgAUtehTgoRUV0Pj8XiJYqvOvPeTb+85H7RrGhztbrbPe2QP7pgCSF7DI/rWpb3Gq34H+jLp8J6vId8n4DoPxraorrlXUteVX7/APA2PMhhZQdud8vb/g7kNrbx20WyMHk5ZmOSx9Se5qaiisG23dnUkkrIKKKKQwooooAKKKKACiiigAoormfGviuy8PafMn2mI6tJG32W2HzO744JX+6DjJOBjvSbSV2NJt2RvXt9aWMYkvbqC2Q8bppAg/M0+2uIbqFZbaWOaJujxsGU/iK+WPEVyxge/WD+1L4z+XPNLgtnB3HLDAGfTAHTirlje6ho127aHPNpl2sS3B2P+4mI4YPEPlPpng9MH05FjI31Wh1vByto9T0z4/QaVqHhV4Z76zg1ezxdW8Usqo8i9GVQTzkZ4HdRWP8ACj4lzalN4X8MGBmuAssdzcP0MccbmML7/KuSfTvnjpUttN+LngCKW+gW2v0LR7l5a1uF4YA91PBx3BHfBHmHwr0DUPDXxktNN1WExzxxzEEcrIvlthlPcH/PNc9b2kMRGcdpWX4n12VvB4vJquHq61KSlJJ9Pdeq7q+tuj+R9LUUUV6h8KFFFFABRRRQAUUUUAFFFFABXK+OAdNOmeIogdulSn7SB3tZMLL/AN84ST/tnXVVi+MdRsNO8PXh1NgY542gSEDc87sCBGijlmPQAUAfNHxMnnuBexz8xalrF0l++cMUjkKRrnsAqp+C+hNfQfwo1yLXvAmlzIw+020S2l0mclJowFYH64DD2YV5V408Iz6bYafHqY2QapbW6ySn5lt9RSJUYN/syBce5DDq4rjvBXibU/AXiBpFikkRm8q9tGfP2hVGRg/89lHKk/fXqeuzysPL2FWdOe7bfyez+Wz7WRtjZSShXXwWUX5Nf57n1pXKuf7H+IAd+LTXYBGG7LdQgkD/AIHGT/36ra0DWLHX9IttT0qdZ7O4Xcjjj6gjqCDkEHkEUzxHo8OuaVJZzSPC+5ZIZ4/vwSqcpIvuCAffoeDXqmJp0Vz/AIV1yW+M2mauqQa9YgC6iXhZF6LNHnrG2Mj0OVPIroKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKgvIpZYitvcGCTswUN+YNT0U07O4muZWZgyafrchwdXRVz1SAA0sXh2F3D6hc3F647Sv8v5Vu0Vt9YqbLT0SX5HP9UpXvK79W3+bI4Yo4I1jhRY0XgKowBSXMKTwSRSoJEdSCp6GpaKxu73OjlVrdDhYv7b0a4eKxtp5LTdlUkXeB+KmtCO88S3YAjtIbb/acY/mT/Kuqorrli1LVwV+5wQwDhpGpJLsYEOgyXDB9ZvZbs5z5QO2P8h1rbjhjjiESRosQGAgGBj6VJRXPOrKe7OqnQhS+Fa99395yMqXHhe8kmt42m0qY5ZB1iNXY/FumyY2i4Ln+ER5NdAQDwRkUyOGKP/Vxop/2VArZ14TV6kby73tf1MI4apSdqM7R7NXt6aooW17d3hzBZNBF/wA9Lg4P4KOfzxVPxjrdr4X8P3esXmJHgTESk4LueFUemT1x2ye1b9fP/wAVtQufHXxDsPB+lSH7Nay7ZXHK+Zj52I/2FyPru9a4MXiPZwvBWb0R9DkOVrHYlRrS9yPvSfaK3/y7lz4G+HbjXdZvPG2vAyyvK32YuOGkP3nA9B90enPoK90qppOn22labbWFjH5dtbxiKNfQAd/U+9W6nD0VRgo9evqLN8xlmOJlWtaO0V2itl/XUKKKq3l/a2alrq4jiHozc/l1roScnZHlSkoq8nZFqqi6haPem0WdDcgZKA81kzX99qymPR4mggbg3coxx/sjr+NZOq6E+ipb6hYvJK8Dbpi3U+/07Guunhot8tSVpPZf59jhrYyaXPSjeK3fl5d/yO3oqvYXcV9ax3EDBkcZ+h9D71Yrkaadmd8ZKSutgopjOqkBmAJ6DuaZD5rSM0gCJ0VO/wBT/hRbqHNrYmooopDCiiigAooooAQ9DjrXxtaWzX2utfX96Xuzm6dypWW4bdkoWJ42nA46g9sYr7KrkdQ+G/hHUL+e9u9Dtnup2MkkgLKSx6sMEYJ7kdazqQlJWTsaU5qDu1c8PGp20aL57pCWO1FGSDwOBx156U2GXztZDKGCC0DAOpU/M/cH/dpnxE8HWngXxxp1ztabS7szPEWaR3gxggYJOdpOARzg89M1i6xrFrekPpzXKXcYKrcD90FyfukHluecEV5FWkqUuVntYf2mIScFc9Y/Z/uCt94ks92UP2e5A7AsHQ/+gLXrk1jbTXlvdywI11bhhFKR8yBhggH0PpXgfwq8b2fg7TRZ63pV2Jp5CbnUUYSMRnCs8fVQAei57nGSa9Sl+J/g2OES/wBvWzqegjV3b/vkAmvUpOLgle55FXnjUbWm52dFefQ/F7wk8+ya6vLZM4864spUj/Pbx+OK723miuII5reRJYZFDI6MGVgehBHUVsmnsYtNbklFFFMQUUUUAFFFZeua/pehrH/aV2sUkvEUKgySyn0SNQWb8AaANSo7iaK3gkmuJEihjUs8jsFVQOpJPQVzR1zXtQGNH8OyQRtkC41WYQAe4jXc5+hC0R+FZNRnS48V351VkIdLNY/Ks42HQ+VklyPVy3sBQBBHquq+Km/4p5zp2i99UkjBluP+vdGGAv8A00cEHspHNaekeFtM0y7F6I5bvUgCv229laebB6gMx+Uey4HtW7VXU7+00uwnvtRuI7a0gUvJLI2FUUAJqmn2mq6dcWOowJcWk6FJInGQw/z37V88fEHwdd21zdaMZ2N4IDNpd9IMm4iU/wCrk9XjYr83X5g3dhXos/xKv7iQyaR4e32XVHvrr7PJKPURhGK57biD6gVS8aa5Z+JfDnh7V7WOSG4g1b7PLFJgSQuYpFkjbHHoeOD8prysXVo16cpUprnhrp/Wz2Z6OHpVKU4xqx9yejv1Mn9mi/lmTXbYkrCUtrzyuySOJFfjt/q1z7g17hXzL8LvET+F9Q8Uw2FvHPf3VykFnE7EIMTXTM7kfwqAeByeBxnj0K08d+I9PmEuqWtlqln/AMtFsomhnQdyqs7B8f3cqfftWkMfQpRhCpKzaOPDYCs6b5FdRbX3M9B17w/Y615MlyJYbu3JMF3bSGKaHPXa45we6nIPcGsZ9V1Tws2PEch1DRc8arFEFkt/+vhF42/9NFAA/iVetdFouq2WtaZBqGl3CXFpMuUkX8iCDyCDkEHkEEGrxAIIIyK9EyGQSxzwxzQSJLFIoZHRgVYHoQR1FPrln8KyabM8/hO/OlF2LvZvH5tnIx5J8vIKE+qFfcGga5run8az4dknQYzcaVMJ1PuY22uPoA340AdTRWXomv6ZriyHTLtJZIjiWFgUliPo8bAMv4gVqUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ8mqQQakbO5PlOyho2Y4Vx9fXOavkgLkkAdc1n6zpFtq0KpcBlZOVdeo/+tWdZ+FbSEjz5p7hR0R2wv5CuhRoyim5NPta5yOWIjNxUU10d7fea0N6tzPttR5kS8PN/CD6D1P8quU2NFjQJGoVFGAqjAAp1YSavodME0veeoUUUUijnPiD4iTwt4Sv9TJXz0TZAp/ilbhePryfYGvPf2ePDbx2N54n1AM11fM0cDPydmcu3/AmH/jvvWV8b76fxP440fwfpz52Oplx0Ej9yP8AZTn/AIEa9w0qwg0vTbWxs0CW9tGsSD2Ax+dcMf32IcukNPmfU1n/AGZlEaS0qYj3n5QWy+b19LlqoLq3W5i2M8qejRuVI/KsvRfFWi63ey2mmXyT3Ealyu1l3qDgshIAdc8ZXI5HrW3Xem07o+VaUlZmDL4d80/vtT1B0/umX/61WbLQNOtGDrbiST+/Kd5/WtWitXiKjVubQwjhKMXzcuv3/mFIwDAhgCDwQaWisToOXn8O3dpdNLol79njc5MTk4H065FWodL1WUj7fq77f7tugQn8cVvUV0PFVGtbX72VzkjgqUXpdLtd2+4rWdlBaKRCh3H7zsSzN9Seas0UVg25O7OqMVFWirIKKKKQwooooAKKKKACiiigDzn47aEur+CJLlQgn06QXAY5DbOjAMOnUH0+WvI9N0Wy08RlIVa4VcGVyXbPcgknHNfS+rWEGqaZd2F2pa3uYmhkA67WGDj86+b9Pkk8nybrPnwlomYjhirlM59TtyR2zXnY6LVpI9HAz0cGTzQRTY8xASO/Q1Ui0q2iQIhlCjoN2ce3Iq5HLHIzrG6s0Z2uAfunGcGqs+p2sSyESq5Q4bBwFOM8n8R+deeubZHe+XdkNzZQpHIYXO9BkqTnA/nXonwD1lVXUvD0s5P2fbdWsTH7sTEhgv8AshhnHbfXnGhaguox35L7ismDhSPlKDGBjnv+VdD8LPCE2uaxqGrwaldabcWIiitp4ArAsdzMGVgcjBUY46124RyVSxxYvllTufQtFQ2STxWsSXUyzzquHlVNgY+u3JxU1eoeYFFFFAHP+KdVu7aSz0vRljbWL8sImkGUt41xvmcdwuVAHdmUcckTeH/DllopknTfdalOP9Iv7g755j7t2X0UYUdhVHRB9t8ceIr5sMtosGmxH+7hPOkx9TKgP+4PSuooAKKKKAEdlRSzsFVRkknAArxLXtabxlqq3hJ/sG1fOnw9BOw4+0sO/wDsDsPm6kY6n4taq0yW3hm1cq18plvWU4K2oOCuexkb5f8AdD+lcLrKamtop0JrRZ4+kNwh2SDHC5Ujb9efpXzudY5xthqbs3u/Lt8z3Mpwal/tE1dLb/M0azJDjTrwZ4/4SC1OPf7Kef0H5VD4T11PEOki7ED206SNDPbucmKRThlz3+vvUsn/AB4Xn/YwWv8A6SmvHy6Eqc6sZbqEj1MdNThSlHZyicN4Px/wsPUMZz5lxnOcf62Xp/8AWr02vMvCBz8Qr8dcPcdv+m0xr02s8z/iR/woWUfwZf4pfmJo2sv4P1dtRQn+xrlx/aUIHEZ6C5Ueo/j9V56qM+2xusiK8bBkYZDKcgj1FeJEAghgCD1BHWup+EmqtFHdeGblyWsFEtkWOS1qxwF/7Ztlf93ZXtZFj3NfVqj1W3p2+R52cYJQft4LR7/5no1FFFfSHgmL4h8OWesmOcmS01OD/j3v7Y7ZoT7HuvqrZU9xUXhXVbu6N3putLGms6eVWYxAiOdGzsmQHorYPHZlYc4yd+uX1kfYvHnh69QYF7FPp0p9fl85Py8qT/vo0AdRRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBlXurxafqKwXv7uGVQY5ccZ6EH9Pzq79sttm/wC0Q7P728YpmpWFtqNv5N3HvUHI5wQfUGs6z8L6ZbSB/JaVhyPNbIH4dK6F7FxTd0zkf1iM2o2cfPRr/MvW16byUG0XdbD70zDAb2X1+vT61epAAAABgDgClrGTTeiOmCaXvO7CiiipKCiiigDzr4zeIpdHsNLtIJrmD7XOWuJbclTHAi8kspDKDI8K8EE7sZGc1H8FPFFzrdnrOm6hLcTXGl3jJDNcDEk1sxPlswJJz8rLySfl5Oa80/aG1WGXxVcQuGaWxS2hRFY7sOJXkYDPP3ohz0wD6Vt/DKBvDnxP0yxeeSaXVtJlluC77gZtyTHb6AbnwPegDpfAngHVdN+Imr+IvEL20zyb2t3hckbpCc8EAjC/L/wKu08f6pJo/g7VLuAMbnyvJgCjJ82QiNMDv8zDiugrzb48T3sHhnSRptvJc3L6pEqQxsFaRgkjIATx99VrOlSjSXLE7cdj6uPqKrW3SSVtkkeK+FPEP9m+JfCN+t4THp7NbyH7PseaCTyYy0p9RkkKcbfKwK+s6+L9A1G3n+F3i62FvdQajEFdzLFsAjAYBVOe0nmce9fYWg3TXuh6ddN96e3jlP1ZQf61ocRyvxh1ubRvCBFmZxc3c8cAMD7HWMHfK2eoAjR+RyO3OK5f4LeJ57nxFregzy3U1kI47zT5Lk/NtKJ5qAEkhQzqVBPRqw/2lNUgXULOwnMYeGyM9uGPLSvMgGB6hYpPzNYvgaNNB8R/D7UkkkaXV5HSbMhZQkkbKiAdBgJEDjqVoA+lqKDXLf2/JpF3JZ6tHI6Kf3U6jJZe2R3rWnRlVuobowrYiFCzqaJ9TqaKxINfivTt0y3nuJPUrsQfVjWnaRSoGe4l8yV+uOFX2ApTpSh8ejHCtGp8Gq79CxRRRWZsFFFFABRRRQAUUUUAFFFFABXzV8U0g03X/EVokasElF0in/pom84/4GW/OvpWvn348WLR+I9QmUD/AEiwhkBI6lDIp/mv51z4mKcNe6OjDNqenZkPi7wpaeDv7M+wB1h1Gx2zb5GfNxGFy2WJxuVug4+XtW54L+HWjeJPhrBeeUi6vdyPdJeOu8xyK5ULt6bcKAR+PXmtD4wTi60fwqGjK3EzPN7Kv2c7h6nll/Krnwy8Q2eifBuHUb6OVbbTmmik8tdxciZhlc9iSOeg59KSjFVZegSlJ0o+rPIliu116eaK3VDHBN/aEB5wsTbWYY645OD1DHvXqXwDknT/AISO0YZt4p4pFb/bZSGH5In515nD4jgN34nuYkkQ6rBIsMY/e7RLcqSMqMfc3H8K9e+BXlyeHdWnRcNJqcoJI6gKgH6VnQglP3fP89DStNuDv5flqek0UUV2nGFFFNkJCMV6gHFAHM/DzbNpF7frn/T9Rurj/gIlZF/8dRa6iub+GwA+H/h04wWsIXb/AHmQFv1JrpKACiiub+I+oSaX4G1q5tzi4+zmKEjtJJ8if+PMKTaSuxpXdkeU/wBpLqmoat4guJFSK8mPku5AC20ZKRc9gRl/+Bmn3F/Z2yb7i7t4UPRpJVUH8zSw2UEWnx2RjV7ZIxDscbgVAxgg9eKwE8B+Go5mkj0qOPJyUR3VM/7oOB+VfnlWrDEVZVarer6L/gn3FOlOjTjTppaIzvBNxGni7xJBbyCS0upBdWzqDsf/AJ6bT0OC46VpaprFrYC8iuZMCDUhqM4AyVijtAoOPd5EA9abqHhKBvKOmNHCsZ3C3n3vEG/vKQwaNscZU4PcGoPh/pA1i/mDWtqsEfmX9xLCzv50UIKwbmckkNKCwHTbGfWvSwXLWrPk+0uV+Xd/cn8zz8XejSXP9l8y/wAvvZheFV2fEi/XJaNw1xC/8LxSbpFZT3HzHn1roNJ1CfTfF9/ol6uYLtmvbGbOchuXjP0IYj2/CuE8LXzWS6fCzPG1tbLNa3oQyC3Vwd8UqjkwkjOc/KT2AGN/WJ7ybxNpV400a3xjP2ZbNFmiZMMPllkKKzEuTtGThRx3oxVJyqcs9uW3zWz/AM+2vkZZfXhKiqlLrK/3vVfft8j0iq7Xv9i6xpWuA7Vs5wlwc9beQhJM+wyr/VBWL4V8QnVJbqxvUEOp2p/eRlSm5ezBSTjrgjJ7EEgg1t31sl5ZXFrIPkmjaNvoRivLpTnhK8ZvdP8AD/go9erGOKouK2Z7rRXPfD3Un1bwRot5Mxed7VFmY95FG1//AB5TXQ1+jJ31R8I1bQK5j4gfutN06+3bRY6nazMfRDKI3P8A3zI1dPXMfE1VPw98Qk9VspHX/eAyv6gUAdPRQvIGaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqt7f2tkm66uI4h6Mefy601FydkTKSirydkWqrQ31rPcyW8M8bzR/eRTkisa4utQ1pTFpkb2to3DXMowWH+yOv41k3+lt4bu7TULUySwIds2evPX8DXXTw0Ze7KVpPZf5nDVxko2nCN4Ld+Xl39TuKKjt5o7iFJYWDxuMqw7ipK42raM7001dBRTGdVOCfmx07mmwmVizSgKD91OuB7+9OwX1seB/H3wTHqOrz3P9mi8udWNrHYybSStyjbXi3D7gePDZPH7tskcUnwg8Napc+KPDV9LZ3Fta+HrOeyunn43XI3RGNMklgvzZbpwMV6nr11FJ41sVuJCtnotlNqlwccKzAxxk/8B881d+H9vLD4VtJrpQt1el7+ZR/C8zmUr+G/H4UhnRVheNtOtdR8N3QvLg2i22LyO6VQxt3iO9ZAD1wV5HcZHet2uS+INwl5aW/hyF83erOEkUH/AFdqrAzyN6LsyvuzgUAeTaB8LY7q+tLS7vWtovEenvqWq2sCf6siVCsUbMSUUidlOcn5OMdvoO3hjt4I4YVCRRqERR0UAYArlvCDprGt6x4ghw9lKI7KwkxgSQx5LOvqrSO+D3CqRxiusoA8c+P/AIWj1G2bVZrEXsT2L6eR5XmNDMzq0DqvXly0ZI5HmA9M1xvw48Day2r6DpVxp32IeG9Ua7v5Ny+UCR5kaR4OWJDrngADNe2eKj9u8R+HNHUkqZ21GcA/8s4B8uf+2rxH/gJo+H5N5p1/rLHP9rXsl0nGP3QxFF+ccaH8aAOpqOWGOYASxo4HZlBqSijYTSejGoiou1FCqOwGKdRRQMKKKKACiiigAooooAKKKKACiiigAr5/8VfD/wAbap4qv5biKDUIrlmihvWutoihY5CGMn5VHGQoOTX0BRUzgpqzKjNwd0fNPxC8U3L65a6BqwhtIdEDRK064luv3ezzdxOArfeGAevfHHrnwat5k+HlpHeW3lpJJM8aMuN8bSMQSD0Bz09MV2dzZ2t0yG6t4ZihypkQNtPtnpU9SqdpudynO8VGx514x8AeBxCt5fpBoQ3hfPtXW2Vm5IyMbSevUetdL4H0vR9I0FLXw/cLc2u9naYSiUu56liOM9OOMYFJ48hR/Dz3Esfmx2ciXUke3dujVv3gx3+TdxXK2eg2ukxSzXMV3cxXMn+jQWSSK6xkf6t2UjKjrhjgcgelc9fExoS1juJJyVrnpdUNW1jTdHh83Vb+1s4+u6eVUz9Mmuc1HQNEt4jcNpjPKp+UwBjLuPTBByDnvkY9a47xHYJZXFnfQWV0qrtQwXKo5klcqA7yFiSVYjLEnAJx61jHMoz0jHUfsz1vT7221G0jurGeO4t5M7ZIzkHBwf1qxWfoGnLpOj2tkjbvKX5m/vMTlj+JJNaFeivMzOX+HwNtpt/pJznSr+a1UnvGSJY/ySVB+FdRXM+EHE+r+LJ1+42qCMe+y3hU/qD+VdNTAK4P4xuT4c0+AHifU7ZWHqFYyf8AtOtb4l61c+HPAms6xYlRcWUPnLuXcMAjIx9M1ifFuRJdF8PzxsGibU4mDdiGilAP/jwrnxbtQm12f5G+GSdaCfdfmcFrOs6bolus+rXsFpEx2qZWxuPoB1P4VhR/ETwvIT5Wp78c/LBIf/Za6CbSbC4v1vLizgmulXYkkiByq5zgZ6c+lcdq2oS+I9RuNH8Pwwtb27GK5udvyhhwV3D7oHQ4+Y9BtHzV8JQp0qi1T03d0kvwZ9lWqVIPRryVm2/xRJ4g8X2lzpEkltLLBprbklu8fvJAB80cKfeLkcFiAFBzWj8OvEOt6JpeqeZodlt1MgrFLdtE8EQjCJFhUbhR75yT0Jqhqvhu10Xw4JYI/Pe3lhkuH2Y/co4ZlRRwqjG7aOuOcnk66OrorowZGGQwOQR6ivay106ac6Pe39f192oqeBWMbWJe1tF/X9eehy2i+EvsiRy3t9cG9SJYVe1kaFYwARxg5J5P3s/SrFtpUJum0u9ZoXusmG5iVfKuSBkpLFjZ5gGTuAG4AkEEV0dZfiVCdFuZo8Ce1X7TC3910+YH9MfjXRWp+1Vtn3OuWW4ejR5aMbKP9f0zmrvStQtfFFhZTX32PUiCNP1BVLpJtGfKfccspBPBJZemWBGPQ9Cn1iRHi1yxtoJkAxNazb45fopAZfoc/WqXjLR38QaAv2F1i1GBku7GY/wSryvPoeh+tT+Etfj1/TvMaM21/AfKvLR+HgkHUEeh6g9x+NeBWqOtRUrbaPy8/R/n6nFSpqlVcb76rz/4K/L0PUPg9KG8Jz246WuoXUQ+hlZ//Z67mvP/AISMtr4U1W6mO2E6jdS5/wBlWwf1U1tfDPWrrxH4D0XWNQ2/ab2Dz2CrgDJJAx9MV9zhW3RhfsvyPj8RpVlbu/zOmrl/iAPtdjpukAA/2pfxQOP+mSkyyfmkTD8a6iuZ8WYh17wldOQI01F4mJ7GS3lVf/HsD8a3MTpqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKrXtr9qj2iaeFh0aJ9p/wqzRTTad0KUVJWZgyeHmlyJtV1B0/u+ZirNloOnWbb47cPJ/fkO8/rWrRWrxFRq19DCOEoxfNy6+ev5hTJo0miaOVQ8bDDKeQRT6Kx2Ohq+jOV/sHUtPnb+xr4R27HPlyHO39DmrsOmapNj7fqrhf7tuoTP44rdorolipy3tfvZXOSOCpx2vbtd2+4r2lpDaqRCmCerEks31J5NZfi/xDb+HNK+0SL511K3lWtsGCmeUgkLnsBglmPCqCT0rcrw/xIR4y+OC6FOS2n2MQhlQHIMYQSzD23loEb/ZBHc1g227s6oxUVZG54S0a98TWs099Mx0m+kE97dY2vqxAACIP+WdqANoH3nUZ4DEt6oAAAAMAdBSKoRQqgBQMAAYAFLSGZPirXLfw5oF3ql0ryJAoCxJ96V2IVEX3ZiB+Nec+CtEu/Gcl7q+vyBtPu5NsyRkhb7YSBED1+zRnIC/8tG3M3Bwav7SmpTRaf4d0m1J868u3kTB53Im1P/IkqH8BXrWjWEWlaTZafbqFhtYUhQAY4VQB/KgC1GiRxqkaqiKAqqowAB0AFZviXW7Tw9pMt/elmVSEjijGXmkY4WNB3ZjwPzPGTWpXifxYuH1/4o+H/C8UrLCI18zyzhlMxbefZhDFIAe3mE0Aanhix1Txe15eXMxgtr0+XfX0LHMyKTi0tT/DCuSGl6uxYrjO4eqW0EVrbxQW8axQRKEjjQYCqBgAD0xSWtvDaWsVtaxJFBCgjjjQYVFAwAB2AFS0AFFZ8uqQW+pfY7kiJnUPG7H5X9Rnsc1fyMZyMetVKLja63IjOMrpPYWiqcV6lxceXajzUU4klB+VT6A9z/KrlJxcdxxkpaoKKKKRQUUUUAFFFFABRRRQAUU2RxGhZiAo5JJxWND4htp4vNtszRC5W1dlGMMxAyM9RkigDbooooA5VvHuiedcRxR63ceRNJbvJbaHfTR+ZG5RwHSEq2GVhkEjINQ3fxF0GztZrq8h8QQW0KNJLLL4e1BUjQDJZmMGAAASSa848b6pe6Z8JwmmarLpd1feLryyWWMshcPqdzlTIpBjGASWBzhcDrVbR9Rv5vh98adJ1O+u5pdLivY47ee5e7W2ja3cqqXD/PIDg/eAK46c0Aew+PRIfCGqGJnVli3kqATtBBI59QCK5HxZ4dbxrpIa/wBQutIFrK00N3p02VlgPzKc/QDP444Nd7qq3WwtBM6RBeUhiDSsc9AWO0fiPxrym30BItWufD7389tpjqJYx5+/7LKWA8lWbgscghVGFyRzxXn46m2lVTtymkH0LNzf2epaQ/g+68Sait1FAZbjUo7cxtJbgbvv9ASpUE98NjmsG60vRPCHhJNE0e8vdTe/Y/6UsnmM0hKqqjaMA/N254711h8Na5ca3Pa3l9dS6M8CRNOZId8qoSQjYjzkljk+mea57X9KTTNc0t9PuYb42MrtPp2C3lpjG4lMHzAGUhT6ZFefRcXNR5tN3/Vi3se02dwlzD5iLKozj97G0Z/JgDU9YvhKS2u9HhvrMjy7kbsJcvMnBI+Ut06cjAIPBGRW1X0BgUNF0yLSbaWGF3k824muXd8ZLSOznp6bsD2Aq/RRQByXxZgS6+HWuW8nKTQiI/RmUf1rlvEBNz8FNMumJ8zSzavIT6wSrHIfyD12HxHUSeFJoM4Nxc2sC/V7iNf61naXp8d9YeMPCl2QEM0xTj/lhdAyBvwdpR/wCpnBTi4vqVCXJJSXQ4g1V06xtNMsltrGCO3t0yQiDA55JPqfc1zPifxJq3hmO106+0Wb+2nTa3msqxEjgyAglmUkHGBzz0wcclc3Gu6ncLPqV+uwHi1EamAfWPnd/wACLV8XRyau/wCPJU4+fW3ZK7frt5n2rxdNpThr/X3/AHJnqumLf+IZWg8MWy3QB2vfS5FrCe/zf8tCP7qZ9yKu6n8Kr7w/p0Unhi6k1EIubmxnKoZGJyzQH7qdeIz8uOhHfzdfGPjy0I+w+IYzGgwkTQBFUdgOGHTjpWppfxk8c6dIq6ppsGoRdCyBWzx/slCP++TX0uBwGCowcKdRNvvdfmkl955NWti3VVWE0mtkr/qrfeyeC7jllkgYPDdRcS20ylJYj6Mh5H8j2qPWf+QPff8AXCT/ANBNV/if48sPGekaYt1oc1jqNvdK6zEnJUq6lA2FYElgQB3FcLqU15NplxbLe6sInQjZIRjHcFyN+D0zmrngJqSUbNd7p/kz0P7enBezr0tbbpxt+f8Amew6KS2jaeSck20eT6/KKdJbWdvczak0ESXAi2yThcMYxzgnuBXHab4gRiI7bX2iC/IItStFkC44ILxlcY55NdHa2uo6vq2maJq72EWnalL5Ul7bO58xQu/ywpGFLqCobcR174FeBW4bx9KfvLR9b9PwHPHU6ULzTTS0uvyO80+GbTPgYici6vLIt7iS6cnH1Bl/Sui+F0SQeAdHgiAEcURjUDsA7AD9KPF+LnUPDuiw/KZ71bqQKOFht8SZ+m8RL/wKl+GgK+DrWJj80M9zCfqlxIv9K+sSUVZHxzbbuzqKz9a0uHVoLeOd3TyLmG6RkxkNG4YDnscYPsTWhXH6nf8AiK78Z3+kaJf6RY2tnp9rds95p8ly7tNJcKQCs8YUAQDsfvGmI7CsvxTrdt4b8OajrV8k0lrYQPcSpCAXKqMkKCQM/UiuI8PeI9d8R3UsOieKdDvFj3A3KeFb37MxU4IWc3PlscnoGPf0NaEdrfePvhjrGl6rdW0F7dvqGlyXNtbsIx5VxLAJBGzk8iMHG88nrQBYsPiPoV/rehaZbG5afV7BtSiYooSGIAnEuWyrcMMYPKtnGKfqfxK8I6fbWly2v6ZcWtxeLZGeC8heOGQqWzI2/CgAc9+RxWFefB7SJbidrW8ubeO6W+W5XG5j9qiCERnPyKp3MFwRl29ar6b8K7zT4Vlh1y2OqxXNrcQ3ctvdTgiBZFVJFlu3yMStjY0ePfoADvLLxV4evry4tLLXtJubq2VnmhhvI3eJV+8WUHIA7k9Krjxx4TOnm/HijQvsIl8k3P8AaEXl+ZjOzduxuxzjriuE1H4Q3us6nc3Ou+K7i8jlgvIFHlShlW4GMANO0ShcKAEjTcF+bJ5rS8R/DzV/EQ0ufUvEFouoacs0MT2lnc2sLwyqgZWSK7V85jHIkC4OCp4oA7SfxLoVvN5M+taZFNtL7Huo1baE8wnBPQJ83+7z0qk3jrwitvBcN4p0EQXDMkMh1GHbIy43BTuwSNy5A6ZHrXOR/C61TQNa01LyOIahb2UKNFbkiD7NGioMO7M6ZQHazHgkEnrUPjb4f+I/GGnNa6j4tggSS2mtpYrSyuIIXD4w+xboFmHIw7OhB+76gHX6n4s0WwdoW1GxlvFmSA2q3kKyhmaNTw7r082MkZzhlwCWUGS18U+H7u7vbW113Sp7myV2uoY7yNngCHDF1ByoB4OcYrmI/hwiaJrFj/aK+bqOp2eotP8AZuVFv9mxGfm+bP2c85GPMPBxzgaj8HbzV9Qu7jWvFd1eLLbXVshMc3mKJmVl+9OyLt2KMRpGGHXnBoA9Q0XWdL1y1N1ompWWo2wYoZrSdZkDDqNykjPI4q/XJ+APCUnhePUGuryK9u72RHknX7Tubau0bjPcTMSBxwQMYGOK6ygAooooAKKKKACiiigAooooAKKKyvE+tR+H9Ia/ltbm7/fQW6QW2zzJJJpUiQDeyqPmkXksABmgDVorlf8AhKNX/wChE8Sf9/8ATv8A5KqXSfFMt5r8OkX/AIf1fSbme1lu4mvGtmSRIniVwDDNIQQZk6gd/SgDpaKybvxNoNnq8elXmt6ZBqkmNlnLdxrM2emEJ3HP0rWoAK8H+Ab/ANufEfx9r+Mxi6kgiY9t0z5H/fMUf6V7xXm/w28AX3gzxl4puoruBtB1ST7RBAud6SF2Y7hjAxuKgg8jGcYoA9IoqCC7tp57mGC4hlmtmCTxo4ZomKhgGA+6SrKcHsQe9T0AeCfGRg/x4+HUN+5TTRh9zD5d/nKevuyxD8RXvdYfiXwro3iZ9PfWrJbh7CcXFu25lKOMHqCMg4GQeDgZq/rOqWei6ZcajqU3k2cC7pJNpbaM46AEnr2FAF2vBvBjnXf2m/Fd2V/d6VEYhnswjjjH85fzr3mvPNK+H0+k/F3UfFmn30cenajbkXVptO5pcKM56bflDeuSexoA9Dooqk+q2aa1DpLTY1Ca3e6SLa3MSMis2cY4MiDGc8+xoAj1nSbbVoFjuAwZeUdeq1nWnhW1hYefcXFwg6Rs2F/ECuioraOIqQjyRloc88JRqT55RuxkUaRRrHEoRFGAqjAAp9FFYnQlYKKKKACiiigAooooAKKKKAKerxQTaZcreLutwhZxnGQOf6VzGlRw3GvxwpEkUKHzWRF2h3iVRn3w0v8A46K6LxDObfRrqQJv+XG31ycH9K8X8d6xqNhf6ZBpV3HaajOoiSeViEVpVMzk4ILEgABR1IoA95or5GHibx/b30v/ABML8mKQjzZNOkCycn+ISltvuoPHavRvAnxgvI7mGz8ZwRRQSuI01CFi0SscYVyQCpyf4gPqaAOvg0PxHb6ZqGj3Hh3wtrOlz6heXSi91ORRIk1zJMoeI2rqCBIB1PIqtqnh/wASy+CdZ8N6N4U8H6PaajaT22LTVZUSNpUKF9i2agnnPbOOtemggjIOQaKAEIyMVxU9jpkWu3EF4sJts20NrFIORMvmSHaeu75t2euc121cZqZt11q/aaDzk+1QCdNoYKpiwshB6AHqRzgVxZg/3L+RcNzdgjWCFIlZ9iDALHcSPqeTWdq8Nu0ZjSKMXM8gG5QAS4UkFu54Bq1c2soslt9PlW32gRhiCcJjHB9R1B9qpmIwahZwJAJrl8zS3LDPlgcEevO9gvpzXzse5uc74J1NfDmpLolyNumXszGzfGFgmJyYMDoGO5lPqWHpXYeKdWn0y1gSwijmv7qQxwpITtGFLMxxycKp4HU4HGc1yfimKz1JJltIp7gOhNyIcDyxzht2eGyMjHPAPTFZEOrXWpxaI81wH1LS7xbaWXoXjlGEZ+yksm1h/eBHevcw+KlKk19pIylHW4+zm1e58S2q6TqeoX1w8kNw8sjFYUiwPNSVAdig87QBuz64Jr1uvPPhy0+neJNd0zULaOCe6YahEIwNoX7hTI6lcIc999eh12Yb+Gne9yJbmZr2kjV1sEeZoo7a8iu2AXPmeWdwX2+bac+1YniqVNC8Q6X4hdtlo4OnXx7CNzuic/7sny/SU111edftB3MNt8Ite84481YoU/3mlQDH06/hXQld2Eld2PArnUp/EOtX+v3u4z3spZFb/lmnRVHpgAD8M9zT6zNJvIRothNIyoZo1KKBkuSM4UDkn6UX2s2NtbXDNeQRyxoxCStsYMBwCpwc57V4GKnKvXlJd9PRaI+gcoJaPT9Ca51KCGZoVWaedfvxwJuKem7sPxNS2d5DdiTyiwePiSN1Ksn1B/n0qhOk+laVaLY232q7mOWRpAm5tpd2LHvwfzGKSK2sdetIbie2SR3UxkZyw5wVyOeufz96dbCyofGree58ws/qJ+0dP929F3I9RuXvn09bSHfatdA/aGbCvs5byx1cDgFugJA5PFbFUrOZRP5Uuoi7uI0EEas67o4l+7HgehzyeT36DF2s6/JdRp3su/U8XNcZ9brc6WiRNpF7a6Xc3EWqwLNo10RJKzJuFrIMAycchSAMnsQD61u28L6Dr2gRQXcb6Fd6lbTwyyPnyGWVXbaRnOVDexBJ6gkweCPDo8Rat59/bGXQ7YMDv4S4nBA246sq/NntuAHODVn4waN4f0jQVurW3trTU2nQwpH8u5d2HwvRRgnJwBnbnnFdmB4ghTrRy+onLmstOl/8v+B3Pq8lhW+qJV/hf327+vby8me6eGgdV8S6zrkg/dROdLs/9yNv3rD/AHpcr9IlrX0LSjpMd9GJzLHcXct0ilceX5h3Fff5ixz71z/wekeT4e6Z55JuVaZZ8jB8zzX3ZHuefxrs69U5Arg9TsJdV8YeNtPt5RDNd+G7G3SQkjYzyagoPHoTmu8rn9Z8I6Vq+qtqVydShvWhS3aSy1S6tN8aM7KGEMihsGRyCRn5jQB5f8IfCXjHw/rPh+C5gv8ATNH0/TpLbUobjUhc295NkiN7eMSN5Y6MThO4x1z1OnaxdeH/AIW+ItWsLM3t1aalrEscA/iI1C45PsOp6cA8jrVnXtD8J6BAkur6zr9t5h2xRt4k1EyTN/djQTlnb2UE1qeC5rLTfDEzLp19oek28ssqNq05Mjq7GR5nZ3Z1y7uf3hDdyB0oA89svirrz+H5tQSHRtTnivBDDaWTxvNeoYtzBFguLgRtGQWO4tlB0U1s6N461DVNdi07/hIvClput7Z7ZpLdydVaVCxa3zOuEDfJjDtkHOOBXYP468JR2cN2/inQVtJmZY521CEI5XbuCtuwSNy5x03D1FTJ4x8MvZ3l2niPRmtLJlS6mF9EUgZjhQ7bsKSeADjJoA88PxI1+fw5qGpJBo+nf2cYLG7N+wjUX24/aUQySxoyoNu0F13FvvDHLfhv4u1HXPiFO154gsfsV/ptrNa2Mtq8DXGDch2t1Nw4GCgZmXzAy7OQAGOte+NNF8JWYh8NWlvqWmyWF3rC3EF95iyuLmJXG/DbizTsS2TjbjHp3mp6tb6bc2MN0VQXbuiu0saBNsbSEkMwLDCH7oYjqQFBIAPPtc8U61aeMrrStHNjFLc6xa6eJrxZp0RHsZJiwjEqgHMYGF2g5OcnmrF7r+sa38C9d1aF0tdaWwv0ElorjEkJlj3RjduVj5eV+YlSR97HOzq3xJ8Jabpy339u6bdW32uCzke1vIXELyttUud+FUDLE9lVjg4rYh8U+H59QisYdd0qS+miE8dul3GZHjK7g4XOSpX5sjjHNAHjGmeJ9Zs9X8QeItM1fQNYih0vSTdyxW7lLkGe5TbGwmbYygsCxL/MPujkDpvD3xG1rU/idL4fns9Pgs0vLm1aCSWFLpUjDFJgDceY4baDgQABWyGIGT02qfE7wdp5sS3iHSp4rq7+xmWC9hZIG8t33Snf8q/JjPqyjHNaC+NvDsdpDPqOsaZp3nPIkaXV/AC+yRoyQVcg/Mp6HI6EBgQADo6KzJPEGjR6zHpEmraeurSLuSya5QTsMZyI87iMAnpWnQAUUUUAFFFFABRRRQAVBdXUVqqNO4RGYJuPQE9M+lT1W1Gzjv7OW2mzskGMjqPQ1UeXmXNsRPm5XyblmuT+JhA8O2QJAJ1rSQPf/iYW9LaaPr1ofKt9SjEA+6Wy2B9COPzo8Q+FJtW0cQrqQGppc211Fd3MJmRGhnjmA8sMvBMeDhgeeta1KUIaqafoYUq9Spo6bXrb+mec/tHR+GrrR9WWa80KDxPFYDyU1C3MlzImWKJaEuu1y2RuQMemR0rrvDhkPiPwD51vc20v/CL3m+C6ffNGd+n5V2wMsOhOBk54FbP2Hxx/0MPhv/wQz/8AyZRpeg65/wAJVa6zr2r6bd/ZbK4s4obLTXtv9c8LszM08mceQAAAPvHmsDqMDSbDV9Gu9Y0ybwmNVhvtXkv01EzweSUkl3qZVdvM3xDCgBCDsXBHUcdo3hr4lpZait/f6x/aEkCIzpcKIpZRcxM0kTtdvsIjEnyiGJSpIIzgV0eg+PtQXxBqX9q2GvTi51afS9NsoY7MxZhR2IBDh9xETZZ2CDcuMAMRry/FLS4LS5vLjS9YisI47x4bpo4ily1qjtMkeJC24COTBYKrbTgkc0AVG0TWNN8W3bCz8Q6pp6pGdLkj1x1ggYKxcXCtOryZkOclZPlIAAC4rkNC8P8AxHa4mS5Gr2NnPNprsh1Mu0W25zc7Gkup2I8rryocDHl54PcJ8UbQXTQ3fh3xBaJFLaxzzTJblIBcsqwu22Ykhi2PlBIwcgVs+N/Gtj4Rl02K9tbm4kv2dYhHLBCoK7eDJPJGgJ3DC7snnAODgA4bxLoHjCGbVbPSINVutMk1GJrSX+15mmhgWzjUlf8AS4WYGUSZDSdfm2txWNa+H/ie8ugPqd3qivFZ2au9tMsphlRv3vmj7ZEkhbAySk2QeMEc+kQ/EKxk15dNfTNVijOoHS/trrF5H2kRmTZxIX5UH5tuM9xWKPi5pN6L+3sklt76zltRIGa2vFKzXSQf8sLggHLYIZgVyG2t90gHReKtI1HVvEugCG4v4dGRLn7f9kvGt9xITygSrBjyG5Xkc8gE58rHhL4hXdhrttq0uoXU1xayxlWkU21zIZkZGQvePsIUHAWGIYJB5xXq/wANdVvNZ8Ki81Kbzrn7dfQ79qr8kd3NGgwABwqKPfHPNdRQB4lcaJ8RYvFWs3Ye/vImkvTbxJcmK1nhdHEERb7YDEVynzJArBl+/glqpWvh/wCIA0bUYrlPEePt0U1pBHegsyeSyyK7HUfNVN+GAW4PODtxlR71RQB4tDoXxBbxlpl1dTahb6ejWLBLW5NxFAixoJ4pTJdx78sJMuYpnIIIbOALnw28O+JLXxrYap4isNUS4h0e4tL69vNSW5jnuWngYGCMSN5cZCMQAiYwARwM+uMQoJYgAckntVKw1Szv5ZY7ScSPH94AEfiPWqUZNNpaIlzjFqLerL1FFFSUFFFFABRRRQAUUUUAFFFFABRRRQBHcQpcQyRSruR1Kkexrx34keD7jVbEWGpaULy3SLyUu4VJYgcIxA5VlHf+lezUUAfC+reFvGOhyL/YOvX11ArELCZykqY7FGOD+GfpTrL4g6tZqbbxboMr27p5UsqW7I7A8cq3ynr04r7D8c6RpmpeHNR/tKyguNsLMpZRuDAfLg9c5xWR4Q8G6R/wj4t7+3a/VZZYj9scy7lV2UBgeDwO9K+tgOH+DvxRtLm70zw285vrK4Bi0++3ZdSqlvImU8ghR8rdwMHnk+5V4l4l/Z60Ce4bUPCl/e6BqiS+fC0beZEsg5XAPzLg+h49K9b8OR6pFoVjHr8tvNqqRBbiW3z5buONwyARnrTA0q5rVFSz8TwyyJm31OH7M525HmJlkB9Mq0g5/ugeldLWN4usze+HrxUZkniTz4XUZZJE+ZSPfIrHEUva03DuOLs7nHWN5NpGuGx1nUpbVYQximkx9nuocZUEn7kijg9N23PPanda5JFpev8AiuFlaKWEWum4O7eiBj5g9dzE4/3Qe9UPiDa3Wp+ArGPVEtbuaZooy5G2OZS6YYhs7cg87ulR67Cl38PPC3277QN0MMHk7epKqC20dTtDcc9fxrwVBNKT6u33G51/w8W7i8P2Ud+PNea1iupLl3BeeWQFnyPbKj8q5zXtOtbbX0SXdHBet/ZszIeVWXHluPQrIEIP19a0fAU8N3ptvJHdg6hpdubOdZCWDxhso578hevruHasnx1q0M8uuJAzIbWCORbkD5BJyRg9CVKg/l07ujJwr8wNXQW9/Jb3ujaqbC4t7qOUC4nb5luV3eXKeCSD8xIDAdMV7FXj/hq1n17xTYJAkn9l6Wf3rmUujlW3o24HHms/LDngHPUV7BXsYOLUPK+hlPcK8q/aBja+8MfYVGVjtrvUnHtBEdp/B5EP1Ar1WuF8T2H9r+MLvTZSoS58O3MCbun7yRVb/wBkrsTs7kp2dzzj4Q+H9O0zwpZzxW8T6iTIk1yy5kyrsu3J5UDGMe1dR4g0LTPEemS2GrWyXFtIwJAJVgQeoYcg8Y4PtWV8M7aW38I2z3O1rieSSaSZc4my52yDPZlCke2Ks+HfC8GteJ/FE9ncvp+p209u0d3ENwIaEbo3jJw6nAbtzjBypr85WFqY7MasaM7NOTT9Hpqtj3pVY0qSbWjsYI8DX2j6/aan4X1CGFLOQTQ216jzAHaVZN+7IRlYjnJGcjtXB3HgnW7XQGI0S6gvZ7siaO0uI5ozbsRwBlSrgZUMvBByRwCO7uvHT6Zql1YxoPEMEJIW/skECFgcFCHbDYORuQkcetWV+I+l4j32GrLn7+LbPl/XB+b/AIDmvUVXO8PaFSn7RLur7ea1+/U8qUcsqJwUlG+6ulr6M4ZvBmrX0RsoPDv2Tam5JZ5Y4lj44KtGXIbp27c11uh/DaNDBJ4jvV1IqnzW0cZihL8ZJ5y4GDweOelWLr4naRFDdzw2WrT21rgSTi28uMOVZgmXK4bCk4quPGMF/PDBqOsLp1kSHluNKtbi4cjrtV2i2gerANkZx60VZZzmbScORelt/W7+4mlhMtwSU78z6Xd/+AdPe6ppPhuzitIViRk2x2+n2oXzHJOAqJkevsO5rhPiJpdzH4J1C71COJNQ1a7ijnVT5jRRFgsUKt6BhGWxxkvjtXdajpGjaTfeEb7QZBcx6g1x5mpSP5r3QeIMMydyfLXHYBCAKg8VaWdZ1rwhYq/J1mK4aMn5XjiV5GB9eF498Vx08E8DmFKhe7bTb+d7el0en7b2tGVRaWud94SRbHxF4n01FKxrPDeJ/uyRKpx/wKJz+NdVXC65rlj4d8fvNeynN5pscUdvAhmuJ5ElkKhIky5ADtlsYGRkipv+Kt8Rv/D4W0s/7lxfyj/x6KH/AMiH/dr708Q3PEHiTSdAEI1S8SOeckQW6KZJ5j6RxqC7n6A1iC48WeInxaQL4Y0s8edcqs99IPVYwTHF7Fy59UFbHh/wtpGgyzT2FsTez/6+9uHaa4m/3pXJYj2zgdgK26AMDw/4S0nRLqS8ghkudTlGJdQvJDNcOPTe3IX/AGVwo7CrniXSxrWg32mkWxFzGY/9JiaWPn+8quhP4MD71p0UAec2Hw5vFe1l1bxDJqM0Ftf2ymWGRwq3IhACmSV3wgiP3nYneeQOKjufhpdrDENI8Qvp0yaXY6YXhgdN62zyMSTHKjgOJMEKykY+8a9Kr59/aI8Tazf6LeW+gXk2n6FZT/Z729hLK88oHKKV5Man5W25O4+itkA6Wy+Dj2+m3FrJr5kea3vYC/2Vzg3NzFOWy8rMdvlbfmYk7sk569x4w8L/APCR3Oky/bPs32B7h8eVv8zzbaWDHUYx5u7vnbjjOR4V8EvFGp2V1qOswxT23gaSWGI6fdXbXEloGGPtCM3OzIBbOM7mI+5g/TVAHml78L2kTT3s9Xjt7ixsdOtYWaz3J5lnP5yuyhwSrHgqCCP71RL8LJT4kl1S51W3uo57r7fLbTQ3Xli4MexmRFuhGFznAZGYKSpY9a9QooA8wsvhtq9pa2Yi8TQ+dYX8V7YxPZzS2tuEhliMYjkuWfaRKeBIANq4AGczQfC5Y7C+t5NVWRrrTtRsN/2T7n2u4ebeBv8A4d+3GecZyOlek0UAeY2nwqFr4qj1RdV860+02949rMLn/XRRqgZdlysQ+4CN8bkZIyRgD06iigAooooAKKKKACiiigAooooAKKKKACioJ7u3gljjmmjjkkOEVmwTU9NprViUk9EYsPhfR4by3uo7PbPb3k2oRt5rnbPKjJI+M4OVdhg8DPAHFZs3w88MTTXskunO4vEuI5IzdTGJROCJjHHv2xlwTlkCk5PNdZRSGYV14S0S6+1efZbvtRtmm/euNxt3Dw9G42sAeOvfNSeJfDWneJLdYNW+2vb7XRooL6e3SRWGGWRY3UOCBjDZHJ9TWzRQBgHwdoJjEZ09PLF6dQCeY+3zzGY92M4xsJG37vtWBZeCPBVpqx0eK2ma8W0gkWCa/uJdlvFOHiVN8h2oskanauB2xgkV31fLvjrxlc2XxkutYsHLf2fMLZUJ4ZEG11PsTv8AzrmxOIVBJvqz28kyaebVKlODs4xbXr0XzPpXRtKstGsfsemw+TbebLNs3M3zySNI5ySTyzsfbPHFXao6HqlrrekWmpWD77a5jEiHuPUH3ByD7in39hDeqBN5ikdGjcoR+VdMHGVm3oeJVjOm3Fr3l0ehaZgoyxAA7ms281zT7U7WuFkl7RxfOx/AVUPhawdszSXU3s8xNadlp1nYj/RLeOM+oHJ/HrW9qMerf4f5nLfES6KPzv8Ahp+Zjzwalro2Tg6fYHqmcySD39B/nms6+sf+Eb1S2v7RXayP7uVc5K56/wCP1FdpUc0STxPHKgeNxhlPQitIYpxdre72/rqZ1MDGa5r+/um/L9PIIJo54UlhcPG4yrDoakrlv+Eau7WdjpWpyW8LHOw5OP6Gr0OhO2DqOoXV3/sbii/kKiVKktVPT0d/8vxKhWrvSVPX1Vv8/wADW89CWWMiR16qp6fX0ogWQAmZgXJ6L0X2FLBDHbxiOCNY0HRVGBUlYNrZHUk95BRRRSKCiiigAooooAKKKKACg9DjiuYj8c6JNfXlpb/2rcS2cksM7W+kXcsavGCXTzFiKFhjoCSTgDJIFa2vavb6J4d1HWbpJntbG1kvJEjX94URC5ADEc4HQ459KAPNNW8O+MtS8RT20txPdaWzcPdTCOFQCedkeCxzjA9OteheFNFm0LTBaTX817glgZFA2knJx3xk9ya1raZbi3imQELIgcA9cEZqSp5Fzc3UL6WCiqWrarZ6RDBLqE3kxz3EVrGdrNullcIi8A9WYDPQZ5xU1tcx3D3CxrMDBJ5T+ZC6AnaGypYAMMMPmXIzkZyCBQE9cv8AEHxEvh3SIpGgWQXUv2ffISI4wVYlnPphSAO5IFdRUV3bQXlu9vdwxTwOMNHKoZWHuDwaT1WgHius2M2oaDpVhBIZ9WWOGCLBdFcK64cRndsIUAsxB6VX8Z6fNefD3RZbS8iKBImuFeRmVXiQBhGR91uGzn+7wM17NpWi6bpIP9m2NvbFhgtGgBI9CeuKin8N6LPdtcz6XZyTM/mEvECC/wDeweN3v1rgWCsl72qdzTnPGfDWn3eqafDcado2q292Qqx3iSyHz4wP+ezOPkJ9PTOK7i18AzX72beIJ4mt4X3vaIWl83oQru3VcgZGOemcdfRBx0orohhacXzbslzbIra3htYEhtoY4YU4VI1CqPoBUtZfiHW7bQbW1nvEmdLm8t7JBEASHmlWNSckcAsM98dj0rUroJCuPFzJqvjG4vrKEvaaJbT2hcdbi4fy2aNf9lBGoJ/vNj+E10mtXy6Zo99fyDKWsEk5Hsqk/wBKxfD2jTQ/D630wyNDez2TebL3E8qlpH+u9mNAHCeBQo8H6QUdXV7dZPl6Lu52j2XO0D0FWtIWU+K/EWmxXAhuNX0dRayuNuHj8xcIf4seYGPcZHUdIfBsvneFtMIhWHbCsexDlRt+XI9jjI+vNVfGmpv4di07xGiRzHSrkSG3d9gl8xWh+9/Djzd2cEYBr85yvEOjmd5dW0/m/wDM93EwUsPp0Vzyi5tbixRdHvIW03UoFRWtZMoSqkZCkdUIBAdT0ORyKr21rdrcTvNGrRux8tGvpWWIbmOMBVZuCo+8Pu5zzxreJvE154wkW28Q6xBOs2Slhb7FjTjPycbzgD7xb8ulZ3g9bPQbjVILzwzBrh3Rmzn1C4bykXDFgww285OOmMAZOa/UXzNJtfcz8+j7KMpRhOy396Kf3N6lO/vobWwSRhJfxWz7YooU220MjAsAuPlV22nqTI3vmrVlcXSxz3GpvBFbAAx/IUZRzktknrxjofUA8Db8deNtQv8Aw9p+nS6Lpdtb217HPC1mTFFH8rrsZTwM7+G6A4yBVc3Mmm6tFYX9vNDM48zNrcW0jLtBIPmKXaME4+ZdrdACM0Qk07bPsOvRjUSknzRe8u3lbodroxXTPB/he0vpXTV4dQnvbfSEhaS5NtJ5q/6pRlOJNwLbQM4JHNa142pXeoaUt8f7FtZrxIIltdlxeh3BAZpDmOHgkHYJGwThxXO6UxW/azsbW7+zvcRXctnavpQmkaPJBaX7eZHySpYuWJ24yATXVWlzcz+KtPu08Na5czaajy/ZFn00keYNqyEC84xtcA47tXzmLpSlj6coQTfWTeqWuiV/xt1PqsPJLDWu7dF/m/8AgnSabptl4L8VxpBaoun6wqQi7YmSYXS7jiaVsu/mLjBZjgpj+IV3Nef+KtV1XV9DuLVvBviO0YFJo7gy6c3kvG4dXx9rHQqD1FaUHi3U7iCOaDwR4ilhkUOjpc6cyspGQQRd8g17BgddRXK/8JRq/wD0IniT/v8A6d/8lUf8JRq//QieJP8Av/p3/wAlUAdVRXK/8JRq/wD0IniT/v8A6d/8lUf8JRq//QieJP8Av/p3/wAlUAXvG+qy6L4U1K+tV3XaRbLdf70zkJGP++mWuE1fwha33ge30R5GhNrEGWRvm3NsYSFxnndvbOCDljyDW343vJL+y8LQ3Frc6dLd6rHI9vOUaSMRK8oyY2desa9CeornPiN4iubC1i0jQyk/iXVz5Fhbq5JhU53Tyf3VTnr1/CgDm/gTolvL8KbR5pEnXUI3WVGTAEasyBOvOQWJPq3tXrfw2vZrvwjaRXjl7yxZ7GcnOS0TFAxz3KhW/wCBV5H4eurj4YTWfhrxFLFP4dnbFhqKRbEtZn5aF8k4BPKsTj19vTfh65h1zxbYupVlvYrog9vMgQEfnGfzoA7eiiigAooooAKKKKACiiigAooooAKKKKACimSp5kbJuZcj7ynBH0rGn0W7kYhdZvFT04z+YxVwjGXxSsZVJzj8Mb/d+ptSSJEpaR1RR3Y4FY1xroldoNHia9uOm5eI09y1Nh8M2e4PeSXF44/57SEj8q2YYo4YxHCixoOiqMAVp+6ht734L/P8jL9/U0dor73/AJL8Tj9T8NXktnNeTXDT6jkOVXpj0Hv6V0Hh7Ul1PTY5dw85RtlXuG9fx61qVzmqaFOt4b3RpxbXDffQ8K3vW3tlXjyVXbs/09DB4d4WXtaKunuur8/U6OkYhRkkAeprn4bXxDIAtxf28K9ykYZv5YrStNNSFhJNLNczf35mzj6DoKwlTjDeSfodMK06m0GvWy/zLO+R5gEXbEOrH+L2H+NTUUVk2bpWEfdtOzG7HGema+Yvi54Fh8HRaPepPNfy3UkhvJZflDyZVhgDoDlu56da+nq4D45aP/a/w8vmRczWJW7TjsuQ3/jpb8q48bRVSk31Wx9HwxmM8Fjqcb2hNpS890vubudB4K0XS9G0ZF0ESpp1zi5iieQuE3AH5ScnB44ya368/wDgbrQ1j4fWUbNmewJtH57Lyv8A46VH4GvQK2oSjKnFx2PLzOlVo4yrTrNuSbV3u/P5hRRUN3cR2sJmmbbGpAZvTJxk1sk27I4G1FXZNRSKQygqQQeQRTZpUhjaSV1RF5LMcAUvILpK4+imQyCWJZArKGGQGGD+VPo2BO6ugooooGFFFFABRRRQAUUUUAFFFFAHmMnw2nfQvHEf2uT+09bfUPsoGoXItUW4jZU8yHPl5GeSEJHYmsbV/hfrF3qWvS2cOiQrqWm3NobieUTzNJJbGJdrfZhJCu7BIErrgHC5JrV1L4sfYfEd3py6XFdWkaXvlXdvNPteS2iaRo2Z7dY8/IynZJIVI5FPT4m6is8djdeHreLVrr7CbOJdRLQst15u3zJPKBQr5L5AV+cAE5oAu+H/AIcWum3+roF+w6TdxWbRwaTdzWTefGkiyOxhKH5ty9zu25PIFYE3wx1lfiFca9DdwTIbk3Ftcy3CCaIeVsETg2zySRjkFftCqQc4B66Hh3VdTuPhP4xvry6kGow3GsBXiuWl8kpLMFWOQhTtXACnC8AcDpUGm+PtRRtJ0jVLI29/nS2MtreicSxXLMg80vD8rfuyWQckHh+9AHK2PwY1wR3jX1t4ZkWRrCcWK7FtppbecvJlY7WNUV42ZMlJGwxBLCurs/hg1xrEMus2GiPpP9qS3z6cuZYkjaxhgWNVMaqdrxnGQBtCnrwLun/ETV9St9Da08PWSS6ysslotzqhjQJECZDIwhbb/DtADEgknbtNZPw78dapF4f8FWep2TSw39jaBtXvrif9/LIMbVZYXUvnHEkiFieM8mgDjtb8D6vpY0vSbvTLfX9Se2063gu/s91MdPEU53+VKYTEqkDJ3SRsB1BG0H2Txr4Pt/FWs+HpNStbK80uwlmkuba6XeJN0RVcKQQcNg846Z61JrHiPUIvFsPh/RdNtLu6+x/bppLu9a2RIjJsATbHIXbIORgAcZPIritT+Mv2C61VTo0V1a29leXtpc29xOI7kW7KGXdJbouTu5MbSBSCD2yAUbD4TarpPhyK20pPD638uiR2F+ZY98d3OsyMzvuiYN8gkCu6MQSPlI4pvh34PXaW9rbeIodGu7GC5v7hLQkSRxieKJUAVYI0+V0duEUDIIGenpPhTxDe6rqWsadq2mw2F9prxblgujcRusiblIYohBHIIxjjgmvN9D+Jt94a8LwSeIdPe9hli1C4trmO9aaeXyZyNsiFPkX5wAwZ+B0HAoAenweuItAh0+BNJj87TdLttRClgt3cW90ks0jfJ8+5QwDHk5AOB00Lb4VHS9Uj1DQbbRbC7h1qa7hljjK+XZvbSIIAAo+XzXDGMEL1Oc12HgLxPe+Jbe+bUdEudKktpFRTJHOsc6lQdyGaGJzg5B+TqOCc11VAHhPhr4TeI9PvzPPJoltE9xplxJBZsqRs9tdebIypFbRKMrwoIZuxcjBHY/DLwTfeFta1W5ntdKtrS5X5BA63FwzbyxLzi3hcrz0cyHP8XavRaKAOX+J7bfAGuL/z0tzD/wB9kL/7NXUAYGB0rl/iL++0CHT1BMuo3tvapjtmRWY/giufwrqKAPJ4bZdC8TarojB44JJDe6erHKmFgu9VP+zIWyOwZexFaUsaSxvHKivG4KsrDIYHqCO4rrPFHh208RWsMdy80Fxbv5tvdW7BZYXxglSQQQQSCCCCO1cz/wAIPrUh8ufxTi3PDNBp6pMR7MWZQffbXx2Z8O1a2IdXDtWlq76WZ6uHx0YwUZ7o4SDwLc694O0+58NxWKf2fe3sVvDIPKE0Bk2j5gCdymMquR93061zuheGrjUdY1iz8S3MGhadowRtRlaYM7K2SFRh8q5Axu5PzDAzyPo3TrKx0DRYbS2CW2n2cWAXbAVQOWZj+JJPuTXgxmTW/jRe3Fp5kuiTK15HMYmENzJEkKIUYjD7TI5yM4OD6V9RWxbwOFcm78q++y/U8Z4Gliq6nJa/10MDxfYWmlTxzeFo9Sn0aWYRldRtpYktlbgN5zAkx5IHzrwP4iK6PTvhV4jCEONF0eyB3PL5plwvdgiqo/NhXfyIskbJIqujAqysMgg9QRXJWCalfy3fha9eUeG9LmR4xJ85u0bDxwljyY4yCCDkt8ozgEHwsDxV7SE3XVuVXVuvS3rr/VjpxGQUHNSit9/8xvgjR7W3u5r7TWV7FBJaQzsQ0t4wk+edyMABmQBVAwFVfoO5+GMEt7LqfiJ9q218EtrVAckxQvIPMP8AvM7ED+6F9cDBj0+XxJqx0C0hEOlWhhfUJQ+wNEckQIFOfmC4Y8AKT1zXq1tBDa20VvbRJDBEoSOONQqooGAAB0AFXlFCpia0syrqzl8K7L+tPxOnEyjSgsPT2Q9gGUqwBBGCDXM/DNmPgbSo2/5YI9sB6CN2jA/JRXT1zPw7Gzw7JGf+WeoXyfldy19GcJ01FFFABRRRQB5R8c9dbQJtFvYmRbi3hu5oQ4yu8qkSkjuB5ufwqHwH4Zi06KTxBetLLr14D5zyfOyRnB2Fu56bm4+6AAoAAxv2iLCfW9StrK3AbybIyEZ55ZpOP+A2z/lU/ij4t6LpmpRWWiWEuqxRS+RLci9WJBIFB2oCDuPQE4Vd3GaAOw8RaXB4g0W70rUo1uLe5TyACqnaxB2v+DbT9a479nHU2u73W7aWbzWgtbSNfmLHavmcZPJxv2j2UV3nhDVdO8W6F9u0WadZYnEU9vdf62GReqSdTn+IHoeDyK82+D1u2h/F7WNMlyqT2lwYwehaO6KnHqdu00Ae+0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVXt7u3uXkS3mjkaPhgrA4p2b1QnJJ2ZYooopDCo54Y7iCSGZQ8UilHU9CCMEVJRQNO2qPAPhJPJ4M+J+r+FL1yIblikRbuy5aM+25CfxxXv8AXiH7QmizWF7pXi7TMx3FvIsUrqOQwO6N/wAwRn/dFeseEtcg8SeHbHVbbAW4jDMoP3HHDL+BBFcWFfs5SoPpqvRn0+fr67Ro5rD7a5Z+U46fitvQ16juIUuIJIZlDRupVh6g1JRXanbVHyzSaszk4ND1mxcx6fqSC2z8ofJwPpgj8q2LPS2V0m1C5kvJ15XdwiH2UcfjWpRW88TOe9vu1Oang6dPa9uzba+4KKKKwOoQEHoc9qWud1v+0tOvze6ahnglAE0OM8jjcB9PT0pbTWNTvQFg0lo2PWSZyqD9Mmuj6vJxU4tW9Vocn1uMZunNNP0bv6WOgJAIBIyeg9aWqdpaNG/nXMvnXJGN2MKo9FHYfqauVhJJOyZ0xbau1YKKKKRQUUUUAFFFFAHO2vhrwxc395qEfh3TRfSSSxz3MmmrHLKSCrksyAuGDMN3IYE8kGqcq6Bq/iLUPD8nhqK9SG3gS9uJLWBrdVG5ooWDHc2MlgApVd3UZrlL74Wyanq7TavDpN7ZCTV5VhnBkAa6eFoW2lMZXy2yexxjPbKn+Dt9Lol+N+lDWLhNPVrgKCbhYYo1mjkd4n+R3Tdyjg4Usp6UAev2ejaZZaY+m2em2Vvpzhw1rFAqRMGzuBQDBzk545zWR4X0rwk9lOPDmkaVDawXzpItvYrCq3MDlCcbR8yspAb24Nee6b8L9RsI9MNzpWha5bW63CnStVvN1vbvJIriSEpaKg6EbRCuB0NVtT+EWoyWl9a6faaBBE2sy6iDGUU30LtKyRTq9rIg8rzBtyso4OApwQAekeMbXw3pfhKSbWdCsrvSNNAmS0+yRSLGc4yiNhQefbvV6Dwl4bgvrW9g8P6RHeWiLHbzpZRiSFVGAqMFyoAOABXkuo/CPWJ9MS0+z6NqB/s+K0gl1S7aWTTHSaR2MBW3VWDBlGQsZGwDkAV3nxW8Lal4r07T7PT4tKmgjnMlxHfRxEkbCFMbSQTqrAnn93kgkAigDptZ8P6NrbwNrWk6fqD253Qm7tkmMZ9V3A46Dp6VUXwZ4XWe5mXw3oomuldZ5BYxbpQ/3w52/MG75696818O/DLXdN1Lwlc3KaNcXGl29tb3d5PMLlisWciFJLbchwcBllT1KnAFdh4z8IaprPiey1HR9WOlxvZy2V/JExWYrkSQmMjoVkBzk4KsR3oA7KK0t4bme4it4kuJ9vmyqgDSbRhdx6nA4GelcNolz4Nj8TXWmaX4btLS+vZrqyuZY7GGMT+UsbyByvLK3mr1Byc5A78Prfwh8Qapb2M17dWF3eSRXDX0azpCiXMs7StLC8lrOVOGCAqqMBGuG7V2mg+CNS0/xdBqk9zbS26Xt7cH94xkZZooEXPygbsxMT0HIx6AA7HQ9B0fQIZIdC0rT9Mikbe6WdskKs2MZIUDJxWlRRQAUUUUAcx4hDS+NPCcWfkje6uSPdYdg/8ARprp65bxcfsmu+F9TOfKivWtJMdhOhRT/wB/BGPxrqaACiiigDB8baRPrnh+S0tTCZhLFOsU+fKm8uRX8t8fwttweD16HpXAavrDar4x0SznsrnTNRsra5nubacfwnykARx8roSc5B/g5APFeu1wfxWiazttL1+EMZLG5S3mAwAbed0R8k4ACt5b57bPSvMzXCPEUJuHxJOxvhpqFRX2OB8Tane6P4xtprR0uI5rAqdOZ233LrINohABzJ854xgjqRjNdGyeJr+D7NZeHr2wvJQALi8eHyrfP8bbXJYgc7QDkjHHWo/hi8OtfEjxNqbxxyLp1vDY2kvUpl5PO+hLKB9FHrXrdeVgMiw9XD06lde9b/hrnVWxk4zlGD0MjwzoFl4d082tj5jtI/mzzzOXknkIALux6ngewAAAAFa9FFfTpKKstjzm76sK5jwMWQ+IbduPI1e4wPQPtl/9qZrp65rwoQ2u+LmQfL/aSAn1ItLfNMDpaKKKACiiigDx3xFnU/G+vyxNk2lrdbc9MRWioP8Ax68k/wC+TXhthrKC18E+EJ4LXT5tLtrp7h53AXzp8qJH7jajFhnknGMjFezafePKNeuIAgvdST7JbM3QNd3lwNx9ljjRvoleJ/FvRPD3hrxUuteFLwyrcKtxab97wSFVIlG/IYEkqVKkryRlSKAPSPHt3oej3ula/wDD/wASxW/iCxRIrtHSb7NfxpGEHnEAorYXAJxnOMggGrOgawt/498G+KkjMEeo300MkIOdv2myt3xn0Emfzrwi48f+JdRtnsJtc1H+zrhVWW2ju5HXf90D5mLkZxlQTkHJ5r1TwTb3Vl8OrG5njdJ7DWbieBZEKlVhtY5F4+kVAH1ZRQCCAR0NFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVS/tHuVHl3U9uw7xkc/UGnFJuzdiZNpXSuW6q3t/aWSlrq4jjHoTyfwrJbw/PK3+kaxfOndQ22rljoWn2b+ZHAHl6+ZKd7frW3JSjvK/ov8/wDI5/aV5aKCXq/0X+Zn3M+oa4hhsEe0sm4a4lGGceiisx7M+F9YtrhGd7CUeW7HqPXOPzrt6hvLaK7t3guEDxuMEGtKeK5fdt7r3X/B7mVXBc/v815rVP8AS3YkRldAyEMrDIIPBp1cpFpGt6c5j0y9ja1z8qy87R+R/StCHT9VmP8Ap+qFV/uWyhf/AB7GaiVGC1U1b53+4uGJqS0dNp/K333Nh3CZzycZ2jqabB5pDNMApJ4Uc4HufWm2trFbJthXGerE5ZvqTyanrB22R1JN6szvEOk22u6Je6ZejMF1GY2I6qezD3BwR7ivFvgpq9x4W8Xal4L1ltm+VjAT080Dt7OoBH0HrXvVeM/H/wALymO18WaQGS8siouGj4baDlJPqp4+hHpXFi4uNq8N4/l1Pp8gr06ynleIdoVdn2mtn89vPQ9morl/hx4qi8XeF7e/Uqt0v7q6jH8EgHP4HqPr7V1FdUJqcVKOzPAxGHqYarKjVVpRdmFFcR4K+IEHijxPrmkxWMtvHYufst0xyl4isUkZeMYVwB1PDKe9dvVGJ418dvGN7oHiPwnbabetbR29wNR1BRIEEturBNnJG7IMnyjPKjjpXsiMHUMpBUjII7ivnrxKT4n+J3iQRWer3ccWzSwlpOkETKqfOGlY5HzuwIX05r2T4d3k1/4H0Wa8z9rW2WG4zj/Wx/JJ04+8rUAdFRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGT4vu59P8J61eWb+Xc29lPNE+AdrrGxBweDyB1rkvgf4i1XxN4Tu7zXLr7VcpevCr+WiYQRxkDCgDqx/Oug+I8hj8A+ImXGTYTLz7oR/WuN/ZvjCeAbhhnL38jH/AL4jH9K5Jyf1mMU9LM+gw9Gm8mrVXFc3PFJ2127nqtFFFdZ8+FFFFAHOfEaGSXwTq7wDM9vD9rix13xESrj3ygrft5kuII5oWDRyKHVh3BGQaS6gS6tZoJRmOVCjD2IwawfhzOZ/A2i7/wDWQ262z5/vxfu2/VDQB0dFFFABUF+IjY3H2hFkh8tt6OAQy45BB6ip64TU/H+g3z+JNDs7tjqljaz7l8s7W2xksVYccHg5wcg1rToVKqlKEW1FXdui7smUoxsm9y98JxC3w58PXMMFvC93Yw3E3kRLGHkZFLMQoAyTXW1xvwa3L8LPC8cnEkVjHCw9Cg2n+VdlWRQUUUUAFcv4AHm2WrXwOVvdVupV/wB1H8ofpEDW9q14mnaVeXsn3LaF5m+iqT/SszwJZNp/g3RbeVdsy2sbSj/pow3P/wCPE0AbtFFFABUV3MLe1mmPSNGc/gM1LWX4qYp4Y1dx1WzmIx/uGgD43+IvizV9K1fTrPRNRaHbYWMc0CL8/nm1yX6dCs7YIPXPHGa6v4TfEPwVp/gufw34305Htkd3imeBpjcMzYZdgBZGUY6dvQ9eG+MVxbp4snsoReQXkQsGeQ3eIyosYwmyEclslstngEDAyc7niDQIIbXWNe1T4d6vZo8CyNLqWpm3WK4z8xjAALbyfu8k84xQBmaVbWerHXbzR7Sa0WyWa/0y+S33z3RjmQruOCVwpX7oHOc7uRXa/C3xDr/i6KO11C1i+wLeXSXF3O7G4nuJNPmQDaRwNqEnPciuY8fa3ZaroWn22oXunT6fp1kRZWej2c8Atn2DYjTurbgCBnnB5OQcY3/gtr2ua34htL/WjGYJ52lWSG3+V2S3mDeZL/eCjhSScOx+oB9PeELhrvwnoty5JaaygkJPcmNTWtWB8P1K+BPDit1Gm24/8hLW/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVHPNHBG0k0ixxr1ZjgCuY1C+1DWt8WiK8dqud1wfl3n0U9a1pUXUfZd3sc9fERoru+iW51dFc/4P1F7uye3uWJubdtp3H5iO2f1H4V0FKrTdKbg+hdCtGtTVSPUKKKq6jfQafbNPdOFQdPUn0HvUKLk7IuUlFc0nZFqiub0LxIdR1FraeAQBxui5OT7H8Oa6Srq0p0pcs1qZ0K8K8eem7oKKKKzNgqO5giubeWC4jWSGVCjowyGUjBB9iKcGBYqCMjqPSnUWBOzuj5ztZLj4PfEp4ZvMfw9qH8WCcxZ4PuyE4PqP94V7L4/8RroHgbUdYtXWSXyALQqQQ8smFix6jcyn6Zqx4z8J6Z4u02Oz1ZH2RyCRJIyFdSOoBweCOD/+qvIv2iJ4tNtfBvhLTWe1spJXnaOE4YJCFCDcefvPn1+WuahRlRlKK+Hp5HuZtmNHMadKtJNV0rSfSSWz9e//AAxleDNKu/DEnh/XPs+nWaWlzFa3EgupZZLmOdliYfMAqjcyyYHdK+jLqeO1tpbidgsUSF3Y9lAyTXgY8OaFb+Adb1C7thJPBp00i3NzI0zxMEJDIXJ2nIGMY5r0HxN4xtz8Eb3xVBmSObSfOjDL/G6bQCP95hkV0nhnkvwwjvNUhl1CTW59PtruaS72xJGrqJHL8yuGyeeuBXr3wgubFtJ1ix0u/a9tLHU5o4pHl81trbZCS/8AECzuQf8ACvH/AIO+G9ImsLVrywt7yRUUbrlfOxjjjdnH0Fex6RNbx/FG4s7aSJJDokLzQoQDxM4jO0egLD6Ee1AHc0UVQv8AVbSwfbdu8eeh8tiD+IGKqMZTdoq5M5xguaTsi/RWC/inT+kAuJ29I4j/AFoF3rF+CLW0WxiP/LW4OW/Bf8a1+rVFrJW9dDn+uUnpB8z8tf8AgFzW9Xg0qANL88zcRxL1Y/4VU8Na42q+dHPGsVxEc7VzyPxqxp+i29rN9omZrq8PWaXk/gO1Zmu2U2m6ius6em4D/j4iH8Q7n/P1raEaMk6S+J7Pz7GFSeIg1Wl8K3jvp3v3XkdRRWTZ+INNuog4uo4zjlZDtIp7a5YeYI4ZvtEp6JCpcn8q53RqJ25WdSxNFq6kvvNOmqwbO0g4OOKhXzLiL51aAHtu+bH4dPwqaNFjQIihVHQCs2rGqd/QdRRRSKCiiigAooooAKKKKAOV+Kchi+HfiBgAc2jrz78f1rm/2d4wnw8DA533crfT7o/pWz8ZpPK+GWutu25jRc/WRRj9ao/ASPZ8M9PbbjzJZmz6/vGGf0x+Fcb1xa/w/qfSU/dyCb71Uv8AyW56HRRRXYfNhRRRQAVzHgbMH9v2DDAs9VnCj0WXbOP/AEca6euX07Fp8RNYgJ4vrK3u0H+0jPG/6eVQB1FFFU9X1K00jTLnUNRmWC0t0MkkjdgP5nsB3NOMXJqMVdsTdtWcj8YPGieDPCks0Lr/AGpdZhtE7hscvj0Uc/XA715l8PvCkmifCjxF4i1BW/tHWLRoot/LLC/AP1ctn6Baz/Dtne/Gf4kS6vqkbx+HbBgBEegQHKxD1ZurH0z0+WvcPiCqDwylsFCpNe2VvtA4w1zEuPyzX0mPayvCLL4/xJ2dR9u0f1f/AATio/7RU9s/hW3+Ynw4VYPD0tiCN1jfXVsR6ATuV/8AHWU/jXUVzHhTbB4h8W2o7X8dwB7SW8X/ALMrV09fNHcFFFFAHMfEn954RubJW2vqEsNgPfzpVjP6Ma6ccDio5oYp9gmiSQIwdd6g7WHQj0I9akoAKKKKACqOu2zXmiajaxjLz28ka/VlIH86vUUAfHnxR8G3WsS3XiWAW3lr4Zs9QjJZhKTHsjlA5A+Vc5znHyjuao+E9XjOg6h4k8ZxaneayLVo9Eu76KSa3R1UgYTbtLKSSCenoOte7eMfC1lcWepeFtTSOO31Dz5NBvXYqsM0uWe2YjHV/mCnhlOMEpSJ430j/hGU8PeIvD+pRavBbrAdMFm8hkcLtBidRgjPRh60Ac/rfhPwTB8JV137XCt/BZ/a/wC0Y7gvJPMEBIySSctjjtmvKfgPqGr3OlavZyea0MSNJZl2PN1cr9mjAU8YPmyNkf3T6V6jqfwb0uP4aaY+oWlvZajCvmai/wBuNt+7IbKbzujVhlASVIIUjvmup+E/hKSOOwv7oP8AYbONFsxIpUzMqFEkCnlY0QssYI3MXeQgFgAAeo2NtHZWVvawDEUEaxIPRVGB/Kp6KKACiiigAooooAKKKKACiiigAooooAzNQm1SOY/YrS3mi7FpSrfiMVS/4qO4yD9is19Rlz/WugoraNblVlFHPPDubu5v0vb9L/iYsOgxvIJdTnlvphyPMOEH0XpWwiqihUAVQMAAYAp1FROpKfxM0p0YU/hX9epyniaBtNvU1WwYxzniRAhKyD3xxn61HB40VkAksZDJ/wBM2yDXX01UVTlVAJ9BXRHEQcFGpC7XW9jklhakajlRnyp9LX+Zzceqa3qH/Hlp6WyH/lpOT0+nFXLbQlecXOqzNe3A6bxhF+i1tUVnKu9qa5fTf7zWOFW9WTk/Pb7tjn/EukyT+VfaeMX1vggD+MDtUmmeJLG7iXz5Vt5xw6Scc98Gtys670XTruYzXFqjyHq3Iz9cVUasJQ5Kt9Nmt/QmdCpCbqUGtd09vXTqNl1zTYyB9rjdz0WPLk/gKtQTSXCFhE8CHoZANx/Dt+P5Uy3srLT42eGGGBFBLPgDA7kmuN8QeOpG0+Wbw1ALi2DCIajKpMUkhO1Y4EGDO5PAwQnq3BrKTh9hfebQjVetRr5f5/8ADHV6nqWm+H7BrnUrqO2g3YLyNlnY9AB1Zj2AyfQVoQyLLEkibtrqGG5SpwfUHkfQ1xHgbwXNZXP9veLLuTVvE8oJEs7BkslP/LKFQAq+7AAn6V3VZt3NUktEFeMftEeE7i/GkeKbJWk/sjfHdxKMt5DkEuMcnYRkj0JPavZ6D0oGfOdvBd+LfDt0UkWLwrZSBZGTltSmTDFQeghRsZPO5lx0BrZ+HmhT+Mv2cdQ0EybHne8gtnPQFbh2TPtuGPpXSX/gLXrKwu9D8Lalplt4duXeSJLmBjNp5kYs4h2na65ZiobG0nGSK7rwroVn4Z8O2GjaapW1s4hGpPVj3Y+5OSfcmgD5t8Katqei2NtpdhbRx+IZJ2tXhulOLQoheR3UckKACBnDZHODXMfD6+vdN/aJ0SRr2e6ub6WSG7nlOXuA6HO72BCkAcDaMdK+l/H3gj+3Ly11nRWtbTxHaK0STzRkpPCww0UmOcdweSpHoSDx/wAN/g7caL43/wCEq8S3lncX0KMtpbWisY4iwwXLNgk4JAGOM5oA9npCARgjIpaKAGqir91QPoKdRRQAUUUUAZcmgaXJKZGsoixOTjIH5dKvW1rBapstoY4l9EUCpqKuVSclaTbM40acHeMUn6BRRRUGgUUUUAFFFFABRRRQAUUUUAee/Hqby/hlqSZA82SFOe/7xW/9lq58FovJ+GOhrhhlJH5/2pXP9a8v+PfiLWLe/vPDd4IpNOnaK8tpduHVMEFDjggMD78dTXYfAnxDqGs6NHZpYw2+kaXAtuZmYtJNN1OOgAA5I56jmvNhWjLFv0t+J9piMtrUeHovSznz3v0cbLzvfSx6tRRRXpHxYUUUUAFcv4kP2LxZ4Y1DIWOSSbTpWPpKm9f/AB+FR/wKuorB8cWE9/4auVsQhv7do7u1DMFBlicOoyeBkrjnjmgDcd1RGd2CooySTgAetfN3xA8R3/xX8X2/hXwox/siGTdJN/DIR1lb/YXPA7/UgC58UPH19441dfBngYNPBM/lz3EZ/wBfjqAe0Yxkt3x6dfVfhh4FsvA2hC2i2zahMA13cgY8xuwHoozgfn3r6jDUY5JRWLxCvWl8Ee395/ov6XBOTxUvZw+Fbvv5I2fCHh2x8K6BbaVpibYYRlnP3pHP3nb3P+A6Cq3je3nubTSkt4ZJduq2kjhFJ2osqsWPsMcmuior5qpUlVm5zd29WzujFRVkczo8bR+P/Eh2sEltbKQNjgn98p5/4CK6aiioGYvifXxoK6cq6dfalc6hdfZILezMQdnEUkpJMrooAWJ/4vSs/wD4SjV/+hE8Sf8Af/Tv/kqjxl/yMfgT/sNSf+m68ry/xv4d0Txr8a9K8PaZoumxppbjWNf1CG1jWWRv+WUDSABiWPJ55Bz/AA0AeteHvEjavqt/ptzo2paTe2cMNw0d60Db45WlVSphlkHWFwQSD09a6A1yum/8lT8Q/wDYF0z/ANH39eefZfFifEOXxxHozNbSXj6UkTSSi4+xf6pM2/l8J5y+cX3/AHGJ2gc0Aezm7txeC0M8X2sxmUQbxvKAgFtvXGSBnpzST3dtbz20E9xDFNcsUgjdwrSsFLEKD94hVY4HYE9q8Etbzxk9zJrkX/CR3GtRaJGLkXOjiFYJftcLTQQL5Q8weWJMcyE44YmtPXX8QeLtXWRLPWY7GLVryOxeXT2t3igbSHUPiRBwZnYAuOrAe1AHt9FeUQR6kv7Pd3b2keqahqsWkmJLXUtLAkEqxAeSIGhUSKDwMq271arcd14xTxQty11qMmnN4hawNibGPyRZeQWE24R7+HAAfdt7HNAHoepWFpqdlLZ6hbxXNrKMPFKoZWH0rAj8L3tmPL0nxLq1tbfwwzeXchB6K0il/wA2NYPxE1PxDY+KNJTR5tVexdVE1rp9mWZmMmNxma2ljAx1UvEQATu5FYdoPH95NYvLrut2iXcuqedGumW2LZYZmFsFLQkjeoBy2dwPGDzQB31t4Qsftcd3q1xeazdRtvjfUJA6Rn1SJQsan3259617HVtOv5TFY39pcyBPMKQzK5CbmTdgHpuR1z6qw7GvGrbxX4+n17wsrWGuQLL/AGcNThlsT9nYSxoZ2XFqdm1nIO64UqVPyYrX+EGk6jYeJLiW+sLu2iOkpGHmhZAX+33z7ckddro2PRlPQigD1uivILn/AITB/EmoWumy6hpNi9xqlwZ7TTIf3xSO1+z5Z4mB3FpRnq20jJ2jGMJ/GVnc67rFqmtLr+oaNp9xFaf2d/ozSiMicF/JYo8eWKoWyScbX4FAHvFFeCy+IPHyaPHM17q8gW5mxFa6VP8Aa5kCRlVLyaaIxhi+CYkVtwG8bGNXtLtNZtNc1ONo9amkn8UQXZtrrS0kt0t3MZMySiHbuAypIclQueDliAe2UV4idT+JVnoUF1DJqOo397pNxcSQXFhHGtpOk8KqE2RA7jE8jBX3linA7V2/wpvtfv8ASb9/Ec0szLc7bdp7eWGUR7FJD77a33fNnDLHjBxkkGgDt6KKKACiiigAooooAKKKKACisrXNZh0uMLjzbp+I4VPJ9z6CofDOsnVoZRMix3ETYZV6EHof6Vt7Cp7P2ttDn+tUva+xv7xt0UUVidAUUU1WDDKkEeooAdWL4g8R2mjPFblZbvU7gE29hbLuml98dFUd2YhR3NZdzr17r1xJY+D/AC/JRjHcaxKu6CIjgrEP+Wrj/vlT1JPy1r+H/D9loaTNbiSa8uCGuLy4bfPO3q7enoowo7AUAZEfh69191ufGMkbwAh49Ht2Jt09PNbgzN9QEHZT1os411zxpPOQDp2g/wCjWyD7rXTIDI+P9hGVB6FpK6yR1jjZ3OFUEknsK5z4cROvgzTriYYuL5Wv5TjkvMxlOf8AvvH4UAcovhPS9d1v4gXMugeH9S1hdUiit5tVs0mVR/Z9mQCdpbaCWOB6npnNc78NbHwv4i8YeKdCu/CPgnUYNGaJV1TTtFjhhkdgd0ZVi/zKQRkMRx2rf1aSz+0/EDRdZj8T2kWrXyPHdaXpV3MWiNjaoWSWOJ1+9G6kexyKq/DhPDvgDT/7P0i48az6cAdttc+GLgAOSCXLR2aOzcYyzHj6DABe0e51S2+BXg7+wbmG3v5dN02JWd41dlMce9YvN+Qylc7Q2RnrUGi+NdXt7qPRYIbvWNZmv5bZotZkgs5LTbAs213tkeOTIOQUH8QB5BNdN4G0SC6+FXhbSvEOmRTKmk2kc9nfW4YK6woCro44II6EcGtqz0LRNGtYf7P0ewtIbMvLClraKvlFhhiiouQSODgZPTmgDzq9+MiQ6ZpOoW+kpPBdW9tcXcKTTNNaedJsG7ZA0QHUgvJHuwcD1t+E/EV5q/xMjhe5vPssdvrMJgkmUozQX8MSNtVVHC7guQWAJBZjknrh4S8LahFY3MnhvSZPJiUWxn05FeFOoUBlymM/dwMHPFattpOm2l19ptdPtIbn95+9jhVX/eOHk5Az8zAM3qQCeaAPN08Xaro3j/xNDPa/bdGfW7HT1ka8YPatNa2+BHDsIK723H5l5YkAnNOs/ilqN3YQ3Nt4YFw1/p7anp0FtfGaWSISxxnzkWLMZAlDYUSfdYDLDFd3Jb6RKt/dPpsTNFcCedpLPa0k0SrtkBZRvKhVCuMj5QAeOMTw1png7xHo7Xtn4YsEt9YtoL24WfS0QTrKBKnmHbskYHk4LYP4UAYfhzxrruu+OdNtraDS/wCzZNOmlu4Fu5Q0EqXAjbh7ZJN6jAKME5Y5xtBN3xh43uvD/iq4sbWye+kMGnLFA9ysMRkuruWAHPlFgRtBJLEEAYVTknqofC3h+H+z/J0LSo/7OJNnttIx9mJOSY+PkyeeMVbudJ027uvtN1p9pNc/u/3skKs/7ty8fJGflYll9CSRzQB54/xN1EyTWUHh+zOrWovZLuObUzHbpHbFAxSXySzk+YuBsXHOcd2ad8V7jUdes7Gx8M308DmyW6miWeQwG4iSTcCsBjKIJF3F5EOASFPGek8ZfD/R/FVqlvdKtrEJZJn8iztXMjuAGcmWJyrcfeTa3vwMaS+D/Dgl0+aTQ9MmudPjjitbia1SSWFYwNm12BYYxxzQB51qPxH8SXUVnDaaRZ6Tqp1OziexvLqZJWhld1O/fa4AJULvjMg+9hsrg9bo3jDUbrxjJoeq6PDpmN/kySTzFrnYAS0WYBG689pNwHJUdK1oPBfhaCxubKDw1okdldFTPAlhEI5ipypdQuGwemelWNM8MaBpV/JfaXoml2V7Iu17i3tI45GHoWUAkcD8qAOPu/iZNF4zvNHtvDt/dWNldJaXN3DDcOyM0YcvhYTHsG5clpVbvtxjOdH8WrtbKG7vPD9tHFeafDqFisWp+YzrNcRwxibMQWLmVSSGcAA9SK6jQE8PeLdSl19fDMH2m1maG21a7tIDJMY3ZC0TAmQKGUgbgvqBis/TfhVodg2sSRyyPPqcBtpZDZWShULbj+7SARuScZMiueBQBn3HxJ1m3tNQeTwzbNLp+oyWF3JDezz20ASGKXzGeO2ZwD5uOY8DaSWFehaXqlpqKYtrq1mnSOOSWOCYSeWHXcpPQ4I5BIGRzXMaD8MfCulaR/Z8+k2Wpx/aXu91/ZwPiVlVSVRY1RPlRBhFUfKK6jT9LstOmvZrOBYpbyUTTtkkuwRUHU8AKigAcADpQBdooooAKKKKACiiigAoorifin8QLXwDo8U7Wc2oahcsUtbSI7d54BZ2/gQFlBb/AGhQByn7RPhubVdP0e/sIWluo7gWhVRywk+7/wCPDH/Aq9E8EeHoPC/hmy0qDaWiTMrj/lpIeWb8+ntgVyU3ifxcultfPbeDmZUEn2H+1m3ZHOPNKbM59se/etb4WfEGw+IWhPfWdvNZ3MLBLi1mIJQnOGVhwyHDAN/sn0rCNCMarq9WenWzWtWwNPAv4YNv1vt92v3naUUUVueYFFFZHijxHpfhfS3v9au0t4BwoPLSN/dVepP+TV06cqklCCu30Qm1FXZp3E8VtBJPcSJFDGpZ5HbaqgdSSegr54+IPxA1X4g6sfCXgKKV7SXKTTr8pnUdef4Y/Unk/oaOqa14q+NWstpmiQvYeHInHmFiQgGeGlYfebuEHH5bq9x8A+CdJ8FaULXTI988gBnupB+8mb39B6AdPc5J+lhQoZGlVxNp1+kekfOXn5f8OuFzninyw0h1ff0KHww+HuneBtMAjC3GrTLi5uyOT/sr6KP16ntjt6KK+exGJq4qo61aV5M7IQjTioxWgUUUVgWFFFFAHP8Ai3RL7V30a40q/trG90y9N5G9zatcRvmCaEqVWSM9Jic7uo6Gqv2Hxx/0MPhv/wAEM/8A8mV1VFAHNeHND1Wz1/U9X1zU7G+uby1trRVs7F7ZI0hedgSGlkLEmc9x90V0tFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBj6hr1vaXT2whuZ7hcZWKPPUZHP41EJta1DiGFNOhP8cvzyY9l6D8a3aK2VSEV7sdfPX8NvzOZ0Zzb5p6dlp+O/3WMzTdGtrJzLhp7luWnlO5j/AIVkavaS6Pqf9r2KF4W4uIh6Hqf6/WuqpCM5B5FOGIkpc0tb7+gqmEhKCjDRrVPs/wCtzKtfEGmXEQcXcaEjJWQ7SKd/bli8nl2zvdS/3YELfr0H50NoOltIXNlFuJz04/LpTdX1LTvDemfaLgCKMsI44YUy80h+6iIOWY9gP5ZpydDeKf4CgsS9JuPyuS6jewWemTXmrTJY2cS75WeQDavuf8K5tLS+8Yov26OfS/DOMJZcx3F6vrLjmOM/88x8x/iwMrVnTNFvNYvodY8VIoeJvMstLDB4rQ9ncjiSb/a6L0Xux6ysG7nSo2I7aCK1t44LaKOGCNQiRxqFVVHQADgCpKKKRRl+Kyy+F9YMf3xZzFfrsNHhQAeFtHC9PscOP++BWhcRLcW8sMgykilGHqCMVgfDmdrjwLoZlz5sVqlvJkfxx/I36qaAOjooooA5j4ieGm8V6Ha6bttnhXUbS5uI7jOySGOdHkXgHJKqQB0OeSOtcPbfCX+z72O50m30izlF/qMhaEFD9knglSKEYX7qu6Ns+6MEjJ6918QPFI8I6Cl+LOS9mluYrWGFA/zPI2BnYjtjr91GPYA5rkJPilqf2KQx+FjDfW1ldahdQ6jdS2aCCFgu6IvB5j7s5G6NMd8UAVD8MNQTRNVURaFdatLa2NvaveR+fHEIoI4psCSNgpYKwDbG/h3A4xWdofwq1rTbK1S/svD2s2sF7dzjR72fFoFmSHawKWwTejRyYAhC4kJGDXTQ/Eu7udQgFvolv/Zraja6XLPLflJlmnjST5IhEdyqJByWUnBwMc1seBPGF54jvL211TSk0e7t0SUWcssxuAjFhuZXhRcZXG6NpFJBGeOQDkNU+Guq3Ny8psvD+oWkl3dzf2Xeyv8AZoxNFCscg/dMC8ZiYAFcYc4Kmqsnwv8AEMfhuHTom0G5P2TS7aeO5VXVhbW7xyFDLBKqkuylWMbcZ4U1qan8XhY6lqkI0mK7tLa01C6trq3nn2Tm0UsyFnt1TJwQTG8m0gg+9sfEjUkvhpVx4ftY9ZmuLWG2iGpE27CeKWVS8phBQgQOCAjZJUDOeACbSfA+r23wVfwhLqUUGqG3mgS5gcsihpGZFztXjaQpwoAGcDHFc54e+EU0c2lprVppkumw6k17c2DTRzQOv2WSJdkUdpBGDvZCQV525JJ4PQeC/Et7Y/BrUvEephr67sDqt08ZuWcOIbm4IjWVhnaAgUHbwAOO1UtR+K95pjy2l/4dX+1TNaRQQ2t1LcxsLiOWRSzRwGQMBA+VWN+q4yCSADHg+Dl/Z6Elnpdxp+nXUmiy6feT25YG4mNxDJGWJT5l2JJHlgSA+ApHFXfDHwpntZdNXV7ewfTor2e5uLEzpNCyvbiMBI47WCMAsAWTZg4zkkkVau/ipqsGnS3f/CJvF9k0uTVb6G8upLaSKNJZI2CI0O5iRHvXcEyCM7TxRf8AxR1C5v8AV7LRfDt28Ns1zarfFLjbHNHEzB3PkGJY9wC58xm5BK4NAHGWfgnVL/xLd6VY2KWN1HbapDP4jS0uIpbhpmAjMjywoGxnA8t5BgEgqMZ9J+Engu78I2mpx38dvGLtoyIbaeKSEbVILBI7W3VScjPDE4GT60tB8ea3/ZujR6tpumm4m0ZdXubw6iyxLAuwO7Yg4Yhi20DAIxnHIwrj4qa7qksdnpOlWtpfw6jpyMZbidIbmC4ZwAGmtVcAlMbghGDlScYoA0/DXwltdMuvDrXOn6Kbaxj1AXccUQxNJNNE0LbdgD7Fjx83QhcZwCMSH4Q6u2mS2UyaHATZC0uLiCWUyas/2mKUz3OUGH2xvjlzmRvmxiut0X4j3mpeMG0dfDd39kjvJLCe9hW4kWGVFJZi3kCLy9w2g+Zu5BKjPGB8W/EviayvfGthp0kMOm2vhlL1JY7pop4JGa4HmptjyWJRVxvAAUMDkkUAaGm/CqDS9f8A7S0yy0izeLX1v7doEMbQ2X2cRtAuF+XMhdig+U5yTnivVa8w1f4nX2jfabTUvDyjV476CyjgtbmW5ifzoWlVi0cBkGAjAhY25xjIyR23g/WZ9f8ADtrqN5ptzpdxLvD2lwjo6FXK5w6q2043AlVJBHA6UAbNFFFABRRRQAUUUUAMnljghkmmdY4o1Lu7HAUAZJNfMWuz6t8S/Goj00RyaY08Yvx54JjtmDeREY9pYY+Z2zld0ihhhRXs/wAWtTitdBisJ5YIob52+0NPN5KC3jUvKC/O0MAI84P+s6V5/wDCbVLUaZceKL+21CHzA8L3F07TPPcvIzOioAXARVjTcQMhRxgUAXvFHgfwl4c0zRvN0rT8HUIPM1KeKJPLcBRllCch9p+UADcewNYutXeqeCvidPfwReXpfmnZAiLFB5bgMyBmwfnKtgfd87bj77CurutRvdZ/sNPFqf8ACP6VeSyTbgwVgyohhjMp5QtukbOEOU2/XnfE0cuuWght9Sur6K2uZxZX7x+Z5kKIjJLJj5SiTbgJCOfLHPPIB7rYXcN9ZW93aOJLe4jWWNx0ZWGQfyNc/wDETxfZ+C/Dk2pXeHmPyW0GeZZD0H0HUn0/Cud+DviOCfwHI9xK3k2I84MYWRvJkXzFwnJwCXQAZ/1fGa8U+ICeM/iJ4je+j8PawLCPMdnE1s6rGmepJGNx6k/QdAK9vI8shjq/NXko047tu1/L5/gvkcuLrulC0FeTPVvHPxt0jRbNIdDCapqskYJCn9zCSP4m7kZ+6PcEiuR8N/DjxL8Q9UTXviDdXFvZtzHbn5ZXX+6q9I1/DJ9Oc1qfAnwJfaJqUk/iXwmUn+/b6hLPG3knH3fL3ZBP94DPbiveK9DF42hlDeHy5Jy61Lpv0jbRfn+ZjTpTxKU6+3bb7yjo2lWGi6dFYaVaxWtpEMJHGMAe59T7nk1eoor5aUnNuUnds70klZBRRRUjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqGu6taaJpkt9fuwijwAqLueRicKiKOWZiQAB1JoAi8Ra3a6FYfaboSSO7iKC3hXdLcSn7saL3Y/kBkkgAms3w/ol1JfjXPEhjk1hlKwQId0VhGeqR+rH+KTqegwuBSeHdIuri/wD7f8RIv9qyIUt7YNuSwiP/ACzU93OBvfueB8oGenoAKKhuzKttK1uAZgpKgjqfSs7TPEFjfRjMqwTdGjlO0g/1q405Si5RV7GUq0ISUJOzZr0VnzarbK/lW7i5uD0ihO4/iegHuat2/m+UDcbfMPJC9B7e9JwcVdlRqRk7R1Ja5bwefsWr+I9HbP7i8N7DnvFcfPke3mecPwrqa5XxJ/xKfFGja4Bi3mP9l3h9FkYGFj9JBt/7ampLOqooooArajYWmp2UtnqVrb3lnMMSQXEYkjcZzgqQQfxrj/FHwv8ADuvaZaaaltBpen23mFYLGwtAuXxuILwuYzx96Moec5yBjR+JHh+XxN4Xl02C3huJGljkCT3AhT5WzyTDMrDj7rRsp7155dfCTUL7Tbg3sXh/+010WGxsZIYvLS0uEuJ5d6BYwEwsiDeiqSQx2qDigDstT+HmhP4itfEVyJmbTljkigitIGI8pMKN6xG4fGM7PMIJxweBUehar4U0PWLnS/D3h5bC6k1CHT5VsrCK38x3thch2A2nasbHJYAg5GD34/Uvhf4kv/Gmpau0mhQR3KahD5luFieWOeF0iEgW3DkglCxaWQHBIA4Fdfong2+sdL8XW101vN/a8UUcSRXDxH5bGK3YNIEJTLRsQwDEAg4zxQB0DeEfDMdxeXv/AAjukfablHW4lWwjMkyuCHDELltwJBBznJFSS6JoOuWBku9Fsrm3vY4meO8sQC6qMxiRHXIK7jhWGVyRgc1znw48I3/hvwzqmmXcGk232h2MEdkicKYwuZHjhhDtkHnywQMAljzXLWnwkvE0mHzxpT6za2ejW9pd5YtbvabfPKNsyu4KQCOT0OKAO/g07w/4g8G6toOjpHa6PKLvS5ksoRAIn3PHMEUrgEOX5wQTzzmrFn4N8N2miNpEOgaSNMkIaS2+xxeXKwxhmXbgnjqRXlWp/B/UpFuorCz8PxQHV7i/whRTexStIyJMslrKgMO8BcrIME42cVoWPwu1C31nw9M1ppU8FlBDb3Umo3KX7mJN2UjVrRSpw20MjxjoShwBQB3WgQeEtQ0fTxouk2T6VqdiwgEWmlYXtidxRvkCqpMhOxsbiWIBw2NNvDGgNrA1ZtD0s6qBgXptI/OA27cb8bvu8denFePx/CDWE8HWujW9v4esZ7fSNQ015reRwLuSdbcJPJiIEMfJbd94j5cFu2l4q+El1cy30fh3+zbPSZL23u00wbEhl2wNG+9XgljDbirZMb5K5ODggA9FbSfDXhjTLi5i0jTrCzjidZfstio/dsQWBVFyVJAJGO2T0rz4eKvhBaWVzZ2umaP9kuQvnwQ6NtSXaSVDKYwGwSSM9Ca9C8CaNL4f8I6dpVyzNJbRlDunE2MsSFDiOMEAEAYRcAAY4ryb4ufCbHna14Ut+PvT2Ea/m0Y/9l/L0rlxU60I81JJnvZFh8txVX2OPlKLezTSXo7p29b2O38FX3gvxRrbajoHh22+3WaAf2i2nRxtF8u1UEmN2duRgduK6zVvDmh6xcpcavo2m39xHG0SS3VqkrKjAhlBYEgEEgjvk14H4Z8H/EHSdCstU8JaiGtruJbgW0cwGCQPvRyDYT+fStYfE7x54fG3xJ4c82NOsr27wk/8DGU/IVjTxrjFe2i1520PRxnDUataSy2rGSWnK5e953vbqe06hoWkajHdR6jpVhdx3W03Cz26SCbb93eCPmx2z0qxpmnWWlWMVlpdnbWVnFkRwW0SxxpkknCqABySfxryPT/j5pMgH9oaNfQHv5EiS/z21vW3xn8HzAeZdXdv/wBdLZj/AOg5reOMoS2kjy6vDmaUvioS+Wv5XPSKK4iL4q+C5FyuuRgZx80Eqn9Vp/8AwtHwZ/0HYf8Av1J/8TV/WKX8y+9HJ/ZGPW9Cf/gMv8jtKK4iX4q+C4wC2uRnP92CVv5LWfc/GbwdDny7u6nxn/V2zDP/AH1ik8TRX2195cMlzGe1Cf8A4C/8j0eivHr3486HHkWWl6jOR/z02Rg/kT7dqqaP8Y9Y1zWrK307w0RZyTokzqXnZULAMRtAAOMms/rtG9lK52LhfM+RzlS5Uu7S/W5P8fbqaNvKiV3V9NeB1WMHKS3MCONxIEeQMeYT8ueOSK2tHnnHhfSobzTri7vJ5HFvaa5JEkyBVJC71DBztBw3U5ye9c3+0jBFssp7qD7RbfZZDJGu8yOEuLdtsYUffILYLfKOSeldDPc6fbeHLO0lmi1oRxyyW8jSpE8AjXbhZkXYJEOV3Da3pXWeAWtR12+1CzmFromsR3FtKBLZ3FrG0d1wCYy53KF5++P5Voa9C2oaLcJpMVnHqV3aqPs95God4sHEZUngjccZBUHqKqrqOr33heym8OQOLmFlS4TUAwlIQDei7h87k5Xccc/lWDq/hay1+C68QwXklpDcM0jxX/7kDadu0yA5jUkdcFh1BBoAr/BWCXSfEN/pTLdqsUU8LfaZEf8A1VxuQLt4AVbgrj1HHGK9krxj4KSjUvF+v6ikKQAB90QU7kLy7QC54kGIMhxwQR3zXs9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJ5Y4IZJp3WOKNS7u5wqqBkknsK5LQIZPE+qReJNQjZLCHP9kWrgjCkYNy4P8bgkKD91D6scafifR59deyspZI10beZL6PnfcBcFIvTYTy3qFC9GNboGBxQAUUUUAFY974c027uDNNAQ7HLbWKhj74rYoq4VJQd4OxnUpQqq00n6laysrayj2WkKRL32jk/U1ZooqW3J3ZcYqKtFWQVR13TINZ0e8067B8i5iaNivVcjhh6EHBB9QKvUUhmD4M1SfUdIMWo4Gq2Mhs71QMfvVx849nUq49mFb1YcmkTQ+LY9XsXjSG4g+z38TZHmbcmKRcfxAllOeqt/sitygAoqpfG+UA2K27nuspI/Iissv4jlbAisYB/eJLVrClzK90vmYVK/I7crfojeJwCTwKwtT1pndrPRU+03Z4LrykfuT0oXQ7i651fUJbhepij/AHafjjrWxa20FpEIraJIox2UYq17Om7/ABP8P82Zv21ZWtyL8f8AJficlpE97pHiAWmpzNIt0uQxYkbuxGffI/KuzrO1vS4tVszE52yL80cg6qaxINX1jT8W99p0t0U4EsefmH1wQa1mvrSU42Uuq2+aMKcvqTdOd3B7Pe3kzrKQ8fSud/tfWbg7bTR2jz/FO2B/Sm/2Rqmo/wDIW1Dy4T1htxjPsT/+usvq/L/Ekl+L/A2+t838KDfysvvZpWus2tzqktlC4Z0XO4Hhj3A+nFadcrqHhcRGG40V/JuIeis33sd8+v6VM2raysIjOjubnoXDfJ9f8mrlQhOzov1voyIYmpTvHER16NJtPyNjVNRg021ae4bA/hUdWPoKTS9Rg1K2E1u2f7ynqp9DWRp+hTXNx9s15xPP/DDn5E/p/nvRP4YWG4+0aRdPZy/3eq/T6fnR7OglyOXvd+np/wAEPa4lv2ih7vb7Xr2+R0UaJGgSNVReuFGBzTqyLa41WDC31pHOB/y1t3GT/wABOK0YLhZuiSofR0K1zypuPn6HXCsp90/Mo3/h/RtQz9v0nT7knqZrdGP5kVhXXwz8HXRJl0G2XP8AzzZ4/wD0EiuxorCVKEviimd1LHYqj/Cqyj6Nr9Tz6T4P+C3bK6XJGPRbqXH6sab/AMKc8Gf9A+b/AMCpP8a9DoqPq1H+RfcdSzvMV/zET/8AAn/mefxfB/wWjZbS5JBjo11L/RhV+2+GXg63x5eg2xx/z0Z3/wDQia7GimsPSW0V9xE84x8/irz/APAn/mY9l4X0GxINnoumwMOjJaoD+eM1rqoVQqgBQMADjFLRWqio7I4qlWdV3nJv1dzz74w6LHq2nad9oleG1eV7K4lXJ2JOhRWIBGR5nlZBIBzzxXl3w8SFvDtvpcujW11NpLT3OraWHEMbud0QkOSVd0MTbl6DeCMkDP0Rqlhbappt1YX0YktbmNopEPdWGDXhEkWpeDvGeoag1nJeX5t1+3eWzCSdY/uXigH51YBVljUDBTjJZdzMzW+Hs76Tr9nYtDdyz3EISd5zJwH/AHi4ZxnaowoD4c9cAYq94q1e8Fr4jOqWswMFobG2jUMEuJZpcRsAM5P+rxg54fjsNNPH1hf+HL68t7m3s3iiLNNPcIsOQQGUOSCGHPDAEHqvavP9A0HUPG3iM29088VoszXOoGVSJuV2rv3IPmZDiPAUqN0hwWUUAdZ4Hhfwb8IPEniCwhtjcR2txd2wJkeKRYISIzgkNsdkaTAxxKeledL8dfHBIAi8NZJx/wAeM/8A8kV7r8UYY7f4S+LoII1jhj0O7REUYCqIHAAHpivnPwBrdhpnh7xFbNqH9k6xdLD9lv8AZISFV8ugKKWXI7gc962pRUk7q50UIRkm2r7HqWi+PvGlt8XNL8H+JV8OyR3DOs0mn28ykYtpJlKs8h7oAcr3P1r2ivm+11qw8QftM6DqOkT/AGizlkcJJsZMkWEwPDAHqD2r6QqJxszOpHlaQUUUVBmFFFFACHODjr2paAc0UAFFFFABRRRQBn+IdVg0HQNT1e7SV7bT7WW7lWIAuyRoWIUEgZwDjJFYv/CUav8A9CJ4k/7/AOnf/JVHxY/5JZ4y/wCwLe/+iHrmPjN461zwjqGg2ugrpv8Ap0VzLK17A8uPKMIUKFkTGfNOc56Cgzq1YUYOpN2SOn/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSq8fPxV+IAsheGDQBaF/KE/8AZdxsL4zt3faMZxzivS/g14t1XxhoWqXOuLYrc2eoG0U2cTxIyeTFICVZ3OcyEdewoOfD5hh8TLkpSu7X2a0+aNX/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+Sq2tJ1vStZa4GkanY35tn8ucWtwkvlN/dbaTtPB4NR3uvafZ61Z6TNJK2oXaGSOKK3klwgIBdyqkIuSBuYgZ4zQdhk/8JRq/wD0IniT/v8A6d/8lUf8JRq//QieJP8Av/p3/wAlV1VUpdW02H7T52oWcf2aWOGfdMo8qR9uxG5+Vm3pgHk7lx1FAGF/wlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV0lzd29qYRc3EUJmkEUQkcL5jkEhVz1OAeB6GpqAOV/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kquqooA4rVvHF7pGlXupah4J8SQ2VnC9xPJ5tg2yNFLMcC6JOADwATXa1yvxY/5JZ4y/wCwLe/+iHrqqACiiigArgLvw5ofiD4p63/b2jabqfkaNp3lfbbVJvL3T327buBxnAzjrgV39crpv/JU/EP/AGBdM/8AR9/QAf8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E11VFAHlVxo/g/+19UsNN+E1tqf9nTLbzz22naakfmNFHLgebKjHCypztxnNH9geHv+iJf+SWj/APyRUPijVvD2iaR8Sb7xhateaRFrduXtlUt5z/YbIohGQCCwHDfL68V5r4P8Xp4c+HOsa1Y38Fj/AGxrURttK0a9tjHo8cu7Z5zOkqQI207vk4wMAHIAB6XcaZ4Ss2tm1P4PRWNtNdQWn2iXT9LZI3mlWJCwSZmxudc4U12H/CuPA/8A0Jvhv/wVwf8AxNeWeCfF2seLPAGp/wBv3kF9PpvjDT7KK5h24kjXULUg5VEVupwwRcjHAr32gDlf+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDia6qigDlf+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDia6qigDlf+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDia6qigDyW30zwleNctpnweivraG6ntPtEWn6WqSPDK0TlQ8ytjcjYyoqC8tPB9jd2lre/CC1t7m8YpbQzQaMjzsOoRTc5YjI4FZfi7xF4X8M/DJ73xbpSawP+Eh1YWVjKu6OWf7ddY3g/LtAJOWBx1AJxXnNn5Ol2Hwk+2+J9ORY9UvnlubO9imh0sMkbCEOxZBsDDhsgZ7jqAezW+j+D/wC19LsNS+E1tpn9ozNbwT3Onaa8fmLFJLg+VK7DKxPztxnFdX/wrjwP/wBCb4b/APBXB/8AE1598P8AxDrPibR/AWoeIHM83/CSXcUF2YRF9rgWwvdku0AAZ5HAA4r2ugDlf+FceB/+hN8N/wDgrg/+Jo/4Vx4H/wChN8N/+CuD/wCJrqqKAOV/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImuqooA5X/hXHgf/oTfDf8A4K4P/ia5/wAQ+HfBOkarYabbfDTTdWvbyGa4WOy02xXZHE0SsWMzRjrMmACT19K9KrkNceOL4laHJOxWFdD1RnIzwomsc9OenpQBzP8AYHh7/oiX/klo/wD8kUf2B4e/6Il/5JaP/wDJFeXeBfEmk6h471fXfhzaaZpVppmkXFtZaX56pda5cKrOrPCG3uBjO45Y+vUL678GPEP/AAkOjWt3feMf7X1qa1WW80v/AEZPsTk/MvloglXafl+dj+tAF/w94O8A69oGmavZ+CvD6W2oWsV3EsulW4dUkQMAwCkZwRnBNaH/AArjwP8A9Cb4b/8ABXB/8TR8J/8Aklng3/sC2X/ohK6qgDhfCeiaVoPxJ8SWuh6ZY6bbPpOmyNFZ26Qozma+BYhQBnAAz7Cu6rldN/5Kn4h/7Aumf+j7+uqoAKKKKACiiigAooriviPptjq+qeCbHVbK2vrKXWX8y3uYlljfFheEZVgQcEA/UCgDtaK8T8WaToWi/FDwf4fj8AeCf7H1t7hWuG0+N5/3UQc4Xy1VOSBnL5HZe/ZeE9E0rQfiT4ktdD0yx022fSdNkaKzt0hRnM18CxCgDOABn2FAHdUV86+FPGFxp3hrUNVg1LTL/XLaCd/KufFV1dzEiXaPMsDhEAGOQ3HGOtdnD4w8W2fiO4s9Tm0G4tbPWbTSZ/s9lNE8ouIkkDqWmYJt8wDBDZweRQB6vWZruh2GuQRx38TF4W8yCaNzHLA/95HXBU/Q8968H8GfETVND8GQ2mmXGiastrpc1y0UMb79PdJ0VUuGEhB3h2wAEI29COa9F1bxR4m0fxJZ6BcxabdXuqmI6dPDbSJEoEhNyJAZGz5cW1gcruJ6DpQA69+Gpub5LhtSs5HTKrPcaTA9ztKspBkAVW4dvvIeueTXY+HtEstA01LLT0YRg7nkkYvJK56u7HkscfoAMAAV5FqHxZ1q2sdXuYjok91b2l/O2mJDL5+mtbthPtJ8zkP/ALsfJ4yOa0PEfxE1rw4+p2GrXekJqFvdwRQ3MdjtgdZIWkKuJrqNEI2nDtKA3QLk4oA9V1bT7XV9KvNN1GLzrK8he3nj3Fd8bqVYZBBGQTyDmuB/4Uh4A/6A91/4Nbz/AOO1w+mfEnxBLfNr0tzYhrjwzHeQaIUf/Sp0kuQ6wfvcbgUDMQrnZtHbcdDS/ixrN3YRPc3Xhuzgmvo7c6zK8T21srQySESxw3cm1tyBVLSoDvHHGC02thptbHc+HvhV4O8Pa1a6tpOlzRX9qWMMj39xKELIyE7XkKn5WYcjvXcV5V4N1y70P4CHWrG3XUru2ju50SNSqyH7RJ82M5C/xYz0HXvWLpvxW1i6s7c3d74ZsLea+Nv/AG1M8UltEohMm144buQK5YEDdMMjnGeKV7ibvue30V4NH8X9ak060uJbnw9Yztb2cqWtxBKZNRM0xRzAPNXaqAc/6w5BzgV2fgfxve63451fRL670qQWomaOLT0WYKqShVLzLO5DYIyjxRnJOMhTkA9GoryC7+J2r2/xGu9FktLCGxtrowNBK8K3LwiLf58Ya4Ej5PIRYDkZw+awtI+M2rXq6gm/R3gRLORNTaAJDaxzSsjSTxx3M2Au0cM8bAt8wXrQB75RXhOr+JtW07xLrPiXSNX8P6ulp4btJ557e2cwXareXY2xFZ22EcgsWfkdOw9I+IXii78KLpF1BZreWlzdGzmjUHzDI8beSFPQbpQiEkHG8HtQB11FeO6h441nWmh+yWq2KjWjpEYYzB0uFsZ5JidjoJVWQKoBGDtJxnaV5bwzr+vXKeGNW0/XtG1LVLPwjdyXEstvJNtKfY2aGbE+4z7sbnJHUnZQB9F0VR0K+Op6Jp9+yCNrq3jnKA5CllDY/Wr1AHK/Fj/klnjL/sC3v/oh68y/aT/5GHwj/wBeuof+h2tem/Fj/klnjL/sC3v/AKIepvF/gjQPF8llJ4gs5riSzEiwNFdzQFQ+3cMxuuc7F656UHNi6DxFGVJO10eAS/2b/wAKzh2/Y/7W/tQ7sbfP8ryj1/i25/DNei/s2EDw14kJOANZbn/t0tq2v+FMeBv+gbff+De8/wDjtdR4S8K6P4RsJ7PQLaS3t55jcSCS4kmZpCqrktIzH7qKMZxxQefgMsnha3tJNfDbT5anAReH/EV9cywvY6tpdnceKXvrlodQSB5bJrV0+9DLux5ix5XIPKnscZEPgfxkY7y+S41CHXI9HltLS5l1R2zILqbYrASYY+QyYLZwxBJDAke5UUHsniOm6B42is4BqKeJbvTft3mXGnQ36211s8kqDHOb6Vym8AlTMnJ4GOKlHhPX7PVfEVxo+neILeXUbrTLm2uJNZ3qkKG0E8UoNwS0oWOUFsNlQVDkEKfaaKAPINT8O/EB4dftLLUrlIrGOVdIna93Pe+dKsh8z5gd0cYaJSxHLZBGNw6X4Yadr2n6HqcevyamZJJy9vFdlWkiXYowjm6uSQSCRvk4JPAGK7qigDwSPwf4qudPtxqum+Ir1LHUra5Uya00V5cIFlWQgC9eJGG5DuR4s5OFUAZW+0z4jR6tq99ard6PafY78brnVDLAh25gcNLdSAH5c5EMQQsc7gM171RQB866W/iLxJZayfBF1rLabDeWQeOfWTfSSoIpfOWKdLsLne0RISdOByR90+z/AA7tNUsfB9hba7Ndz6gnmb2uwolAMjFVbbLKDhcDPmMSACTnNdHRQByvxY/5JZ4y/wCwLe/+iHrqq5X4sf8AJLPGX/YFvf8A0Q9dVQAUUUUAFcrpv/JU/EP/AGBdM/8AR9/XVVyum/8AJU/EP/YF0z/0ff0AdVRXAXHxAnXxpNoMNhpymK6jttl3qi213OGVSZYYGTEiAN1Dgna2BnAN+H4k+FJRO39pvFHDFNMZZ7SeKN1ibbJ5bugWQqeCEJOe1AA3h/xHZ65rd5oeuaRBbandJdtDeaVJO8brBFCQHW4jBBEIP3e561N9h8cf9DD4b/8ABDP/APJlJ/wsHw39nWZ7y5jLXQshBLYXCT+cY2kVPJZBJlkUlfl+boMkgUR/ELwy15LbNqLwtH5u6Se1miiBiQvInmsgTeigllzuXacgYNAFXUfDvirV1tLfVfEGiNZRXtreSJbaNLFI/kTpMFDNdMFyYwM7TwTxXa1zdh420O9ltY0mvIDdBzAbzT7i2WUIm9irSooI2/NkHkA4zg1QPxI0Ca0uZdMa/vnhtPthEOm3RQKYfOUM4jKoWTBAbBO5eDkZAOzori9E+I+jalZaU7RapFe39ulwLRNLu5GjVsDccRcJuOBIQFOMg11t9eWun2r3V/cw2ttHjfLM4RFycDJPA5IH40N2HGLk7LcnorC/4TLwx/0Mei/+B0X/AMVXD33xi03SfE9zp2oLDdafkNBf6dKsylSM4ZQeo6HB7dKxniKcNZM9DD5RjcS3GlTbaV9rfdff03PVaKytA8Q6R4htvP0a/gu0xkhG+Zf95TyPxFcV4x+JzeHfF9xoiadY3DQQW84STUfKurnzXZNlvB5beay7ckbl6jpWqkpK6OGpTnSk4VE010ejNXTvDvirSFu7fSvEGiLZS3t1eRpc6NLLInnzvMVLLdKGwZCM7RwBxVv7D44/6GHw3/4IZ/8A5MqaTxx4ei1aTTpb9o543eJpHt5VgEiIXdPPK+XvCgkruyMHjiubg+Jtvd+KJLWyVf7JMGnGGa7trm1eSS5uZIsrujO9cKhUhQpJOXAyVZBsL4f8R3muaJea5rmkT22mXT3aw2elSQPI7QSwgF2uJAABMT93sOldhXLyePfD0Nze293dXVnNaQtcSJd2Fxblo1cIWj3oPMG5lHybslhjqK1PD+v6fr8M8mmyTH7PL5M0c9vJbyxPtDYaORVZeGUjI5BBoA1KKyb7xLoWn3T2t/rWmWtzHjfDNdRo65GRkE5HBB/Gue8XfEDStL0Oa90bVdF1C5gKsbUXybpUzhguD97v0PTGOazlVhFNt7HZQwGJryjGEH722mmu2u3zO3orz7wp8WfDOvFIprk6bdtx5V3hVJ9n+7+eD7V1viTW7fQfD17rE6STQW0Rl2QgM0noq9skkAduaKdWFRXg7k4vBYjBz5MRBxfn+nf5GpXNeI9D1W81/TNX0PU7GxubO1ubRlvLF7lJEmeFiQFljKkGAdz941VTxRqmmRtc+MNHttKsiieXLaXrXrtKzBVh8pYlcyHPRA44PNSw/EDw3NJbRRXs7T3AlKQCyn80eXIscgaPZuQqzjIYAgZY8AkaHKH2Hxx/0MPhv/wQz/8AyZR9h8cf9DD4b/8ABDP/APJlOs/HWiXunyX1kNXubNSuJYNHvJFlDZw0ZER8xePvJkdOeRmH/hYfhyW3hezvXuJLi2N1Ci2s5Jj3Mm5wsZKKGRgxI+XHIHFAGz4T0j/hH/CujaN5/wBo/s6yhs/O2bPM8tAm7bk4zjOMnHrWrXLweONI3aRFdvcwzamkPkSCyuTbO8qhlVZzEEyewJU+oB4qfw/4x0PxBfNaaVdyTTeUZ0L20sSTRhgpeJ3ULIoJA3ISOR6igCtpv/JU/EP/AGBdM/8AR9/XVVyum/8AJU/EP/YF0z/0ff11VABRRRQAUUUUAFcf8QJjZ6h4Q1Bra+ntrPVnkn+x2kt08aNZXUYYpErNjc6DOP4hXYUUAeQ+KV0PxF4q0nXptS8e2l3pJdrKO28N3Hlwl1CucPZMW3AD7xOO2K6nwrfLq/j/AMQalbWmpQ2TaZp9usl7p89pvkSW8ZgomRS2BImSBj5hXa0hGQQCQT3HagDL0jxHoetXFxb6NrOm6hPb/wCujtbpJWi5x8wUkjkEc1gaP4+0/U/Gmr6GlxpMUWnzizDvqK/aJrnarFEg2/dGWXduzuRht4JGf4G+Huo+H/Fb65q3iSXWbg2L2X72OYMwaRX3kvPIoPykbUVF56CrGo+AZ5nvbiy1WOC+k15Ndt3ltDJHE6wJD5boHUuCqschl+8PTkAd4n+IVto97LDZ28Ooxx23nGWK6GN4uo7do+FPKs5z6FSMdxvI2gXutWGqx3dnPqDRzWdpItyGDAMDKka7tpYGP5iBkbcHpXEQfCeYWTxXOvCaeRZhJKtlsDNJfrdkhd5xyNmM98+1aGieBYpPGnia/wBYskl0id2jsrK6EcsZ85Y2uZQvIAd0Xhuflc4wwoA2fiL430vwR4evdQv7my+1xQPNbWU12sD3TKPuJnJJPTgGtOfxPoNvqM+nz65pcV/BG001s93GssaKu4syk5CheSSMY5ri/FvwuGpJqFv4bvrDQrDUNK/sme2TTRIqRiSRw0QV0EZJlfIwQeDweafbfC+OHxlNq8t+t1p8l9NqH2K4+0sUkkRlbbi4EOPmI5hJ2kgk9QAdpeeIdFsYpJL3V9Ot444kuHea5RAsTkhXJJ4UkEA9CRxWTH430p9ZlgF3Y/2SmmrqX9qC7TyCplaPG77uBt+9u9q5RPhBHH4dewTXLlr1L6C5trxldDFFApjggPlyI5VELDIdSWJbjpRD8I/KgBTVoo7tFidWW3mkjM8d2bkSOs08juCxwyl+TkgjPAB3E/jHwzb6db39x4j0aKxuM+TcvfRLHLggHaxbBwSM49areIL3wzqsljpOo69FBc3RWa1gttXe0nuAQQpXypFd1OTxyDwewrjrnwH4httf0u803UbB7yS4v7u+vpdP3QRPNHEgCQecG5EfXe3OS2c1FZfBiDT7ywNpq8kthClks1vdG6PmNbBQrKIriNAflBG9HCnkccUAXbdfBmq+NtM8Kab5V7DpuntP5FprErQW5t5ogkctsj7GbdJu3OCfk5z27LUfGHhnTL+Wx1LxFo1pexDMlvcX0UciDaH5UsCPlIb6HNc54G8AXnhrVtMuLjWYLyz0vTJdKtII7HyXEbyROGkfzGDOPKAJCrnOcA5zZv8AwDHeazqF+96mbvWLPVtht87fs8UcYjzu5z5ZO7tu6HuAbSeLNFkeB4tRsZLGa1ku1vkvITDsR1Q879xG5wNwBUEYJBIBB4w8Mm8trMeItGN3cnbBD9ui3yneUwq7st8ysvHdSOorjLz4TrcjUV/tcKt5HqMe37JkILu8juf7/O3y9nvnPGMVZ8c/Dm/8Uawk6+I5bTTEe1kSx8uUpE0Mgf5QkyRndtA+eNyOqkUAdPdeMdBiv2sINV0+61FJ47eWzhvYBNEXkWPLKzgjDOox945AAJIBx9Z+JOjWHiEaXa3FlqDxWd3d3n2e/hD2pgMY2OGYKpbzG5dkA2H8Kdr8PtQg0+20n+27RtFtNTi1K3j/ALOIuAUuluNry+btbOGXOwHkHnGDkXXwiu7nSRpUviGAafBpt9ptmq6cRJGtyyMXkbzcSMNg6Bc5z1ySAemjV9NLhRqFmWNwbMDzlz54GTF1+/gE7euO1Y6/EDway5Xxb4eI3KuRqUPVs4H3upwcfSsQ/D+8HiRL2PWol0tdaOufYzZEymYxGNl83zMbeSR8mRnqeMU7f4URReG49K/tNGZPDU3h4TfZBnMmP32N3Y87c85+9QB6bRUVnD9mtIIN27ykVN2MZwMZqWgDlfix/wAks8Zf9gW9/wDRD15f+07q2p6dqXhSLTNV1KwjmivWkFleSW/mFTbhd2xhnG5sZ9TXqHxY/wCSWeMv+wLe/wDoh68f/aynht9V8HPcSxxIYb8BnYKM7rbjmrp25lc0pW51c5XwjpPjDxBZ6leS+JfF1lY2tjLeR3LX920czJj92G8wDJ55yenSvV/2Z9Rv9S8H60+qahfX8kWrNHHJeXLzuqfZ4G2hnJOMsxxnua81t/iv4UFv50txPHdnw82i/Z4/KMKv2dW8wEA9xt/Ou9/ZSljm8E69JDIkkZ1p8MhyD/o1v3rSpa2xrWty7HaWPxEsrm7QTaRq9pp0l/JpkepTJCbdp0lMO35JGdQ0g2gsgBJHTNaieNPDypZ/btY03T57tmWCC5voA8uHKfLtchvmGOCfQ4OQOesfh/qCAWGoa7bz+H11STVfscNgYpZJGuTcIkkplYFFcjgIpO0c9axNd+EOo6no0ekx+LZodOETo0HkTBN7TvLvCxzopPzquJA4+XIAzWBzHoz+KfD8ertpUmu6UuqKGZrNryMTABSxJTO7hQWPHQE1Hb+L/DVxZXl5b+IdHltLPabmdL2Jkg3fd3sGwue2etea/wDCEa/L42jtI43h8Nw3+o6h9pnghDF7qCVCA6zs8mGmON0cZCjBJwK27v4Xb30ya01aOC602xsLW3LWe+MyWsjOHdN43K24jaCCOoagDrpvGHhmC1s7mbxFo0dteZFtK99EEnwcHYS2G544rN0L4haBrs3k6XdxTzDUZNNeIXMAdHTzcOV8zJRvJYrtBYjnbgMRz03wy1EmKe18QwWepPcTXFzfW1nLDITLIHZIwlwFVPlHyyCUZ+Y5NWpfhvPcE21zrMbaYus3OrxxR2hSZTOlwskZk8wg83GVYIMbcEHOQAdno3iDRtce5TRdX0/UWtiFnFpcpMYic4DbSducHr6GsHW/iX4R0iHzJde0yfbdw2cqQXkLNA0j7A0g3jaq8liegVjjitDwTo2qaBpEOm6jqNjfW1rDHBam2sTbMqKMfP8AvXDEjb90KODxzxyEfwy1FLaeKPxDDBGtzbXlnaw2kxtbeWGcTA+VJcOcEgKVjaNcZ4zQB21j4s8OahfixsNf0i6vSnmC3hvI3kKbd27aGzjaQc+hzUdt4z8L3VveXFt4k0WaCyAa6kjvomWAE4BchsLk8c4rhdU+Feqavrq6lrnima9jQ3LCCKGZCBNbvEyRhrho0A8wlSE3YADM3WsTS/hz4h8Rtdt4heTSBbWmn2unOIVgfNtJK4LJb3L/AC/vAMrKhz0C4GQDv/iLqNlqvwe8W3ul3lte2cui3pjnt5VkjfELg4ZSQeQRXaV5nr/hz/hGPgj40snminmk03ULiWWMTYd3hclj500r5Pclzk+lemUAFFFFABXK6b/yVPxD/wBgXTP/AEff11Vcrpv/ACVPxD/2BdM/9H39ADNW8ER6tfNJf65rM2nNdR3h0x3iMHmIwZcEx+aqhlB2hwPwJFc7ovwogk0dbbxPqV5eyIl3FBDFIiw2YmlLloiI1cvgLy5bBzjivT6KAOPtPAVnHfW1/eanqmoajDfpqBubl4g0jpA8KoQkaqECyMcKoOeSTzmrdfDHR7ye4W7vNTm0yWW6nGmNKgt45blHSZ1wgfJEsuAXIG84AruqKAPPfFPw/udZ8M22iza1e6jGLyF2ub9o0mggUFZFiMMSZZ0LJ83Z2Oexvan8O9L1LxNHrNxcXKvGhiS3hit4lVDGY9nmLEJimCTsMhXOOOAB2lFAHn83wvsbm10a2vda1W6h0oItt5sNn5iqhG1RKLcSLwoGUZSR1J613N9Z2uoWr2t/bQ3VtJjfFMgdGwcjIPB5AP4VPRQ1ccZOLutzC/4Q3wx/0Lmi/wDgDF/8TXD33wd03VvE9zqOoNDa6fkLBYadEsKhQMZZgOp6nA79a7/xD4i07w8tm2qPcot3OttD5NpLPukbhVPlq2M9s4rWrGeHpz0kj0MPm+NwzcqVRptW3v8Adfb13MrQPD2keHrbyNGsILRMYJRfmb/eY8n8TWXrHgfSdX1HVr28a5M+o29vAxRwvkGBnaOWI4ysgaQnOT0HHXPU0VqoqKsjhqVJ1ZOdRtt9XqzzlPhD4d/tm71GYyXEl55jXKzWlmxmeRCkjeb5HmqWyWwjqAScADirNt8MrBLqO5vNZ1q/ni+wiNrh4flS0mM0SfJEuRuJBJySO+ea6fxNr1r4d0m81C+jupIbW1nvHEELPlIk3sN33VJA4DMMnp3qW51mxtYdOkupTENQlSC3BQktI6lgvGccA8njjrTIPPYPgd4YSS+aae/uRd20lq4lW3B2tIkmWZYg0jK0a4Mhf0ORXY+CfCNh4QsJ7XTmDrNL5rN9ktrc5wBjFvFGp6dSCeeuMVuWtylyJDGsq+XI0TeZE8eSDgkbgMj0YZB7E1NQBk33hrQtQunur/RdMurmTG+aa1jd2wMDJIyeAB+Fc94u+H+lapoc1lo2laLp9zOVU3QsU3RJnLFcD73bqOuc8V29FZypQkmmtzsoY/E0JRlCb93bXTTbTb5Hn3hT4TeGdBKSzWx1K7XnzbvDKD7J9388n3rsda0iy1nRbvSdQhEljcxGGSMfL8pGOCOhHYjpWhRRTpQpq0FYnF43EYyfPiJuT8/07fI4LVfhpaa1prWWva/rurQKEEIvGt3WEowZW2eUEkbjBMivkEg5zVvw38PNI0G4t5rd5JDFaXFns8i3gjdJnjdyyQRRrn90oBAHGc54I7KitDlPPbz4XWd54etdDu9f1ufS7N42tLeZbWVIVRWVUw0BEi4YcSh/uqQQRmrvhr4caR4esja2NxetEbCTTv3jRjEbyySkgKgAO6VgMDGAOK7WigDzU/B3QDrmnao93qLy2LWjxJItu+DbqioN7RGRVIQblV1Ukk4Ga0/Avw00PwVqMl1owIDRGFI3tLVTGhYHHmpCszdAPnds98kAjt6KAOV03/kqfiH/ALAumf8Ao+/rqq5XTf8AkqfiH/sC6Z/6Pv66qgAooooAKKKKACiiigApCcAk5wPQZpaKAPBNO+M+q30+qrYjS76KK0S6tnMAgIJuooSkiJcysp2yg/MI2BHKdq2da+IfiXRvHcPh65i0eQrLbIWfyrX7YsrfM0Pm3YYFQdoCpLuZT93IA9iooA87+KXjS88L6vo1na6loWmQ3tpeztcatGzqXh8nZGgEiZLeY3GSeOBxg8q/xe1IeKPDunNBaQvevYRX1hPAsc1u1wiM21zcB2ClxyICvUFga9huNLsrjV7PVJod19ZxSwwS7mGxJChcYzg58tOo4xxjJq7QB4ba/FfWZdG1Kd9Q8L/bbWWANsaE20aOXyFn+2iOV/k4R2gbALFcECi4+LetjVdKt7WDTTBcwWsyveLFZ/bvMch/K827UptAwNonye4BFe5UUAeKeEfFFz4p+KHhq5vr3SzOmn6oG021jZZ9PPm248udjI25yFH8KYweoINbWueKdatPGV1pWjmxiludYtdPE14s06Ij2MkxYRiVQDmMDC7QcnOTzXqNFAHmmo+ItU1f4D+INaLwWuqx6dqAaSBGCBoTKhZBuyufLyPmO0kfexzyWneMNW8H61pXhKx07w/b2sf2RQiRQWK3gmILvCJLpWDDOMKku51OSu4Ae8UUAeLT/FLVo/C91qqXegy3wmWKXSI4sXGlKZthe5L3CghRgHIiXLD5gOTXtvivrTf2M13c+HYYbqVo2a3eC8mn/fbFZIY73Kgjg7GmIYHjAr3GigAooooAKKKKACiiigAooooA5/4hafdav4B8S6bp8XnXt5plzbwR7gu+R4mVRkkAZJHJIFVf+Eo1f/oRPEn/AH/07/5KrqqKAOV/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kquqooA5X/hKNX/AOhE8Sf9/wDTv/kqj/hKNX/6ETxJ/wB/9O/+Sq6qigDlf+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5KrqqKAOV/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kquqooA5X/hKNX/AOhE8Sf9/wDTv/kqj/hKNX/6ETxJ/wB/9O/+Sq6qigDlf+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5KrqqKAPOvG+p69r3gvX9ItPA/iBLnUNPuLSJpbjTwivJGygsRdE4yRnANei0UUAFFFFABXK6b/wAlT8Q/9gXTP/R9/XVVzWreFpbzX5tXsPEGr6Tcz2sVpKtmtsySJE8rISJoZCCDM/Qjt6UAdLRXK/8ACL6v/wBD34k/78ad/wDItH/CL6v/AND34k/78ad/8i0AdVRXK/8ACL6v/wBD34k/78ad/wDItH/CL6v/AND34k/78ad/8i0AdVRXK/8ACL6v/wBD34k/78ad/wDItH/CL6v/AND34k/78ad/8i0AdVRXK/8ACL6v/wBD34k/78ad/wDItH/CL6v/AND34k/78ad/8i0AHj7SdV1eHRk0eKxc2mpQXs32q4eL5Y23YXbG+SenOK5zw/8ADiXSfFVlriJpqXY1fU7y7uIsiWa3uDKYoy23LbS6EqTtBBIz36P/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWgDD8ReC9Qv8A4l6d4hs7XSvJhaETT3brNIEQkkRRtbkxtzgMky+pU4Arl7D4Sapo/h21tdHj8PR3h0NdOv8AzIt0d3OJomLuGiYP8iyBWdGwWHykZr0T/hF9X/6HvxJ/3407/wCRaP8AhF9X/wCh78Sf9+NO/wDkWgDzXTvhJr8Hhu+057jS4zNFq0cMaS/JELu3jjRfkgjUAOrk7Y1GDkAkkV3fj/wdJ4i0HQrdbDSdRuNMu4bg2+o8QzKqMroW2OQDnP3T0GRV/wD4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaAOA174XatexKbez0GS4W+vLqL7VMJbeFJnVlUwSW0ivjaOVMbDGA4DGjVvhZq97qPimW2i0W1TVY52WeRxcTvK0qSJ8/wBnSSNMqcoZJQBtCgBee/8A+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWgDz7xL8NfFHiK9v9RvX0eN7rUI7ttNS4EsDotsIRuea1kUspXIzCep+6cGvUPBOkS6D4T0vSp2dpLSAREtP55GOg37E3ADgfIvA6VQ/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoA6qiuV/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoA6qiuV/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoA6qiuV/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoA6qiuV/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5FoANN/5Kn4h/7Aumf+j7+uqrn/D3httI1W/1K51nUtWvbyGG3aS9WBdkcTSsoUQxRjrM5JIJ6eldBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adults release fully embryonated eggs each with a fully-developed miracidium, and eggs are passed in the host's feces",
"    <strong>",
"     (1)",
"    </strong>",
"    . After ingestion by a suitable snail (first intermediate host), the eggs hatch and release miracidia, which penetrate the snail's intestine",
"    <strong>",
"     (2)",
"    </strong>",
"    . Snails of the genus",
"    <em>",
"     Semisulcospira",
"    </em>",
"    are the most frequent intermediate host for",
"    <em>",
"     Metagonimus yokogawai",
"    </em>",
"    . The miracidia undergo several developmental stages in the snail (ie, sporocysts",
"    <strong>",
"     (2a)",
"    </strong>",
"    , rediae",
"    <strong>",
"     (2b)",
"    </strong>",
"    , and cercariae",
"    <strong>",
"     (2c)",
"    </strong>",
"    ). Many cercariae are produced from each rediae. The cercariae are released from the snail",
"    <strong>",
"     (3)",
"    </strong>",
"    and encyst as metacercariae in the tissues of a suitable fresh/brackish water fish (second intermediate host)",
"    <strong>",
"     (4)",
"    </strong>",
"    . The definitive host becomes infected by ingesting undercooked or salted fish containing metacercariae",
"    <strong>",
"     (5)",
"    </strong>",
"    . After ingestion, the metacercariae excyst, attach to the mucosa of the small intestine",
"    <strong>",
"     (6)",
"    </strong>",
"    , and mature into adults (measuring 1.0 mm to 2.5 mm by 0.4 mm to 0.75 mm)",
"    <strong>",
"     (7)",
"    </strong>",
"    . In addition to humans, fish-eating mammals (eg, cats and dogs) and birds can also be infected by",
"    <em>",
"     M. yokogawai",
"    </em>",
"    <strong>",
"     (8)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Metagonimiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Metagonimiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Metagonimiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30504=[""].join("\n");
var outline_f29_50_30504=null;
var title_f29_50_30505="Management of status epilepticus in children";
var content_f29_50_30505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of status epilepticus in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30505/contributors\">",
"     Angus Wilfong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30505/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30505/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/50/30505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Status epilepticus (SE) is a serious and often life-threatening medical emergency and requires prompt intervention. It can be a complication of acute illness and occurs as the first seizure in 12 percent of children with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/1\">",
"     1",
"    </a>",
"    ]. Between 10 and 20 percent of children with epilepsy will have at least one episode of SE.",
"   </p>",
"   <p>",
"    The management of SE in children is reviewed here. The definition, pathophysiology, risk factors, and outcome of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18888?source=see_link\">",
"     \"Clinical features and complications of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with generalized motor seizures that are frequent or separated by a period of significantly impaired consciousness or who are medically unstable require immediate assessment and treatment, which usually is accomplished in the setting of the emergency department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief physical examination should assess respiratory and circulatory status. A rapid neurologic examination should be performed to provide a preliminary classification of the type of SE. A history obtained from a parent or caregiver may help to determine the cause of the seizures.",
"   </p>",
"   <p>",
"    An adequate airway should be established immediately if there is respiratory compromise, and supportive therapy (eg, oxygen, mechanical ventilation) should be instituted as needed. A secure intravenous catheter should be placed for sampling of blood and administration of medications. Ongoing monitoring of vital signs should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood should be obtained for rapid determination of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum glucose and a rapid \"finger-stick\" glucose",
"     </li>",
"     <li>",
"      Serum electrolytes, calcium, and magnesium levels",
"     </li>",
"     <li>",
"      Arterial blood gases and pH",
"     </li>",
"     <li>",
"      A complete blood count and general chemical screen",
"     </li>",
"     <li>",
"      Urine and blood toxicology",
"     </li>",
"     <li>",
"      Serum antiepileptic drug (AED) levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An evidence-based review provided the strongest support for obtaining AED levels; subtherapeutic levels are found in almost one-third of children presenting in SE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/2\">",
"     2",
"    </a>",
"    ]. While the yield of other testing was relatively low (3.6 percent had evidence of ingestion, 6 percent had abnormal electrolyte or glucose levels), these findings impact management strategies, and these tests are recommended as well.",
"   </p>",
"   <p>",
"    Other testing in specific clinical circumstances may include (",
"    <a class=\"graphic graphic_table graphicRef69291 \" href=\"mobipreview.htm?20/54/21356\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood cultures and lumbar puncture (LP) should be obtained if there is evidence of systemic or central nervous system infection; there are insufficient data to support whether these tests should be routine.",
"     </li>",
"     <li>",
"      Metabolic studies for inborn errors of metabolism should be considered if there are other suggestive indicators. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical and laboratory diagnosis of seizures in infants and children\", section on 'Laboratory screening in undiagnosed epilepsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuroimaging is generally deferred until the patient is stabilized. However, if LP is considered, computed tomography (CT) may be recommended beforehand to exclude a mass lesion, especially in a patient with focal neurologic signs. Later, a magnetic resonance imaging study (MRI) is recommended if the etiology of SE is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac monitoring, frequent measurement of blood pressure, and pulse oximetry should be instituted. In general, hypotension is not a problem unless the child has a systemic illness, but it should be corrected if significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of an adequate airway and normal gas exchange remains a priority to avoid the consequences of hypoxemia.",
"   </p>",
"   <p>",
"    It requires continued assessment and intervention as needed. Respiratory failure can result from continuing seizures or respiratory depression from anticonvulsants.",
"   </p>",
"   <p>",
"    Metabolic abnormalities should be corrected. Most children with acute seizures have elevated blood glucose levels that do not require treatment. However, nonketotic or ketotic hyperglycemia can occasionally can precipitate SE and may be an early manifestation of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoglycemia should be treated with 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 25 percent dextrose solution. Continued seizures, especially in the setting of hypoxemia, may lower brain glucose levels, worsening brain lactic acidosis and leading to further neuronal damage if prolonged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic children with hypoglycemia may present in the emergency department with generalized or focal seizures, or focal syndromes such as hemitonic posturing and hemiparesis, which may mimic seizures or a postictal state, respectively. These children should be treated with glucose, not anticonvulsants. This situation emphasizes the importance of obtaining a rapid assessment of blood glucose in a child with seizures in order to provide appropriate therapy.",
"   </p>",
"   <p>",
"    Metabolic acidosis often is present but usually resolves without treatment after the seizures are controlled. If the patient is febrile, antipyretics should be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;When there is uncertainty regarding the presence of SE, an urgent electroencephalogram (EEG) should be obtained. In the emergency department, this can be a limited study, with application of only a few electrodes to determine if the background is consistent with a normal awake individual (pseudoseizure) or the diffusely slow and depressed background of SE. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Nonepileptic seizures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If an urgent EEG cannot be obtained, an EEG should be done to evaluate background activity as soon as possible after the seizure stops, ideally within one to two hours. The background usually remains abnormally slow for hours or even days after generalized convulsive or prolonged partial SE but is normal in pseudoseizures, unless large doses of sedating antiepileptic drugs (AEDs) have been given. If the patient has not regained a relatively normal mental state within a few hours after SE has stopped, an EEG should be performed to evaluate the possibility of subclinical seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A recent study of continuous EEG monitoring in critically ill children without clinically-apparent seizures revealed a high incidence of electrographic seizures (44 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/7\">",
"     7",
"    </a>",
"    ]. Similar findings have been reported in critically ill adults. The benefit of continuous EEG monitoring in unselected patients is unclear. However, the possibility of nonconvulsive seizures should be considered in such patients when the degree of coma is not adequately explained by their underlying condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neuroimaging study is essential when status epilepticus is the first presentation of epilepsy as well as in children whose recovery from SE does not follow the expected course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Computed tomography may be performed in the emergency department setting, but magnetic resonance imaging has superior yield for determining the underlying etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18888?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and complications of status epilepticus in children\", section on 'Causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PARTIAL OR BRIEF SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with partial seizures or brief generalized motor seizures with relatively preserved interictal consciousness may require less emergent intervention than do those with SE. Emergency departments that follow strict protocols for management of seizures may emphasize IV therapy, which is unnecessary in many children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/10\">",
"     10",
"    </a>",
"    ]. Repeated bolus infusions of benzodiazepines and barbiturates often leads to respiratory depression, endotracheal intubation, and hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/10\">",
"     10",
"    </a>",
"    ]. In one study, the risk of respiratory depression increased when more than two doses of benzodiazepines were administered, including doses administered in the field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with oral or intramuscular medication may be considered if the seizures are not generalized convulsive (tonic, clonic, tonic-clonic), have stopped before the child arrives in the emergency department, are short in duration, or the child is conscious despite multiple seizures. Oral loading with the commonly used antiepileptic drugs (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , valproic acid,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/46/16104?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ) avoids excessive sedation and respiratory depression.",
"   </p>",
"   <p>",
"    This is illustrated by a retrospective series that examined AED use in a university hospital emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/12\">",
"     12",
"    </a>",
"    ]. Of 55 adolescent and adult patients treated with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    , 45 percent could have been loaded orally with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    because they were awake on arrival, alert, had no emesis, and did not have repeated seizures or SE or require endotracheal intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the patient's previous response to antiepileptic drugs (AEDs) and current medication use may guide approach to management. In deciding initial therapy, the following issues should be considered:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Previous response",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the child has a history of previous SE, knowing which AED was effective in arresting the seizures is helpful. If the child did not respond to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    , for example, another drug, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    or valproic acid (VPA) would be preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Missed medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the child is on chronic antiepileptic drug therapy, it should be determined whether medication has been recently missed or if prescriptions have not been refilled. AED levels obtained upon admission may not be available for many hours and initial treatment decisions may be made without them. If, for example, VPA has provided good seizure control, and the child is known to have missed one or more doses, intravenous VPA, rather than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , should be considered as initial treatment.",
"   </p>",
"   <p>",
"    However, low AED levels are often not the cause of SE. In one series of 51 children with SE, at least one or all AEDs level were therapeutic in 82 and 66 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Paradoxical effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;AEDs can paradoxically trigger SE, although the underlying mechanisms are poorly understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AEDs, including",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"       gabapentin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/27/25015?source=see_link\">",
"       vigabatrin",
"      </a>",
"      , can precipitate generalized convulsive SE, particularly the myoclonic type, as well as nonconvulsive (absence) SE",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"       lamotrigine",
"      </a>",
"      may worsen myoclonic seizures",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      may worsen complex partial seizures and increase generalized tonic-clonic seizures at high serum levels",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      is known to precipitate drop attacks, often with atypical absence seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizures may be worsened or precipitated even when AED blood levels are in the therapeutic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/15\">",
"     15",
"    </a>",
"    ]. If a new AED has been added or the dose has been increased in the previous months, the drug may be causing seizures and should not be used in an attempt to control SE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonprescription medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonprescription medications, including over-the-counter drugs, illicit substances, and, rarely, herbal preparations, can precipitate seizures. Specific questioning is usually required to ascertain use of these substances, especially illicit drug use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1784?source=see_link\">",
"     \"Designer drugs of abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some AEDs commonly used to treat SE may worsen seizures caused by illicit drugs. As an example,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    could worsen the toxicity of cocaine, as both block sodium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/16\">",
"     16",
"    </a>",
"    ]. When SE is induced by cocaine, treatment with benzodiazepines is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Alternative routes of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of an intravenous catheter may be difficult in some patients. If IV access is delayed or impossible, many AEDs can be given by alternative routes. Examples include buccal and intranasal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    , rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    , and intramuscular",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    and benzodiazepines, all of which are safe, well tolerated, and absorbed quickly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/17\">",
"     17",
"    </a>",
"    ]. However, if intravenous access is available, drugs administered by this route are more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Transmucosal AED administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nonepileptic seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychogenic nonepileptic seizures (PNES) are dramatic behavioral events in a conscious individual that are often misdiagnosed as epileptic seizures and are sometimes treated with large doses of AEDs. The history and presentation may provide clues to diagnosis. PNES typically occur in teenage patients with affective or anxiety disorders and a family history of seizures may be present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29175?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PNES can be distinguished from SE by an EEG. An urgent EEG should be obtained when PNES are suspect. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Electroencephalography'",
"    </a>",
"    above.) Therapy may need to be initiated before an EEG can be obtained. In this case, sedating medication should be avoided if possible.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     Fosphenytoin",
"    </a>",
"    or VPA are reasonable alternatives. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on the efficacy and pharmacokinetics of drugs used to treat SE in children is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"     5",
"    </a>",
"    ]. The drugs are described briefly here. Specific recommendations for use in SE are given below. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are the first-line treatment for SE because they can rapidly control seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"     5",
"    </a>",
"    ]. The three most commonly used benzodiazepines to treat SE are",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    . All are thought to increase chloride conductance in central nervous system GABA(A) receptors and thus decrease neuronal excitability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Diazepam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     Diazepam",
"    </a>",
"    has high lipid solubility, rapidly crosses the blood-brain barrier, and is highly effective in terminating seizures. An effect upon seizure activity can be seen as early as 10 to 20 seconds after administration; cerebrospinal fluid (CSF) concentrations reach one-half of their maximum value in three minutes. However, because of subsequent redistribution of the drug into adipose tissue, the duration of diazepam's acute anticonvulsant effect is typically &lt;20 minutes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     Diazepam",
"    </a>",
"    has been the drug of first choice in many settings, especially outside the emergency department, because it is stable in liquid form for long periods at room temperature. Therefore, diazepam is available in resuscitation kits in premixed form, whereas",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    are not. However, in controlled trials, diazepam is less effective and causes more respiratory depression than lorazepam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rectal gel formulation of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    (Diastat&reg;) provides rapid delivery when intravenous access is problematic. Some families will have this at home and may have already administered to the child prior to evaluation in the emergency department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lorazepam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     Lorazepam",
"    </a>",
"    appears to be more effective than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    in the treatment of acute SE and causes less respiratory depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/20,21,23\">",
"     20,21,23",
"    </a>",
"    ]. In one trial, for example, seizures were more likely to be controlled by one dose of lorazepam than diazepam (76 versus 51 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/20\">",
"     20",
"    </a>",
"    ]. Respiratory depression occurred in fewer patients treated with lorazepam (3 versus 15 percent). As with diazepam, rectal administration of lorazepam can be effective when intravenous access cannot be achieved. An intranasal formulation of lorazepam is another probably effective treatment option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time from injection to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    's maximum effect can be as long as two minutes. The effective duration of action, as long as four to six hours, is longer than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    because of its less pronounced redistribution into adipose tissue. The half-life of lorazepam (which is much longer than the period of seizure suppression) is significantly prolonged in newborns (approximately 40 hours) compared to older children or adults (10 and 13 hours, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Midazolam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     Midazolam",
"    </a>",
"    is also very effective in acutely terminating seizures, frequently in less than one minute, but it has a short half-life in the central nervous system. In addition to intravenous administration, it can be given by the intramuscular, intranasal, oral, buccal, or rectal routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5,28\">",
"     5,28",
"    </a>",
"    ]. Thus, it is a useful agent when intravenous access cannot be established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Buccal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intramuscular",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    was shown to be at least as effective as intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    in terminating status epilepticus in clinical trial of 893 patients (145, 16 percent, were younger than 20 years) treated in the prehospital setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/29\">",
"     29",
"    </a>",
"    ]. On arrival to the emergency department, seizure remission was more likely in patients treated with IM midazolam compared with IV lorazepam (73 versus 63 percent). The dose of midazolam was 5 mg for children whose weight was 13 to 40 kg and 10 mg in those over 40 kg. While among responders, lorazepam treatment was associated with a shorter median time from active treatment to cessation of convulsions (1.6 versus 3.3 minutes), this was offset in this prehospital setting by a shorter median time to active treatment administration in the midazolam group (1.2 versus 4.8 minutes). The need for endotracheal intubation, recurrence of seizures, and other adverse event rates were similar in the treatment groups.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     Midazolam",
"    </a>",
"    can be given as a continuous infusion for refractory SE and is associated with minimal cardiovascular side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. However, few studies of efficacy or pharmacokinetics in children with SE have been performed, and midazolam is not approved for the treatment of SE in the United States. More information is needed before midazolam can be recommended as a first-line agent for SE.",
"   </p>",
"   <p>",
"    Buccal administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    was found in one study of 177 children to be more effective than rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    in terminating seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/28\">",
"     28",
"    </a>",
"    ]. Fewer children required further antiepileptic drug treatment in the midazolam compared with the diazepam-treated group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Transmucosal AED administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Clonazepam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11383?source=see_link\">",
"     Clonazepam",
"    </a>",
"    has been used to treat SE outside the United States in settings where intravenous formulations are available. It has effects similar to those of other benzodiazepines, with a rapidity of onset that is intermediate between that of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    and a more prolonged duration of action than diazepam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Phenytoin and fosphenytoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     Phenytoin",
"    </a>",
"    is a long-acting drug that has been widely used to treat acute and chronic seizures in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"     5",
"    </a>",
"    ]. Its principal advantage is in preventing recurrence of SE for extended periods of time. However, because its onset of action may be delayed for 10 to 30 minutes, a rapidly acting agent, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    , usually must be given first.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     Phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    may be less effective for the treatment of seizures due to toxins or drugs and may intensify seizures caused by cocaine, other local anesthetics,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/21/40275?source=see_link\">",
"     lindane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     Phenytoin",
"    </a>",
"    is not water soluble; in order to have a liquid preparation, it is dissolved in propylene glycol at a very high pH. This contributes in large part to the phenytoin's side effects of hypotension and cardiac arrhythmias. Thus, heart rate and blood pressure should be monitored during the initial infusion. However, these complications are less common in children than adults and can be minimized by an infusion rate that does not exceed 50 mg per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"     5",
"    </a>",
"    ]. Phenytoin must not be infused along with a dextrose containing IV fluid, as it may form a precipitate.",
"   </p>",
"   <p>",
"    The risks of local pain and injury, including venous thrombosis and the purple glove syndrome, also increase with more rapid rates of infusion. The purple glove syndrome is characterized by edema, discoloration, and pain in the extremity distal to the site of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    infusion. Severe cases can lead to skin necrosis and limb ischemia, sometimes requiring amputation. More common in older adults, a few cases have been reported in children, usually late in the first decade, and adolescents. Venous extravasation must be avoided because the high pH and osmolality of this drug cause tissue inflammation and necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fosphenytoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     Fosphenytoin",
"    </a>",
"    is a pro-drug of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    that is hydrolyzed into phenytoin by serum phosphatases. Fosphenytoin is highly water soluble at neutral pH and therefore unlikely to precipitate during intravenous administration. Compared with phenytoin, the drug has fewer side effects, including a reduced risk of local irritation at the site of infusion; therefore, fosphenytoin can be infused much more rapidly. Hypotension and cardiac arrhythmias remain a risk, so cardiac monitoring is still required.",
"   </p>",
"   <p>",
"    Little information is available on the pharmacokinetics of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    in infants and children. Subtherapeutic free",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    levels may occur rarely in children after fosphenytoin infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    is converted on a 1:1 molar basis to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , the dosing of fosphenytoin in terms of moles is identical. However, the molecular weight of fosphenytoin is greater than that of phenytoin; hence, a greater weight of fosphenytoin must be given in order to yield the same concentration of phenytoin. To eliminate potential confusion, fosphenytoin is prescribed as milligrams of phenytoin equivalent (PE); as an example, 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PE load, at a rate of 3 mg",
"    <span class=\"nowrap\">",
"     PE/kg",
"    </span>",
"    per minute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barbiturates are similar to benzodiazepines in that they also bind to the GABA-A receptor, amplifying the actions of GABA by extending GABA-mediated chloride channel openings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/19\">",
"     19",
"    </a>",
"    ]. This process permits an increasing flow of chloride ions across the membrane, causing neuronal hyperpolarization (eg, membrane inhibition to depolarization).",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    are the most commonly used barbiturates in the treatment of SE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Phenobarbital",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    is a long-acting antiepileptic drug (AED) that has been used for many years to treat seizures. Side effects of intravenous administration include sedation and respiratory depression, especially when it is preceded by a benzodiazepine. As a result, phenobarbital is considered a second-line long-acting agent after",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    and usually is used only when benzodiazepines and fosphenytoin are not effective. Respiratory and cardiac monitoring should be performed, because endotracheal intubation and mechanical ventilation may be needed. The risk of prolonged sedation with phenobarbital is greater than with the other anticonvulsants because its half-life is 87 to 100 hours, and often longer in newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Pentobarbital",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"     Pentobarbital",
"    </a>",
"    is a short-acting barbiturate with a rapid onset of action. It is most commonly used as a continuous intravenous infusion to treat refractory SE and is effective in stopping seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5,40\">",
"     5,40",
"    </a>",
"    ]. However, significant side effects include respiratory depression, hypotension, myocardial depression, and reduced cardiac output. Thus, intubation and mechanical ventilation and intravascular monitoring are required prior to treatment, and inotropic agents frequently are needed. Other complications include pulmonary edema, ileus, and prolonged sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Thiopental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some centers use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    instead of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    for refractory SE. However, animal studies suggest that thiopental carries a higher incidence of adverse cardiovascular effects than pentobarbital. The half-life of thiopental is shorter than that of pentobarbital, but this is counterbalanced by the fact that thiopental is degraded to active metabolites (including pentobarbital), which accumulate with longer-term infusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Propofol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"     Propofol",
"    </a>",
"    is an intravenous anesthetic with rapid onset and short duration of action that is often used for elective procedures in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/41\">",
"     41",
"    </a>",
"    ]. The drug is a hindered phenolic compound with anticonvulsant properties that is unrelated to any of the currently used barbiturate, opioid, benzodiazepine, arylcyclohexylamine, or imidazole intravenous anesthetic agents. Use of propofol to treat SE has been reported in small studies in adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects include hypotension, especially with rapid infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"     5",
"    </a>",
"    ]. Other side effects include apnea and bradycardia. However, adverse cardiovascular effects occur less often with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    than with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    . Hypertriglyceridemia and pulmonary edema may occur after prolonged use. Of significant concern is that maintenance infusions of propofol have been associated with fatal acidosis and rhabdomyolysis of the skeletal and cardiac muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Others have found that propofol may be used without severe adverse effects if the dose is maximized at 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour and with continuous monitoring and stopping the infusion if side effects appear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"     Propofol",
"    </a>",
"    should not be used in children on the ketogenic diet. A report of a fatality in a 10-year-old boy illustrates the incompatibility of these treatments which both involve fatty acid metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Valproic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravenous preparation of valproic acid (VPA) can be used for short-term replacement in patients maintained on this drug when oral medication cannot be given or to rapidly attain therapeutic levels in patients with inadequate seizure control. Intravenous VPA is not approved for initial treatment of SE, and data are limited regarding its use in other settings.",
"   </p>",
"   <p>",
"    However, in small case series and clinical trials, it appears to be effective in treating SE in patients refractory to first-line anticonvulsants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/49\">",
"     49",
"    </a>",
"    ]. In a series of 41 children with SE unresponsive to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , VPA stopped seizures in 78 percent of cases and had no adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/50\">",
"     50",
"    </a>",
"    ]. In another series of children age one month to 19 years, VPA stopped seizures within 20 minutes of loading in all 18 patients with SE and in 21 of 22 patients with acute repetitive seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/51\">",
"     51",
"    </a>",
"    ]. Treatment was not associated with significant changes in heart rate or blood pressure, although one SE patient had transient tremors. Finally, in an open-label, randomized study of 40 patients with refractory SE, VPA stopped seizures more quickly than diazepam infusion (median time 5 versus 17 minutes), and none of the VPA treated group required ventilation or developed hypotension, compared with 60 and 50 percent in the diazepam group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VPA usually is well tolerated, even in unstable patients, and is less sedating than barbiturates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5,49\">",
"     5,49",
"    </a>",
"    ]. In one randomized study, children treated with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    gained consciousness more rapidly than those treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , with a similar rate of other adverse effects and of seizure control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/53\">",
"     53",
"    </a>",
"    ]. Severe hypotension has been reported in an 11-year-old girl following intravenous administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/60/21448?source=see_link\">",
"     Topiramate",
"    </a>",
"    has a broad spectrum of efficacy against many seizure types. Case reports and small case series report that it may be efficacious in refractory SE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Some have used low initial doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], others a higher loading dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/57\">",
"     57",
"    </a>",
"    ]. There is no formulation for parenteral administration. Further prospective study is needed to define the role of topiramate in SE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Levetiracetam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/0/25608?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    is available in intravenous as well as oral formulations. While cases documenting its efficacy in the treatment of SE in adults are accumulating, there are limited published data in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A review of 11 patients who received levetiracetam for refractory SE concluded that it was clearly beneficial in five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many protocols are available for treatment of SE, data are limited, and these approaches have not been validated by clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/61\">",
"     61",
"    </a>",
"    ]. The approach presented below applies to children older than four weeks of age (ie,",
"    <strong>",
"     not",
"    </strong>",
"    newborns) with generalized convulsive SE (tonic-clonic, clonic, or tonic) or partial motor SE. The overall treatment approach is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef55368 \" href=\"mobipreview.htm?29/20/30029\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Initial pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     Lorazepam",
"    </a>",
"    0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV should be administered at a rate of 2",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    and its effect assessed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/23\">",
"     23",
"    </a>",
"    ]. If seizures continue, additional doses of lorazepam can be repeated in five to ten minutes (up to a cumulative dose of 10 mg over 20 minutes) (",
"    <a class=\"graphic graphic_table graphicRef55368 \" href=\"mobipreview.htm?29/20/30029\">",
"     table 2",
"    </a>",
"    ). The risk of respiratory depression increases if more than two doses of benzodiazepines are administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/11,18\">",
"     11,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If seizures continue for 10 minutes after at least two injections of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    , begin treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    in a dose of 20",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    equivalents",
"    <span class=\"nowrap\">",
"     (PE)/kg",
"    </span>",
"    IV at a rate of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute (maximum rate 150",
"    <span class=\"nowrap\">",
"     mg/min).",
"    </span>",
"    The maximum dose in 24 hours is 1500 mg PE (",
"    <a class=\"graphic graphic_table graphicRef81062 \" href=\"mobipreview.htm?8/58/9131\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Alternative initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     Midazolam",
"    </a>",
"    can be given in an initial dose of 0.1 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, followed by IV infusion of 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute, increased as needed every 15 minutes until effect or a maximum dose of 8 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/33\">",
"     33",
"    </a>",
"    ]. Midazolam IM (5 mg for children whose weight is 13 to 40 kg and 10 mg in those over 40 kg) is another effective alternative to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    and should be considered, especially in the prehospital setting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when intravenous access is not immediately available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     Diazepam",
"    </a>",
"    is NOT considered first-line therapy for SE. Compared to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    , diazepam resulted in less efficacy and more respiratory depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When intravenous access is unavailable, rectal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    or buccal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    are treatment options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/23,28\">",
"     23,28",
"    </a>",
"    ]. Buccal midazolam appears to be more effective than rectal diazepam. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Transmucosal AED administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Alternative second drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    slowly infused IV (maximum infusion rate 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute or 50",
"    <span class=\"nowrap\">",
"     mg/min)",
"    </span>",
"    in an initial dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and followed by repeated increments of approximately 8 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 30 minutes, can achieve high levels and seizure control without significant hypotension or respiratory depression.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    is unavailable,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    can be given in an initial dose of 18 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV at a rate of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute (maximum rate 50",
"    <span class=\"nowrap\">",
"     mg/min).",
"    </span>",
"   </p>",
"   <p>",
"    Valproic acid can be used as a second or third-line treatment. Valproic acid is given in a loading dose of 20 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV (diluted 1:1 with normal saline or 5 percent dextrose in water) over 5 to 10 minutes and may be repeated after 10 to 15 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/50\">",
"     50",
"    </a>",
"    ]. This is followed by an IV infusion of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    may sometimes be used as initial therapy in children who did not respond to benzodiazepines and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    in previous episodes of SE. Valproate may also be used as the initial treatment in children on chronic valproic acid therapy who are known to be recently noncompliant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Refractory seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;If SE persists for 30 minutes after initial measures are instituted, further pharmacologic therapy is based upon the patient's hemodynamic status. In children who are hemodynamically stable,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/24/17801?source=see_link\">",
"     pentobarbital",
"    </a>",
"    anesthesia is used. This requires intubation, mechanical ventilation, and vasopressor agents. Pentobarbital is given as an initial bolus infusion of 5 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV followed by a continuous infusion of 0.5 to 5.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who are hemodynamically unstable,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    may be better tolerated. Midazolam is given as an initial bolus infusion of 0.15 to 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV followed by a continuous infusion of 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min; the infusion is increased by 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min every 15 minutes until seizures are controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    has been used to treat SE, data are limited, and significant associated complications have been reported. It is contraindicated in the setting of ketogenic diet.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/1\">",
"      Shinnar S, Berg AT, Moshe SL, et al. The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: an extended follow-up. Pediatrics 1996; 98:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/2\">",
"      Riviello JJ Jr, Ashwal S, Hirtz D, et al. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2006; 67:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/3\">",
"      Singh BM, Strobos RJ. Epilepsia partialis continua associated with nonketotic hyperglycemia: clinical and biochemical profile of 21 patients. Ann Neurol 1980; 8:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/4\">",
"      Placidi F, Floris R, Bozzao A, et al. Ketotic hyperglycemia and epilepsia partialis continua. Neurology 2001; 57:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/5\">",
"      Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. Pediatr Clin North Am 2001; 48:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/6\">",
"      Tay SK, Hirsch LJ, Leary L, et al. Nonconvulsive status epilepticus in children: clinical and EEG characteristics. Epilepsia 2006; 47:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/7\">",
"      Jette N, Claassen J, Emerson RG, Hirsch LJ. Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children. Arch Neurol 2006; 63:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/8\">",
"      Singh RK, Stephens S, Berl MM, et al. Prospective study of new-onset seizures presenting as status epilepticus in childhood. Neurology 2010; 74:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/9\">",
"      Yoong M, Madari R, Martinos M, et al. The role of magnetic resonance imaging in the follow-up of children with convulsive status epilepticus. Dev Med Child Neurol 2012; 54:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/10\">",
"      Freeman JM. Status epilepticus: it's not what we've thought or taught. Pediatrics 1989; 83:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/11\">",
"      Chin RF, Verhulst L, Neville BG, et al. Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psychiatry 2004; 75:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/12\">",
"      Johnson J, Wrenn K. Inappropriate fosphenytoin use in the ED. Am J Emerg Med 2001; 19:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/13\">",
"      Maytal J, Novak G, Ascher C, Bienkowski R. Status epilepticus in children with epilepsy: the role of antiepileptic drug levels in prevention. Pediatrics 1996; 98:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/14\">",
"      Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/15\">",
"      Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 2000; 41:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/16\">",
"      Smith PE, McBride A. Illicit drugs and seizures. Seizure 1999; 8:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/17\">",
"      Figin T, G&uuml;rer Y, Senbil N, et al. Nasal midazolam effects on childhood acute seizures. J Child Neurol 2000; 15:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/18\">",
"      Chin RF, Neville BG, Peckham C, et al. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008; 7:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/19\">",
"      Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/20\">",
"      Appleton R, Sweeney A, Choonara I, et al. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995; 37:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/21\">",
"      Chiulli DA, Terndrup TE, Kanter RK. The influence of diazepam or lorazepam on the frequency of endotracheal intubation in childhood status epilepticus. J Emerg Med 1991; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/22\">",
"      Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/23\">",
"      Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2008; :CD001905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/24\">",
"      Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. Lancet 2006; 367:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/25\">",
"      McDermott CA, Kowalczyk AL, Schnitzler ER, et al. Pharmacokinetics of lorazepam in critically ill neonates with seizures. J Pediatr 1992; 120:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/26\">",
"      Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/27\">",
"      Relling MV, Mulhern RK, Dodge RK, et al. Lorazepam pharmacodynamics and pharmacokinetics in children. J Pediatr 1989; 114:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/28\">",
"      McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 366:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/29\">",
"      Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/30\">",
"      Rivera R, Segnini M, Baltodano A, P&eacute;rez V. Midazolam in the treatment of status epilepticus in children. Crit Care Med 1993; 21:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/31\">",
"      Igartua J, Silver P, Maytal J, Sagy M. Midazolam coma for refractory status epilepticus in children. Crit Care Med 1999; 27:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/32\">",
"      Hanley DF, Kross JF. Use of midazolam in the treatment of refractory status epilepticus. Clin Ther 1998; 20:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/33\">",
"      Yoshikawa H, Yamazaki S, Abe T, Oda Y. Midazolam as a first-line agent for status epilepticus in children. Brain Dev 2000; 22:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/34\">",
"      Papavasiliou AS, Kotsalis C, Paraskevoulakos E, et al. Intravenous midazolam in convulsive status epilepticus in children with pharmacoresistant epilepsy. Epilepsy Behav 2009; 14:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/35\">",
"      Wills B, Erickson T. Chemically induced seizures. Clin Lab Med 2006; 26:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/36\">",
"      Paloucek FP, Rodvold KA. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med 1988; 17:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/37\">",
"      Blake KV, Massey KL, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 1988; 17:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/38\">",
"      Koul R, Deleu D. Subtherapeutic free phenytoin levels following fosphenytoin therapy in status epilepticus. Neurology 2002; 58:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/39\">",
"      Donn SM, Grasela TH, Goldstein GW. Safety of a higher loading dose of phenobarbital in the term newborn. Pediatrics 1985; 75:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/40\">",
"      Barberio M, Reiter PD, Kaufman J, et al. Continuous infusion pentobarbital for refractory status epilepticus in children. J Child Neurol 2012; 27:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/41\">",
"      Hertzog JH, Dalton HJ, Anderson BD, et al. Prospective evaluation of propofol anesthesia in the pediatric intensive care unit for elective oncology procedures in ambulatory and hospitalized children. Pediatrics 2000; 106:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/42\">",
"      Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001; 42:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/43\">",
"      Harrison AM, Lugo RA, Schunk JE. Treatment of convulsive status epilepticus with propofol: case report. Pediatr Emerg Care 1997; 13:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/44\">",
"      Tobias JD. The use of propofol to treat status epilepticus in a nine-month-old female patient. Pediatr Emerg Care 1998; 14:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/45\">",
"      Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998; 50:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/46\">",
"      Stelow EB, Johari VP, Smith SA, et al. Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings. Clin Chem 2000; 46:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/47\">",
"      van Gestel JP, Bluss&eacute; van Oud-Alblas HJ, Malingr&eacute; M, et al. Propofol and thiopental for refractory status epilepticus in children. Neurology 2005; 65:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/48\">",
"      Baumeister FA, Oberhoffer R, Liebhaber GM, et al. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics 2004; 35:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/49\">",
"      Sofou K, Kristj&aacute;nsd&oacute;ttir R, Papachatzakis NE, et al. Management of prolonged seizures and status epilepticus in childhood: a systematic review. J Child Neurol 2009; 24:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/50\">",
"      Uberall MA, Trollmann R, Wunsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology 2000; 54:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/51\">",
"      Yu KT, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003; 44:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/52\">",
"      Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol 2007; 22:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/53\">",
"      Rai A, Aggarwal A, Mittal H, Sharma S. Comparative efficacy and safety of intravenous valproate and phenytoin in children. Pediatr Neurol 2011; 45:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/54\">",
"      White JR, Santos CS. Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. J Child Neurol 1999; 14:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/55\">",
"      Kahriman M, Minecan D, Kutluay E, et al. Efficacy of topiramate in children with refractory status epilepticus. Epilepsia 2003; 44:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/56\">",
"      Blumkin L, Lerman-Sagie T, Houri T, et al. Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol 2005; 20:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/57\">",
"      Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. Epilepsia 2006; 47:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/58\">",
"      Abend NS, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol 2008; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/59\">",
"      Reiter PD, Huff AD, Knupp KG, Valuck RJ. Intravenous levetiracetam in the management of acute seizures in children. Pediatr Neurol 2010; 43:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/60\">",
"      Gallentine WB, Hunnicutt AS, Husain AM. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav 2009; 14:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30505/abstract/61\">",
"      Appleton R, Choonara I, Martland T, et al. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party. Arch Dis Child 2000; 83:415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6192 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-7D7969DF47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30505=[""].join("\n");
var outline_f29_50_30505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PARTIAL OR BRIEF SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Previous response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Missed medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Paradoxical effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonprescription medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Alternative routes of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PHARMACOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Diazepam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lorazepam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Midazolam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Clonazepam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Phenytoin and fosphenytoin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fosphenytoin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Phenobarbital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Pentobarbital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Thiopental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Propofol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Valproic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Levetiracetam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Initial pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Alternative initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Alternative second drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Refractory seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6192\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6192|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/54/21356\" title=\"table 1\">",
"      Laboratory studies in child with status epilepticus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/20/30029\" title=\"table 2\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/58/9131\" title=\"table 3\">",
"      Primary AED therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18888?source=related_link\">",
"      Clinical features and complications of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_50_30506="Interpretation of liver biopsy specimens";
var content_f29_50_30506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interpretation of liver biopsy specimens",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30506/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30506/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30506/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30506/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/50/30506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/50/30506/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/50/30506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1763618394\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic examination of the liver can provide otherwise unobtainable information regarding its structural integrity and the type and degree of injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrosis that affect the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30506/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also useful for monitoring the efficacy of treatment and permits the definitive diagnosis of tumors.",
"   </p>",
"   <p>",
"    A liver biopsy is usually performed only after a thorough noninvasive clinical evaluation in patients with chronically (greater than six months) elevated liver biochemical tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .) The pertinent clinical information should be made available to the pathologist so that the histopathological findings can be interpreted in the appropriate clinical context [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30506/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on the interpretation of liver biopsy specimens. The examples presented represent a collection of specimens spanning four decades. Thus, they may not always reflect contemporary diagnostic techniques or management approaches. Methods to obtain a liver biopsy are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=see_link\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9814?source=see_link\">",
"     \"Transjugular liver biopsy\"",
"    </a>",
"    .) Scoring systems for grading the severity of liver biopsy specimens are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=see_link\">",
"     \"Histologic scoring systems for chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618055\">",
"    <span class=\"h1\">",
"     SEGMENTAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver can be divided into the right and left hemiliver, each of which has its own blood supply. The right hemiliver comprises 50 to 70 percent of the liver mass (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"mobipreview.htm?13/35/13878\">",
"     figure 1",
"    </a>",
"    ). The liver can be further subdivided into eight segments based upon the vascular or bile duct distribution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618062\">",
"    <span class=\"h1\">",
"     LOBULE AND ACINAR MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two conceptual models have been proposed relating to the architecture of the hepatic parenchyma. Terminal portal veins and hepatic venules interdigitate between sinusoids. The \"lobule\" model considers the terminal hepatic venules to be the center of the hepatic microcirculation, while the \"acinar\" model (also known as the Rappaport classification) considers it to represent the periphery (",
"    <a class=\"graphic graphic_figure graphicRef59968 \" href=\"mobipreview.htm?6/19/6456\">",
"     figure 2",
"    </a>",
"    ) .",
"   </p>",
"   <p>",
"    An appealing feature of the acinar model is that the blood supply to an area of hepatic parenchyma and the bile duct draining it are all located in one \"portal triad\". The acinus consists of a cluster of hepatocytes (approximately 2 mm in diameter) that are grouped around terminal branches of a hepatic arteriole and portal venule. Blood from a branch of the portal vein and hepatic artery enter the acinus in the portal and periportal regions, flow through the hepatic sinusoids, and drain into a terminal hepatic venule.",
"   </p>",
"   <p>",
"    The acinar model also defines areas or \"zones\" representing gradients where the nutrient and oxygen content of the hepatic microcirculation differ. The center of the acinus (periportal) is known as zone 1, the periphery (perivenular) as zone 3, and the region in between as zone 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30506/abstract/3\">",
"     3",
"    </a>",
"    ]. Zone 1 receives blood with the highest levels of oxygen and nutrients compared with zone 3. Thus, zone 3 is particularly vulnerable to a circulatory insult.",
"   </p>",
"   <p>",
"    Hepatocytes within these zones are adapted to their micro-location. Zone 1 hepatocytes have high oxidative activities and contain many large mitochondria. Their dominant processes include gluconeogenesis, beta oxidation of fatty acids, amino acid catabolism, ureagenesis, cholesterol synthesis, and bile acid secretion. By contrast, zone 3 hepatocytes are more involved with glycolysis and lipogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180144294\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial step in evaluating a liver biopsy is a visual inspection of the adequacy of the sample and the type and quality of staining. A liver biopsy samples only about",
"    <span class=\"nowrap\">",
"     1/50,000",
"    </span>",
"    of the liver and thus is always vulnerable to sampling variability. Nevertheless, it is generally agreed that the specimen should be at least 15 mm in length and contain six to eight complete portal tracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30506/abstract/4\">",
"     4",
"    </a>",
"    ]. Longer specimens are better to improve reliability of grading for fibrosis and histologic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30506/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard staining of specimens typically includes hematoxylin and eosin (H&amp;E) or Masson or Gomori trichrome stains. H&amp;E staining colors the nuclei of cells blue, while other structures appear as various hues of pink or red. Masson and Gomori trichrome staining are useful for distinguishing connective tissue from cells. The connective tissue (ie, fibrosis or cirrhosis) appears as various shades of blue or purple. The Masson stain requires three sequential steps, while the Gomori requires only one. Poor staining can occur and can be recognized with experience. It can be appreciated even before looking at the slides under a microscope; we generally hold the slide up to a bright white light while placing it against a white background (such as the cuff of a white shirt).",
"   </p>",
"   <p>",
"    Special staining may occasionally be performed when specific disorders are sought [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30506/abstract/7\">",
"     7",
"    </a>",
"    ]. Examples include periodic Schiff with diastase digestion to confirm the presence of alpha-1-antitrypsin inclusions, iron stains (eg, Prussian blue and Perl's stain) in patients with suspected hemochromatosis, oil red O staining performed on fresh frozen specimens in patients with suspected acute fatty liver of pregnancy, stains for copper (eg, rhodanine) in patients with suspected Wilson disease, and reticulin stains (for type III collagen) in patients in whom a detailed evaluation of the liver microarchitecture, hepatocyte necrosis, and regeneration are desired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618401\">",
"    <span class=\"h1\">",
"     HISTOLOGIC PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biopsy specimens described below are grouped, as much as possible, according to the pathophysiology of the underlying disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first section includes diseases that are characterized by damage to hepatocytes. These diseases are usually associated with greatly elevated levels of serum aminotransferases. Bilirubin levels may be elevated in patients who have extensive damage to hepatocytes. Included in this section are cases of acute viral hepatitis, chronic hepatitis C, fulminant hepatic failure due to drug toxicity, autoimmune chronic hepatitis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      toxicity, acute Budd-Chiari syndrome, and patients with left- and right-sided heart failure.",
"     </li>",
"     <li>",
"      The next section includes patients with metabolic forms of liver disease and fatty liver and thus includes cases of hemochromatosis, alcoholic hepatitis and cirrhosis, and nonalcoholic steatohepatitis (NASH).",
"     </li>",
"     <li>",
"      The third section includes patients who presented with a fever of unknown etiology in whom a percutaneous liver established the diagnosis. It also includes examples of hepatic malignancy.",
"     </li>",
"     <li>",
"      The fourth section includes patients with cholestatic liver diseases, examples of which are bile duct obstruction secondary to choledocholithiasis, iatrogenic chronic bile duct obstruction after cholecystectomy, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). The final section is a quiz. It presents brief case histories and diagnostic histological finding that should allow a diagnosis to be made.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278983621\">",
"    <span class=\"h1\">",
"     NORMAL LIVER BIOPSY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618069\">",
"    <span class=\"h2\">",
"     Normal liver, low power",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal liver biopsy was obtained in a 49-year-old Caucasian man who was being evaluated for fever of unknown etiology (",
"    <a class=\"graphic graphic_picture graphicRef82380 \" href=\"mobipreview.htm?30/5/30810\">",
"     picture 1",
"    </a>",
"    ). He was eventually diagnosed with Familial Mediterranean Fever (FMF). A liver biopsy is not needed to diagnosis FMF and is usually normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618076\">",
"    <span class=\"h2\">",
"     Normal liver, medium power",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal wedge liver biopsy obtained in a 45-year-old woman during a laparotomy (",
"    <a class=\"graphic graphic_picture graphicRef64876 \" href=\"mobipreview.htm?29/60/30665\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278983613\">",
"    <span class=\"h1\">",
"     HEPATOCELLULAR INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618083\">",
"    <span class=\"h2\">",
"     Acute lobular hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 56-year-old woman was being followed by a urologist for a possible mass lesion in her right kidney noted on intravenous pyelography before contemporary imaging technologies (eg, ultrasound, CT scans, MRI, or viral hepatitis serologies) were available. She developed nausea, anorexia, and jaundice. Her bilirubin level was 8.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (149",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    and ALT 1100",
"    <span class=\"nowrap\">",
"     U/L.",
"    </span>",
"    Her urologist planned surgery, assuming that her sudden worsening was caused by a renal cell carcinoma. However, a liver biopsy demonstrated acute lobular hepatitis, and surgery was canceled (",
"    <a class=\"graphic graphic_picture graphicRef73617 \" href=\"mobipreview.htm?38/34/39465\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53654 \" href=\"mobipreview.htm?18/54/19301\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62330 \" href=\"mobipreview.htm?35/20/36164\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75167 \" href=\"mobipreview.htm?32/14/32997\">",
"     picture 6",
"    </a>",
"    ). The patient made an uneventful recovery, and all of her liver tests became normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618090\">",
"    <span class=\"h2\">",
"     Mononucleosis hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 57-year-old man with myelodysplastic syndrome developed postoperative hepatitis following splenectomy and recovered uneventfully in a time before hepatitis serologies were available. The clinical picture is compatible with Epstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection (",
"    <a class=\"graphic graphic_picture graphicRef55213 \" href=\"mobipreview.htm?24/37/25176\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618097\">",
"    <span class=\"h2\">",
"     Acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 58-year-old man",
"    <strong>",
"    </strong>",
"    developed fever four days after undergoing transurethral prostatectomy under halothane anesthesia. The fever persisted, and he became jaundiced. His ALT was 3200",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    his AST 2850",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and his bilirubin was 10.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (183",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    His bilirubin continued to increase, while the ALT and AST remained elevated in the same range. He became comatose and was unresponsive to treatment for hepatic encephalopathy. He died of acute hepatic failure two weeks after surgery. His family allowed an aspiration biopsy of his liver immediately post-mortem, which was consistent with toxic hepatitis from halothane (",
"    <a class=\"graphic graphic_picture graphicRef80090 \" href=\"mobipreview.htm?21/53/22361\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59723 \" href=\"mobipreview.htm?35/18/36134\">",
"     picture 9",
"    </a>",
"    ). Halothane, once the most popular anesthetic agent of its day, is no longer used now because of its association with acute liver failure. It can damage the liver in two ways: by an allergic reaction or by conversion of halothane into a hepatotoxin by its metabolism in the liver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34871?source=see_link\">",
"     \"Halothane hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618104\">",
"    <span class=\"h2\">",
"     Acute viral hepatitis with very high ALT levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 22-year-old nurse was seen by her doctor because of the onset of nausea, anorexia, right upper quadrant discomfort, and jaundice. She had cared for an eight-year-old boy who had died of acute hepatitis one month earlier. Her ALT was 7500",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    serum bilirubin 10.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (176",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and prothrombin INR 1.1. Several experienced hepatologists expressed concern because of the high ALT levels and recommended a liver biopsy, which was consistent with acute lobular hepatitis (",
"    <a class=\"graphic graphic_picture graphicRef66995 \" href=\"mobipreview.htm?36/30/37350\">",
"     picture 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74692 \" href=\"mobipreview.htm?35/0/35847\">",
"     picture 11",
"    </a>",
"    ). The patient made a rapid and uneventful recovery.",
"   </p>",
"   <p>",
"    Although ALT levels are of little prognostic value in patients with acute hepatitis, very high levels often alarm clinicians. The only blood test that is of prognostic importance in patients with acute viral hepatitis is the prothrombin INR. The normal INR in this patient made it highly unlikely that she would develop acute hepatic failure. One possible cause of the very high ALT level was that all of the liver cell necrosis occurred in a very short period of time, several days, rather than being spread over several weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618111\">",
"    <span class=\"h2\">",
"     Acute lobular hepatitis in a 62-year-old woman with an unusually high serum bilirubin level",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 62-year-old woman consulted her clinician because her husband noted that her skin had turned yellow. She was fatigued and anorectic but had no other symptoms. Her ALT was 680",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 55",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (941",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and prothrombin INR 1.1. A percutaneous liver biopsy was done because of the very high bilirubin level (",
"    <a class=\"graphic graphic_picture graphicRef57802 \" href=\"mobipreview.htm?13/24/13703\">",
"     picture 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69560 \" href=\"mobipreview.htm?23/44/24263\">",
"     picture 13",
"    </a>",
"    ). Several experienced hepatologists were worried that there may be some other underlying liver disease to account for the very high serum bilirubin level. There were no signs of hemolysis, and her renal function was normal. Hemolysis and renal insufficiency may elevate serum bilirubin levels in jaundiced patients. The biopsy was consistent with acute lobular hepatitis, and the patient made an uneventful recovery. As in the previous patient with a very high ALT level, the only blood test that is prognostically important is the prothrombin INR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618118\">",
"    <span class=\"h2\">",
"     Chronic hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 21-year-old man with ongoing intravenous drug use was found to have persistently elevated levels of ALT, 50 to 100",
"    <span class=\"nowrap\">",
"     U/L.",
"    </span>",
"    Serum bilirubin, albumin, and prothrombin INR were normal. He was asymptomatic. A percutaneous liver biopsy showed relatively benign chronic hepatitis C, a lesion once referred to as chronic persistent hepatitis (",
"    <a class=\"graphic graphic_picture graphicRef82726 \" href=\"mobipreview.htm?20/45/21207\">",
"     picture 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81474 \" href=\"mobipreview.htm?7/34/7721\">",
"     picture 15",
"    </a>",
"    ). The patient declined treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618125\">",
"    <span class=\"h2\">",
"     Rapidly progressive non A non B hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 52-year-old head nurse on an infectious disease service was noted to have icteric sclerae by a medical resident. She recalled that she tired much more readily during the past year and often went to bed after dinner and slept more than she used to. She had no other symptoms. Her ALT was 386",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    serum bilirubin 4.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (82",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    while her prothrombin INR, serum albumin, and alkaline phosphatase were normal. Tests for hepatitis A and B were negative. A percutaneous liver biopsy showed early stage 4 fibrosis and grade 2 activity on the METAVIR scale (",
"    <a class=\"graphic graphic_picture graphicRef64327 \" href=\"mobipreview.htm?4/44/4806\">",
"     picture 16",
"    </a>",
"    ). Hoping that she might have autoimmune chronic hepatitis, she was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and then prednisone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . The ALT decrease to the 100",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    range but never normalized, while her serum bilirubin stayed in the 2 to 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (34 to 51",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    range. A liver biopsy was performed after two years of immunosuppressive therapy and showed that her cirrhosis had worsened (",
"    <a class=\"graphic graphic_picture graphicRef77179 \" href=\"mobipreview.htm?41/4/42054\">",
"     picture 17",
"    </a>",
"    ). Prednisone and azathioprine were discontinued. Her liver disease gradually worsened, and she died of liver failure after three more years. An autopsy showed advanced cirrhosis, most likely due to chronic hepatitis C (",
"    <a class=\"graphic graphic_picture graphicRef57229 \" href=\"mobipreview.htm?36/34/37416\">",
"     picture 18",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618132\">",
"    <span class=\"h2\">",
"     Autoimmune chronic hepatitis 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 46-year-old woman complained of fatigue. Her ALT was 400",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 295",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and her serum bilirubin was normal. Her ALT and AST fluctuated in the same range for more than 10 months. Serum tests for hepatitis A, B, and C were negative. A percutaneous liver biopsy was performed and was consistent with autoimmune chronic hepatitis (",
"    <a class=\"graphic graphic_picture graphicRef73532 \" href=\"mobipreview.htm?26/20/26951\">",
"     picture 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80142 \" href=\"mobipreview.htm?40/31/41465\">",
"     picture 20",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59948 \" href=\"mobipreview.htm?1/39/1655\">",
"     picture 21",
"    </a>",
"    ). She was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (20 mg daily), and her ALT and AST returned to normal within eight weeks.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    at 100 mg (1.8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day) was added, and prednisone was gradually tapered and discontinued. She has remained well. A repeat liver biopsy 18 months later showed a marked decrease in inflammation and liver cell necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618139\">",
"    <span class=\"h2\">",
"     Autoimmune chronic hepatitis 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 68-year-old clinician noted fatigue and then painless jaundice in 1966, a time before hepatitis A, B, and C had been discovered and ultrasound and CT scanning were available. His serum bilirubin was 18.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    <span class=\"nowrap\">",
"     (318&micro;mol/L),",
"    </span>",
"    alkaline phosphatase 484 IU, and AST 60",
"    <span class=\"nowrap\">",
"     U/L.",
"    </span>",
"    Convinced that he had terminal cancer of the pancreas and desiring a definitive diagnosis,",
"    <strong>",
"    </strong>",
"    he persuaded a surgeon to perform an exploratory laparotomy. The pancreas was normal, but his liver was beefy, red, and enlarged. A needle biopsy was performed and was consistent with autoimmune chronic hepatitis (",
"    <a class=\"graphic graphic_picture graphicRef75795 \" href=\"mobipreview.htm?0/49/794\">",
"     picture 22",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    He responded nicely to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (30 mg daily). All of his blood tests became normal, and his fatigue remitted. A percutaneous liver biopsy was performed earlier than usual, three months after prednisone was begun, because his biochemical tests were not typical of autoimmune hepatitis. The biopsy showed remarkable improvement and was close to normal. There was stage I fibrosis and no inflammation or liver cell necrosis. He remained well on a low dose of prednisone (10 mg daily). His AST and bilirubin levels increased whenever the prednisone dose was decreased to below 10 mg daily.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    was ineffective. On one occasion, he kept his prednisone dose at 7.5 mg daily for three months but increased it after his AST rose to 245 IU, his serum bilirubin to 4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (68.4",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and he noted scleral icterus. Despite the atypical pattern of his liver enzyme test, his response to prednisone was most consistent with autoimmune chronic hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618146\">",
"    <span class=\"h2\">",
"     Autoimmune chronic hepatitis 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 19-year-old previously obese male saw his clinician because of a 60 pound unintentional weight loss. His clinician noted hepatosplenomegaly. His ALT was 880 IU, AST 780, alkaline phosphatase 210 IU, and serum bilirubin 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (22.2",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    Tests for hepatitis A, B, and C were negative. A liver biopsy was consistent with autoimmune chronic hepatitis (",
"    <a class=\"graphic graphic_picture graphicRef74663 \" href=\"mobipreview.htm?29/36/30277\">",
"     picture 23",
"    </a>",
"    ). He responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (initially 30 mg daily). All of his biochemical tests improved and were normal within two months of starting prednisone.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    was added, and the prednisone dose was gradually tapered and discontinued. A liver biopsy, performed 16 months after starting immunosuppressive therapy, was normal (",
"    <a class=\"graphic graphic_picture graphicRef54752 \" href=\"mobipreview.htm?22/42/23206\">",
"     picture 24",
"    </a>",
"    ). The dramatic improvement in liver histology in response to immunosuppressive therapy is typical of autoimmune chronic hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618153\">",
"    <span class=\"h2\">",
"     Autoimmune chronic hepatitis 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 21-year-old man was diagnosed with autoimmune chronic hepatitis based upon a persistent elevation of ALT and AST levels and a percutaneous liver biopsy that was diagnostic of this disease. He was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and then prednisone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , but there was no improvement in his blood tests. After one year of treatment, his ALT was 354, AST 584, serum bilirubin 2.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (46.2",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and alkaline phosphatase 181 IU. Tests for hepatitis A, B, and C were negative. Iron studies and serum ceruloplasmin were normal. He did not drink alcohol or abuse drugs. His mother confirmed that he was taking his medications and, indeed, administered them to him.",
"   </p>",
"   <p>",
"    A liver biopsy was repeated and demonstrated stage 4 fibrosis and grade 3 activity (METAVIR scale) (",
"    <a class=\"graphic graphic_picture graphicRef61138 \" href=\"mobipreview.htm?34/19/35128\">",
"     picture 25",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71917 \" href=\"mobipreview.htm?0/17/279\">",
"     picture 26",
"    </a>",
"    ). An astute social worker then discovered that he had not been taking his medications. He had heard the term \"steroids\" and equated it with estrogen, and thought that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was a type of estrogen. He thought that treatment would cause feminization, but he never mentioned his concerns to his clinicians or mother. After a lengthy discussion with our social worker, he recognized his error and took his medications as prescribed. His biochemical tests were normal four months after taking his medications. A liver biopsy was repeated in one year and was normal (",
"    <a class=\"graphic graphic_picture graphicRef69762 \" href=\"mobipreview.htm?22/30/23014\">",
"     picture 27",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50862 \" href=\"mobipreview.htm?27/10/27815\">",
"     picture 28",
"    </a>",
"    ). The patient has remained well on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Failure to take medications as prescribed is a common problem in teenagers and some young adults and may be difficult to detect. This patient lived at home and was given his medications by his mother. He put them in his mouth, acted as if he had swallowed them, and then spit them out when his mother was not present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4622234\">",
"    <span class=\"h2\">",
"     Acetaminophen toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24-year-old woman complained of diffuse myalgias for which she took several different",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -containing medications several times per day and also drank alcoholic beverages (amount unclear). She developed anorexia and weight loss. Her clinician noted greatly elevated ALT and AST levels (1260 and 1530",
"    <span class=\"nowrap\">",
"     U/L).",
"    </span>",
"    A percutaneous liver biopsy revealed acute pericentral necrosis, consistent with acetaminophen toxicity (",
"    <a class=\"graphic graphic_picture graphicRef54144 \" href=\"mobipreview.htm?32/44/33477\">",
"     picture 29",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78808 \" href=\"mobipreview.htm?40/22/41318\">",
"     picture 30",
"    </a>",
"    ). She was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (Mucomyst) and recovered uneventfully.",
"   </p>",
"   <p>",
"    Patients are often not aware that most over-the-counter pain medications contain",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . Even moderate alcohol consumption can shift the metabolism of acetaminophen to the hepatotoxin, N-acetyl-p-benzoquinoneimine (NAPQI) by inducing the CYP2E1 pathway. In addition, the chronic alcoholic is more often malnourished, more likely to have a period of recent fasting, and more likely to have depleted hepatic glutathione stores than the nonalcoholic, all of which predispose to hepatic injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20652043\">",
"    <span class=\"h2\">",
"     Left-sided heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 61-year-old business man who was taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    for four years was admitted because of fatigue and weight loss. He had been able to play several sets of tennis daily until one week before admission. His ALT was 332",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 490",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 3.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (59.9",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and alkaline phosphatase was normal. His cardiologist was concerned that he had hepatitis. A liver biopsy showed signs of left-side heart failure, confirmed when his ejection fraction was found to be 14 percent (",
"    <a class=\"graphic graphic_picture graphicRef56590 \" href=\"mobipreview.htm?31/35/32310\">",
"     picture 31",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69358 \" href=\"mobipreview.htm?20/48/21256\">",
"     picture 32",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79671 \" href=\"mobipreview.htm?34/40/35463\">",
"     picture 33",
"    </a>",
"    ). His heart failure was treated more aggressively, and his blood test improved but never returned to normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43701?source=see_link\">",
"     \"Congestive hepatopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20652058\">",
"    <span class=\"h2\">",
"     Right-sided heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 73-year-old woman complained of nausea, fullness in her right upper quadrant, and a 10 pound weight loss. She was known to have mitral regurgitation but was not thought to be in heart failure by the cardiologist who cared for her. She was taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    . Her liver was enlarged and felt 5 cm below the right costal margin. ALT, AST, and alkaline phosphatase were normal, and her serum bilirubin was minimally elevated (1.4",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    23.9",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    A 99Tc liver-spleen scan showed a patchy uptake in an enlarged liver with an uptake of isotope in the bone marrow. Her liver biopsy was diagnostic of right-sided heart failure (",
"    <a class=\"graphic graphic_picture graphicRef52308 \" href=\"mobipreview.htm?41/12/42183\">",
"     picture 34",
"    </a>",
"    ). Her symptoms resolved after diuretics were added. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43701?source=see_link\">",
"     \"Congestive hepatopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20652065\">",
"    <span class=\"h2\">",
"     Budd-Chiari syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 37-year-old man was admitted to a local hospital because of jaundice, nausea, and vomiting. His ALT was 241",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 258",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    alkaline phosphatase 270 IU, and bilirubin 8.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (140.2",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    A liver biopsy was thought to be consistent with chronic hepatitis, and he was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40 mg daily), but his condition worsened (",
"    <a class=\"graphic graphic_picture graphicRef77952 \" href=\"mobipreview.htm?2/48/2821\">",
"     picture 35",
"    </a>",
"    ). He developed ascites and hepatic encephalopathy. He was transferred to our hospital. Further medical history revealed extensive exposure to organic solvents that he used to strip floors in old houses that he restored. A hepatic venogram was consistent with Budd-Chiari syndrome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65113 \" href=\"mobipreview.htm?7/43/7856\">",
"     image 1",
"    </a>",
"    ). His liver biopsy was reviewed and was thought to be diagnostic of Budd-Chiari syndrome. Prednisone was tapered and discontinued. He was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and fresh frozen plasma, the latter to provide plasminogen. Plasminogen levels had been measured and were undetectable, most likely due to consumption and decreased synthesis by his failing liver. He was oozing from esophageal varices and required five units of blood during his admission. The patient gradually improved, was converted from IV heparin to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and was discharged well and with normal blood tests. He developed post transfusion non-A non-B hepatitis several months after discharge and recovered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3434?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    He was re-admitted to hospital three years after discharge because of ascites and a low serum albumin level. A liver biopsy demonstrated recanalized blood clots in central veins (",
"    <a class=\"graphic graphic_picture graphicRef53805 \" href=\"mobipreview.htm?15/24/15751\">",
"     picture 36",
"    </a>",
"    ). He had large esophageal varices that were actively bleeding. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    was discontinued and the varices were treated with banding. His liver condition worsened, and he died of liver failure. At autopsy, his inferior vena cava and hepatic veins were thrombosed, and the clot extended into his right atrium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4622205\">",
"    <span class=\"h1\">",
"     METABOLIC LIVER DISEASE AND FATTY LIVER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618188\">",
"    <span class=\"h2\">",
"     Hemochromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 36-year-old woman was found to have elevated liver enzyme levels and an enlarged liver during an annual visit. Her ALT was 103",
"    <span class=\"nowrap\">",
"     U/L.",
"    </span>",
"    AST 88",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and bilirubin, alkaline phosphatase, and albumin levels were normal. Her serum iron was 280",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    TIBC 300, and ferritin 7500. Her liver biopsy showed cirrhosis and excess iron (",
"    <a class=\"graphic graphic_picture graphicRef62470 \" href=\"mobipreview.htm?36/29/37333\">",
"     picture 37",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75245 \" href=\"mobipreview.htm?21/40/22151\">",
"     picture 38",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55260 \" href=\"mobipreview.htm?19/62/20453\">",
"     picture 39",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68058 \" href=\"mobipreview.htm?6/34/6696\">",
"     picture 40",
"    </a>",
"    ). Her blood tests all returned to normal after treatment with phlebotomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=see_link\">",
"     \"Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618195\">",
"    <span class=\"h2\">",
"     Hemochromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 43-year-old white woman with sarcoidosis of the lung was found to have mildly elevated lever enzyme levels and an enlarged liver on physical examination. Her ALT was 37",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    (normal &lt;30), and her AST was 67",
"    <span class=\"nowrap\">",
"     U/L.",
"    </span>",
"    Serum bilirubin, alkaline phosphatase and albumin levels were normal. Her serum iron was 210",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    TIBC 240, and ferritin 6500.",
"   </p>",
"   <p>",
"    A liver biopsy demonstrated multiple granulomas, cirrhosis, and increased iron stores (",
"    <a class=\"graphic graphic_picture graphicRef63243 \" href=\"mobipreview.htm?31/2/31782\">",
"     picture 41",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76096 \" href=\"mobipreview.htm?0/54/869\">",
"     picture 42",
"    </a>",
"    ). She was treated with 76 weekly one-unit phlebotomies until her hematocrit was below 35 for two consecutive weeks, a sign that she had been depleted of excess iron. Approximately 19 grams of iron had been removed. She then had four phlebotomies per year. Her liver enzyme tests remained normal. A liver biopsy done two years after her treatment began was normal, although there was still excess iron in pericentral areas (",
"    <a class=\"graphic graphic_picture graphicRef52026 \" href=\"mobipreview.htm?29/0/29702\">",
"     picture 43",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64593 \" href=\"mobipreview.htm?31/2/31781\">",
"     picture 44",
"    </a>",
"    ). She was followed with annual right upper quadrant ultrasounds and twice yearly serum alpha fetoprotein serum levels because of her increased risk of developing liver cell cancer. She developed a hepatocellular carcinoma in the left lobe of her liver 12 years after her diagnosis that was successfully resected. Unfortunately, two years later she had multiple hepatocellular carcinomas throughout the right lobe and died of liver failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618202\">",
"    <span class=\"h2\">",
"     Alcoholic fatty liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 43-year-old male pathologist drank one fifth of scotch during his workday. He noted a \"mass\" in his abdomen while lying in bed and consulted his clinician. His clinician noted an enlarged nontender liver and a slight elevation of AST, 64",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    with normal ALT, bilirubin, alkaline phosphatase and albumin levels.",
"   </p>",
"   <p>",
"    A percutaneous liver biopsy found fatty infiltration of the liver (",
"    <a class=\"graphic graphic_picture graphicRef77408 \" href=\"mobipreview.htm?20/18/20774\">",
"     picture 45",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57614 \" href=\"mobipreview.htm?34/4/34882\">",
"     picture 46",
"    </a>",
"    ). His liver became nonpalpable after one week of abstinence from alcohol, and his AST level returned to normal. Studies done almost 40 years ago by Dr. Charles Lieber demonstrated that drinking more than 10 ounces of 80 proof alcohol per day caused fatty liver in virtually 100 percent of individuals and that it was rapidly reversible with abstinence from alcohol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618209\">",
"    <span class=\"h2\">",
"     Alcoholic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 38-year-old female bartender drank wine and hard liquor while at work. She saw her clinician because of abdominal swelling and ankle edema.",
"    <strong>",
"    </strong>",
"    Her serum bilirubin was 4.8",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    ALT 60",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 115",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    alkaline phosphatase 215 IU, and serum albumin 3.1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (53",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"     <strong>",
"     </strong>",
"    </span>",
"    A liver biopsy showed alcoholic steatohepatitis and cirrhosis (",
"    <a class=\"graphic graphic_picture graphicRef66297 \" href=\"mobipreview.htm?12/49/13079\">",
"     picture 47",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75015 \" href=\"mobipreview.htm?37/62/38887\">",
"     picture 48",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55051 \" href=\"mobipreview.htm?13/18/13606\">",
"     picture 49",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82544 \" href=\"mobipreview.htm?9/19/9526\">",
"     picture 50",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65537 \" href=\"mobipreview.htm?0/51/823\">",
"     picture 51",
"    </a>",
"    ). She was urged to stop drinking but continued to drink and eventually died of complications of cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618216\">",
"    <span class=\"h2\">",
"     Alcoholic steatohepatitis with prominent central hyalinizing sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 30-year-old woman complained of nausea, vomiting, and a 20 pound weight loss during the preceding eight months. Her clinician noted numerous spider telangiectasias over her chest and upper arms, palmar erythema, and an enlarged liver that was palpated 4 cm below the right costal margin. Her AST was slightly elevated, 64",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    while her ALT was 16",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    alkaline phosphatase 82 IU, and albumin 4.2",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    A percutaneous liver biopsy demonstrated steatohepatitis with many areas of central hyalinizing sclerosis (",
"    <a class=\"graphic graphic_picture graphicRef69522 \" href=\"mobipreview.htm?3/43/3766\">",
"     picture 52",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79208 \" href=\"mobipreview.htm?22/57/23442\">",
"     picture 53",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58312 \" href=\"mobipreview.htm?37/9/38037\">",
"     picture 54",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71004 \" href=\"mobipreview.htm?1/46/1765\">",
"     picture 55",
"    </a>",
"    ). The patient eventually admitted to drinking two to four whiskey sours after work each evening and buying at least three bottles of bourbon whiskey each week. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618223\">",
"    <span class=\"h2\">",
"     Nonalcoholic steatohepatitis 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 52-year-old college administrator was noted to have persistently elevated levels of ALT and AST in the 100 to 150",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    range. All of his other blood tests were normal. He did not drink alcohol and exercised regularly. He was not overweight, diabetic, or hypertensive. A liver biopsy demonstrated steatohepatitis, 10 years before nonalcoholic steatohepatitis (NASH) was recognized as a distinct disease entity (",
"    <a class=\"graphic graphic_picture graphicRef74205 \" href=\"mobipreview.htm?8/37/8790\">",
"     picture 56",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50175 \" href=\"mobipreview.htm?33/13/34008\">",
"     picture 57",
"    </a>",
"    ). His ALT and AST levels remained elevated, and a repeat liver biopsy done two years later was similar. He and his clinicians were relieved when steatohepatitis was recognized as a distinct disease entity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618230\">",
"    <span class=\"h2\">",
"     Nonalcoholic steatohepatitis 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 53-year-old man with type 2 diabetes mellitus and hypertension was found to have elevated liver enzyme test, ALT 48",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and AST 46",
"    <span class=\"nowrap\">",
"     U/L.",
"    </span>",
"    Other blood tests were normal. His liver biopsy demonstrated steatohepatitis and one noncaseating giant-cell granuloma (",
"    <a class=\"graphic graphic_picture graphicRef77393 \" href=\"mobipreview.htm?13/19/13622\">",
"     picture 58",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54833 \" href=\"mobipreview.htm?20/26/20904\">",
"     picture 59",
"    </a>",
"    ). Dr. Gerald Klatskin found that isolated non-caseating granulomas are often seen in liver biopsies of patients with a variety of diseases not usually associated with granulomas and may be nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30506/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4622213\">",
"    <span class=\"h1\">",
"     FEVER OF UNKNOWN ORIGIN AND MALIGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618237\">",
"    <span class=\"h2\">",
"     Miliary TBC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 63-year-old man was admitted to the hospital because of four weeks of fatigue, drenching night sweats, occasional shaking chills, and a cough productive of yellow sputum. He had experienced a painful swelling in his left scrotum three months earlier. The scrotal mass was now painless. His hemoglobin was 8.7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and WBC 5500. There were bilateral miliary infiltrates on a chest X-ray. His sputum smears and cultures were negative for pathogens. ALT was 127",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 117",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and alkaline phosphatase was 160 IU. There were small deposits in both retinas. A percutaneous liver biopsy demonstrated numerous noncaseating granulomas (",
"    <a class=\"graphic graphic_picture graphicRef66594 \" href=\"mobipreview.htm?37/33/38423\">",
"     picture 60",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79111 \" href=\"mobipreview.htm?26/51/27447\">",
"     picture 61",
"    </a>",
"    ). He was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    for presumed miliary TBC. His sputum drew acid fast bacilli after two weeks of culture. His fevers resolved, and he recovered uneventfully. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618244\">",
"    <span class=\"h2\">",
"     Miliary TBC",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 28-year-old woman noted a 10 pound weight loss over a one month period. She then noted the sudden onset of pleuritic chest pain without cough, sputum, dyspnea, or night sweats. A PPD skin test was positive, and her chest X-ray showed a large right-sided pleural effusion and apical scarring. Repeated thoracenteses and pleural biopsies were unrevealing. Her ALT, AST, alkaline phosphatase, and bilirubin were normal, but her serum albumin was low (3.2",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    A percutaneous liver biopsy revealed numerous granulomas, some of which were caseating (",
"    <a class=\"graphic graphic_picture graphicRef71601 \" href=\"mobipreview.htm?31/10/31911\">",
"     picture 62",
"    </a>",
"    ). She was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and recovered. Her sputum grew acid fast bacilli 2.5 weeks after the biopsy was read. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40406?source=see_link\">",
"     \"Hepatic granulomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618251\">",
"    <span class=\"h2\">",
"     Hodgkin disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 58-year-old man was evaluated for fever of unknown etiology of three weeks duration in the days before ultrasound and CT scanning were widely available. His physical examination was normal as were multiple blood cultures. Chest X-rays and GI X-rays were normal. His ALT was 63",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 61",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and alkaline phosphatase 397 IU with serum albumin and bilirubin normal. A 99TC liver spleen scan showed a patchy uptake in the liver and splenic enlargement. A percutaneous liver biopsy was diagnostic of Hodgkin disease (",
"    <a class=\"graphic graphic_picture graphicRef53189 \" href=\"mobipreview.htm?36/39/37493\">",
"     picture 63",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64934 \" href=\"mobipreview.htm?4/18/4387\">",
"     picture 64",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618258\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 56-year-old man, previously healthy, was noted to have an enlarged liver at his annual check-up. All blood tests were normal, including tests for hepatitis B and C. A CT scan demonstrated several enhancing lesions in the liver. A CT-guided liver biopsy was diagnostic of hepatocellular carcinoma (",
"    <a class=\"graphic graphic_picture graphicRef72633 \" href=\"mobipreview.htm?2/57/2967\">",
"     picture 65",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51615 \" href=\"mobipreview.htm?22/13/22742\">",
"     picture 66",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63204 \" href=\"mobipreview.htm?20/17/20758\">",
"     picture 67",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4622221\">",
"    <span class=\"h1\">",
"     CHOLESTATIC LIVER DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618265\">",
"    <span class=\"h2\">",
"     Acute cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 61-year-old man noted fevers to 103 degrees F (39.4 degrees C) and drenching night sweats for one week. He saw his clinician at a time before ultrasound or CT scanning was available. His physical examination was normal. His hematocrit was 43, WBC 13,500 with a left shift, and platelet count was 425,000. His ALT was 85",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 79",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (30.8",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and alkaline phosphatase 1325 IU. A percutaneous liver biopsy was consistent with acute cholangitis (",
"    <a class=\"graphic graphic_picture graphicRef65773 \" href=\"mobipreview.htm?35/29/36311\">",
"     picture 68",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77609 \" href=\"mobipreview.htm?9/28/9671\">",
"     picture 69",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79382 \" href=\"mobipreview.htm?5/19/5431\">",
"     picture 70",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50589 \" href=\"mobipreview.htm?38/32/39431\">",
"     picture 71",
"    </a>",
"    ). At surgery, a 1 cm in diameter common duct stone, blocking the ampulla of Vater, was removed. The patient recovered uneventfully, and all of his blood tests were normal two months after surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618272\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 71-year-old asymptomatic woman was found to have an elevated serum alkaline phosphatase level, 318 IU with ALT 21",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 49",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and serum bilirubin 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.6",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    Her antimitochondrial antibody was positive. A percutaneous liver biopsy was diagnostic of early PBC, stage I-II (",
"    <a class=\"graphic graphic_picture graphicRef75168 \" href=\"mobipreview.htm?42/46/43751\">",
"     picture 72",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1763618279\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 45-year-old asymptomatic woman was found to have an elevated serum alkaline phosphatase level, 523 IU with ALT 87",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 91",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and serum bilirubin 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.6",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    Her antimitochondrial antibody was positive. A percutaneous liver biopsy was diagnostic of early PBC, stage I-II (",
"    <a class=\"graphic graphic_picture graphicRef61942 \" href=\"mobipreview.htm?33/38/34406\">",
"     picture 73",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66595 \" href=\"mobipreview.htm?6/8/6279\">",
"     picture 74",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697511\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 51-year-old woman was found to have a greatly elevated serum alkaline phosphatase level (358 IU) at the time of an annual check-up (",
"    <a class=\"graphic graphic_picture graphicRef70360 \" href=\"mobipreview.htm?38/34/39463\">",
"     picture 75",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57117 \" href=\"mobipreview.htm?8/62/9190\">",
"     picture 76",
"    </a>",
"    ). Her ALT was 56",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 0.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and albumin 4.8",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Her AMA was positive, titer 1:160. She was asymptomatic. She was initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodiol",
"    </a>",
"    was added after it became available in the United States. A liver biopsy, done after she had been on colchicine for three years, showed less inflammation and no florid bile duct lesions. All of her liver function tests had been normal for 12 years when she was lost to follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697533\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 48-year-old man consulted his primary care clinician because of pruritus. His serum alkaline phosphatase was 488 IU, ALT 63",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 59",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 0.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (15.39",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and serum albumin 3.9",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    His AMA was positive, titer 1:640. A percutaneous liver biopsy was diagnostic of PBC stage II and contained several florid bile duct lesions (",
"    <a class=\"graphic graphic_picture graphicRef54506 \" href=\"mobipreview.htm?28/7/28790\">",
"     picture 77",
"    </a>",
"    ). His pruritus responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    . He was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    at a time when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodiol",
"    </a>",
"    was not available in the United States. His condition gradually worsened; he developed intractable pruritus and liver failure and had one of the first successful liver transplantations performed in the United States in 1984.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697548\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 64-year-old woman was found to have an elevated serum alkaline phosphatase (237 IU) at the time of her annual check-up (",
"    <a class=\"graphic graphic_picture graphicRef68889 \" href=\"mobipreview.htm?27/44/28359\">",
"     picture 78",
"    </a>",
"    ). All of her other liver function tests were normal. Her AMA was positive, titer 1:160. She was initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , and then",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodiol",
"    </a>",
"    was added when it became available. She has remained asymptomatic for 22 years on ursodiol and colchicine. All of her liver function tests have remained normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697565\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 35-year-old woman sought medical attention because of new onset pruritus that kept her awake at night. Her serum alkaline phosphatase was 197 IU, ALT 99",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 40",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 0.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.68",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    albumin 4.2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and AMA positive, titer 1:160. A percutaneous liver biopsy was diagnostic of stage I-II PBC (",
"    <a class=\"graphic graphic_picture graphicRef79032 \" href=\"mobipreview.htm?42/7/43127\">",
"     picture 79",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59508 \" href=\"mobipreview.htm?13/43/14007\">",
"     picture 80",
"    </a>",
"    ). There were several florid bile duct lesions in her biopsy specimen. Her pruritus responded to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , and her blood tests became normal on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (15 mg weekly).",
"   </p>",
"   <p>",
"    A repeat liver biopsy done one year after treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    showed a disappearance of the inflammation, an absence of florid bile duct lesions, and portal scarring that looked somewhat like the onion skin lesion that is found in primary sclerosing cholangitis (",
"    <a class=\"graphic graphic_picture graphicRef71257 \" href=\"mobipreview.htm?11/26/11688\">",
"     picture 81",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70121 \" href=\"mobipreview.htm?42/27/43446\">",
"     picture 82",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     Ursodiol",
"    </a>",
"    was added four years later when it became available in the United States. She remained well on methotrexate and ursodiol for 12 years when the methotrexate was stopped. A liver biopsy at that time was normal. Nineteen years after the onset of her PBC, her ALT and AST began to increase. Her alkaline phosphatase remained normal (80 IU). There was no response to the addition of methotrexate, and it was discontinued. A liver biopsy performed when her ALT and AST were in the 400",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    range showed severe interface hepatitis and normal bile ducts, findings consistent with autoimmune chronic hepatitis. All of her blood tests returned to normal after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (15 mg daily) was added. A follow-up liver biopsy, done six months after prednisone was added, was normal.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (125 mg daily, 2 mg per kg body weight per day) was added, and the prednisone tapered and discontinued. She has been well for two years on ursodiol and azathioprine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697580\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 40-year-old woman complained of severe fatigue and right upper quadrant discomfort, and she was found to have a greatly elevated serum alkaline phosphatase, 850 IU with ALT 51",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 90",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    total bilirubin 1.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (29.07",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and serum albumin 3.9",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Her AMA was positive, titer 1:640. Her liver biopsy was diagnostic of PBC and was notable for the atypical bile duct hyperplasia that is characteristic of longstanding cholestasis (",
"    <a class=\"graphic graphic_picture graphicRef80480 \" href=\"mobipreview.htm?29/5/29781\">",
"     picture 83",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697631\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 32-year-old woman was seen in 1972 because of jaundice and pruritus. At presentation, her serum bilirubin was 13.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (234.27",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    alkaline phosphatase 1870 IU, ALT 130",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 100",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    serum cholesterol 1300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and albumin 3.7",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    On physical examination, she had striking xanthelasmas and xanthomas over her elbows and knees. She had the type of PBC that is rarely seen today (",
"    <a class=\"graphic graphic_picture graphicRef60916 \" href=\"mobipreview.htm?20/11/20662\">",
"     picture 84",
"    </a>",
"    ). Over the course of her illness, she developed severe osteoporosis and lost over six inches in height because of multiple compression fractures of her spine (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74002 \" href=\"mobipreview.htm?25/16/25859\">",
"     image 2",
"    </a>",
"    ). She developed painful and debilitating xanthomas of the palms of her hands and soles of her feet that responded only to large-volume plasmapheresis (",
"    <a class=\"graphic graphic_picture graphicRef51686 \" href=\"mobipreview.htm?31/7/31857\">",
"     picture 85",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62451 \" href=\"mobipreview.htm?27/40/28288\">",
"     picture 86",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75269 \" href=\"mobipreview.htm?23/30/24033\">",
"     picture 87",
"    </a>",
"    ). She eventually had a successful liver transplantation in 1984. She died one year after transplantation from complications of cytomegalovirus infection, an illness that became widespread with the advent of potent immunosuppressive therapy",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697638\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 40-year-old woman consulted her primary care clinician because of severe fatigue. Her alkaline phosphatase was 344 IU, ALT 120",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 61",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 0.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (16.4",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    serum albumin 4.7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and AMA positive, titer 1:1280. She was treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (15 mg weekly) (",
"    <a class=\"graphic graphic_picture graphicRef50803 \" href=\"mobipreview.htm?11/27/11702\">",
"     picture 88",
"    </a>",
"    ). All of her liver function tests returned to normal after six months, and repeat liver biopsies done one and two years after treatment showed minimal inflammation and less than stage I fibrosis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     Ursodiol",
"    </a>",
"    was added three years after diagnosis, shortly after it became available in the United States.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    was added, and methotrexate discontinued after she had been on it for four years. She remained well on ursodiol and colchicine 23 years after her PBC was diagnosed, but still complained of fatigue. Her fatigue responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    . However, she takes it only on days when she knows that she will be busy because it keeps her awake at night.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697645\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 54-year-old man with longstanding PBC had portacaval shunt surgery performed because of uncontrollable hemorrhaging from esophageal varices at a time before TIPSS (transjugular intrahepatic portasystemic stent shunt) and liver transplantation were available. His liver was cirrhotic, and a wedge biopsy was performed by his surgeon (",
"    <a class=\"graphic graphic_picture graphicRef61497 \" href=\"mobipreview.htm?36/2/36904\">",
"     picture 89",
"    </a>",
"    ). The patient was a Child's class A and did well after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697652\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis stage 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 56-year-old woman complained of severe fatigue and lower back pain following an automobile accident. Her alkaline phosphatase was 883 IU, ALT 180",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 135",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (15.7",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    serum albumin 3.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and AMA positive, titer 1:320. A liver biopsy was diagnostic of stage IV PBC (",
"    <a class=\"graphic graphic_picture graphicRef67519 \" href=\"mobipreview.htm?26/35/27193\">",
"     picture 90",
"    </a>",
"    ). There was no known treatment for PBC in 1969, the time of diagnosis. She developed pruritus that responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , and she eventually died of liver failure. Interestingly, her liver biopsy also demonstrated numerous \"Mallory Bodies\" although she denied drinking alcohol. Her family allowed an autopsy. Her liver was used as the source from which Mallory's alcoholic hyaline was first isolated and chemically identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697659\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis, response to methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 42-year-old nurse with Raynaud's phenomenon and Sicca syndrome was seen in 1988 because of a five-year history of primary biliary cirrhosis. Her alkaline phosphatase was 263 IU, ALT 57",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 51",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    bilirubin 0.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10.26",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    serum albumin 4.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and AMA positive, titer 1:640. She was very anxious because an aunt had died recently of complications of PBC. Liver biopsies done five and three years earlier were consistent with stage I-II PBC. She had been on no treatment for her PBC. A third liver biopsy done in 1989, six years after her diagnosis, showed significant worsening and was now stage III-IV (",
"    <a class=\"graphic graphic_picture graphicRef74316 \" href=\"mobipreview.htm?0/54/870\">",
"     picture 91",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because her alkaline phosphatase had increased and was 335 IU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (15 mg weekly) was begun.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     Ursodiol",
"    </a>",
"    was not yet available in the United States. Her serum enzyme levels fluctuated at their elevated levels for the first five months after starting methotrexate and then began to decrease. Her alkaline phosphatase was 194 IU eight months after starting methotrexate. It continued to decrease gradually but irregularly and was 157 IU three years after starting methotrexate. All of her other liver function tests were normal. A liver biopsy repeated one year after starting methotrexate was slightly improved. It had less inflammation and scarring but was still stage III. A liver biopsy done two years after starting methotrexate was unequivocally improved and was now stage II. Ursodiol (300 mg twice) was added in 1992. Her alkaline phosphatase became normal and has remained so until now. A biopsy done two years later in 1994 (",
"    <a class=\"graphic graphic_picture graphicRef57230 \" href=\"mobipreview.htm?15/42/16038\">",
"     picture 92",
"    </a>",
"    ) was normal, as was a biopsy done in 1996. She tapered and discontinued methotrexate in 2003 and has continued to take ursodiol. Her last liver biopsy, done in 2004, was normal except for minimal portal inflammation (grade 0.5 on the METAVIR scale, 0-3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697666\">",
"    <span class=\"h2\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 39-year-old man with a seven-year history of ulcerative colitis that had responded nicely to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    was noted to have an elevated alkaline phosphatase (362 IU). All of his other liver function tests were normal. An ERCP was diagnostic of PSC and showed alternating areas of narrowing and dilatation in both the intra- and extrahepatic bile ducts. A liver biopsy was done because the patient wanted to know the stage of his PSC (",
"    <a class=\"graphic graphic_picture graphicRef65071 \" href=\"mobipreview.htm?38/50/39718\">",
"     picture 93",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The staging of PSC is similar to that of PBC. In stage I PSC, the disease is confined to portal triads. In stage II, scarring and inflammation extend into the parenchyma surrounding the portal triad, a process called \"interface hepatitis\". In stage III, there is linkage of adjacent portal triads by scar tissue and occasional inflammation. In stage IV, there is frank cirrhosis. Some have noted that sampling variation with percutaneous liver biopsy appears to be greater in PSC than in any other liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/50/30506/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697681\">",
"    <span class=\"h2\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 28-year-old graduate student with an eight-year history of Crohn's colitis was found to have an unexplained elevation of his alkaline phosphatase (317 IU). His ALT and AST were both slightly elevated (48 and 45",
"    <span class=\"nowrap\">",
"     U/l,",
"    </span>",
"    respectively). Serum bilirubin and albumin levels were normal. His Crohn's disease was quiescent on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    . An ERCP was diagnostic of PSC and showed beading of both his intra- and extrahepatic bile ducts. A percutaneous liver biopsy was done in order to stage his PSC and was consistent with stage II PSC (",
"    <a class=\"graphic graphic_picture graphicRef75746 \" href=\"mobipreview.htm?23/23/23926\">",
"     picture 94",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697688\">",
"    <span class=\"h1\">",
"     A CLINICAL AND HISTOLOGICAL QUIZ",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697696\">",
"    <span class=\"h2\">",
"     Case 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 3-year-old girl",
"    <strong>",
"    </strong>",
"    was seen because her ALT was elevated at 180",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST was 155",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    and other liver function tests were normal. The patient's 12-year-old sister had recently died of liver failure in a time before liver transplantation was available. The biopsy findings, hepatic steatosis, portal fibrosis, glycogen nuclei, and elevated liver enzyme tests are nonspecific and seen in many inherited diseases of altered metabolism (",
"    <a class=\"graphic graphic_picture graphicRef70017 \" href=\"mobipreview.htm?20/31/20984\">",
"     picture 95",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76639 \" href=\"mobipreview.htm?20/57/21395\">",
"     picture 96",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patient's older sister had died of complications of Wilson's disease. The 3-year-old had a very low serum ceruloplasmin (2",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    This, along with the liver biopsy findings, confirmed that the patient had Wilson's disease. She was treated with D-penicillamine and vitamin B-6 and has been well for 44 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697703\">",
"    <span class=\"h2\">",
"     Case 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 17-year-old woman was seen because of a worsening mental status, elevated liver enzymes, and elevated blood ammonia levels. She had been well until one week earlier when she had flu-like symptoms that she treated with regular doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Several days later, her parents noted that she was lethargic and brought her to the emergency department. Her ALT was 440 IU, and blood ammonia was five times higher than normal. She was admitted to her local hospital and transferred when she became frankly comatose. A percutaneous liver biopsy was done (",
"    <a class=\"graphic graphic_picture graphicRef60656 \" href=\"mobipreview.htm?2/9/2199\">",
"     picture 97",
"    </a>",
"    ). A fresh frozen specimen, stained with oil red O, was consistent with microvesicular fatty infiltration. Supportive measures were continued, but her condition continued to worsen and she died of liver failure. Her illness occurred 15 years before liver transplantation became available.",
"   </p>",
"   <p>",
"    The clinical findings and liver biopsy findings, microvesicular fatty infiltration, were diagnostic of Reye's syndrome (often called white liver disease because of the liver's color at autopsy). Although never proven with a prospective clinical trial, the disease was almost certainly caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    's effects on fat metabolism in a susceptible host. Because of the suspected relationship between aspirin and Reye's syndrome, aspirin use was sharply curtailed in children, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    was used in its place. This coincided with a virtual disappearance of Reye's syndrome, and sadly, with an increased incidence of liver failure due to acetaminophen toxicity. Epidemiologic studies have demonstrated an almost perfect relationship between the cessation of aspirin use and a disappearance of Reye's syndrome. Microvesicular fatty infiltration is caused by free fatty acids accumulating in the liver rather than neutral triglyceride. Free fatty acids are toxic to the liver, and neutral triglycerides are not. Microvesicular fatty infiltration can only be demonstrated on liver biopsy by staining fresh frozen specimens with special fat stains such as oil red O.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697710\">",
"    <span class=\"h2\">",
"     Case 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 14-year-old girl was diagnosed with \"juvenile cirrhosis\" after she complained of abdominal swelling. Ascites and esophageal varices were found. Her history revealed that she had had \"neonatal hepatitis\" from which she had recovered spontaneously. A liver biopsy was performed after her ascites had responded to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef73466 \" href=\"mobipreview.htm?38/48/39686\">",
"     picture 98",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There were numerous periportal eosinophilic inclusion bodies in a cirrhotic liver that were seen best after Periodic Acid Schiff staining (PAS) and diastase digestion. Immunohistologic staining indicated that the inclusions were alpha-a-antitrypsin. The patient had the zz genotype and had alpha-1-antitrypsin deficiency. It is unclear why some patients with this genotype develop early onset emphysema, some cirrhosis, some both diseases, and some remain well. The emphysema is caused by digestion of elastin in the lung, particularly in heavy smokers. It is caused by the lack of alpha-1-antitrypsin that normally neutralizes elastase and trypsin, which are released by activated neutrophiles in the lung. The liver disease is caused by the toxic effects of alpha-1-antiptrypsin on hepatocytes. Affected hepatocytes synthesize alpha-1-antitrypsin but cannot secrete it normally because the protein is improperly folded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697717\">",
"    <span class=\"h2\">",
"     Case 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 58-year-old woman was found to have an enlarged firm liver that was felt 10 cm below the right costal margin and an enlarged spleen that was felt 2 cm below the left costal margin. This was in 1966, before ultrasonography and CT scanning had been invented. The patient had a 14-year history of rheumatoid arthritis, which had led to marked deformities of her hands, wrists, ankles, elbows and shoulders. Blood tests were normal, except for an elevation of her serum alkaline phosphatase (523 IU) and a decreased serum albumin (2.8",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"   </p>",
"   <p>",
"    The biopsy was diagnostic of amyloid liver disease (",
"    <a class=\"graphic graphic_picture graphicRef51373 \" href=\"mobipreview.htm?27/46/28390\">",
"     picture 99",
"    </a>",
"    ). The hepatocytes were compressed and distorted by amyloid deposits. It seemed remarkable that the patient's ALT, AST, and serum bilirubin levels remained normal in the face of such liver pathology. One of the clinicians caring for the patient, a trainee in liver disease at the time, had been reluctant to perform a liver biopsy because of his belief that the patient had amyloidosis, for which there was no treatment, and that she might bleed from the biopsy. The attending clinician was concerned that the patient might have metastatic liver disease and insisted that a biopsy be done. The patient bled six units after the biopsy and was treated conservatively with abdominal compression and blood transfusions. Review of the liver unit records indicated that there had been eight previous liver biopsies done in patients who had amyloid liver disease and that three had bled, suggesting that liver biopsy should be avoided in patients with suspected amyloid liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697724\">",
"    <span class=\"h2\">",
"     Case 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 35-year-old man was seen because of intermittent elevations of his total and direct bilirubin levels. These episodes tended to occur at the time of intercurrent upper respiratory infections. Bilirubin levels were as high as 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (85.5",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    during these episodes and then decreased to values that were slightly above normal. ALT, AST, and alkaline levels remained normal, and there was no pruritus that accompanied his clinical jaundice.",
"   </p>",
"   <p>",
"    The biopsy was normal except for striking deposits of lipofuscin, a finding common in Dubin Johnson syndrome, the patient's diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef60062 \" href=\"mobipreview.htm?4/34/4646\">",
"     picture 100",
"    </a>",
"    ). These deposits stain positively with the periodic acid Schiff stain, PAS. Iron stains are negative. It can be difficult to distinguish lipofuscin from hemosiderin in liver biopsy specimens without special stains. Lipofuscin deposits can be so dense that they darken the gross appearance of the liver. Because of this finding, the disorder was once called \"Black Liver Disease\". (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8314?source=see_link&amp;anchor=H3#H3\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\", section on 'Dubin-Johnson syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697731\">",
"    <span class=\"h2\">",
"     Case 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 59-year-old man was admitted to the hospital because of recurrent bleeding from esophageal varices in 1969, a time before TIPS had been invented. He had no history of liver disease. Physical examination was normal except for striking splenomegaly. All of his liver function tests were normal. A percutaneous liver biopsy was read as normal (",
"    <a class=\"graphic graphic_picture graphicRef70777 \" href=\"mobipreview.htm?29/32/30214\">",
"     picture 101",
"    </a>",
"    ). The patient failed to respond to medical treatment, required daily blood transfusions, and was eventually taken to the operating room to have a portacaval shunt.",
"   </p>",
"   <p>",
"    An experienced vascular surgeon noted that the patient's spleen was unusually large and pale (as he explored the abdomen). It looked quite different from the spleens of the many patients with cirrhosis on whom he had performed portacaval shunts. Because of this, he biopsied the spleen and awaited the results of the pathologist's examination of a frozen specimen. It was diagnostic of Gaucher's Disease. A splenectomy was performed instead of a portacaval shunt. The patient recovered fully and did not rebleed. Review of his earlier percutaneous liver biopsy found several typical Gaucher cells that had not been noticed. They had the characteristic crinkled tissue paper appearance caused by the accumulation of glucocerebroside in Kupffer cells and macrophages. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697738\">",
"    <span class=\"h2\">",
"     Case 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 29-year-old Puerto Rican-born woman had repeated hospital admissions because of bleeding from esophageal varices. Despite multiple bleeds and many blood transfusions, her liver function was well preserved, and she had never had an episode of hepatic encephalopathy. After this biopsy, she had a successful distal splenorenal shunt, recovered uneventfully, and has not rebled.",
"   </p>",
"   <p>",
"    The biopsy is diagnostic of Schistosoma mansoni (",
"    <a class=\"graphic graphic_picture graphicRef50787 \" href=\"mobipreview.htm?42/50/43815\">",
"     picture 102",
"    </a>",
"    ). A schistosome egg is seen at the center of a granuloma in a portal triad. Liver function is typically well preserved in this form of presinusoidal portal hypertension. Eggs are laid in the walls of the intestines, enter the portal vein, and are trapped in the small branches of the portal veins in the portal triads of the liver. The trapped eggs typically cause a granulomatous reaction, and eventually portal hypertension develops. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3047697745\">",
"    <span class=\"h2\">",
"     Case 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 60-year-old man was transferred to our hospital in 1975 because of unexplained jaundice and a 25-pound weight loss. He recalled that he had avoided sun exposure from the time of adolescence because exposure to sunlight caused his skin to become red and pruritic. His serum bilirubin was 11.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (194.94",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    alkaline phosphatase 104 IU, ALT 140",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    AST 204",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    and albumin 2.3",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    He failed to respond to supportive measures and eventually died of liver failure.",
"   </p>",
"   <p>",
"    A percutaneous liver biopsy was diagnostic. It showed cirrhosis with severe interface and parenchymal hepatitis and widespread liver cell necrosis (",
"    <a class=\"graphic graphic_picture graphicRef65623 \" href=\"mobipreview.htm?10/28/10695\">",
"     picture 103",
"    </a>",
"    ). These findings were nonspecific. However, his history of avoiding sunlight because it caused his skin to redden and become pruritic was characteristic of erythropoietic protoporphyria. Examination of an H&amp;E-stained slide under polarized light demonstrated numerous red \"Maltese crosses\" (",
"    <a class=\"graphic graphic_picture graphicRef78587 \" href=\"mobipreview.htm?18/38/19053\">",
"     picture 104",
"    </a>",
"    ). These are caused by the high concentrations of protoporphyrin within the liver and are thought to be pathognomonic of this disease. The finding of greatly elevated protoporphyrin levels in his red blood cells confirmed the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24907691\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The histopathologic examination of the liver can provide otherwise unobtainable information regarding its structural integrity and the type and degree of injury",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrosis that affect the liver.",
"     </li>",
"     <li>",
"      The examples presented in this topic review represent a collection of specimens spanning more than four decades. Thus, they may not always reflect contemporary diagnostic techniques or management approaches. Methods to obtain a liver biopsy are described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=see_link\">",
"       \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9814?source=see_link\">",
"       \"Transjugular liver biopsy\"",
"      </a>",
"      .) Scoring systems for grading the severity of liver biopsy specimens are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=see_link\">",
"       \"Histologic scoring systems for chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The liver can be divided into the right and left hemiliver, each of which has its own blood supply. The right hemiliver comprises 50 to 70 percent of the liver mass (",
"      <a class=\"graphic graphic_figure graphicRef81897 \" href=\"mobipreview.htm?13/35/13878\">",
"       figure 1",
"      </a>",
"      ). The liver can be further subdivided into eight segments based upon the vascular or bile duct distribution. (See",
"      <a class=\"local\" href=\"#H1763618055\">",
"       'Segmental anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two conceptual models have been proposed relating to the architecture of the hepatic parenchyma. Terminal portal veins and hepatic venules interdigitate between sinusoids. The \"lobule\" model considers the terminal hepatic venules to be the center of the hepatic microcirculation, while the \"acinar\" model (also known as the Rappaport classification) considers it to represent the periphery (",
"      <a class=\"graphic graphic_figure graphicRef59968 \" href=\"mobipreview.htm?6/19/6456\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1763618062\">",
"       'Lobule and acinar models'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An initial step in evaluating a liver biopsy is a visual inspection of the adequacy of the sample and the type and quality of staining. (See",
"      <a class=\"local\" href=\"#H180144294\">",
"       'Principles of evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H806377781\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. The examples presented in this topic represent Dr. Kaplan's collection of specimens spanning four decades and have been used in training generations of gastroenterology and hepatology fellows. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this content, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30506/abstract/1\">",
"      Jones KL, Berry M, Kong MF, et al. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999; 22:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30506/abstract/2\">",
"      Clugston RD, Klattig J, Englert C, et al. Teratogen-induced, dietary and genetic models of congenital diaphragmatic hernia share a common mechanism of pathogenesis. Am J Pathol 2006; 169:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30506/abstract/3\">",
"      Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30506/abstract/4\">",
"      Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30506/abstract/5\">",
"      Schiano TD, Azeem S, Bodian CA, et al. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30506/abstract/6\">",
"      Schlichting P, H&oslash;lund B, Poulsen H. Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol 1983; 18:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/50/30506/abstract/7\">",
"      Lefkowitch JH. Special stains in diagnostic liver pathology. Semin Diagn Pathol 2006; 23:190.",
"     </a>",
"    </li>",
"    <li>",
"     Klatskin G, Conn HO. Hepatic granulomas. In: Histopthology of the liver, Oxford University Press, 1993. p.293.",
"    </li>",
"    <li>",
"     Personal communication from Marshall Kaplan, MD.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15756 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-201.248.109.99-864BEB8FFD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30506=[""].join("\n");
var outline_f29_50_30506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24907691\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618394\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618055\">",
"      SEGMENTAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618062\">",
"      LOBULE AND ACINAR MODELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180144294\">",
"      PRINCIPLES OF EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618401\">",
"      HISTOLOGIC PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H278983621\">",
"      NORMAL LIVER BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618069\">",
"      Normal liver, low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618076\">",
"      Normal liver, medium power",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H278983613\">",
"      HEPATOCELLULAR INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618083\">",
"      Acute lobular hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618090\">",
"      Mononucleosis hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618097\">",
"      Acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618104\">",
"      Acute viral hepatitis with very high ALT levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618111\">",
"      Acute lobular hepatitis in a 62-year-old woman with an unusually high serum bilirubin level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618118\">",
"      Chronic hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618125\">",
"      Rapidly progressive non A non B hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618132\">",
"      Autoimmune chronic hepatitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618139\">",
"      Autoimmune chronic hepatitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618146\">",
"      Autoimmune chronic hepatitis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618153\">",
"      Autoimmune chronic hepatitis 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4622234\">",
"      Acetaminophen toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20652043\">",
"      Left-sided heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20652058\">",
"      Right-sided heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20652065\">",
"      Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4622205\">",
"      METABOLIC LIVER DISEASE AND FATTY LIVER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618188\">",
"      Hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618195\">",
"      Hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618202\">",
"      Alcoholic fatty liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618209\">",
"      Alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618216\">",
"      Alcoholic steatohepatitis with prominent central hyalinizing sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618223\">",
"      Nonalcoholic steatohepatitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618230\">",
"      Nonalcoholic steatohepatitis 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4622213\">",
"      FEVER OF UNKNOWN ORIGIN AND MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618237\">",
"      Miliary TBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618244\">",
"      Miliary TBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618251\">",
"      Hodgkin disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618258\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4622221\">",
"      CHOLESTATIC LIVER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618265\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618272\">",
"      Primary biliary cirrhosis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1763618279\">",
"      Primary biliary cirrhosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697511\">",
"      Primary biliary cirrhosis stage 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697533\">",
"      Primary biliary cirrhosis stage 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697548\">",
"      Primary biliary cirrhosis stage 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697565\">",
"      Primary biliary cirrhosis stage 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697580\">",
"      Primary biliary cirrhosis stage 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697631\">",
"      Primary biliary cirrhosis stage 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697638\">",
"      Primary biliary cirrhosis stage 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697645\">",
"      Primary biliary cirrhosis stage 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697652\">",
"      Primary biliary cirrhosis stage 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697659\">",
"      Primary biliary cirrhosis, response to methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697666\">",
"      Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697681\">",
"      Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697688\">",
"      A CLINICAL AND HISTOLOGICAL QUIZ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697696\">",
"      Case 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697703\">",
"      Case 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697710\">",
"      Case 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697717\">",
"      Case 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697724\">",
"      Case 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697731\">",
"      Case 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697738\">",
"      Case 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3047697745\">",
"      Case 8",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24907691\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H806377781\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/15756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15756|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/43/7856\" title=\"diagnostic image 1\">",
"      Hepatic venogram - jaundice and elevated ALT and AST levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/16/25859\" title=\"diagnostic image 2\">",
"      Primary biliary cirrhosis x-rays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15756|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/35/13878\" title=\"figure 1\">",
"      Segmental anatomy of liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/19/6456\" title=\"figure 2\">",
"      Liver microcirculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15756|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/5/30810\" title=\"picture 1\">",
"      Normal liver - low power Masson trichrome stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/60/30665\" title=\"picture 2\">",
"      Normal liver formalin fixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/34/39465\" title=\"picture 3\">",
"      Acute lobular hepatitis - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/54/19301\" title=\"picture 4\">",
"      Apoptotic hepatocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/20/36164\" title=\"picture 5\">",
"      Necrotic hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/14/32997\" title=\"picture 6\">",
"      Periphlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/37/25176\" title=\"picture 7\">",
"      Mononucleosis hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/53/22361\" title=\"picture 8\">",
"      Acute liver failure caused by halothane anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/18/36134\" title=\"picture 9\">",
"      Acute liver failure - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/30/37350\" title=\"picture 10\">",
"      Acute lobular hepatitis high ALT - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/0/35847\" title=\"picture 11\">",
"      Acute lobular hepatitis high ALT - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/24/13703\" title=\"picture 12\">",
"      Acute lobular hepatitis high serum bilirubin - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/44/24263\" title=\"picture 13\">",
"      Acute lobular hepatitis high serum bilirubin - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/45/21207\" title=\"picture 14\">",
"      Chronic hepatitis C - low power Gomori trichrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/34/7721\" title=\"picture 15\">",
"      Chronic hepatitis C - high power Gomori trichrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/44/4806\" title=\"picture 16\">",
"      Early cirrhosis in a 52-year-old",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/4/42054\" title=\"picture 17\">",
"      Advanced cirrhosis in a 52-year-old",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/34/37416\" title=\"picture 18\">",
"      Cirrhotic bile stained liver in a 52-year-old",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/20/26951\" title=\"picture 19\">",
"      Steroid responsive autoimmune chronic hepatitis - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/31/41465\" title=\"picture 20\">",
"      Steroid responsive autoimmune chronic hepatitis - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/39/1655\" title=\"picture 21\">",
"      Steroid responsive autoimmune chronic hepatitis - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/49/794\" title=\"picture 22\">",
"      Steroid responsive autoimmune chronic hepatitis in a 68-year-old",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/36/30277\" title=\"picture 23\">",
"      Autoimmune chronic hepatitis enlarged portal triad",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/42/23206\" title=\"picture 24\">",
"      Autoimmune chronic hepatitis after immunosupportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/19/35128\" title=\"picture 25\">",
"      Autoimmune chronic hepatitis in a 21-year-old - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/17/279\" title=\"picture 26\">",
"      Autoimmune chronic hepatitis in a 21-year-old - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/30/23014\" title=\"picture 27\">",
"      Autoimmune chronic hepatitis after treatment - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/10/27815\" title=\"picture 28\">",
"      Autoimmune chronic hepatitis after treatment - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/44/33477\" title=\"picture 29\">",
"      Acetaminophen hepatotoxicity - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/22/41318\" title=\"picture 30\">",
"      Acetaminophen hepatotoxicity - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/35/32310\" title=\"picture 31\">",
"      Left-sided heart failure - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/48/21256\" title=\"picture 32\">",
"      Left-sided heart failure - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/40/35463\" title=\"picture 33\">",
"      Left-sided heart failure - very high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/12/42183\" title=\"picture 34\">",
"      Right-sided heart failure - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/48/2821\" title=\"picture 35\">",
"      Budd-Chiari syndrome - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/24/15751\" title=\"picture 36\">",
"      Budd-Chiari syndrome - recanalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/29/37333\" title=\"picture 37\">",
"      Hemochromatosis - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/40/22151\" title=\"picture 38\">",
"      Hemochromatosis - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/62/20453\" title=\"picture 39\">",
"      Hemochromatosis - low power Perls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/34/6696\" title=\"picture 40\">",
"      Hemochromatosis - medium power Perls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/2/31782\" title=\"picture 41\">",
"      Hemochromatosis and sarcoidosis - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/54/869\" title=\"picture 42\">",
"      Hemochromatosis and sarcoidosis - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/0/29702\" title=\"picture 43\">",
"      Hemochromatosis after phlebotomy treatment - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/2/31781\" title=\"picture 44\">",
"      Hemochromatosis after phlebotomy treatment - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/18/20774\" title=\"picture 45\">",
"      Alcohol induced fatty liver - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/4/34882\" title=\"picture 46\">",
"      Alcohol induced fatty liver - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/49/13079\" title=\"picture 47\">",
"      Alcoholic steatohepatitis - lower power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/62/38887\" title=\"picture 48\">",
"      Alcoholic steatohepatitis - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/18/13606\" title=\"picture 49\">",
"      Alcoholic steatohepatitis - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/19/9526\" title=\"picture 50\">",
"      Alcoholic steatohepatitis and cirrhosis - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/51/823\" title=\"picture 51\">",
"      Alcoholic steatohepatitis and cirrhosis II - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/43/3766\" title=\"picture 52\">",
"      Central hyalinizing sclerosis - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/57/23442\" title=\"picture 53\">",
"      Mallory body alcoholic steatohepatitis - very high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/9/38037\" title=\"picture 54\">",
"      Acidophilic body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/46/1765\" title=\"picture 55\">",
"      Mallory body alcoholic steatohepatitis- high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/37/8790\" title=\"picture 56\">",
"      Nonalcoholic steatohepatitis I - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/13/34008\" title=\"picture 57\">",
"      Nonalcoholic steatohepatitis II - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/19/13622\" title=\"picture 58\">",
"      Nonalcoholic steatohepatitis III - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/26/20904\" title=\"picture 59\">",
"      Nonalcoholic steatohepatitis with a granuloma - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/33/38423\" title=\"picture 60\">",
"      Miliary tuberculosis - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/51/27447\" title=\"picture 61\">",
"      Miliary tuberculosis - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/10/31911\" title=\"picture 62\">",
"      Miliary tuberculosis caseating granuloma - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/39/37493\" title=\"picture 63\">",
"      Hodgkins disease - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/18/4387\" title=\"picture 64\">",
"      Hodgkins disease - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/57/2967\" title=\"picture 65\">",
"      Hepatocellular carcinoma - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/13/22742\" title=\"picture 66\">",
"      Hepatocellular carcinoma - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/17/20758\" title=\"picture 67\">",
"      Hepatocellular carcinoma - very high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/29/36311\" title=\"picture 68\">",
"      Acute cholangitis - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/28/9671\" title=\"picture 69\">",
"      Acute cholangitis II - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/19/5431\" title=\"picture 70\">",
"      Acute cholangitis III - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/32/39431\" title=\"picture 71\">",
"      Bile duct hyperplasia - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/46/43751\" title=\"picture 72\">",
"      Primary biliary cirrhosis I - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/38/34406\" title=\"picture 73\">",
"      Florid bile duct lesion in PBC - I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/8/6279\" title=\"picture 74\">",
"      Florid bile duct lesion in PBC - II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/34/39463\" title=\"picture 75\">",
"      Primary biliary cirrhosis V - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/62/9190\" title=\"picture 76\">",
"      Primary biliary cirrhosis VI - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/7/28790\" title=\"picture 77\">",
"      Primary biliary cirrhosis IV - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/44/28359\" title=\"picture 78\">",
"      Primary biliary cirrhosis VII - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/7/43127\" title=\"picture 79\">",
"      Primary biliary cirrhosis VIII - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/43/14007\" title=\"picture 80\">",
"      Primary biliary cirrhosis IX - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/26/11688\" title=\"picture 81\">",
"      Primary biliary cirrhosis X - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/27/43446\" title=\"picture 82\">",
"      Primary biliary cirrhosis XI - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/5/29781\" title=\"picture 83\">",
"      Stage II PBC - high power HE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/11/20662\" title=\"picture 84\">",
"      Stage II PBC - high power Masson",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/7/31857\" title=\"picture 85\">",
"      PBC palmar xanthomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/40/28288\" title=\"picture 86\">",
"      PBC eruptive xanthomas on buttocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/30/24033\" title=\"picture 87\">",
"      PBC xanthomas on elbows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/27/11702\" title=\"picture 88\">",
"      Stage III PBC - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/2/36904\" title=\"picture 89\">",
"      Stage IV PBC - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/35/27193\" title=\"picture 90\">",
"      Stage IV PBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/54/870\" title=\"picture 91\">",
"      Stage III-IV PBC - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/42/16038\" title=\"picture 92\">",
"      PBC after treatment - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/50/39718\" title=\"picture 93\">",
"      Primary sclerosing cholangitis - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/23/23926\" title=\"picture 94\">",
"      Primary sclerosing cholangitis - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/31/20984\" title=\"picture 95\">",
"      Percutaneous liver biopsy - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/57/21395\" title=\"picture 96\">",
"      Percutaneous liver biopsy - very high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/9/2199\" title=\"picture 97\">",
"      Percutaneous liver biopsy - medium power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/48/39686\" title=\"picture 98\">",
"      Juvenile cirrhosis - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/46/28390\" title=\"picture 99\">",
"      Greatly enlarged liver - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/34/4646\" title=\"picture 100\">",
"      Percutaneous liver biopsy - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/32/30214\" title=\"picture 101\">",
"      Liver biopsy - bleeding from esophageal varices and splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/50/43815\" title=\"picture 102\">",
"      Liver biopsy - recurrent bleeding from esophageal varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/28/10695\" title=\"picture 103\">",
"      Liver biopsy - jaundice and weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/38/19053\" title=\"picture 104\">",
"      Liver biopsy II - jaundice and weight loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43701?source=related_link\">",
"      Congestive hepatopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34871?source=related_link\">",
"      Halothane hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=related_link\">",
"      Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9814?source=related_link\">",
"      Transjugular liver biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_50_30507="IDUS accuracy versus EUS";
var content_f29_50_30507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic accuracy of endoscopic ultrasound (EUS) and intraductal ultrasound (IDUS) for bile duct strictures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        EUS (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        IDUS (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        p value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Sensitivity",
"        </strong>",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        &lt;0.002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Specificity",
"        </strong>",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Positive predictive value",
"        </strong>",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Negative predictive value",
"        </strong>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Accuracy",
"        </strong>",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        &lt;0.002",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Menzel J, Poremba C, Dietl KH, Domschke W. Scand J Gastroenterol 2000; 35:77.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30507=[""].join("\n");
var outline_f29_50_30507=null;
var title_f29_50_30508="Opioids children with burns";
var content_f29_50_30508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Opioid analgesics for use in children with burns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Equianalgesic dose*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Oral dose and frequency",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        IV dose and frequency",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Oral (mg)",
"       </td>",
"       <td class=\"subtitle2\">",
"        IV (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.3 mg/kg every three to four hours",
"       </td>",
"       <td>",
"        0.1 mg/kg every two to four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydromorphone",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.04 to 0.08 mg/kg every three to four hours",
"       </td>",
"       <td>",
"        0.015 mg/kg every two to four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxycodone",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        0.1 to 0.2 mg/kg every three to four hours",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        0.1 (100 mcg)",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        0.5 to 1 mcg/kg every one to two hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methadone",
"       </td>",
"       <td>",
"        &sect;",
"       </td>",
"       <td>",
"        &sect;",
"       </td>",
"       <td>",
"        0.1 mg/kg every eight to twelve hours",
"       </td>",
"       <td>",
"        0.5 to 0.1 mg/kg every eight to twelve hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N/A: not available.",
"     <br/>",
"     * Approximate equianalgesic dose for estimation when changing opioid agents.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Doses are for individuals over 6 months of age with a maximum weight of 50 kg. Oral doses refer to immediate release products.",
"     <br/>",
"     &Delta; Dose adjustment for renal insufficiency may be required. Not recommended in severe renal insufficiency.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Oral transmucosal fentanyl is commonly used in pediatric burn patients for procedural pain, due to its acceptance by children, its relatively fast onset of action, and its relatively short duration of action, at a dose of 10-20 mcg/kg.",
"     <br/>",
"     &sect; Due to gradual drug accumulation at tissue sites, the dose and frequency of methadone differ for initial compared with repeated use; dose and interval given is usual after repeated use; methadone should be initiated and titrated by a clinician experienced with its use.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gutstein HB, Akil H. Opioid analgesics. In: Goodman &amp; Gilmans pharmacological basis of therapeutics, 11th ed, McGraw-Hill, New York 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30508=[""].join("\n");
var outline_f29_50_30508=null;
var title_f29_50_30509="Inspiratory flow rate vs work";
var content_f29_50_30509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Inspiratory flow rate effects inspiratory work",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of changing inspiratory flow rate on rate of inspiratory work of breathing during controlled mechanical ventilation (circles) and assist-control ventilation (squares). At all flow rates, the work of breathing was significantly greater during assist-control ventilation versus controlled ventilation. During both modes of mechanical ventilation, work increased as flow rate was decreased. Values are mean &plusmn; SE.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Ward, ME, Corbeil, C, Gibbons, W, et al, Anesthesiology 1988; 69:29.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30509=[""].join("\n");
var outline_f29_50_30509=null;
var title_f29_50_30510="Adjusting Rx 0 to 4 yrs";
var content_f29_50_30510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78322%7EPULM%2F64986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78322%7EPULM%2F64986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control and adjusting therapy in children 0-4 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (0-4 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;1x/month",
"       </td>",
"       <td>",
"        &gt;1x/month",
"       </td>",
"       <td>",
"        &gt;1x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Risk",
"       </td>",
"       <td>",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         2-3/year",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &gt;3/year",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Recommended action for treatment",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Maintain current treatment.",
"        </p>",
"        <p>",
"         &bull; Regular followups every 1-6 months.",
"        </p>",
"        <p>",
"         &bull; Consider step down if well controlled for at least 3 months.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Step up (1 step) and",
"        </p>",
"        <p>",
"         &bull; Reevaluate in 2-6 weeks.",
"        </p>",
"        <p>",
"         &bull; If no clear benefit in 4-6 weeks, consider alternative diagnoses or adjusting therapy.",
"        </p>",
"        <p>",
"         &bull; For side effects, consider alternative treatment options.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Consider short course of oral systemic corticosteroids,",
"        </p>",
"        <p>",
"         &bull; Step up (1-2 steps), and",
"        </p>",
"        <p>",
"         &bull; Reevaluate in 2 weeks.",
"        </p>",
"        <p>",
"         &bull; If no clear benefit in 4-6 weeks, consider alternative diagnoses or adjusting therapy.",
"        </p>",
"        <p>",
"         &bull; For side effects, consider alternative treatment options.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The stepwise approach is meant to assist, not replace, the clinical decisionmaking required to meet individual patient needs. The level of control is based on the most severe impairment or risk category. Assess impairment domain by caregiver's recall of previous 2-4 weeks. Symptom assessment for longer periods should reflect a global assessment such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma.",
"    <br>",
"     <strong>",
"      Before step up in therapy:",
"     </strong>",
"     <br>",
"      - Review adherence to medication, inhaler technique, and environmental control.",
"      <br>",
"       - If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step.",
"       <div class=\"footnotes\">",
"        EIB: exercise-induced bronchospasm.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control and adjusting therapy in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week but not more than once on each day",
"       </td>",
"       <td>",
"        &gt;2 days/week or multiple times on &le;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;1x/month",
"       </td>",
"       <td>",
"        &ge;2x/month",
"       </td>",
"       <td>",
"        &ge;2x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Lung function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         or peak flow",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; &gt;80 percent predicted/personal best",
"        </p>",
"        <p>",
"         &bull; &gt;80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; 60-80 percent predicted/personal best",
"        </p>",
"        <p>",
"         &bull; 75-80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; &lt;60 percent predicted/personal best",
"        </p>",
"        <p>",
"         &bull; &lt;75 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduction in lung growth",
"       </td>",
"       <td colspan=\"3\">",
"        Evaluation requires long-term followup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Recommended action for treatment",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Maintain current step.",
"        </p>",
"        <p>",
"         &bull; Regular followup every 1-6 months.",
"        </p>",
"        <p>",
"         &bull; Consider step down if well controlled for at least 3 months.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Step up at least 1 step and",
"        </p>",
"        <p>",
"         &bull; Reevaluate in 2-6 weeks.",
"        </p>",
"        <p>",
"         &bull; For side effects, consider alternative treatment options.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Consider short course of oral systemic corticosteroids,",
"        </p>",
"        <p>",
"         &bull; Step up 1-2 steps, and",
"        </p>",
"        <p>",
"         &bull; Reevaluate in 2 weeks.",
"        </p>",
"        <p>",
"         &bull; For side effects, consider alternative treatment options.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The stepwise approach is meant to assist, not replace, the clinical decisionmaking required to meet individual patient needs. The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <br>",
"     <strong>",
"      Before step up in therapy:",
"     </strong>",
"     <br>",
"      - Review adherence to medication, inhaler technique, environmental control, and comorbid conditions.",
"      <br>",
"       - If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step.",
"       <div class=\"footnotes\">",
"        EIB: exercise-induced bronchospasm; FEV",
"        <sub>",
"         1",
"        </sub>",
"        : forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30510=[""].join("\n");
var outline_f29_50_30510=null;
var title_f29_50_30511="Juvenile Tillaux fx";
var content_f29_50_30511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile Tillaux fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tillaux fracture of the distal tibia. The medial aspect of the epiphysis is closing. The fracture line runs vertically through the epiphysis (black arrow) and then laterally along the open and slightly widened physis (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_50_30511=[""].join("\n");
var outline_f29_50_30511=null;
